US8609715B2 - Heteroarylcarboxylic acid ester derivative - Google Patents

Heteroarylcarboxylic acid ester derivative Download PDF

Info

Publication number
US8609715B2
US8609715B2 US13/484,822 US201213484822A US8609715B2 US 8609715 B2 US8609715 B2 US 8609715B2 US 201213484822 A US201213484822 A US 201213484822A US 8609715 B2 US8609715 B2 US 8609715B2
Authority
US
United States
Prior art keywords
group
substituent
optionally
mmol
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
US13/484,822
Other versions
US20120283222A1 (en
Inventor
Atsushi Konishi
Munetaka Tokumasu
Tamotsu Suzuki
Takahiro Koshiba
Koji Ohsumi
Osamu Ikehara
Yuko Kodama
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
EA Pharma Co Ltd
Original Assignee
Ajinomoto Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ajinomoto Co Inc filed Critical Ajinomoto Co Inc
Assigned to AJINOMOTO CO., INC. reassignment AJINOMOTO CO., INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: IKEHARA, OSAMU, KODAMA, YUKO, KONISHI, ATSUSHI, KOSHIBA, TAKAHIRO, OHSUMI, KOJI, SUZUKI, TAMOTSU, TOKUMASU, MUNETAKA
Publication of US20120283222A1 publication Critical patent/US20120283222A1/en
Priority to US14/089,040 priority Critical patent/US8877805B2/en
Application granted granted Critical
Publication of US8609715B2 publication Critical patent/US8609715B2/en
Priority to US14/496,363 priority patent/US9115107B2/en
Priority to US14/799,130 priority patent/US20150313889A1/en
Assigned to EA PHARMA CO., LTD. reassignment EA PHARMA CO., LTD. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: AJINOMOTO CO., INC.
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/15—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing halogen
    • C07C53/16—Halogenated acetic acids
    • C07C53/18—Halogenated acetic acids containing fluorine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3808—Acyclic saturated acids which can have further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/65515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring

Definitions

  • the present invention relates to novel heteroarylcarboxylic acid ester derivatives having a serine protease (particularly trypsin and enteropeptidase) inhibitory activity.
  • the present invention also relates to pharmaceutical compositions which contain such a heteroarylcarboxylic acid ester derivative and drugs for the treatment or prophylaxis of diabetes.
  • the present invention further relates to methods for the treatment and/or prophylaxis of diabetes by administering such a heteroarylcarboxylic acid ester derivative.
  • insulin secretagogues sulfonylurea
  • glucose absorption inhibitors ⁇ -glucosidase inhibitor
  • insulin sensitizers biguanide, thiazolidine derivative
  • side effects such as hypoglycemia, diarrhea, lactic acidosis, edema, and the like, show an insufficient effect, and the like, a medicament satisfying clinical needs is still demanded.
  • a benzoic acid ester having a protease inhibitory activity which is represented by the following compound, has been reported to show a blood glucose elevation suppressing action in diabetes animal model (see WO2006/057152, which is incorporated herein by reference in its entirety).
  • the following compound is considered to show an enzyme inhibitory activity on trypsin, thrombin, pancreatic, and plasma kallikreins, plasmin and the like and a leukotriene receptor antagonistic action.
  • an enteropeptidase inhibitory activity of the following compound has also been reported (see Biomedical Research (2001), 22(5) 257-260, which is incorporated herein by reference in its entirety).
  • many unclear points remain in the relationship between such actions and a blood glucose elevation suppressing action.
  • JP-A-55-161385 which is incorporated herein by reference in its entirety, discloses a compound as a therapeutic drug for pancreatitis.
  • heteroarylcarboxylic acid ester compounds wherein the substituent of the heteroarylcarboxylic acid moiety is a methyl group or a methoxy group or unsubstituted compounds are disclosed, as represented by the following formula. While these compounds are disclosed as showing an inhibitory activity on trypsin, chymotrypsin and thrombin, no description is given as to the enteropeptidase inhibitory activity and blood glucose elevation suppressing action.
  • WO99/41231 which is incorporated herein by reference in its entirety, describes a compound represented by the following formula. However, it has a structure wherein an aryl group substituted by a carboxyl group is directly bonded to the heteroaryl moiety, which is completely different from the compound of the present invention.
  • the document discloses an inhibitory activity against blood coagulation factor VIIa; however, no description is given as to the enteropeptidase inhibitory activity and blood glucose elevation suppressing action.
  • trypsin is one of the intestinal serine proteases and is produced by degradation of inactive trypsinogen by enteropeptidase. Trypsin is known to activate various digestive enzymes by acting on chymotrypsinogen, proelastase, procarboxylesterase, procolipase and pro-sucrase-isomaltase, and the like. Therefore, it is considered that an inhibitor of enteropeptidase and trypsin lowers the digestive capacity for protein, lipid, and carbohydrates, and is effective as a drug for the treatment or prophylaxis of obesity and hyperlipidemia.
  • WO2006/050999 which is incorporated herein by reference in its entirety describes that a medicament that inhibits both enteropeptidase and trypsin is interesting as a body fat-reducing agent.
  • WO2009/071601 which is incorporated herein by reference in its entirety reports a compound having an inhibitory activity against enteropeptidase, trypsin, plasmin, kallikrein, and the like as an antiobesity drug.
  • neither of these publications describe suppression of blood glucose elevation and hypoglycemic effect afforded by simultaneous inhibition of enteropeptidase and trypsin, and the protease inhibitor described therein has a structure completely different from that of the compound of the present invention.
  • a hyperglycemic inhibitor having a serine protease inhibitory action which is a new drug for the treatment or prophylaxis of diabetes.
  • heteroarylcarboxylic acid ester derivatives described below have serine protease inhibitory activity and are useful for the treatment and/or prophylaxis of any of diabetes, obesity, hyperlipidemia, diabetic complication, and metabolic syndrome.
  • the present inventors have conducted intensive studies and considered that simultaneous inhibition of trypsin and enteropeptidase is particularly effective for the suppression of blood glucose elevation. They have synthesized various heteroarylcarboxylic acid ester derivatives, which are novel compounds, evaluated trypsin and enteropeptidase inhibitory activity, and found that certain heteroarylcarboxylic acid ester derivatives are protease inhibitors that simultaneously inhibit them, which resulted in the completion of the present invention. Furthermore, they have also found that such representative compounds show a blood glucose elevation suppressing effect in diabetes animal model.
  • the present invention provides a heteroarylcarboxylic acid ester derivative represented by the following formula (I):
  • R1, R2, R3, and R4 may be the same or different and are each independently a hydrogen atom, a nitro group, a halogeno group, a cyano group, a hydroxyl group, a thiol group, an amino group, a guanidino group, a formyl group, a lower alkyl group, a lower alkenyl group, a lower alkynyl group, a lower acyl group, a carboxyl group, a sulfo group, a phosphono group, a lower alkoxyl group, a lower alkylthio group, a lower alkylamino group, a lower acyloxy group, a lower acylamino group, a lower alkoxycarbonyl group, a carbamoyl group, a lower alkylcarbamoyl group, a lower alkylsulfonylamino group, or a sulfamoyl group,
  • HetAr is a heteroaromatic ring optionally having substituent(s),
  • X is a lower alkylene group optionally having substituent(s), a lower alkenylene group optionally having substituent(s), a lower alkynylene group optionally having substituent(s), a phenylene group, or a thiophenylene group,
  • Y is a carbonyl group, a thiocarbonyl group, or a sulfonyl group
  • A is —OR5 (R5 is a hydrogen atom or a lower alkyl group);
  • R6 and R7 may be the same or different and are each independently a hydrogen atom, a hydroxyl group, a lower alkyl group optionally having substituent(s), a lower alkenyl group optionally having substituent(s), a lower alkynyl group optionally having substituent(s) or a lower alkoxyl group optionally having substituent(s), or R6 and R7 may be bonded to form a cyclic amino group optionally having substituent(s);
  • R6′ and R7′ may be the same or different and are each independently a hydrogen atom, a hydroxyl group, a carboxyl group, a lower alkyl group optionally having substituent(s), a lower alkenyl group optionally having substituent(s), a lower alkynyl group optionally having substituent(s) or a lower alkoxyl group optionally having substituent(s), or R6′ and R7′ may be bonded to form a cyclic amino group optionally having substituent(s); or
  • R6′′ and R7′′ may be the same or different and are each independently a hydrogen atom, a hydroxyl group, a lower alkyl group optionally having substituent(s), a lower alkenyl group optionally having substituent(s), a lower alkynyl group optionally having substituent(s) or a lower alkoxyl group optionally having substituent(s), or R6′′ and R7′′ may be bonded to form a cyclic amino group optionally having substituent(s),
  • the compound of the present invention or a pharmaceutically acceptable salt thereof (hereinafter sometimes to be simply referred to as “the compound of the present invention”), a pharmaceutical composition containing the same, or a serine protease inhibitor containing the same as an active ingredient.
  • the present invention also provides a compound represented by the aforementioned formula (I) wherein
  • R1, R2, R3, and R4 may be the same or different and are each independently a hydrogen atom, a nitro group, a halogeno group, a cyano group, a hydroxyl group, a thiol group, an amino group, a guanidino group, a formyl group, a lower alkyl group, a lower alkenyl group, a lower alkynyl group, a lower acyl group, a carboxyl group, a sulfo group, a phosphono group, a lower alkoxyl group, a lower alkylthio group, a lower alkylamino group, a lower acyloxy group, a lower acylamino group, a lower alkoxycarbonyl group, a carbamoyl group, a lower alkylcarbamoyl group, a lower alkylsulfonylamino group, or a sulfamoyl group,
  • HetAr is a heteroaromatic ring optionally having substituent(s),
  • X is a lower alkylene group optionally having substituent(s), a lower alkenylene group optionally having substituent(s), or a lower alkynylene group optionally having substituent(s),
  • Y is a carbonyl group, a thiocarbonyl group, or a sulfonyl group
  • R5 is a hydrogen atom or a lower alkyl group
  • II formula (I):
  • R6 and R7 may be the same or different and are each independently a hydrogen atom, a hydroxyl group, a lower alkyl group optionally having substituent(s), a lower alkenyl group optionally having substituent(s), a lower alkynyl group optionally having substituent(s) or a lower alkoxyl group optionally having substituent(s), or R6 and R7 may be bonded to form a cyclic amino group optionally having substituent(s),
  • the present invention also provides a compound represented by the aforementioned formula (I) wherein R1, R2, R3, and R4 are each independently a hydrogen atom, a nitro group or a halogeno group,
  • the present invention also provides a compound represented by the aforementioned formula (I) wherein HetAr is a 5- to 10-membered aromatic ring containing 1 to 3 hetero atoms, which optionally has substituent(s),
  • the present invention also provides a compound represented by the aforementioned formula (I) wherein -HetAr— is a heteroaromatic ring group represented by the following formula (III-1) or (III-2):
  • Z1 and Z2 are each independently CRa or a nitrogen atom, and Z3 is an oxygen atom, a sulfur atom, or NRb, wherein Ra and Rb may be the same or different and are each independently a hydrogen atom, a nitro group, a halogeno group, a cyano group, a hydroxyl group, a thiol group, an amino group, a guanidino group, a formyl group, a lower alkyl group, a lower alkenyl group, a lower alkynyl group, a lower acyl group, a carboxyl group, a sulfo group, a phosphono group, a lower alkoxyl group, a lower alkylthio group, a lower alkylamino group, a lower acyloxy group, a lower acylamino group, a lower alkoxycarbonyl group, a carbamoyl group, a lower alkylcarbamo
  • the present invention also provides a compound represented by the aforementioned formula (I) wherein -HetAr— is a group containing a heteroaromatic ring group represented by the formula (III-1) or (III-2), and
  • Z1 and Z2 are each independently CRa or a nitrogen atom, and Z3 is an oxygen atom or a sulfur atom,
  • the present invention also provides a compound represented by the aforementioned formula (I) wherein X is a lower alkylene group optionally having substituent(s) or a lower alkenylene group optionally having substituent(s), and the substituent is selected from the group consisting of a halogeno group, a hydroxyl group, an amino group, a lower alkyl group, a lower alkoxyl group, and a lower acyl group,
  • the present invention also provides a compound represented by the aforementioned formula (I) wherein Y is a carbonyl group or a sulfonyl group,
  • the present invention also provides a compound represented by the aforementioned formula (I) wherein A is —OR5 (R5 is a hydrogen atom or a lower alkyl group),
  • the present invention also provides a compound represented by the aforementioned formula (I) wherein A is a group of the following formula (IV):
  • R60 is a carboxyl group, a sulfo group, a phosphono group, a lower alkoxycarbonyl group, or a hydroxyl group
  • D is a lower alkylene group optionally having substituent(s), a lower alkenylene group optionally having substituent(s), or a lower alkynylene group optionally having substituent(s), wherein the substituent is selected from the group consisting of a nitro group, a halogeno group, a cyano group, a hydroxyl group, a thiol group, an amino group, a guanidino group, a formyl group, a lower acyl group, a carboxyl group, a sulfo group, a phosphono group, a lower alkoxyl group, a lower alkylthio group, a lower alkylamino group, a lower acyloxy group, a lower acylamino group, a lower alkoxycarbonyl group, a carbamoyl group, a lower alkylcarbamoyl group, a lower alkylsulfonylamino group, an aryl
  • R70 is a hydrogen atom, a hydroxyl group, a lower alkyl group optionally having substituent(s) or a lower alkoxyl group optionally having substituent(s), or R70 and D may be bonded to form a cyclic amino group optionally having substituent(s),
  • the present invention also provides a compound represented by the aforementioned formula (I) wherein
  • A is a group of the aforementioned formula (IV),
  • R60 is a carboxyl group, a sulfo group, a lower alkoxycarbonyl group, or a hydroxyl group
  • D is a lower alkylene group optionally having substituent(s), wherein the substituent is selected from the group consisting of a halogeno group, a hydroxyl group, a thiol group, an amino group, a guanidino group, a carboxyl group, a sulfo group, a lower alkoxyl group, a lower alkylthio group, a lower alkylamino group, a lower acylamino group, a lower alkoxycarbonyl group, a carbamoyl group, a lower alkylcarbamoyl group, a lower alkylsulfonylamino group, an arylsulfonylamino group optionally having substituent(s), an aryl group optionally having substituent(s), a heterocyclic group optionally having substituent(s), and an oxo group, and
  • R70 is a hydrogen atom, a hydroxyl group, a lower alkyl group optionally having substituent(s), or a lower alkoxyl group optionally having substituent(s), or R70 and D may be bonded to form a cyclic amino group optionally having substituent(s),
  • the present invention also provides a compound represented by the aforementioned formula (I) wherein R1, R2, R3, and R4 are each independently a hydrogen atom, a nitro group, or a fluorine atom, and
  • HetAr is furan, thiophene, or thiazole each optionally having substituent(s),
  • the present invention also provides an intestinal serine protease inhibitor, comprising the above-mentioned heteroarylcarboxylic acid ester derivative, or a pharmaceutically acceptable salt thereof as an active ingredient.
  • the present invention also provides a dual inhibitor of trypsin and enteropeptidase, comprising the above-mentioned heteroarylcarboxylic acid ester derivative, or a pharmaceutically acceptable salt thereof as an active ingredient.
  • the present invention also provides a hyperglycemic inhibitor or hypoglycemic agent, comprising the above-mentioned heteroarylcarboxylic acid ester derivative, or a pharmaceutically acceptable salt thereof as an active ingredient.
  • the present invention also provides a prophylactic or therapeutic drug for diabetes, comprising the above-mentioned heteroarylcarboxylic acid ester derivative, or a pharmaceutically acceptable salt thereof as an active ingredient.
  • the present invention also provides an insulin sensitizer comprising the above-mentioned heteroarylcarboxylic acid ester derivative, or a pharmaceutically acceptable salt thereof as an active ingredient.
  • the present invention also provides a prophylactic or therapeutic drug for obesity, hyperlipidemia, diabetic complication or metabolic syndrome, comprising the above-mentioned heteroarylcarboxylic acid ester derivative, or a pharmaceutically acceptable salt thereof as an active ingredient.
  • the present invention also provides a method for preventing or treating diabetes, comprising administering an effective amount of the above-mentioned heteroarylcarboxylic acid ester derivative, or a pharmaceutically acceptable salt thereof.
  • the present invention also provides a method for improving insulin resistance, comprising administering an effective amount of the above-mentioned heteroarylcarboxylic acid ester derivative, or a pharmaceutically acceptable salt thereof.
  • the present invention also provides a method for preventing or treating obesity, hyperlipidemia, diabetic complication or metabolic syndrome, comprising administering an effective amount of the above-mentioned heteroarylcarboxylic acid ester derivative, or a pharmaceutically acceptable salt thereof.
  • the present invention also provides use of the above-mentioned heteroarylcarboxylic acid ester derivative, or a pharmaceutically acceptable salt thereof for the prophylaxis or treatment of diabetes.
  • the present invention also provides use of the above-mentioned heteroarylcarboxylic acid ester derivative, or a pharmaceutically acceptable salt thereof for the improvement of insulin resistance.
  • the present invention also provides use of the above-mentioned heteroarylcarboxylic acid ester derivative, or a pharmaceutically acceptable salt thereof for the prophylaxis or treatment of obesity, hyperlipidemia, diabetic complication or metabolic syndrome.
  • the compound of the present invention has a blood glucose elevation suppressing action and can be preferably used as a drug for the treatment or prophylaxis of diabetes.
  • substituent(s) means “being substituted or unsubstituted”.
  • position and number of the substituents may be any, and are not particularly limited. When substituted by two or more substituents, the substituents may be the same or different.
  • substituents examples include a nitro group, a halogeno group, a cyano group, a hydroxyl group, a thiol group, an amino group, a guanidino group, a formyl group, a phenyl group, a lower alkyl group, a lower alkenyl group, a lower alkynyl group, a lower acyl group, a carboxyl group, a sulfo group, a phosphono group, a lower alkoxyl group, a lower alkylthio group, a lower alkylamino group, a lower alkoxycarbonyl group, a carbamoyl group, a lower alkylcarbamoyl group, a lower alkylsulfonylamino group, a sulfamoyl group, and the like.
  • examples of the substituent of the “arylsulfonylamino group optionally having substituent(s)”, “cycloalkyl group optionally having substituent(s)”, “aryl group optionally having substituent(s)”, “aryloxy group optionally having substituent(s)”, “arylthio group optionally having substituent(s)”, “aralkyl group optionally having substituent(s)”, “aralkyloxy group optionally having substituent(s)”, “aralkylthio group optionally having substituent(s)”, “heterocyclic group optionally having substituent(s)”, “heterocyclic oxy group optionally having substituent(s)” and “heterocyclic thio group optionally having substituent(s)” include a nitro group, a halogeno group, a cyano group, a hydroxyl group, a thiol group, an amino group, a guanidino group, a formyl group, a lower alky
  • heteromatic ring in the present specification is a 5- to 10-membered aromatic ring optionally containing 1 to 3 hetero atoms such as a nitrogen atom, an oxygen atom, a sulfur atom, and the like, and examples thereof include a monocycle, and a fused aromatic ring wherein two aromatic rings are fused.
  • the monocycle include furan, thiophene, pyrrole, oxazole, isoxazole, thiazole, isothiazole, imidazole, pyrazole, oxadiazole, thiadiazole, pyridine, pyridazine, pyrimidine, pyrazine, and the like.
  • fused aromatic ring examples include indole, isoindole, benzofuran, benzothiophene, indolizine, quinoline, isoquinoline, purine, 1H-indazole, quinazoline, cinnoline, quinoxaline, phthalazine, pteridine, benzoxazole, benzothiazole, benzimidazole, and the like.
  • the “cyclic amino group” in the present specification is a saturated or unsaturated cyclic amino group having a carbon number of 2 to 7, which may contain one or more hetero atoms in the ring, such as a nitrogen atom, an oxygen atom, a sulfur atom, and the like.
  • a pyrrolidinyl group, a pyrrolinyl group, a piperidinyl group, a morpholinyl group, a piperazinyl group, a thiomorpholinyl group, a piperidinonyl group, a piperazinonyl group and the like can be mentioned.
  • the “lower alkyl group” is a straight chain or branched chain or cyclic alkyl group having a carbon number of 1 to 6.
  • a methyl group, an ethyl group, an n-propyl group, an n-butyl group, an n-pentyl group, an n-hexyl group, an isopropyl group, an isobutyl group, a sec-butyl group, a tert-butyl group, an isopentyl group, a tert-pentyl group, a neopentyl group, a 2-pentyl group, a 3-pentyl group, a 2-hexyl group, a cyclopropyl group, a cyclopentyl group, and the like can be mentioned.
  • the “lower alkenyl group” is a straight chain or branched chain alkenyl group having a carbon number of 2 to 6, which includes each isomer.
  • a vinyl group, an allyl group, a propenyl group, a butenyl group, a pentenyl group, a hexenyl group, and the like can be mentioned.
  • the “lower alkynyl group” is a straight chain or branched chain alkynyl group having a carbon number of 2 to 6, which includes each isomer.
  • an ethynyl group, a 1-propynyl group, a 2-propynyl group, a 2-butynyl group, a 3-butynyl group, a pentynyl group, and the like can be mentioned.
  • the “lower alkylene group” is a straight chain or branched chain or cyclic alkylene group having a carbon number of 1 to 6, with preference given to a straight chain or a branched chain.
  • the “lower alkenylene group” is a straight chain or branched chain alkenylene group having a carbon number of 2 to 6, which includes each isomer.
  • a vinylene group, a 1-propenylene group, a 2-propenylene group, a 2-butenylene group, a 3-butenylene group, a pentenylene group, a hexenylene group, —CH ⁇ C(CH 3 )—, and the like can be mentioned.
  • the “lower alkynylene group” is a straight chain or branched chain alkynylene group having a carbon number of 2 to 6, which includes each isomer.
  • an ethynylene group, a 1-propynylene group, a 2-propynylene group, a 2-butynylene group, a 3-butynylene group, a pentynylene group, and the like can be mentioned.
  • halogeno group examples include a fluorine atom, a chlorine atom, a bromine atom, an iodine atom, and the like.
  • the “lower acyl group” is an acyl group having a straight chain or branched chain or cyclic alkyl group or alkenyl group having a carbon number of 1 to 6.
  • an acetyl group, a propionyl group, a butyryl group, an isobutyryl group, a valeryl group, an isovaleryl group, a pivaloyl group, a hexanoyl group, an acryloyl group, a methacryloyl group, a crotonoyl group, an isocrotonoyl group, a cyclopropanoyl group, a cyclobutanoyl group, a cyclopentanoyl group, a cyclohexanoyl group, and the like can be mentioned.
  • the “lower alkoxyl group” is an alkoxyl group having a straight chain or branched chain or cyclic alkyl group having a carbon number of 1 to 6.
  • the “lower alkylthio group” is an alkylthio group having a straight chain or branched chain or cyclic alkyl group having a carbon number of 1 to 6.
  • a methylthio group, an ethylthio group, an n-propylthio group, an isopropylthio group, an n-butylthio group, an isobutylthio group, a sec-butylthio group, a tert-butylthio group, a cyclopropylthio group, a cyclobutylthio group, a cyclopentylthio group, a cyclobutylthio group, and the like can be mentioned.
  • the “lower alkylamino group” is an amino group mono- or di-substituted by the aforementioned “lower alkyl group”.
  • a methylamino group, an ethylamino group, a propylamino group, an isopropylamino group, a dimethylamino group, a diethylamino group, a dipropylamino group, a diisopropylamino group, an ethylmethylamino group, and the like can be mentioned.
  • the “lower acyloxy group” is a group wherein an oxygen atom is bonded to the carbon of the carbonyl moiety of the aforementioned “lower acyl group”.
  • an acetyloxy group, a propionyloxy group, a butyryloxy group, an isobutyryloxy group, a valeryloxy group, an isovaleryloxy group, a pivaloyloxy group, a hexanoyloxy group, an acryloyloxy group, a methacryloyloxy group, a crotonoyloxy group, an isocrotonoyloxy group, and the like can be mentioned.
  • the “lower acylamino group” is a group wherein a nitrogen atom is bonded to the carbon of the carbonyl moiety of the aforementioned “lower acyl group”.
  • the “lower alkoxycarbonyl group” is a carbonyl group having the aforementioned “lower alkoxyl group”.
  • a methoxycarbonyl group, an ethoxycarbonyl group, a propoxycarbonyl group, an isopropoxycarbonyl group, an n-butoxycarbonyl group, an isobutoxycarbonyl group, a sec-butoxycarbonyl group, a tert-butoxycarbonyl group, and the like can be mentioned.
  • the “lower alkylcarbamoyl group” is a group wherein a nitrogen atom of the aforementioned “lower alkylamino group” or “cyclic amino group”, and a carbon atom of the carbonyl group are bonded.
  • an N-methylcarbamoyl group, an N-ethylcarbamoyl group, an N,N-dimethylcarbamoyl group, a 1-pyrrolidinylcarbonyl group, a 1-piperidinylcarbonyl group, a 4-morpholinylcarbonyl group, and the like can be mentioned.
  • the “lower alkylsulfonylamino group” is a group wherein a nitrogen atom is bonded to a sulfonyl group wherein the aforementioned “lower alkyl group” is bonded to a sulfur atom.
  • a methylsulfonylamino group, an ethylsulfonylamino group, a propylsulfonylamino group, an isopropylsulfonylamino group, a butylsulfonylamino group, an isobutylsulfonylamino group, and the like can be mentioned.
  • arylsulfonylamino group is a group wherein a nitrogen atom is bonded to a sulfur atom of a sulfonyl group substituted by an aryl group.
  • a phenylsulfonylamino group, a naphthylsulfonylamino group, and the like can be mentioned.
  • aryl group examples include an aryl group having a carbon number of 6 to 14 such as a phenyl group, a naphthyl group, and the like.
  • heterocyclic group is a 5- to 14-membered monocyclic to tricyclic heterocyclic group containing, as a ring atom, 1 to 4 hetero atoms selected from an oxygen atom, a sulfur atom, and a nitrogen atom. Any carbon atom as a ring atom may be substituted by an oxo group, and a sulfur atom or a nitrogen atom may be oxidized to form an oxide. In addition, it may be condensed with a benzene ring.
  • a thiadiazolyl group an imidazolyl group, a tetrazolyl group, a piperidinyl group, a piperazinyl group, a thiazolidinyl group, and the like can be mentioned.
  • phenylene group a 1,4-phenylene group, a 1,3-phenylene group, and the like can be mentioned.
  • the “thiophenylene group” is divalent thiophene.
  • a thiophene-2,5-diyl group and the like can be mentioned.
  • the “serine protease” in the present specification is a protease having, as a catalytic residue, a serine residue having nucleophilicity.
  • trypsin, chymotrypsin, elastase, enteropeptidase, kallikrein, thrombin, factor Xa, and tryptase, and the like can be mentioned.
  • the “serine protease inhibition” in the present specification means decrease or disappearance of the aforementioned serine protease activity.
  • it is an inhibition of the activity of intestinal serine proteases such as trypsin, enteropeptidase, chymotrypsin, elastase and the like, particularly preferably inhibition of trypsin and enteropeptidase activities.
  • intestinal serine proteases such as trypsin, enteropeptidase, chymotrypsin, elastase and the like, particularly preferably inhibition of trypsin and enteropeptidase activities.
  • the serine protease inhibitor of the present invention is a dual inhibitor that simultaneously inhibits at least trypsin and enteropeptidase.
  • the diabetes in the present specification means type I diabetes mellitus and type II diabetes mellitus, with preference given to type II diabetes mellitus.
  • heteroarylcarboxylic acid ester derivative represented by formula (I) or a pharmaceutically acceptable salt thereof is preferably as follows.
  • R1, R2, R3, and R4 are each independently a hydrogen atom, a nitro group, a halogeno group, and the like, more preferably a hydrogen atom, a nitro group, a fluorine atom, a chlorine atom, a bromine atom, and the like, particularly extremely preferably a hydrogen atom, a fluorine atom, and the like.
  • the group represented by HetAr is preferably a 5- to 10-membered aromatic ring containing 1 to 3 hetero atoms, which optionally has substituent(s), and furan, thiophene, oxazole, isoxazole, thiazole, isothiazole, benzofuran, benzothiophene, benzoxazole, benzothiazole, and the like can be mentioned.
  • a 5-membered heteroaryl ring is more preferable, and furan, thiophene, oxazole, isoxazole, thiazole, isothiazole, and the like can be mentioned, and particularly preferably, furan, thiophene, thiazole, and the like can be mentioned.
  • hetero atom an oxygen atom, a sulfur atom, a nitrogen atom, and the like can be mentioned.
  • examples of the substituent include a nitro group, a halogeno group, a cyano group, a hydroxyl group, a thiol group, an amino group, a guanidino group, a formyl group, a lower alkyl group, a lower alkenyl group, a lower alkynyl group, a lower acyl group, a carboxyl group, a sulfo group, a phosphono group, a lower alkoxyl group, a lower alkylthio group, a lower alkylamino group, a lower acyloxy group, a lower acylamino group, a lower alkoxycarbonyl group, a carbamoyl group, a lower alkylcarbamoyl group, a lower alkylsulfonylamino group, a sulfamoyl group, and the like.
  • a halogeno group a hydroxyl group, an amino group, a lower alkyl group, a lower alkenyl group, a lower alkynyl group, a lower acyl group, a carboxyl group, a sulfo group, a phosphono group, a lower alkoxyl group, a lower alkylamino group, a lower alkoxycarbonyl group, a carbamoyl group, a lower alkylcarbamoyl group, a lower alkylsulfonylamino group, a sulfamoyl group, and the like can be mentioned.
  • a halogeno group a hydroxyl group, an amino group, a lower alkyl group, a lower alkoxyl group, a lower alkylamino group, and the like can be mentioned.
  • the number of the substituents is preferably 1 to 3, more preferably 1 or 2, further preferably 1.
  • the group represented by HetAr is preferably unsubstituted.
  • a group represented by HetAr is preferably a group of the following formula (III-1) or (III-2).
  • Z1 and Z2 are each independently CRa or a nitrogen atom, and Z3 is an oxygen atom, a sulfur atom or NRb, wherein Ra and Rb may be the same or different, and are each independently selected from a hydrogen atom, a nitro group, a halogeno group, a cyano group, a hydroxyl group, a thiol group, an amino group, a guanidino group, a formyl group, a lower alkyl group, a lower alkenyl group, a lower alkynyl group, a lower acyl group, a carboxyl group, a sulfo group, a phosphono group, a lower alkoxyl group, a lower alkylthio group, a lower alkylamino group, a lower acyloxy group, a lower acylamino group, a lower alkoxycarbonyl group, a carbamoyl group, a lower alkylcarb
  • Z1 is preferably CH or a nitrogen atom, and CH is particularly preferable.
  • Z2 is preferably CH.
  • Z3 is preferably an oxygen atom or a sulfur atom.
  • Ra and Rb are each independently a hydrogen atom, a halogeno group, a hydroxyl group, an amino group, a lower alkyl group, a lower alkenyl group, a lower alkynyl group, a lower acyl group, a carboxyl group, a sulfo group, a phosphono group, a lower alkoxyl group, a lower alkylamino group, a lower alkoxycarbonyl group, a carbamoyl group, a lower alkylcarbamoyl group, a lower alkylsulfonylamino group, a sulfamoyl group, and the like, and a hydrogen atom, a halogeno group, a hydroxyl group, an amino group, a lower alkyl group, a lower alkoxyl group, a lower alkylamino group, and the like are more preferable.
  • X is preferably a straight chain or branched chain lower alkylene group having a carbon number of 1 to 6 or a straight chain or branched chain lower alkenylene group having a carbon number of 2 to 4, and a straight chain or branched chain lower alkylene group having a carbon number of 1 to 5 is more preferable.
  • X is a phenylene group or a thiophenylene group, it is an unsubstituted phenylene group or an unsubstituted thiophenylene group.
  • examples of the substituent include a nitro group, a halogeno group, a cyano group, a hydroxyl group, a thiol group, an amino group, a lower alkyl group, a guanidino group, a formyl group, a lower acyl group, a carboxyl group, a sulfo group, a phosphono group, a lower alkoxyl group, a lower alkylthio group, a lower alkylamino group, a lower acyloxy group, a lower acylamino group, a lower alkoxycarbonyl group, a carbamoyl group, a lower alkylcarbamoyl group, a lower alkylsulfonylamino group, a sulfamoyl group, and the like, and a halogeno group, a hydroxyl group, an amino group,
  • Y is preferably a carbonyl group.
  • A is preferably a group represented by —OR5, a group of the following formula (II), a group of the following formula (IV), —U—CH(R6′)R7′ or —NH—N(R6′′)R7′′.
  • A is preferably a group represented by —OR5, a group of the following formula (II) or a group of the following formula (IV).
  • a group represented by the following formula (IV) is particularly preferable.
  • R5 is a hydrogen atom.
  • R6 and R7 are each independently a hydrogen atom, a hydroxyl group, a lower alkyl group, a lower alkoxyl group, and the like, and a hydrogen atom, a lower alkyl group having a carbon number of 1 to 3, or the like is particularly preferable.
  • examples of the substituent include a nitro group, a halogeno group, a cyano group, a hydroxyl group, a thiol group, an amino group, a guanidino group, a formyl group, a lower acyl group, a carboxyl group, a sulfo group, a phosphono group, a lower alkoxyl group, a lower alkylthio group, a lower alkylamino group, a lower acyloxy group, a lower acylamino group, a lower alkoxycarbonyl group, a carbamoyl group, a lower alkylcarbamoyl group, a lower alkylsulfonylamino group, an arylsulfonylamino group optionally having substituent(s), a cycloalkyl group optionally having substituent(s), an aryl group optionally having substituent(s), a cycloalkyl group optionally
  • a halogeno group, a hydroxyl group, a carboxyl group, a sulfo group, a phosphono group, a lower alkoxycarbonyl group, an aryl group optionally having substituent(s), a heterocyclic group optionally having substituent(s), an oxo group, and the like are preferable, and a hydroxyl group, a carboxyl group, a sulfo group, a lower alkoxycarbonyl group, and the like are particularly preferable.
  • the number of the substituents is preferably 1 to 3, more is preferably 1 or 2.
  • a cyclic amino group formed by R6 and R7 bonded to each other a pyrrolidinyl group, a piperidinyl group, and the like are preferable.
  • examples of the substituent include a nitro group, a halogeno group, a cyano group, a hydroxyl group, a thiol group, an amino group, a guanidino group, a formyl group, a lower alkyl group, a lower alkenyl group, a lower alkynyl group, a lower acyl group, a carboxyl group, a sulfo group, a phosphono group, a lower alkoxyl group, a lower alkylthio group, a lower alkylamino group, a lower alkoxycarbonyl group, a carbamoyl group, a lower alkylcarbamoyl group, a lower alkylsulfonylamino group, a sulfamoyl group, an oxo group, and the like.
  • a hydroxyl group, a carboxyl group, a sulfo group, a phosphono group, a lower alkoxycarbonyl group, and the like are preferable.
  • the number of the substituents is preferably 1 to 3, more preferably 1 or 2.
  • R60 is preferably a carboxyl group or a sulfo group, and a carboxyl group is particularly preferable.
  • D is preferably a lower alkylene group optionally having substituent(s), and a lower alkylene group having a carbon number of 1 to 3 is particularly preferable.
  • a group represented by D when a group represented by D has a substituent, preferable examples of the substituent include a halogeno group, a hydroxyl group, a carboxyl group, a sulfo group, a phosphono group, a lower alkoxycarbonyl group, an aryl group optionally having substituent(s), a heterocyclic group optionally having substituent(s), an oxo group, and the like, and a hydroxyl group, a carboxyl group, a sulfo group, a lower alkoxycarbonyl group, and the like are particularly preferable.
  • the number of the substituents is preferably 1 to 3, more preferably 1 or 2, further preferably 1.
  • the group represented by D is preferably unsubstituted.
  • R70 is preferably a hydrogen atom, a lower alkyl group having a carbon number of 1 to 3, a lower alkoxyl group having a carbon number of 1 to 2, or the like, and a hydrogen atom, a lower alkyl group having a carbon number of 1 to 3, and the like are particularly preferable.
  • examples of the substituent include a nitro group, a halogeno group, a cyano group, a hydroxyl group, a thiol group, an amino group, a guanidino group, a formyl group, a lower acyl group, a carboxyl group, a sulfo group, a phosphono group, a lower alkoxyl group, a lower alkylthio group, a lower alkylamino group, a lower acyloxy group, a lower acylamino group, a lower alkoxycarbonyl group, a carbamoyl group, a lower alkylcarbamoyl group, a lower alkylsulfonylamino group, an arylsulfonylamino group optionally having substituent(s), a cycloalkyl group optionally having substituent(s), an arylsulfonylamino group optionally having substituent(s), a
  • a halogeno group, a hydroxyl group, a carboxyl group, a sulfo group, a phosphono group, a lower alkoxycarbonyl group, an aryl group optionally having substituent(s), a heterocyclic group optionally having substituent(s), an oxo group, and the like are preferable, and a hydroxyl group, a carboxyl group, a sulfo group, and a lower alkoxycarbonyl group are particularly preferable.
  • the number of the substituents is preferably 1 to 3, more preferably 1 or 2, further preferably 1.
  • a pyrrolidinyl group, a piperidinyl group, and the like are preferable.
  • examples of the substituent include a nitro group, a halogeno group, a cyano group, a hydroxyl group, a thiol group, an amino group, a guanidino group, a formyl group, a lower alkyl group, a lower alkenyl group, a lower alkynyl group, a lower acyl group, a carboxyl group, a sulfo group, a phosphono group, a lower alkoxyl group, a lower alkylthio group, a lower alkylamino group, a lower alkoxycarbonyl group, a carbamoyl group, a lower alkylcarbamoyl group, a lower alkylsulfonylamino group, a sulfamoyl group, an oxo group, and the like, and a hydroxyl group,
  • a heteroarylcarboxylic acid ester derivative represented by any of the following formulas or a pharmaceutically acceptable salt thereof is preferable.
  • a heteroarylcarboxylic acid ester derivative represented by any of the following formulas or a pharmaceutically acceptable salt thereof is also preferable.
  • heteroarylcarboxylic acid ester derivative represented by the formula (I) or a pharmaceutically acceptable salt thereof the following can also be mentioned.
  • R1 is a hydrogen atom, a nitro group, a halogeno group, or a straight chain or branched chain alkoxyl group having a carbon number of 1 to 6;
  • R6 is a straight chain or branched chain alkyl group having a carbon number of 1 to 6, which optionally has 1 or 2 substituents selected from the group consisting of an aryl group having a carbon number of 6 to 14 and optionally having a hydroxyl group, a hydroxyl group, a carboxyl group, sulfo group, a phosphono group, an amino group mono- or di-substituted by a straight chain or branched chain alkyl group having a carbon number of 1 to 6 and a carbamoyl group and
  • R6 and R7 are optionally bonded to form a pyrrolidinyl group or a piperidinyl group, each of which optionally has 1 or 2 substituents selected from the group consisting of a hydroxyl group and a carboxyl group;
  • R6′ and R7′ may be the same or different and are each independently a straight chain or branched chain alkyl group having a carbon number of 1 to 6 and optionally having a carboxyl group, or a carboxyl group; or
  • R6′′ and R7′′ may be the same or different and are each independently a straight chain or branched chain alkyl group having a carbon number of 1 to 6 and optionally having a carboxyl group,
  • R1 is a hydrogen atom, a nitro group, a halogeno group or a straight chain or branched chain alkoxyl group having a carbon number of 1 to 6;
  • R6 is a straight chain or branched chain alkyl group having a carbon number of 1 to 6 and having 1 or 2 substituents selected from the group consisting of an aryl group having a carbon number of 6 to 14 and optionally having a hydroxyl group, a hydroxyl group, a carboxyl group, a sulfo group, a phosphono group, an amino group mono- or di-substituted by a straight chain or branched chain alkyl group having a carbon number of 1 to 6, and a carbamoyl group, and
  • R6 and R7 are optionally bonded to form a pyrrolidinyl group or a piperidinyl group each having 1 or 2 substituents selected from the group consisting of a hydroxyl group and a carboxyl group,
  • R6′ and R7′ may be the same or different and are each independently a straight chain or branched chain alkyl group having a carbon number of 1 to 6 and having a carboxyl group or a carboxyl group, or
  • R6′′ and R7′′ may be the same or different and are each independently a straight chain or branched chain alkyl group having a carbon number of 1 to 6 and having a carboxyl group,
  • R1 is a hydrogen atom, a nitro group, a halogeno group, or a straight chain or branched chain alkoxyl group having a carbon number of 1-6;
  • R60 is a carboxyl group, a sulfo group, phosphono group, or a hydroxyl group
  • D is a straight chain or branched chain alkylene group having a carbon number of 1 to 6 and optionally having substituent(s), and the substituent is selected from the group consisting of an aryl group having a carbon number of 6 to 14 and optionally having a hydroxyl group, a hydroxyl group, a carboxyl group, a sulfo group, and a carbamoyl group, and
  • R70 and D are optionally bonded to form a pyrrolidinyl group or a piperidinyl group each optionally having 1 or 2 substituents selected from the group consisting of a hydroxyl group and a carboxyl group,
  • serine protease inhibitory activity an activity of simultaneously inhibiting trypsin and enteropeptidase is preferable.
  • a pharmaceutically acceptable salt is preferable.
  • pharmaceutically acceptable salts for a compound having an acidic group such as a carboxyl group and the like include an ammonium salt, salts with alkali metals such as sodium, potassium, and the like, salts with alkaline earth metals such as calcium, magnesium, and the like, an aluminum salt, a zinc salt, salts with an organic amines such as triethylamine, ethanolamine, morpholine, pyrrolidine, piperidine, piperazine, dicyclohexylamine, and the like, and salts with a basic amino acid such as arginine, lysine, and the like.
  • Examples of such pharmaceutically acceptable salts for a compound having a basic group include salts with an inorganic acid such as hydrochloric acid, sulfuric acid, phosphoric acid, nitric acid, hydrobromic acid, and the like, salts with an organic carboxylic acid such as acetic acid, citric acid, benzoic acid, maleic acid, fumaric acid, tartaric acid, succinic acid, tannic acid, butyric acid, hibenzic acid (2-(4-hydroxybenzoyl)benzoic acid), pamoic acid, enanthic acid, decanoic acid, teoclic acid, salicylic acid, lactic acid, oxalic acid, mandelic acid, malic acid, and the like, and salts with an organic sulfonic acid such as methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, and the like.
  • an organic carboxylic acid such as acetic acid,
  • the compound of the present invention also encompasses all optical isomers, stereoisomers, tautomers, rotamers, and mixtures thereof at optional ratios. These can be obtained each as a single product according to a synthesis method and separation method known per se.
  • an optical isomer can be obtained by using an optically active synthesis intermediate or by optically resolving a racemate of a synthesis intermediate or final product by a conventional method.
  • the compound of the present invention also includes solvates of the compound such as hydrates, alcohol adducts, and the like.
  • the compound of the present invention may be converted to a prodrug.
  • the prodrug of the present invention means a compound that is converted in the body to produce the compound of the present invention.
  • an active form contains a carboxyl group or a phosphoric acid group, an ester thereof, amide thereof, and the like can be mentioned.
  • an active form contains a carboxyl group
  • a group to be converted to a carboxyl group by oxidative metabolism, such as a hydroxymethyl group and the like can be mentioned.
  • the active form contains an amino group
  • examples thereof include amide thereof, a carbamate thereof and the like.
  • examples thereof include esters thereof, carbonates thereof, carbamates thereof, and the like.
  • the compound of the present invention is is converted to a prodrug, it may be bonded to amino acid or saccharide.
  • the present invention also encompasses a metabolite of the compound of the present invention.
  • the metabolite of the compound of present invention means a compound resulting from the conversion of the compound of the present invention by a metabolic enzyme and the like in the body.
  • a compound wherein a hydroxyl group is introduced on the benzene ring of the compound of the present invention due to the metabolism a compound wherein glucuronic acid, glucose, or an amino acid is bonded to the carboxylic acid moiety of the compound of the present invention or a hydroxyl group is added by the metabolism, and the like can be mentioned.
  • the compound of the present invention and a pharmaceutically acceptable salt thereof have a superior blood glucose elevation suppressing action for mammals such as humans, bovines, horses, dogs, mice, rats, and the like, and can be used as a medicament, which is administered as it is or as a pharmaceutical composition containing the same mixed with a pharmaceutically acceptable carrier according to a method known per se. While oral administration is generally preferable, parenteral administration can also be employed (e.g., routes such as intravenous, subcutaneous, intramuscular, suppository, enema, ointment, patch, sublingual, eye drop, inhalation administrations, and the like).
  • a daily dose of 1 ⁇ g to 10 g for oral administration and 0.01 ⁇ g to 1 g, preferably 0.1 ⁇ g to 1 g, for parenteral administration is used, which is generally administered to an adult by an oral or parenteral route in one to several portions per day.
  • the content of the compound of the present invention in the above-mentioned pharmaceutical composition is about 0.01 wt % to 100 wt % of the whole composition.
  • Examples of the pharmaceutically acceptable carrier for the pharmaceutical composition of the present invention include various organic or inorganic carrier substances conventionally used as preparation materials.
  • an excipient, lubricant, binder, disintegrant, water-soluble polymer, and basic inorganic salt in a solid preparation; a solvent, solubilizing agents, suspending agent, isotonicity agent, buffering agent, and soothing agent in a liquid preparation, and the like can be mentioned.
  • general additives such as a preservative, antioxidant, colorant, sweetening agent, souring agent, effervescing agent, flavor, and the like can also be used.
  • the dosage form of such pharmaceutical composition may be a tablet, powder, pill, granule, capsule, suppository, solution, sugar-coated agent, depot, syrup, suspension, emulsion, troche, sublingual agent, adhesive preparation, oral disintegrant (tablet), inhalant, enema, ointment, patch, tape, or eye drop, and these can be produced using conventional formulation auxiliaries and according to a conventional method.
  • the pharmaceutical composition of the present invention can be produced according to a method conventionally used in the technical field of pharmaceutical formulation, for example, the method described in the Japanese Pharmacopoeia and the like. Specific production methods of the preparation are explained in detail in the following.
  • a excipient and, where necessary, a binder, disintegrant, lubricant, colorant, flavoring agent, and the like are further added, and the mixture is processed to give, for example, a tablet, powder, pill, granule, capsule, suppository, solution, sugar-coated agent, depot, syrup, and the like according to a conventional method.
  • the excipient include lactose, cornstarch, sucrose, glucose, sorbitol, crystalline cellulose, and the like.
  • binder examples include polyvinyl alcohol, polyvinyl ether, ethylcellulose, methylcellulose, gum arabic, tragacanth, gelatin, shellac, hydroxypropylcellulose, hydroxypropylstarch, polyvinylpyrrolidone, and the like.
  • disintegrant examples include starch, agar, gelatin powder, crystalline cellulose, calcium carbonate, sodium hydrogen carbonate, calcium citrate, dextran, pectin, and the like.
  • lubricant examples include magnesium stearate, talc, polyethylene glycol, silica, hydrogenated vegetable oil, and the like.
  • the colorant one acceptable to add to a pharmaceutical product is used, and as the flavoring agent, cocoa powder, menthol, aromatic acid, peppermint oil, borneol, powdered cinnamon bark, and the like are used. Where necessary, these tablets and granules are applied with a coating as appropriate such as sugar coating, gelatin coating, and the like.
  • a pH adjuster, buffering agent, stabilizer, preservative, and the like are added where necessary, and the mixture is processed to give subcutaneous, intramuscular, or intravenous injection according to a conventional method.
  • the compound of the present invention can be used as an agent for the treatment or prophylaxis of diabetes as mentioned above, it can also be used in combination with other therapeutic agents for diabetes and agents for the treatment or prophylaxis of diabetic complications, which are used generally.
  • the therapeutic agents for diabetes and agents for the treatment or prophylaxis of diabetic complications include combinations and mixtures of one or more kinds of insulin preparation, insulin derivative, insulin-like agent, insulin secretagogue, insulin sensitizer, biguanide, gluconeogenesis inhibitor, glucose absorption inhibitor, renal glucose reabsorption inhibitor, ⁇ 3 adrenoceptor agonist, glucagon-like peptide-1 (7-37), glucagon-like peptide-1 (7-37) analogs, glucagon-like peptide-1 receptor agonist, dipeptidyl peptidase IV inhibitor, aldose reductase inhibitor, inhibitor of advanced glycation end product formation, glycogen synthase kinase-3 inhibitor, glycogen synthase
  • a medicament to be used in combination with the compound of the present invention may be mixed to give a single agent or each may be formulated into separate preparations, or prepared into a combination preparation (set, kit, pack) obtained by packaging each of the separately formulated preparations in one container.
  • the administration form of combined use is not particularly limited and, for example, (1) administration as a single preparation, (2) simultaneous administration of separate preparations by the same administration route, (3) administration of separate preparations in a staggered manner by the same administration route, (4) simultaneous administration of separate preparations by different administration routes, (5) administration of separate preparations in a staggered manner by different administration routes, and the like can be mentioned.
  • the compound of the present invention is also useful even when contained in food.
  • a food composition containing the compound of the present invention is useful as a food for the treatment or prophylaxis of diabetes.
  • the “food” of the present invention means general foods, which include food for specified health uses and food with nutrient function claims defined by Food with Health Claims of Consumer Affairs Agency, Government of Japan, in addition to general foods including so-called health food, and further encompasses dietary supplements.
  • the form of the food composition of the present invention is not particularly limited, and the composition may take any form as long as it can be orally ingested.
  • Examples thereof include powder, granule, tablet, hard capsules, soft capsule, liquid (drinks, jelly drinks, and the like), candy, chocolate, and the like, all of which can be produced according to a method known per se in the technical field.
  • the content of the compound of the present invention in the food composition is appropriately determined to afford an appropriate dose within the indicated range.
  • the food composition of the present invention can use other food additives as necessary.
  • food additives include those generally used as components of health foods such as a fruit juice, dextrin, cyclic oligosaccharide, saccharides (monosaccharides such as fructose, glucose, and the like, and polysaccharides), acidulant, flavor, powdered green tea, and the like, which are used for controlling and improving taste, emulsifier, collagen, whole milk powder, polysaccharide thickener, agar, and the like, which are used for improving texture, and further, vitamins, eggshell calcium, calcium pantothenate, the other minerals, royal jelly, propolis, honey, dietary fiber, Agaricus, chitin, chitosan, flavonoids, carotenoids, lutein, traditional Japanese herbal medicine, chondroitin, various amino acids, and the like.
  • Heteroarylcarboxylic acid ester derivative (F) represented by the formula (I) wherein X is a lower alkylene group or a lower alkenylene group, A is —OR5, and R5 is a lower alkyl group can be produced as follows.
  • Alkenylene derivative (C) can be synthesized by reacting aldehyde (A) (wherein E 1 is a protecting group such as a methyl group, an ethyl group, a tert-butyl group, a benzyl group, and the like) with Wittig reagent (B) (wherein X′ is X or a group capable of chemically converting to X together with methyne between HetAr and X′ in (C)) in, for example, a solvent that does not adversely influence the reaction, such as tetrahydrofuran and the like, in the presence of, for example, a base such as sodium hydride and the like.
  • A aldehyde
  • E 1 is a protecting group such as a methyl group, an ethyl group, a tert-butyl group, a benzyl group, and the like
  • Wittig reagent (B) wherein X′ is X or
  • Alkenylene derivative (C) can be converted to carboxylic acid derivative (D) by deprotection such as hydrolysis and the like in, for example, a solvent that does not adversely influence the reaction, such as tetrahydrofuran, methanol, and the like, by using, for example, a base such as sodium hydroxide and the like.
  • Objective heteroarylcarboxylic acid ester derivative (F) wherein X is a lower alkenylene group can be produced by esterifying carboxylic acid derivative (D) with amidinophenol derivative (E).
  • heteroarylcarboxylic acid ester derivative (F) wherein X is a lower alkylene group can be produced by, during any stage in the production steps, conducting a step of treating with a catalyst such as 10% palladium/carbon under a hydrogen atmosphere in, for example, a solvent that does not adversely influence the reaction such as methanol, ethanol, ethyl acetate, and the like.
  • a catalyst such as 10% palladium/carbon under a hydrogen atmosphere
  • a solvent that does not adversely influence the reaction such as methanol, ethanol, ethyl acetate, and the like.
  • the esterification reaction can be performed by a known method which is, for example, (1) a method using acid halide, (2) a method using a condensation agent, and the like.
  • the method using acid halide is performed, for example, by reacting an acid chloride obtained by reaction with thionyl chloride, oxalyl chloride, and the like in a solvent that does not adversely influence the reaction, such as dichloromethane and the like, or without solvent in the presence or absence of, for example, a catalyst such as N,N-dimethylformamide and the like, with alcohol in a solvent that does not adversely influence the reaction such as dichloromethane, tetrahydrofuran, and the like in the presence of a base such as pyridine and triethylamine.
  • a solvent that does not adversely influence the reaction such as dichloromethane and the like
  • a catalyst such as N,N-dimethylformamide and the like
  • the method using a condensation agent is performed, for example, by reacting carboxylic acid with alcohol in, for example, a solvent that does not adversely influence the reaction such as tetrahydrofuran, N,N-dimethylformamide, dichloromethane, and the like in, for example, the presence or absence of a base such as pyridine, triethylamine, and the like, by using a condensation agent such as 1-ethyl-3-(3′-dimethylaminopropyl)carbodiimide (WSC), 1,3-dicyclohexylcarbodiimide, and the like.
  • a condensation agent such as 1-ethyl-3-(3′-dimethylaminopropyl)carbodiimide (WSC), 1,3-dicyclohexylcarbodiimide, and the like.
  • Heteroarylcarboxylic acid ester derivative (i) of the formula (I) wherein A is —OR5 and R5 is a hydrogen atom can be produced by subjecting ester derivative (H) obtained by using Wittig reagent (G) (wherein E 2 is a protecting group such as a methyl group, an ethyl group, an isopropyl group, a tert-butyl group, a benzyl group, and the like) instead of Wittig reagent (B) to, for example, deprotection by hydrolysis with a base such as sodium hydroxide and the like, hydrolysis with an acid such as hydrochloric acid, trifluoroacetic acid and the like, or treating with, for example, 10% palladium/carbon and the like under a hydrogen atmosphere, and the like.
  • Wittig reagent (G) wherein E 2 is a protecting group such as a methyl group, an ethyl group, an isopropyl group, a
  • heteroarylcarboxylic acid ester derivative (K) of the formula (I) wherein A is a group of the formula (II) can be produced by amidating carboxylic acid, thiocarboxylic acid, or sulfonic acid derivative (i) with amine (J).
  • the amidation reaction of carboxylic acid and thiocarboxylic acid derivative is performed using the corresponding amine instead of alcohol and in the same manner as in the aforementioned esterification reaction.
  • the amidation reaction of the sulfonic acid derivative is performed using the corresponding amine instead of alcohol in the same manner as in (1) the method using acid halide for the aforementioned esterification reaction.
  • heteroarylcarboxylic acid ester derivative (K) of the formula (I) wherein A is a group of the formula (II) can also be produced as follows.
  • Carboxylic acid, thiocarboxylic acid, or sulfonic acid derivative (M) can be obtained by deprotecting ester, thioester, or sulfonic acid ester derivative (L) by, for example, hydrolysis with a base such as sodium hydroxide and the like, hydrolysis with an acid such as hydrochloric acid, trifluoroacetic acid, and the like or treatment with, for example, 10% palladium/carbon and the like under a hydrogen atmosphere.
  • Amide derivative (N) can be synthesized by amidating carboxylic acid, thiocarboxylic acid, or sulfonic acid derivative (M) with amine (J).
  • Amide derivative (N) can be converted to carboxylic acid derivative (O) by hydrolysis in, for example, a solvent that does not adversely influence the reaction, such as tetrahydrofuran, methanol, and the like, by using, for example, a base such as sodium hydroxide and the like.
  • the objective heteroarylcarboxylic acid ester derivative (K) can be produced by esterifying carboxylic acid derivative (O) with amidinophenol derivative (E).
  • heteroarylcarboxylic acid ester derivative (S) of the formula (I) wherein Y is a thiocarbonyl group and A is a group of the formula (II) can also be produced as follows.
  • Thioamide derivative (Q) can be synthesized by reacting amide derivative (P) with Lawesson's reagent and the like in, for example, a solvent that does not adversely influence the reaction such as toluene and the like.
  • Thioamide derivative (Q) can be converted to carboxylic acid derivative (R) by hydrolysis in, for example, a solvent that does not adversely influence the reaction, such as tetrahydrofuran, methanol, and the like, by using, for example, a base such as sodium hydroxide and the like.
  • the objective heteroarylcarboxylic acid ester derivative (S) can be produced by esterifying carboxylic acid derivative (R) with amidinophenol derivative (E).
  • step 1 The crude product obtained in step 1 was dissolved in toluene (3.0 mL), acrylic acid tert-butyl ester (173 ⁇ L, 1.19 mmol) was added, and the mixture was stirred under reflux for 6 hours. The solvent was evaporated under reduced pressure, and crudely purified by silica gel column chromatography (0-4% methanol/dichloromethane mixed solvent) to give the title compound as a crude product.
  • A-3 (87 mg, 0.20 mmol) was dissolved in thionyl chloride (500 ⁇ L), and the mixture was stirred at 70° C. for 10 minutes. Thionyl chloride was evaporated under reduced pressure to give acid chloride. The obtained acid chloride was dissolved in dichloromethane (500 ⁇ L), the amine obtained in step 2 and pyridine (250 ⁇ L) were added thereto, and the mixture was stirred at room temperature for 30 minutes. After evaporation of the solvent, trifluoroacetic acid (500 ⁇ L: containing 5% water) was added, and the mixture was stirred at room temperature overnight.
  • Trifluoroacetic acid was evaporated under reduced pressure, saturated aqueous sodium hydrogen carbonate solution (1 mL) was added, and the mixture was stirred for 1 hour.
  • the object product was extracted by high performance liquid chromatography (5-35% water (containing 0.1% trifluoroacetic acid)/acetonitrile (containing 0.1% trifluoroacetic acid) mixed solution) to give the title compound (4.0 mg, 0.007 mmol, 3.5%).
  • A-3 (49 mg, 0.11 mmol) was dissolved in thionyl chloride (0.5 mL), and the mixture was heated at 70° C. for 5 minutes. Thionyl chloride was evaporated under reduced pressure, and the obtained residue was dissolved in dichloromethane (0.35 mL). Glutamic acid di-tert-butyl ester hydrochloride (50.8 mg, 0.17 mmol) and pyridine (0.15 ml) were added, and the mixture was stirred at room temperature for 40 minutes. The solvent was evaporated under reduced pressure, trifluoroacetic acid (0.5 mL: containing 5% water) was added, and the mixture was stirred at room temperature for 2 hours.
  • step 1 The crude product obtained in step 1 and 10% palladium/carbon (30 mg) were suspended in ethanol (3.0 mL), and the suspension was stirred overnight at ambient temperature and normal pressure under a hydrogen atmosphere. Palladium/carbon was removed by celite filtration, and the solvent was evaporated under reduced pressure to give the title compound as a crude product.
  • step 2 The crude product obtained in step 2 and 4-hydroxybenzamidine hydrochloride (180 mg, 1.04 mmol) were dissolved in pyridine (3.0 mL), and WSC hydrochloride (217 mg, 1.13 mmol) was added with stirring at room temperature. After stirring at room temperature for 100 minutes, the solvent was evaporated under reduced pressure. Trifluoroacetic acid (3.0 mL) was added to the obtained residue, and the mixture was stirred at room temperature for 15 minutes.
  • step 1 5-Ethoxycarbonylfuran-2-ylacetic acid (0.61 g, 3.08 mmol) obtained in step 1 was dissolved in thionyl chloride (10 mL), and the mixture was stirred at 70° C. for 1 hour. The solvent was evaporated under reduced pressure, tert-butanol (5 ml) and triethylamine (2 mL) were added, and the mixture was stirred for 30 minutes. The solvent was evaporated, and the residue was purified by silica gel column chromatography to give the title compound (0.37 g).
  • step 1 To 5-[(1E)-2-(tert-butoxycarbonyl)-2-methyl-prop-1-en-1-yl]thiophene-2-carboxylic acid methyl ester (600 mg, 2.13 mmol) obtained in Example 12, step 1 was added trifluoroacetic acid (5 mL), and the mixture was stirred at room temperature for 10 minutes. The reaction mixture was concentrated under reduced pressure. The obtained residue was dissolved in dichloromethane (15 ml), oxalyl chloride (0.37 ml, 4.26 mmol) and N,N-dimethylformamide (50 ⁇ L) were added, and the mixture was stirred at room temperature for 15 minutes.
  • step 1 The compound (477 mg, 0.86 mmol) obtained in step 1 was dissolved in tetrahydrofuran (15 mL) and methanol (3 mL), and water (1 mL), and 1N aqueous sodium hydroxide solution (1.0 mL, 1.0 mmol) were added thereto. After stirring at room temperature for 22 hours, 1N aqueous sodium hydroxide solution (0.43 mL, 0.43 mmol) was added to the reaction mixture, and the mixture was further stirred for 4 hours. 1N Aqueous sodium hydroxide solution (1.2 mL, 1.2 mmol) was added to the reaction mixture, and the mixture was stirred for 3 hours and acidified with 1N hydrochloric acid. To the reaction mixture was added saturated brine, and the mixture was extracted three times with dichloromethane. The extract was dried over sodium sulfate, and the solvent was evaporated under reduced pressure to give a residue (430 mg).
  • the compounds B-13 to B-15 shown in the following Table 2 were each synthesized using M-1 to M-16 and commercially available reagents and by an operation in the same manner as in the above-mentioned Example 28.
  • CHIRALCEL registered trademark
  • the optically active S form (105 mg, 0.39 mmol) obtained in step 1 was dissolved in ethanol (1.3 mL), 1N aqueous lithium hydroxide solution (1 mol/L, 0.47 mL, 0.47 mmol) was added, and the mixture was stirred at room temperature for 4 hours.
  • 1N Hydrochloric acid (0.47 mL) was added to the reaction mixture, and the mixture was concentrated under reduced pressure.
  • 0.5N Hydrochloric acid and ethyl acetate were added to the obtained residue, the organic layer was extracted, and the aqueous layer was extracted three times with ethyl acetate. The organic layers were collected, washed with saturated brine, and dried by dehydration with sodium sulfate. After filtration, the solvent of the filtrate was evaporated under reduced pressure.
  • the optically active R form (130 mg, 0.48 mmol) obtained in Example 31, step 1 was dissolved in ethanol (1.0 mL), 1N aqueous lithium hydroxide solution (1 mol/L, 0.73 mL, 0.73 mmol) was added, and the mixture was stirred at room temperature for 2 hours.
  • 1N Hydrochloric acid (0.73 mL) was added to the reaction mixture, and the mixture was concentrated under reduced pressure.
  • 0.5N Hydrochloric acid and ethyl acetate were added to the obtained residue, the organic layer was extracted, and the aqueous layer was extracted three times with ethyl acetate. The organic layers were collected, washed with saturated brine, and dried by dehydration with sodium sulfate. After filtration, the solvent of the filtrate was evaporated under reduced pressure.
  • A-41 (31 mg, 0.072 mmol) was dissolved in thionyl chloride (500 ⁇ L), and the mixture was stirred at 70° C. for 20 minutes.
  • Thionyl chloride was evaporated under reduced pressure, and the obtained residue and L-aspartic acid di-tert-butyl ester hydrochloride (30.4 mg, 0.11 mmol) were dissolved in dichloromethane (350 ⁇ L). Pyridine (150 ⁇ L) was added, and the mixture was stirred at room temperature overnight.
  • the reaction mixture was concentrated under reduced pressure, trifluoroacetic acid (500 ⁇ L) was added to the obtained residue, and the mixture was stirred at room temperature for 30 minutes.
  • A-42 (30.8 mg, 0.072 mmol) was dissolved in thionyl chloride (500 ⁇ L), and the mixture was stirred at 70° C. for 20 minutes.
  • Thionyl chloride was evaporated under reduced pressure, and the obtained residue and L-aspartic acid di-tert-butyl ester hydrochloride (30.3 mg, 0.11 mmol) were dissolved in dichloromethane (350 ⁇ L). Pyridine (150 ⁇ L) was added, and the mixture was stirred at room temperature overnight.
  • the reaction mixture was concentrated under reduced pressure, trifluoroacetic acid (500 ⁇ L) was added to the obtained residue, and the mixture was stirred at room temperature for 30 minutes.
  • A-41 (31 mg, 0.072 mmol) was dissolved in thionyl chloride (500 ⁇ L), and the mixture was stirred at 70° C. for 20 minutes. Thionyl chloride was evaporated under reduced pressure, and the obtained residue and D-aspartic acid dibenzyl ester tosylate (56.7 mg, 0.12 mmol) were dissolved in dichloromethane (350 ⁇ L). Pyridine (150 ⁇ L) was added, and the mixture was stirred at room temperature for 2 hours. The reaction mixture was concentrated under reduced pressure, and the obtained residue was dissolved in ethanol (1 mL). 10% Palladium/carbon (5 mg) was added, and the mixture was stirred at room temperature overnight under a hydrogen atmosphere.
  • A-42 (34.4 mg, 0.080 mmol) was dissolved in thionyl chloride (500 ⁇ L), and the mixture was stirred at 70° C. for 20 minutes. Thionyl chloride was evaporated under reduced pressure, and the obtained residue and D-aspartic acid dibenzyl ester tosylate (58.2 mg, 0.12 mmol) were dissolved in dichloromethane (350 ⁇ L). Pyridine (150 ⁇ L) was added, and the mixture was stirred at room temperature for 2 hours. The reaction mixture was concentrated under reduced pressure, and the obtained residue was dissolved in ethanol (1 mL). 10% Palladium/carbon (5 mg) was added, and the mixture was stirred at room temperature overnight under a hydrogen atmosphere.
  • A-6 (30 mg, 0.07 mmol), nipecotic acid tert-butyl ester (13 mg, 0.07 mmol), and WSC hydrochloride (63 mg, 0.33 mmol) were dissolved in pyridine (3 mL), and the mixture was stirred at room temperature overnight. The solvent was evaporated under reduced pressure, trifluoroacetic acid (3 mL) was added, and the mixture was stirred at room temperature for 30 minutes. The solvent was evaporated under reduced pressure and the residue was purified by high performance liquid chromatography to give the title compound (20 mg).
  • ⁇ -Alanine tert-butyl ester hydrochloride (1.0 g, 5.5 mmol) was dissolved in dichloromethane (10 ml), triethylamine (1.52 mL, 11.1 mmol) and bromoacetic acid tert-butyl ester (0.57 g, 2.9 mmol) were added, and the mixture was stirred for 2 hours. The solvent was evaporated, and the residue was purified by high performance liquid chromatography. To the fraction containing the object product was added 0.1N hydrochloric acid (30 mL), and the mixture was freeze-dried to give the title compound (0.52 g).
  • step 2 To 5-(2-tert-butoxycarbonylethenyl)furan-2-carboxylic acid benzyl ester (0.15 g, 0.46 mmol) obtained in Example 41, step 2 was added trifluoroacetic acid (3 ml), and the mixture was stirred for 30 minutes. The solvent was evaporated under reduced pressure to give the title compound.
  • A-37 (31.5 mg, 0.076 mmol) was dissolved in thionyl chloride (500 ⁇ L), and the mixture was stirred at room temperature for 30 minutes.
  • the reaction mixture was concentrated under reduced pressure, M-21 (38.9 mg, 0.23 mmol), dichloromethane (300 ⁇ L), and pyridine (200 ⁇ L) were added to the obtained residue, and the mixture was stirred at room temperature for 25 minutes.
  • the reaction mixture was concentrated under reduced pressure, trifluoroacetic acid (containing 5% water, 500 ⁇ L) was added to the obtained residue, and the mixture was stirred at room temperature for 35 minutes.
  • step 1 The compound (0.5 g, 1.45 mmol) obtained in step 1 was dissolved in methanol (5 mL) and chloroform (0.5 ml), palladium hydroxide (0.1 g) was added, and the mixture was stirred at room temperature overnight under a hydrogen atmosphere. The reaction mixture was filtered through celite, and the solvent was evaporated under reduced pressure to give the title compound.
  • the reaction mixture was concentrated under reduced pressure, and the obtained residue was purified by high performance liquid chromatography (acetonitrile-water, each containing 0.1% trifluoroacetic acid, 5-35%) to give the title compound (25.5 mg, 0.047 mmol, 55%).
  • step 2 To a solution of the compound (149 mg, 0.435 mmol) obtained in step 2 in ethanol (3 mL) was added 5% palladium/carbon (15 mg), and the mixture was stirred under a hydrogen atmosphere for 9 hours. The catalyst was filtered off, and the solvent was evaporated under reduced pressure. The obtained residue was purified by high performance liquid chromatography (water-acetonitrile, each containing 0.1% trifluoroacetic acid) to give the title compound (75 mg, 0.30 mmol, 68%).
  • step 3 To the compound (75 mg, 0.30 mmol) obtained in step 3, 4-amidinophenol hydrochloride (56 mg, 0.32 mmol), and WSC hydrochloride (68 mg, 0.35 mmol) was added pyridine (1.5 mL), and the mixture was stirred at room temperature overnight. The reaction mixture was concentrated under reduced pressure, and the obtained residue was purified by high performance liquid chromatography (water-acetonitrile, each containing 0.1% trifluoroacetic acid) to give the title compound (80 mg, 0.16 mmol, 55%).
  • step 4 To the compound (77 mg, 0.16 mmol) obtained in step 4 were added 4N hydrochloric acid (1 mL) and 1,4-dioxane (1 ml), and the mixture was stirred at 60° C. for 5 hours. The reaction mixture was concentrated under reduced pressure, and the obtained residue was purified by high performance liquid chromatography (water-acetonitrile, each containing 0.1% trifluoroacetic acid) to give the title compound (33 mg, 0.072 mmol, 46%).
  • 3-Furfural (0.96 g, 10 mmol) was dissolved in toluene (10 mL), N,N′-dimethylethylenediamine (1.08 mL, 10.0 mmol) and p-toluenesulfonic acid monohydrate (10 mg, 0.11 mmol) were added, and the mixture was stirred at 105° C. overnight.
  • the solvent was evaporated under reduced pressure and the residue was partitioned between ethyl acetate and 5% aqueous sodium hydrogen carbonate solution.
  • the organic layer was washed with saturated brine, and dried over anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure.
  • step 1 Using diethylphosphonoacetic acid tert-butyl ester instead of M-13 and in the same manner as in Example 55, step 1, the title compound was synthesized.
  • the aqueous layer was acidified with 1N hydrochloric acid, and the mixture was extracted with ethyl acetate.
  • the ethyl acetate layer was washed with saturated brine, dried over anhydrous sodium sulfate and concentrated under reduced pressure to give the title compound as a pale-yellow powder (0.58 g, 2.3 mmol, 91%).
  • step 2 To the carboxylic acid obtained by using the compound (100 mg, 0.41 mmol) obtained in step 1 and 4-amidinophenol hydrochloride (70 mg, 0.41 mmol) instead of B-6 and M-18, and by an operation in the same manner as in Example 46, step 2 were added L-aspartic acid di-tert-butyl ester hydrochloride (114 mg, 0.41 mmol), WSC hydrochloride (93 mg, 0.48 mmol), and pyridine (5 mL), and the mixture was stirred at room temperature overnight. The reaction mixture was concentrated under reduced pressure, and trifluoroacetic acid (5 mL) was added to the obtained residue.
  • L-aspartic acid di-tert-butyl ester hydrochloride 114 mg, 0.41 mmol
  • WSC hydrochloride 93 mg, 0.48 mmol
  • pyridine pyridine
  • A-6 (34.5 mg, 0.08 mmol) was dissolved in thionyl chloride (500 ⁇ L), and the mixture was stirred at 70° C. for 15 minutes.
  • the reaction mixture was concentrated under reduced pressure, D-malic acid dibenzyl ester (37.8 mg, 0.12 mmol), dichloromethane (350 ⁇ L), and pyridine (150 ⁇ L) were added to the obtained residue, and the mixture was stirred at room temperature for 25 minutes.
  • the reaction mixture was concentrated under reduced pressure, water was added, and the mixture was freeze-dried overnight. After freeze-drying, palladium/carbon (10 mg) and ethanol (1 mL) were added, and the mixture was stirred at room temperature for 3 hours.
  • the reaction mixture was filtered through celite to remove palladium/carbon.
  • the filtrate was concentrated under reduced pressure, and the obtained residue was purified by high performance liquid chromatography (acetonitrile-water, each containing 0.1% trifluoroacetic acid, 15-55%) to give the title compound (14.4 mg, 0.026 mmol, 33%).
  • A-6 (30 mg, 0.070 mmol) was dissolved in thionyl chloride (500 ⁇ L), and the mixture was stirred at 60° C. for 10 minutes.
  • the reaction mixture was concentrated under reduced pressure, and thiomalic acid diethyl ester (21.6 mg, 0.105 mmol), dichloromethane (350 ⁇ L), and pyridine (150 ⁇ L) were added to the obtained residue, and the mixture was stirred at room temperature for 45 minutes.
  • the reaction mixture was concentrated under reduced pressure, and the obtained residue was purified by high performance liquid chromatography (acetonitrile-water, each containing 0.1% trifluoroacetic acid, 5-45%) to give the title compound (40 mg, 0.065 mmol, 93%).
  • Benzyloxycarbonylhydrazine (3.0 g, 18 mmol), bromoacetic acid tert-butyl ester (7.9 mL, 54 mmol), and diisopropylethylamine (6.3 ml, 36 mmol) were dissolved in toluene (30 mL), and the mixture was stirred at 75° C. overnight. After allowing to cool to room temperature, saturated brine was added, and the mixture was extracted three times with dichloromethane.
  • step 2 To the compound (15 mg, 0.056 mmol) obtained in step 2 were added A-6 (20 mg, 0.046 mmol), WSC hydrochloride (13 mg, 0.070 mmol), and pyridine (1 mL), and the mixture was stirred at room temperature overnight. The reaction mixture was concentrated under reduced pressure, and trifluoroacetic acid (1 mL) was added to the obtained residue. After stirring at room temperature for 2 hours, the reaction mixture was concentrated under reduced pressure, and the obtained residue was purified by high performance liquid chromatography (water-acetonitrile, each containing 0.1% trifluoroacetic acid) to give the title compound (13 mg, 0.023 mmol, 50%).
  • 2,2′-Bithiophene (0.50 g, 3.0 mmol) was dissolved in tetrahydrofuran (10 mL), n-butyllithium (2.76 M hexane solution, 2.4 mL, 6.6 mmol) was added at room temperature under an argon atmosphere, and the mixture was stirred at 50° C. for 30 minutes. After cooling to room temperature, carbon dioxide was blown into the reaction mixture. The reaction mixture was concentrated under reduced pressure and the obtained residue was washed with hexane to give a yellow powder (0.97 g) containing a lithium salt of the title compound as a main component. The obtained powder was dissolved in water and acidified with 1N hydrochloric acid, and the precipitate was collected by filtration to give the title compound as a green powder (0.55 g, 2.2 mmol, 72%).
  • step 1 To the compound (0.20 g, 0.79 mmol) obtained in step 1, 4-amidinophenol hydrochloride (0.14 g, 0.79 mmol), and WSC hydrochloride (0.18 g, 0.94 mmol) was added pyridine (10 mL), and the mixture was stirred at room temperature overnight.
  • L-aspartic acid di-tert-butyl ester hydrochloride (0.22 g, 0.79 mmol) and WSC hydrochloride (0.18 g, 0.79 mmol) were added to the reaction mixture, and the mixture was further stirred at room temperature overnight.
  • the reaction mixture was concentrated under reduced pressure, and trifluoroacetic acid (2 mL) was added to the obtained residue.
  • step 1 The compound (4.5 g, 20 mmol) obtained in step 1 was dissolved in tetrahydrofuran (30 mL), and 2.5M n-butyllithium/hexane solution (16 mL, 40 mmol) was added dropwise at ⁇ 78° C. The reaction mixture was stirred at ⁇ 78° C. for 35 minutes, N,N-dimethylformamide (4 mL) was added dropwise, and the mixture was stirred at ⁇ 30° C. for 1 hour. The reaction mixture was neutralized with water and 2N hydrochloric acid, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel chromatography to give the title compound (1.6 g).
  • step 3 The compound (0.5 g, 1.4 mmol) obtained in step 3 was dissolved in ethanol (20 ml), palladium/carbon (0.1 g) was added, and the mixture was stirred at 50° C. for 20 hours under a hydrogen atmosphere (55 psi). The reaction mixture was filtered, and the solvent was evaporated under reduced pressure to give the title compound (0.3 g).
  • step 1 The compound (0.45 g, 1.51 mmol) obtained in step 1 was dissolved in trifluoroacetic acid (10 mL), and the mixture was stirred for 1 hour. The solvent was evaporated to give a white solid (0.36 g). The white solid (0.26 g, 1.06 mmol) was dissolved in dichloromethane (15 mL), oxalyl chloride (0.15 mL, 1.75 mmol) and N,N-dimethylformamide (1 drop) were added, and the mixture was stirred for 10 minutes.
  • step 2 The compound (0.4 g, 0.85 mmol) obtained in step 2 was dissolved in methanol (9 mL) and chloroform (1 mL), palladium hydroxide (0.08 g) was added, and the mixture was stirred at room temperature overnight under a hydrogen atmosphere. The reaction mixture was filtered through celite, and the solvent was evaporated. The residue was dissolved in methanol (1 mL), 1N aqueous lithium hydroxide solution (1.55 ml) was added, and the mixture was stirred for 3 hours. The mixture was neutralized with 1N hydrochloric acid, and extracted with ethyl acetate. The reaction mixture was concentrated under reduced pressure, and the obtained residue was purified by high performance liquid chromatography (acetonitrile-water, each containing 0.1% trifluoroacetic acid) to give the title compound (0.26 g).
  • 1,3-Dimethyl-2-(3-methylthiophen-2-yl)imidazolidine (3.1 g, 15.8 mmol) obtained in step 1 was dissolved in tetrahydrofuran (80 mL), 2.76N n-butyllithium/hexane solution (6.9 mL) was added dropwise at ⁇ 78° C., and the mixture was stirred for 30 minutes. Dry ice was added to the reaction mixture, and the mixture was stirred at room temperature for 1 hour.
  • N-allyl-L-aspartic acid di-tert-butyl ester was dissolved in acetonitrile (10 mL), and water (17 mL) and 1N hydrochloric acid (1.8 mL, 1.8 mmol) were added. The solution was concentrated under reduced pressure and freeze-dried to give the title compound (0.54 g, 1.7 mmol, 47%).
  • step 2 The crude product obtained in step 2 was dissolved in thionyl chloride (3.0 mL), and the mixture was stirred at 60° C. for 30 minutes.
  • the reaction mixture was concentrated under reduced pressure, L-aspartic acid dimethyl ester hydrochloride (460 mg, 2.33 mmol), dichloromethane (1.0 ml), and pyridine (2.0 mL) were added to the obtained residue, and the mixture was stirred at room temperature for 1 hour.
  • the reaction mixture was concentrated under reduced pressure, trifluoroacetic acid (3.0 mL) was added to the obtained residue, and the mixture was stirred at room temperature for 5 hours.
  • Compound B-37 shown in the following Table 2 was synthesized using M-20 and by an operation in the same manner as in the above-mentioned Example 18.
  • Compound B-36 shown in the following Table 2 was synthesized using M-1 to M-23 and commercially available reagents and by an operation in the same manner as in the above-mentioned Example 35.
  • the compounds B-30, B-31, and B-34 shown in the following Table 2 were each synthesized using M-1 to M-23 and commercially available reagents and by an operation in the same manner as in the above-mentioned Example 40.
  • Compound B-45 shown in the following Table 2 was synthesized using M-1 to M-23 and commercially available reagents and by an operation in the same manner as in the above-mentioned Examples 44 and 46.
  • Compound B-46 shown in the following Table 2 was synthesized using M-1 to M-23 and commercially available reagents and by an operation in the same manner as in the above-mentioned Examples 44 and 47.
  • Compound A-70 shown in the following Table 2 was synthesized using M-1 to M-23 and commercially available reagents and by an operation in the same manner as in the above-mentioned Examples 47 and 57.
  • the compounds B-47 and B-48 shown in the following Table 2 were each synthesized using M-1 to M-23 and commercially available reagents and by an operation in the same manner as in the above-mentioned Example 48.
  • the compounds B-49 and B-50 shown in the following Table 2 were each synthesized using M-1 to M-23 and commercially available reagents and by an operation in the same manner as in the above-mentioned Example 49.
  • Compound B-55 shown in the following Table 2 was synthesized using M-1 to M-23 and commercially available reagents and by an operation in the same manner as in the above-mentioned Examples 55 and 56.
  • Compound B-58 shown in the following Table 2 was synthesized using M-1 to M-23 and commercially available reagents and by an operation in the same manner as in the above-mentioned Example 58.
  • the compounds B-62, B-65, and B-66 shown in the following Table 2 were each synthesized using M-11, M-23, and commercially available reagents and by an operation in the same manner as in the above-mentioned Example 33.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Furan Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Compounds represented by formula (I):
Figure US08609715-20131217-C00001
wherein each symbol is as defined in the description, and pharmaceutically acceptable salts thereof are useful as hyperglycemic inhibitors having a serine protease inhibitory action and as prophylactic or therapeutic drugs for diabetes.

Description

CROSS REFERENCES TO RELATED APPLICATIONS
This application is a continuation of International Patent Application No. PCT/JP2010/071929, filed on Dec. 7, 2010, and claims priority to Japanese Patent Application No. 2009-277827, filed on Dec. 7, 2009, and Japanese Patent Application No. 2010-214406, filed on Sep. 24, 2010, all of which are incorporated herein by reference in their entireties.
BACKGROUND OF THE INVENTION
1. Field of the Invention Description
The present invention relates to novel heteroarylcarboxylic acid ester derivatives having a serine protease (particularly trypsin and enteropeptidase) inhibitory activity. The present invention also relates to pharmaceutical compositions which contain such a heteroarylcarboxylic acid ester derivative and drugs for the treatment or prophylaxis of diabetes. The present invention further relates to methods for the treatment and/or prophylaxis of diabetes by administering such a heteroarylcarboxylic acid ester derivative.
2. Discussion of the Background
At present, insulin secretagogues (sulfonylurea), glucose absorption inhibitors (α-glucosidase inhibitor), insulin sensitizers (biguanide, thiazolidine derivative), and the like are clinically used as therapeutic drugs for diabetes. However, since all of them are accompanied by side effects such as hypoglycemia, diarrhea, lactic acidosis, edema, and the like, show an insufficient effect, and the like, a medicament satisfying clinical needs is still demanded.
In recent years, a benzoic acid ester having a protease inhibitory activity, which is represented by the following compound, has been reported to show a blood glucose elevation suppressing action in diabetes animal model (see WO2006/057152, which is incorporated herein by reference in its entirety). The following compound is considered to show an enzyme inhibitory activity on trypsin, thrombin, pancreatic, and plasma kallikreins, plasmin and the like and a leukotriene receptor antagonistic action. Moreover, an enteropeptidase inhibitory activity of the following compound has also been reported (see Biomedical Research (2001), 22(5) 257-260, which is incorporated herein by reference in its entirety). However, many unclear points remain in the relationship between such actions and a blood glucose elevation suppressing action.
Figure US08609715-20131217-C00002
On the other hand, as for a heteroarylcarboxylic acid ester structure, JP-A-55-161385, which is incorporated herein by reference in its entirety, discloses a compound as a therapeutic drug for pancreatitis. In this document, only heteroarylcarboxylic acid ester compounds wherein the substituent of the heteroarylcarboxylic acid moiety is a methyl group or a methoxy group or unsubstituted compounds are disclosed, as represented by the following formula. While these compounds are disclosed as showing an inhibitory activity on trypsin, chymotrypsin and thrombin, no description is given as to the enteropeptidase inhibitory activity and blood glucose elevation suppressing action.
Figure US08609715-20131217-C00003
In addition, Advances in Experimental Medicine and Biology (1989), 247B (Kinins 5, Pt. B), 271-6, which is incorporated herein by reference in its entirety, also describes a heteroarylcarboxylic acid ester having a protease inhibitory activity, which is represented by the following formula. However, only compounds wherein the heteroaryl moiety is unsubstituted are disclosed, and no description is given as to the enteropeptidase inhibitory activity and blood glucose elevation suppressing action of these compounds.
Figure US08609715-20131217-C00004
Furthermore, WO99/41231, which is incorporated herein by reference in its entirety, describes a compound represented by the following formula. However, it has a structure wherein an aryl group substituted by a carboxyl group is directly bonded to the heteroaryl moiety, which is completely different from the compound of the present invention. The document discloses an inhibitory activity against blood coagulation factor VIIa; however, no description is given as to the enteropeptidase inhibitory activity and blood glucose elevation suppressing action.
Figure US08609715-20131217-C00005
On the other hand, trypsin is one of the intestinal serine proteases and is produced by degradation of inactive trypsinogen by enteropeptidase. Trypsin is known to activate various digestive enzymes by acting on chymotrypsinogen, proelastase, procarboxylesterase, procolipase and pro-sucrase-isomaltase, and the like. Therefore, it is considered that an inhibitor of enteropeptidase and trypsin lowers the digestive capacity for protein, lipid, and carbohydrates, and is effective as a drug for the treatment or prophylaxis of obesity and hyperlipidemia.
WO2006/050999, which is incorporated herein by reference in its entirety describes that a medicament that inhibits both enteropeptidase and trypsin is interesting as a body fat-reducing agent. In addition, WO2009/071601, which is incorporated herein by reference in its entirety reports a compound having an inhibitory activity against enteropeptidase, trypsin, plasmin, kallikrein, and the like as an antiobesity drug. However, neither of these publications describe suppression of blood glucose elevation and hypoglycemic effect afforded by simultaneous inhibition of enteropeptidase and trypsin, and the protease inhibitor described therein has a structure completely different from that of the compound of the present invention.
Accordingly, there remains a need for compounds which are useful for the treatment or prophylaxis of diabetes. Therefore, to further satisfy the clinical needs from the aspects of effect, safety and the like, a hyperglycemic inhibitor having a serine protease inhibitory action, which is a new drug for the treatment or prophylaxis of diabetes, is desired.
SUMMARY OF THE INVENTION
Accordingly, it is one object of the present invention to provide novel compounds which are useful for the treatment or prophylaxis of diabetes.
It is another object of the present invention to provide novel compounds having a serine protease inhibitory action.
It is another object of the present invention to provide novel serine protease (particularly trypsin and enteropeptidase) inhibitors.
It is another object of the present invention to provide novel hyperglycemic inhibitors or hypoglycemic agents, and further, drug for the treatment and/or prophylaxis of any of diabetes, obesity, hyperlipidemia, diabetic complication, and metabolic syndrome.
It is another object of the present invention to provide novel methods for the treatment and/or prophylaxis of any of diabetes, obesity, hyperlipidemia, diabetic complication, and metabolic syndrome.
These and other objects, which will become apparent during the following detailed description, have been achieved by the inventors' discovery that the heteroarylcarboxylic acid ester derivatives described below have serine protease inhibitory activity and are useful for the treatment and/or prophylaxis of any of diabetes, obesity, hyperlipidemia, diabetic complication, and metabolic syndrome.
Thus, in view of the above-mentioned current situation, the present inventors have conducted intensive studies and considered that simultaneous inhibition of trypsin and enteropeptidase is particularly effective for the suppression of blood glucose elevation. They have synthesized various heteroarylcarboxylic acid ester derivatives, which are novel compounds, evaluated trypsin and enteropeptidase inhibitory activity, and found that certain heteroarylcarboxylic acid ester derivatives are protease inhibitors that simultaneously inhibit them, which resulted in the completion of the present invention. Furthermore, they have also found that such representative compounds show a blood glucose elevation suppressing effect in diabetes animal model.
Accordingly, the present invention provides a heteroarylcarboxylic acid ester derivative represented by the following formula (I):
Figure US08609715-20131217-C00006
wherein
R1, R2, R3, and R4 may be the same or different and are each independently a hydrogen atom, a nitro group, a halogeno group, a cyano group, a hydroxyl group, a thiol group, an amino group, a guanidino group, a formyl group, a lower alkyl group, a lower alkenyl group, a lower alkynyl group, a lower acyl group, a carboxyl group, a sulfo group, a phosphono group, a lower alkoxyl group, a lower alkylthio group, a lower alkylamino group, a lower acyloxy group, a lower acylamino group, a lower alkoxycarbonyl group, a carbamoyl group, a lower alkylcarbamoyl group, a lower alkylsulfonylamino group, or a sulfamoyl group,
HetAr is a heteroaromatic ring optionally having substituent(s),
X is a lower alkylene group optionally having substituent(s), a lower alkenylene group optionally having substituent(s), a lower alkynylene group optionally having substituent(s), a phenylene group, or a thiophenylene group,
Y is a carbonyl group, a thiocarbonyl group, or a sulfonyl group, and
A is —OR5 (R5 is a hydrogen atom or a lower alkyl group);
a group of the following formula (II):
Figure US08609715-20131217-C00007
wherein R6 and R7 may be the same or different and are each independently a hydrogen atom, a hydroxyl group, a lower alkyl group optionally having substituent(s), a lower alkenyl group optionally having substituent(s), a lower alkynyl group optionally having substituent(s) or a lower alkoxyl group optionally having substituent(s), or R6 and R7 may be bonded to form a cyclic amino group optionally having substituent(s);
a group of the following formula (II-2):
—U—CH(R6′)R7′  (II-2)
wherein U is O or S, and R6′ and R7′ may be the same or different and are each independently a hydrogen atom, a hydroxyl group, a carboxyl group, a lower alkyl group optionally having substituent(s), a lower alkenyl group optionally having substituent(s), a lower alkynyl group optionally having substituent(s) or a lower alkoxyl group optionally having substituent(s), or R6′ and R7′ may be bonded to form a cyclic amino group optionally having substituent(s); or
a group of the following formula (II-3):
—NH—N(R6″)R7″  (II-3)
wherein R6″ and R7″ may be the same or different and are each independently a hydrogen atom, a hydroxyl group, a lower alkyl group optionally having substituent(s), a lower alkenyl group optionally having substituent(s), a lower alkynyl group optionally having substituent(s) or a lower alkoxyl group optionally having substituent(s), or R6″ and R7″ may be bonded to form a cyclic amino group optionally having substituent(s),
or a pharmaceutically acceptable salt thereof (hereinafter sometimes to be simply referred to as “the compound of the present invention”), a pharmaceutical composition containing the same, or a serine protease inhibitor containing the same as an active ingredient.
The present invention also provides a compound represented by the aforementioned formula (I) wherein
R1, R2, R3, and R4 may be the same or different and are each independently a hydrogen atom, a nitro group, a halogeno group, a cyano group, a hydroxyl group, a thiol group, an amino group, a guanidino group, a formyl group, a lower alkyl group, a lower alkenyl group, a lower alkynyl group, a lower acyl group, a carboxyl group, a sulfo group, a phosphono group, a lower alkoxyl group, a lower alkylthio group, a lower alkylamino group, a lower acyloxy group, a lower acylamino group, a lower alkoxycarbonyl group, a carbamoyl group, a lower alkylcarbamoyl group, a lower alkylsulfonylamino group, or a sulfamoyl group,
HetAr is a heteroaromatic ring optionally having substituent(s),
X is a lower alkylene group optionally having substituent(s), a lower alkenylene group optionally having substituent(s), or a lower alkynylene group optionally having substituent(s),
Y is a carbonyl group, a thiocarbonyl group, or a sulfonyl group, and
A is —OR5 (R5 is a hydrogen atom or a lower alkyl group), or a group of the following formula (II):
Figure US08609715-20131217-C00008
wherein R6 and R7 may be the same or different and are each independently a hydrogen atom, a hydroxyl group, a lower alkyl group optionally having substituent(s), a lower alkenyl group optionally having substituent(s), a lower alkynyl group optionally having substituent(s) or a lower alkoxyl group optionally having substituent(s), or R6 and R7 may be bonded to form a cyclic amino group optionally having substituent(s),
or a pharmaceutically acceptable salt thereof.
The present invention also provides a compound represented by the aforementioned formula (I) wherein R1, R2, R3, and R4 are each independently a hydrogen atom, a nitro group or a halogeno group,
or a pharmaceutically acceptable salt thereof.
The present invention also provides a compound represented by the aforementioned formula (I) wherein HetAr is a 5- to 10-membered aromatic ring containing 1 to 3 hetero atoms, which optionally has substituent(s),
or a pharmaceutically acceptable salt thereof.
The present invention also provides a compound represented by the aforementioned formula (I) wherein -HetAr— is a heteroaromatic ring group represented by the following formula (III-1) or (III-2):
Figure US08609715-20131217-C00009
wherein Z1 and Z2 are each independently CRa or a nitrogen atom, and Z3 is an oxygen atom, a sulfur atom, or NRb, wherein Ra and Rb may be the same or different and are each independently a hydrogen atom, a nitro group, a halogeno group, a cyano group, a hydroxyl group, a thiol group, an amino group, a guanidino group, a formyl group, a lower alkyl group, a lower alkenyl group, a lower alkynyl group, a lower acyl group, a carboxyl group, a sulfo group, a phosphono group, a lower alkoxyl group, a lower alkylthio group, a lower alkylamino group, a lower acyloxy group, a lower acylamino group, a lower alkoxycarbonyl group, a carbamoyl group, a lower alkylcarbamoyl group, a lower alkylsulfonylamino group, or a sulfamoyl group,
or a pharmaceutically acceptable salt thereof.
The present invention also provides a compound represented by the aforementioned formula (I) wherein -HetAr— is a group containing a heteroaromatic ring group represented by the formula (III-1) or (III-2), and
in the formulas (III-1) and (III-2), Z1 and Z2 are each independently CRa or a nitrogen atom, and Z3 is an oxygen atom or a sulfur atom,
or a pharmaceutically acceptable salt thereof.
The present invention also provides a compound represented by the aforementioned formula (I) wherein X is a lower alkylene group optionally having substituent(s) or a lower alkenylene group optionally having substituent(s), and the substituent is selected from the group consisting of a halogeno group, a hydroxyl group, an amino group, a lower alkyl group, a lower alkoxyl group, and a lower acyl group,
or a pharmaceutically acceptable salt thereof.
The present invention also provides a compound represented by the aforementioned formula (I) wherein Y is a carbonyl group or a sulfonyl group,
or a pharmaceutically acceptable salt thereof.
The present invention also provides a compound represented by the aforementioned formula (I) wherein A is —OR5 (R5 is a hydrogen atom or a lower alkyl group),
or a pharmaceutically acceptable salt thereof.
The present invention also provides a compound represented by the aforementioned formula (I) wherein A is a group of the following formula (IV):
Figure US08609715-20131217-C00010
wherein R60 is a carboxyl group, a sulfo group, a phosphono group, a lower alkoxycarbonyl group, or a hydroxyl group,
D is a lower alkylene group optionally having substituent(s), a lower alkenylene group optionally having substituent(s), or a lower alkynylene group optionally having substituent(s), wherein the substituent is selected from the group consisting of a nitro group, a halogeno group, a cyano group, a hydroxyl group, a thiol group, an amino group, a guanidino group, a formyl group, a lower acyl group, a carboxyl group, a sulfo group, a phosphono group, a lower alkoxyl group, a lower alkylthio group, a lower alkylamino group, a lower acyloxy group, a lower acylamino group, a lower alkoxycarbonyl group, a carbamoyl group, a lower alkylcarbamoyl group, a lower alkylsulfonylamino group, an arylsulfonylamino group optionally having substituent(s), a cycloalkyl group optionally having substituent(s), an aryl group optionally having substituent(s), an aryloxy group optionally having substituent(s), an arylthio group optionally having substituent(s), an aralkyl group optionally having substituent(s), an aralkyloxy group optionally having substituent(s), an aralkylthio group optionally having substituent(s), a heterocyclic group optionally having substituent(s), a heterocyclic oxy group optionally having substituent(s), a heterocyclic thio group optionally having substituent(s), and an oxo group, and
R70 is a hydrogen atom, a hydroxyl group, a lower alkyl group optionally having substituent(s) or a lower alkoxyl group optionally having substituent(s), or R70 and D may be bonded to form a cyclic amino group optionally having substituent(s),
or a pharmaceutically acceptable salt thereof.
The present invention also provides a compound represented by the aforementioned formula (I) wherein
A is a group of the aforementioned formula (IV),
in the group of the formula (IV), R60 is a carboxyl group, a sulfo group, a lower alkoxycarbonyl group, or a hydroxyl group,
D is a lower alkylene group optionally having substituent(s), wherein the substituent is selected from the group consisting of a halogeno group, a hydroxyl group, a thiol group, an amino group, a guanidino group, a carboxyl group, a sulfo group, a lower alkoxyl group, a lower alkylthio group, a lower alkylamino group, a lower acylamino group, a lower alkoxycarbonyl group, a carbamoyl group, a lower alkylcarbamoyl group, a lower alkylsulfonylamino group, an arylsulfonylamino group optionally having substituent(s), an aryl group optionally having substituent(s), a heterocyclic group optionally having substituent(s), and an oxo group, and
R70 is a hydrogen atom, a hydroxyl group, a lower alkyl group optionally having substituent(s), or a lower alkoxyl group optionally having substituent(s), or R70 and D may be bonded to form a cyclic amino group optionally having substituent(s),
or a pharmaceutically acceptable salt thereof.
The present invention also provides a compound represented by the aforementioned formula (I) wherein R1, R2, R3, and R4 are each independently a hydrogen atom, a nitro group, or a fluorine atom, and
HetAr is furan, thiophene, or thiazole each optionally having substituent(s),
or a pharmaceutically acceptable salt thereof.
The present invention also provides an intestinal serine protease inhibitor, comprising the above-mentioned heteroarylcarboxylic acid ester derivative, or a pharmaceutically acceptable salt thereof as an active ingredient.
The present invention also provides a dual inhibitor of trypsin and enteropeptidase, comprising the above-mentioned heteroarylcarboxylic acid ester derivative, or a pharmaceutically acceptable salt thereof as an active ingredient.
The present invention also provides a hyperglycemic inhibitor or hypoglycemic agent, comprising the above-mentioned heteroarylcarboxylic acid ester derivative, or a pharmaceutically acceptable salt thereof as an active ingredient.
The present invention also provides a prophylactic or therapeutic drug for diabetes, comprising the above-mentioned heteroarylcarboxylic acid ester derivative, or a pharmaceutically acceptable salt thereof as an active ingredient.
The present invention also provides an insulin sensitizer comprising the above-mentioned heteroarylcarboxylic acid ester derivative, or a pharmaceutically acceptable salt thereof as an active ingredient.
The present invention also provides a prophylactic or therapeutic drug for obesity, hyperlipidemia, diabetic complication or metabolic syndrome, comprising the above-mentioned heteroarylcarboxylic acid ester derivative, or a pharmaceutically acceptable salt thereof as an active ingredient.
The present invention also provides a method for preventing or treating diabetes, comprising administering an effective amount of the above-mentioned heteroarylcarboxylic acid ester derivative, or a pharmaceutically acceptable salt thereof.
The present invention also provides a method for improving insulin resistance, comprising administering an effective amount of the above-mentioned heteroarylcarboxylic acid ester derivative, or a pharmaceutically acceptable salt thereof.
The present invention also provides a method for preventing or treating obesity, hyperlipidemia, diabetic complication or metabolic syndrome, comprising administering an effective amount of the above-mentioned heteroarylcarboxylic acid ester derivative, or a pharmaceutically acceptable salt thereof.
The present invention also provides use of the above-mentioned heteroarylcarboxylic acid ester derivative, or a pharmaceutically acceptable salt thereof for the prophylaxis or treatment of diabetes.
The present invention also provides use of the above-mentioned heteroarylcarboxylic acid ester derivative, or a pharmaceutically acceptable salt thereof for the improvement of insulin resistance.
The present invention also provides use of the above-mentioned heteroarylcarboxylic acid ester derivative, or a pharmaceutically acceptable salt thereof for the prophylaxis or treatment of obesity, hyperlipidemia, diabetic complication or metabolic syndrome.
The compound of the present invention has a blood glucose elevation suppressing action and can be preferably used as a drug for the treatment or prophylaxis of diabetes.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
The present invention is explained in detail in the following.
In the present specification, the phrase “optionally having substituent(s)” means “being substituted or unsubstituted”. Unless otherwise specified, the position and number of the substituents may be any, and are not particularly limited. When substituted by two or more substituents, the substituents may be the same or different. Examples of the substituent include a nitro group, a halogeno group, a cyano group, a hydroxyl group, a thiol group, an amino group, a guanidino group, a formyl group, a phenyl group, a lower alkyl group, a lower alkenyl group, a lower alkynyl group, a lower acyl group, a carboxyl group, a sulfo group, a phosphono group, a lower alkoxyl group, a lower alkylthio group, a lower alkylamino group, a lower alkoxycarbonyl group, a carbamoyl group, a lower alkylcarbamoyl group, a lower alkylsulfonylamino group, a sulfamoyl group, and the like.
In the present specification, examples of the substituent of the “arylsulfonylamino group optionally having substituent(s)”, “cycloalkyl group optionally having substituent(s)”, “aryl group optionally having substituent(s)”, “aryloxy group optionally having substituent(s)”, “arylthio group optionally having substituent(s)”, “aralkyl group optionally having substituent(s)”, “aralkyloxy group optionally having substituent(s)”, “aralkylthio group optionally having substituent(s)”, “heterocyclic group optionally having substituent(s)”, “heterocyclic oxy group optionally having substituent(s)” and “heterocyclic thio group optionally having substituent(s)” include a nitro group, a halogeno group, a cyano group, a hydroxyl group, a thiol group, an amino group, a guanidino group, a formyl group, a lower alkyl group, a lower alkenyl group, a lower alkynyl group, a lower acyl group, a carboxyl group, a sulfo group, a phosphono group, a lower alkoxyl group, a lower alkylthio group, a lower alkylamino group, a lower alkoxycarbonyl group, a carbamoyl group, a lower alkylcarbamoyl group, a lower alkylsulfonylamino group, a sulfamoyl group, and the like.
The “heteroaromatic ring” in the present specification is a 5- to 10-membered aromatic ring optionally containing 1 to 3 hetero atoms such as a nitrogen atom, an oxygen atom, a sulfur atom, and the like, and examples thereof include a monocycle, and a fused aromatic ring wherein two aromatic rings are fused. Examples of the monocycle include furan, thiophene, pyrrole, oxazole, isoxazole, thiazole, isothiazole, imidazole, pyrazole, oxadiazole, thiadiazole, pyridine, pyridazine, pyrimidine, pyrazine, and the like. Examples of the fused aromatic ring include indole, isoindole, benzofuran, benzothiophene, indolizine, quinoline, isoquinoline, purine, 1H-indazole, quinazoline, cinnoline, quinoxaline, phthalazine, pteridine, benzoxazole, benzothiazole, benzimidazole, and the like.
The “cyclic amino group” in the present specification is a saturated or unsaturated cyclic amino group having a carbon number of 2 to 7, which may contain one or more hetero atoms in the ring, such as a nitrogen atom, an oxygen atom, a sulfur atom, and the like. For example, a pyrrolidinyl group, a pyrrolinyl group, a piperidinyl group, a morpholinyl group, a piperazinyl group, a thiomorpholinyl group, a piperidinonyl group, a piperazinonyl group and the like can be mentioned.
The “lower alkyl group” is a straight chain or branched chain or cyclic alkyl group having a carbon number of 1 to 6. For example, a methyl group, an ethyl group, an n-propyl group, an n-butyl group, an n-pentyl group, an n-hexyl group, an isopropyl group, an isobutyl group, a sec-butyl group, a tert-butyl group, an isopentyl group, a tert-pentyl group, a neopentyl group, a 2-pentyl group, a 3-pentyl group, a 2-hexyl group, a cyclopropyl group, a cyclopentyl group, and the like can be mentioned.
The “lower alkenyl group” is a straight chain or branched chain alkenyl group having a carbon number of 2 to 6, which includes each isomer. For example, a vinyl group, an allyl group, a propenyl group, a butenyl group, a pentenyl group, a hexenyl group, and the like can be mentioned.
The “lower alkynyl group” is a straight chain or branched chain alkynyl group having a carbon number of 2 to 6, which includes each isomer. For example, an ethynyl group, a 1-propynyl group, a 2-propynyl group, a 2-butynyl group, a 3-butynyl group, a pentynyl group, and the like can be mentioned.
The “lower alkylene group” is a straight chain or branched chain or cyclic alkylene group having a carbon number of 1 to 6, with preference given to a straight chain or a branched chain. For example, a methylene group, an ethylene group, an n-propylene group (—(CH2)3—), an n-butylene group (—(CH2)4—), an n-pentylene group (—(CH2)5—), an n-hexylene group (—(CH2)6—), an isopropylene group, an isobutylene group, an isopentylene group, —CH2—CH(CH3)—, —CH2—CH(CH2CH3)—, —CH2—CH(CH2CH2CH3)—, —CH2—CH(CH3)—CH2CH2—, —CH2—CH(CH(CH3)2)—, —CH(CH2CH3)—, —CH(CH3)—, —CH2—C(CH3)2—, and the like can be mentioned.
The “lower alkenylene group” is a straight chain or branched chain alkenylene group having a carbon number of 2 to 6, which includes each isomer. For example, a vinylene group, a 1-propenylene group, a 2-propenylene group, a 2-butenylene group, a 3-butenylene group, a pentenylene group, a hexenylene group, —CH═C(CH3)—, and the like can be mentioned.
The “lower alkynylene group” is a straight chain or branched chain alkynylene group having a carbon number of 2 to 6, which includes each isomer. For example, an ethynylene group, a 1-propynylene group, a 2-propynylene group, a 2-butynylene group, a 3-butynylene group, a pentynylene group, and the like can be mentioned.
Examples of the “halogeno group” include a fluorine atom, a chlorine atom, a bromine atom, an iodine atom, and the like.
The “lower acyl group” is an acyl group having a straight chain or branched chain or cyclic alkyl group or alkenyl group having a carbon number of 1 to 6. For example, an acetyl group, a propionyl group, a butyryl group, an isobutyryl group, a valeryl group, an isovaleryl group, a pivaloyl group, a hexanoyl group, an acryloyl group, a methacryloyl group, a crotonoyl group, an isocrotonoyl group, a cyclopropanoyl group, a cyclobutanoyl group, a cyclopentanoyl group, a cyclohexanoyl group, and the like can be mentioned.
The “lower alkoxyl group” is an alkoxyl group having a straight chain or branched chain or cyclic alkyl group having a carbon number of 1 to 6. For example, a methoxy group, an ethoxy group, an n-propoxy group, an n-butoxy group, an n-pentyloxy group, an n-hexyloxy group, an isopropoxy group, an isobutoxy group, a sec-butoxy group, a tert-butoxy group, a cyclopropyloxy group, a cyclobutyloxy group, a cyclopentyloxy group, and a cyclohexyloxy group can be mentioned.
The “lower alkylthio group” is an alkylthio group having a straight chain or branched chain or cyclic alkyl group having a carbon number of 1 to 6. For example, a methylthio group, an ethylthio group, an n-propylthio group, an isopropylthio group, an n-butylthio group, an isobutylthio group, a sec-butylthio group, a tert-butylthio group, a cyclopropylthio group, a cyclobutylthio group, a cyclopentylthio group, a cyclobutylthio group, and the like can be mentioned.
The “lower alkylamino group” is an amino group mono- or di-substituted by the aforementioned “lower alkyl group”. For example, a methylamino group, an ethylamino group, a propylamino group, an isopropylamino group, a dimethylamino group, a diethylamino group, a dipropylamino group, a diisopropylamino group, an ethylmethylamino group, and the like can be mentioned.
The “lower acyloxy group” is a group wherein an oxygen atom is bonded to the carbon of the carbonyl moiety of the aforementioned “lower acyl group”. For example, an acetyloxy group, a propionyloxy group, a butyryloxy group, an isobutyryloxy group, a valeryloxy group, an isovaleryloxy group, a pivaloyloxy group, a hexanoyloxy group, an acryloyloxy group, a methacryloyloxy group, a crotonoyloxy group, an isocrotonoyloxy group, and the like can be mentioned.
The “lower acylamino group” is a group wherein a nitrogen atom is bonded to the carbon of the carbonyl moiety of the aforementioned “lower acyl group”. For example, an acetylamino group, a propionylamino group, a butyrylamino group, an isobutyrylamino group, a valerylamino group, an isovalerylamino group, a pivaloylamino group, a hexanoylamino group, an acryloylamino group, a methacryloylamino group, a crotonoylamino group, an isocrotonoylamino group, and the like can be mentioned.
The “lower alkoxycarbonyl group” is a carbonyl group having the aforementioned “lower alkoxyl group”. For example, a methoxycarbonyl group, an ethoxycarbonyl group, a propoxycarbonyl group, an isopropoxycarbonyl group, an n-butoxycarbonyl group, an isobutoxycarbonyl group, a sec-butoxycarbonyl group, a tert-butoxycarbonyl group, and the like can be mentioned.
The “lower alkylcarbamoyl group” is a group wherein a nitrogen atom of the aforementioned “lower alkylamino group” or “cyclic amino group”, and a carbon atom of the carbonyl group are bonded. For example, an N-methylcarbamoyl group, an N-ethylcarbamoyl group, an N,N-dimethylcarbamoyl group, a 1-pyrrolidinylcarbonyl group, a 1-piperidinylcarbonyl group, a 4-morpholinylcarbonyl group, and the like can be mentioned.
The “lower alkylsulfonylamino group” is a group wherein a nitrogen atom is bonded to a sulfonyl group wherein the aforementioned “lower alkyl group” is bonded to a sulfur atom. For example, a methylsulfonylamino group, an ethylsulfonylamino group, a propylsulfonylamino group, an isopropylsulfonylamino group, a butylsulfonylamino group, an isobutylsulfonylamino group, and the like can be mentioned.
The “arylsulfonylamino group” is a group wherein a nitrogen atom is bonded to a sulfur atom of a sulfonyl group substituted by an aryl group. For example, a phenylsulfonylamino group, a naphthylsulfonylamino group, and the like can be mentioned.
Examples of the “aryl group” include an aryl group having a carbon number of 6 to 14 such as a phenyl group, a naphthyl group, and the like.
The “heterocyclic group” is a 5- to 14-membered monocyclic to tricyclic heterocyclic group containing, as a ring atom, 1 to 4 hetero atoms selected from an oxygen atom, a sulfur atom, and a nitrogen atom. Any carbon atom as a ring atom may be substituted by an oxo group, and a sulfur atom or a nitrogen atom may be oxidized to form an oxide. In addition, it may be condensed with a benzene ring. For example, a pyridyl group, a pyridazinyl group, a pyrimidinyl group, a pyrazinyl group, a furyl group, a thienyl group, a pyrrolyl group, an isoxazolyl group, an oxazolyl group, an isothiazolyl group, a thiazolyl group, a pyrazolyl group, an imidazolyl group, an oxadiazolyl group, a thiadiazolyl group, a triazolyl group, a tetrazolyl group, a benzofuranyl group, a benzothienyl group, an indolyl group, an isoindolyl group, a benzoxazolyl group (=a benzooxazolyl group), a benzothiazolyl group, a benzimidazolyl group (=a benzoimidazolyl group), an indazolyl group, a benzisoxazolyl group, a benzisothiazolyl group, a benzofurazanyl group, a benzothiadiazolyl group, a purinyl group, a quinolinyl group, an isoquinolyl group, a cinnolinyl group, a phthalazinyl group, a quinazolinyl group, a quinoxalinyl group, a pteridinyl group, an imidazooxazolyl group, an imidazothiazolyl group, an imidazoimidazolyl group, a dibenzofuranyl group, a dibenzothienyl group, a carbazolyl group, an acridinyl group, a pyrrolidinyl group, a pyrazolidinyl group, an imidazolidinyl group, a pyrrolinyl group, a pyrazolinyl group, an imidazolinyl group, a tetrahydrofuranyl group, a tetrahydrothiophenyl group, a thiazolidinyl group, a piperidinyl group, a piperazinyl group, a quinuclidinyl group, a tetrahydropyranyl group, a tetrahydrothiopyranyl group, a morpholinyl group, a thiomorpholinyl group, a dioxolanyl group, a homopiperidinyl group, a homopiperazinyl group, an indolinyl group, an isoindolinyl group, a chromanyl group, an isochromanyl group, a tetrahydronaphthyridinyl group, an azaindolyl group, and the like can be mentioned. Preferably, a thiadiazolyl group, an imidazolyl group, a tetrazolyl group, a piperidinyl group, a piperazinyl group, a thiazolidinyl group, and the like can be mentioned.
As the “phenylene group”, a 1,4-phenylene group, a 1,3-phenylene group, and the like can be mentioned.
The “thiophenylene group” is divalent thiophene. For example, a thiophene-2,5-diyl group and the like can be mentioned.
The “serine protease” in the present specification is a protease having, as a catalytic residue, a serine residue having nucleophilicity. For example, trypsin, chymotrypsin, elastase, enteropeptidase, kallikrein, thrombin, factor Xa, and tryptase, and the like can be mentioned. In addition, the “serine protease inhibition” in the present specification means decrease or disappearance of the aforementioned serine protease activity. Preferably, it is an inhibition of the activity of intestinal serine proteases such as trypsin, enteropeptidase, chymotrypsin, elastase and the like, particularly preferably inhibition of trypsin and enteropeptidase activities.
The serine protease inhibitor of the present invention is a dual inhibitor that simultaneously inhibits at least trypsin and enteropeptidase.
The diabetes in the present specification means type I diabetes mellitus and type II diabetes mellitus, with preference given to type II diabetes mellitus.
In the present invention, the heteroarylcarboxylic acid ester derivative represented by formula (I) or a pharmaceutically acceptable salt thereof is preferably as follows.
In formula (I), preferably, R1, R2, R3, and R4 are each independently a hydrogen atom, a nitro group, a halogeno group, and the like, more preferably a hydrogen atom, a nitro group, a fluorine atom, a chlorine atom, a bromine atom, and the like, particularly extremely preferably a hydrogen atom, a fluorine atom, and the like.
In formula (I), the group represented by HetAr is preferably a 5- to 10-membered aromatic ring containing 1 to 3 hetero atoms, which optionally has substituent(s), and furan, thiophene, oxazole, isoxazole, thiazole, isothiazole, benzofuran, benzothiophene, benzoxazole, benzothiazole, and the like can be mentioned. A 5-membered heteroaryl ring is more preferable, and furan, thiophene, oxazole, isoxazole, thiazole, isothiazole, and the like can be mentioned, and particularly preferably, furan, thiophene, thiazole, and the like can be mentioned.
Here, as the hetero atom, an oxygen atom, a sulfur atom, a nitrogen atom, and the like can be mentioned.
In addition, when a group represented by HetAr has a substituent, examples of the substituent include a nitro group, a halogeno group, a cyano group, a hydroxyl group, a thiol group, an amino group, a guanidino group, a formyl group, a lower alkyl group, a lower alkenyl group, a lower alkynyl group, a lower acyl group, a carboxyl group, a sulfo group, a phosphono group, a lower alkoxyl group, a lower alkylthio group, a lower alkylamino group, a lower acyloxy group, a lower acylamino group, a lower alkoxycarbonyl group, a carbamoyl group, a lower alkylcarbamoyl group, a lower alkylsulfonylamino group, a sulfamoyl group, and the like. Preferably, a halogeno group, a hydroxyl group, an amino group, a lower alkyl group, a lower alkenyl group, a lower alkynyl group, a lower acyl group, a carboxyl group, a sulfo group, a phosphono group, a lower alkoxyl group, a lower alkylamino group, a lower alkoxycarbonyl group, a carbamoyl group, a lower alkylcarbamoyl group, a lower alkylsulfonylamino group, a sulfamoyl group, and the like can be mentioned. More preferably, a halogeno group, a hydroxyl group, an amino group, a lower alkyl group, a lower alkoxyl group, a lower alkylamino group, and the like can be mentioned. The number of the substituents is preferably 1 to 3, more preferably 1 or 2, further preferably 1. In addition, the group represented by HetAr is preferably unsubstituted.
A group represented by HetAr is preferably a group of the following formula (III-1) or (III-2).
Figure US08609715-20131217-C00011
wherein Z1 and Z2 are each independently CRa or a nitrogen atom, and Z3 is an oxygen atom, a sulfur atom or NRb, wherein Ra and Rb may be the same or different, and are each independently selected from a hydrogen atom, a nitro group, a halogeno group, a cyano group, a hydroxyl group, a thiol group, an amino group, a guanidino group, a formyl group, a lower alkyl group, a lower alkenyl group, a lower alkynyl group, a lower acyl group, a carboxyl group, a sulfo group, a phosphono group, a lower alkoxyl group, a lower alkylthio group, a lower alkylamino group, a lower acyloxy group, a lower acylamino group, a lower alkoxycarbonyl group, a carbamoyl group, a lower alkylcarbamoyl group, a lower alkylsulfonylamino group, and a sulfamoyl group.
In groups of the formulas (III-1) and (III-2), Z1 is preferably CH or a nitrogen atom, and CH is particularly preferable.
In groups of the formulas (III-1) and (III-2), Z2 is preferably CH.
In groups of the formulas (III-1) and (III-2), Z3 is preferably an oxygen atom or a sulfur atom.
In groups of the formulas (III-1) and (III-2), preferably, Ra and Rb are each independently a hydrogen atom, a halogeno group, a hydroxyl group, an amino group, a lower alkyl group, a lower alkenyl group, a lower alkynyl group, a lower acyl group, a carboxyl group, a sulfo group, a phosphono group, a lower alkoxyl group, a lower alkylamino group, a lower alkoxycarbonyl group, a carbamoyl group, a lower alkylcarbamoyl group, a lower alkylsulfonylamino group, a sulfamoyl group, and the like, and a hydrogen atom, a halogeno group, a hydroxyl group, an amino group, a lower alkyl group, a lower alkoxyl group, a lower alkylamino group, and the like are more preferable.
In the formula (I), X is preferably a straight chain or branched chain lower alkylene group having a carbon number of 1 to 6 or a straight chain or branched chain lower alkenylene group having a carbon number of 2 to 4, and a straight chain or branched chain lower alkylene group having a carbon number of 1 to 5 is more preferable.
When X is a phenylene group or a thiophenylene group, it is an unsubstituted phenylene group or an unsubstituted thiophenylene group.
In the formula (I), when a group represented by X has a substituent, examples of the substituent include a nitro group, a halogeno group, a cyano group, a hydroxyl group, a thiol group, an amino group, a lower alkyl group, a guanidino group, a formyl group, a lower acyl group, a carboxyl group, a sulfo group, a phosphono group, a lower alkoxyl group, a lower alkylthio group, a lower alkylamino group, a lower acyloxy group, a lower acylamino group, a lower alkoxycarbonyl group, a carbamoyl group, a lower alkylcarbamoyl group, a lower alkylsulfonylamino group, a sulfamoyl group, and the like, and a halogeno group, a hydroxyl group, an amino group, a lower alkyl group, a lower acyl group, a carboxyl group, a sulfo group, a phosphono group, a lower alkoxyl group, a lower alkylthio group, a lower alkylamino group, a lower acyloxy group, a lower acylamino group, a lower alkoxycarbonyl group, a carbamoyl group, a lower alkylcarbamoyl group, a lower alkylsulfonylamino group, a sulfamoyl group, and the like are preferable. The number of the substituents is preferably 1 to 3, more preferably 1 or 2, further preferably 1. In addition, the group represented by X is preferably unsubstituted.
In the formula (I), Y is preferably a carbonyl group.
In the formula (I), A is preferably a group represented by —OR5, a group of the following formula (II), a group of the following formula (IV), —U—CH(R6′)R7′ or —NH—N(R6″)R7″.
In addition, in the formula (I), A is preferably a group represented by —OR5, a group of the following formula (II) or a group of the following formula (IV). Among these, a group represented by the following formula (IV) is particularly preferable.
Figure US08609715-20131217-C00012
When the group represented by A is —OR5, preferred as R5 is a hydrogen atom.
In a group of formula (II), preferably, R6 and R7 are each independently a hydrogen atom, a hydroxyl group, a lower alkyl group, a lower alkoxyl group, and the like, and a hydrogen atom, a lower alkyl group having a carbon number of 1 to 3, or the like is particularly preferable.
Here, when a group represented by R6 or R7 has a substituent, examples of the substituent include a nitro group, a halogeno group, a cyano group, a hydroxyl group, a thiol group, an amino group, a guanidino group, a formyl group, a lower acyl group, a carboxyl group, a sulfo group, a phosphono group, a lower alkoxyl group, a lower alkylthio group, a lower alkylamino group, a lower acyloxy group, a lower acylamino group, a lower alkoxycarbonyl group, a carbamoyl group, a lower alkylcarbamoyl group, a lower alkylsulfonylamino group, an arylsulfonylamino group optionally having substituent(s), a cycloalkyl group optionally having substituent(s), an aryl group optionally having substituent(s), an aryloxy group optionally having substituent(s), an arylthio group optionally having substituent(s), an aralkyl group optionally having substituent(s), an aralkyloxy group optionally having substituent(s), an aralkylthio group optionally having substituent(s), a heterocyclic group optionally having substituent(s), a heterocyclic oxy group optionally having substituent(s), a heterocyclic thio group optionally having substituent(s), an oxo group, and the like. A halogeno group, a hydroxyl group, a carboxyl group, a sulfo group, a phosphono group, a lower alkoxycarbonyl group, an aryl group optionally having substituent(s), a heterocyclic group optionally having substituent(s), an oxo group, and the like are preferable, and a hydroxyl group, a carboxyl group, a sulfo group, a lower alkoxycarbonyl group, and the like are particularly preferable. The number of the substituents is preferably 1 to 3, more is preferably 1 or 2.
As a cyclic amino group formed by R6 and R7 bonded to each other, a pyrrolidinyl group, a piperidinyl group, and the like are preferable.
When the cyclic amino group formed by R6 and R7 bonded to each other has a substituent, examples of the substituent include a nitro group, a halogeno group, a cyano group, a hydroxyl group, a thiol group, an amino group, a guanidino group, a formyl group, a lower alkyl group, a lower alkenyl group, a lower alkynyl group, a lower acyl group, a carboxyl group, a sulfo group, a phosphono group, a lower alkoxyl group, a lower alkylthio group, a lower alkylamino group, a lower alkoxycarbonyl group, a carbamoyl group, a lower alkylcarbamoyl group, a lower alkylsulfonylamino group, a sulfamoyl group, an oxo group, and the like. A hydroxyl group, a carboxyl group, a sulfo group, a phosphono group, a lower alkoxycarbonyl group, and the like are preferable. The number of the substituents is preferably 1 to 3, more preferably 1 or 2.
In a group of formula (IV), R60 is preferably a carboxyl group or a sulfo group, and a carboxyl group is particularly preferable.
In a group of formula (IV), D is preferably a lower alkylene group optionally having substituent(s), and a lower alkylene group having a carbon number of 1 to 3 is particularly preferable.
In a group of formula (IV), when a group represented by D has a substituent, preferable examples of the substituent include a halogeno group, a hydroxyl group, a carboxyl group, a sulfo group, a phosphono group, a lower alkoxycarbonyl group, an aryl group optionally having substituent(s), a heterocyclic group optionally having substituent(s), an oxo group, and the like, and a hydroxyl group, a carboxyl group, a sulfo group, a lower alkoxycarbonyl group, and the like are particularly preferable. The number of the substituents is preferably 1 to 3, more preferably 1 or 2, further preferably 1. In addition, the group represented by D is preferably unsubstituted.
In a group of the formula (IV), R70 is preferably a hydrogen atom, a lower alkyl group having a carbon number of 1 to 3, a lower alkoxyl group having a carbon number of 1 to 2, or the like, and a hydrogen atom, a lower alkyl group having a carbon number of 1 to 3, and the like are particularly preferable.
In a group of formula (IV), when the group represented by R70 has a substituent, examples of the substituent include a nitro group, a halogeno group, a cyano group, a hydroxyl group, a thiol group, an amino group, a guanidino group, a formyl group, a lower acyl group, a carboxyl group, a sulfo group, a phosphono group, a lower alkoxyl group, a lower alkylthio group, a lower alkylamino group, a lower acyloxy group, a lower acylamino group, a lower alkoxycarbonyl group, a carbamoyl group, a lower alkylcarbamoyl group, a lower alkylsulfonylamino group, an arylsulfonylamino group optionally having substituent(s), a cycloalkyl group optionally having substituent(s), an aryl group optionally having substituent(s), an aryloxy group optionally having substituent(s), an arylthio group optionally having substituent(s), an aralkyl group optionally having substituent(s), an aralkyloxy group optionally having substituent(s), an aralkylthio group optionally having substituent(s), a heterocyclic group optionally having substituent(s), a heterocyclic oxy group optionally having substituent(s), a heterocyclic thio group optionally having substituent(s), an oxo group, and the like. A halogeno group, a hydroxyl group, a carboxyl group, a sulfo group, a phosphono group, a lower alkoxycarbonyl group, an aryl group optionally having substituent(s), a heterocyclic group optionally having substituent(s), an oxo group, and the like are preferable, and a hydroxyl group, a carboxyl group, a sulfo group, and a lower alkoxycarbonyl group are particularly preferable. The number of the substituents is preferably 1 to 3, more preferably 1 or 2, further preferably 1.
As the cyclic amino group formed by R70 and D bonded to each other, a pyrrolidinyl group, a piperidinyl group, and the like are preferable.
When the cyclic amino group formed by R70 and D bonded to each other has a substituent, examples of the substituent include a nitro group, a halogeno group, a cyano group, a hydroxyl group, a thiol group, an amino group, a guanidino group, a formyl group, a lower alkyl group, a lower alkenyl group, a lower alkynyl group, a lower acyl group, a carboxyl group, a sulfo group, a phosphono group, a lower alkoxyl group, a lower alkylthio group, a lower alkylamino group, a lower alkoxycarbonyl group, a carbamoyl group, a lower alkylcarbamoyl group, a lower alkylsulfonylamino group, a sulfamoyl group, an oxo group, and the like, and a hydroxyl group, a carboxyl group, a sulfo group, a phosphono group, a lower alkoxycarbonyl group, and the like are preferable. The number of the substituents is preferably 1 to 3, more preferably 1 or 2, further preferably 1.
A heteroarylcarboxylic acid ester derivative wherein, in a group of the formula (IV), R60 is a carboxyl group, D is a lower alkylene group optionally having a carboxyl group, and R70 is a lower alkyl group optionally having a carboxyl group or a hydrogen atom, or a pharmaceutically acceptable salt thereof is particularly preferable.
A heteroarylcarboxylic acid ester derivative represented by any of the following formulas or a pharmaceutically acceptable salt thereof is preferable.
Figure US08609715-20131217-C00013
Figure US08609715-20131217-C00014
Figure US08609715-20131217-C00015
Figure US08609715-20131217-C00016
A heteroarylcarboxylic acid ester derivative represented by any of the following formulas or a pharmaceutically acceptable salt thereof is also preferable.
Figure US08609715-20131217-C00017
Figure US08609715-20131217-C00018
Figure US08609715-20131217-C00019
Figure US08609715-20131217-C00020
Figure US08609715-20131217-C00021
Figure US08609715-20131217-C00022
Figure US08609715-20131217-C00023
As preferable embodiments of the heteroarylcarboxylic acid ester derivative represented by the formula (I) or a pharmaceutically acceptable salt thereof, the following can also be mentioned.
Compound a
A compound represented by the formula (I) wherein R1 is a hydrogen atom, a nitro group, a halogeno group, or a straight chain or branched chain alkoxyl group having a carbon number of 1 to 6;
  • R3 is a hydrogen atom or a halogeno group;
  • R2 and R4 are hydrogen atoms;
  • HetAr is furan, thiophene, or thiazole each optionally having 1 or 2 substituents selected from a straight chain or branched chain alkyl group having a carbon number of 1 to 6;
  • X is
(1) a straight chain or branched chain alkylene group having a carbon number of 1 to 6, which optionally has a carboxyl group,
(2) a straight chain or branched chain alkenylene group having a carbon number of 2 to 6,
(3) a phenylene group, or
(4) a thiophenylene group;
  • Y is a carbonyl group or a sulfonyl group; and
  • A is —OR5 (R5 is a hydrogen atom);
a group of the following formula (II):
Figure US08609715-20131217-C00024
wherein R6 is a straight chain or branched chain alkyl group having a carbon number of 1 to 6, which optionally has 1 or 2 substituents selected from the group consisting of an aryl group having a carbon number of 6 to 14 and optionally having a hydroxyl group, a hydroxyl group, a carboxyl group, sulfo group, a phosphono group, an amino group mono- or di-substituted by a straight chain or branched chain alkyl group having a carbon number of 1 to 6 and a carbamoyl group and
R7 is
(1) a hydrogen atom,
(2) a straight chain or branched chain alkyl group having a carbon number of 1 to 6 and optionally having 1 or 2 substituents selected from the group consisting of an aryl group having a carbon number of 6 to 14, a hydroxyl group, and a carboxyl group, or
(3) a straight chain or branched chain alkenyl group having a carbon number of 2 to 6, or
R6 and R7 are optionally bonded to form a pyrrolidinyl group or a piperidinyl group, each of which optionally has 1 or 2 substituents selected from the group consisting of a hydroxyl group and a carboxyl group;
a group of the following formula (II-2):
—U—CH(R6′)R7′  (II-2)
wherein U is O or S, and R6′ and R7′ may be the same or different and are each independently a straight chain or branched chain alkyl group having a carbon number of 1 to 6 and optionally having a carboxyl group, or a carboxyl group; or
a group of the following formula (II-3):
—NH—N(R6″)R7″  (II-3)
wherein R6″ and R7″ may be the same or different and are each independently a straight chain or branched chain alkyl group having a carbon number of 1 to 6 and optionally having a carboxyl group,
or a pharmaceutically acceptable salt thereof.
Compound b.
A compound represented by the formula (I) wherein R1 is a hydrogen atom, a nitro group, a halogeno group or a straight chain or branched chain alkoxyl group having a carbon number of 1 to 6;
  • R3 is a hydrogen atom or a halogeno group;
  • R2 and R4 are hydrogen atoms;
  • HetAr is furan, thiophene, or thiazole each optionally having 1 or 2 substituents selected from a straight chain or branched chain alkyl group having a carbon number of 1 to 6;
  • X is
(1) a straight chain or branched chain alkylene group having a carbon number of 1 to 6 and optionally having a carboxyl group,
(2) a straight chain or branched chain alkenylene group having a carbon number of 2 to 6,
(3) a phenylene group, or
(4) a thiophenylene group;
  • Y is a carbonyl group or a sulfonyl group, and
  • A is —OR5 (R5 is a hydrogen atom),
a group of the following formula (II):
Figure US08609715-20131217-C00025
wherein R6 is a straight chain or branched chain alkyl group having a carbon number of 1 to 6 and having 1 or 2 substituents selected from the group consisting of an aryl group having a carbon number of 6 to 14 and optionally having a hydroxyl group, a hydroxyl group, a carboxyl group, a sulfo group, a phosphono group, an amino group mono- or di-substituted by a straight chain or branched chain alkyl group having a carbon number of 1 to 6, and a carbamoyl group, and
R7 is
(1) a hydrogen atom,
(2) a straight chain or branched chain alkyl group having a carbon number of 1 to 6 and optionally having 1 or 2 substituents selected from the group consisting of an aryl group having a carbon number of 6 to 14, a hydroxyl group and a carboxyl group, or
(3) a straight chain or branched chain alkenyl group having a carbon number of 2 to 6, or
R6 and R7 are optionally bonded to form a pyrrolidinyl group or a piperidinyl group each having 1 or 2 substituents selected from the group consisting of a hydroxyl group and a carboxyl group,
a group of the following formula (II-2):
—U—CH(R6′)R7′  (II-2)
wherein U is O or S, and R6′ and R7′ may be the same or different and are each independently a straight chain or branched chain alkyl group having a carbon number of 1 to 6 and having a carboxyl group or a carboxyl group, or
a group of the following formula (II-3):
—NH—N(R6″)R7″  (II-3)
wherein R6″ and R7″ may be the same or different and are each independently a straight chain or branched chain alkyl group having a carbon number of 1 to 6 and having a carboxyl group,
or a pharmaceutically acceptable salt thereof.
Compound c.
A compound represented by the formula (I) wherein R1 is a hydrogen atom, a nitro group, a halogeno group, or a straight chain or branched chain alkoxyl group having a carbon number of 1-6;
  • R3 is a hydrogen atom or a halogeno group;
  • R2 and R4 are hydrogen atoms;
  • HetAr is furan, thiophene or thiazole each optionally having 1 or 2 substituents selected from a straight chain or branched chain alkyl group having a carbon number of 1 to 6,
  • X is
(1) a straight chain or branched chain alkylene group having a carbon number of 1 to 6 and optionally having a carboxyl group,
(2) a straight chain or branched chain alkenylene group having a carbon number of 2 to 6,
(3) a phenylene group, or
(4) a thiophenylene group;
  • Y is a carbonyl group or a sulfonyl group; and
  • A is —OR5 (R5 is a hydrogen atom) or
a group of the following formula (IV):
Figure US08609715-20131217-C00026
wherein R60 is a carboxyl group, a sulfo group, phosphono group, or a hydroxyl group,
D is a straight chain or branched chain alkylene group having a carbon number of 1 to 6 and optionally having substituent(s), and the substituent is selected from the group consisting of an aryl group having a carbon number of 6 to 14 and optionally having a hydroxyl group, a hydroxyl group, a carboxyl group, a sulfo group, and a carbamoyl group, and
R70 is
(1) a hydrogen atom,
(2) a straight chain or branched chain alkyl group having a carbon number of 1 to 6 and optionally having 1 or 2 substituents selected from the group consisting of an aryl group having a carbon number of 6 to 14, a hydroxyl group, and a carboxyl group, or
(3) a straight chain or branched chain alkenyl group having a carbon number of 2 to 6, or
R70 and D are optionally bonded to form a pyrrolidinyl group or a piperidinyl group each optionally having 1 or 2 substituents selected from the group consisting of a hydroxyl group and a carboxyl group,
or a pharmaceutically acceptable salt thereof.
As the serine protease inhibitory activity, an activity of simultaneously inhibiting trypsin and enteropeptidase is preferable.
When the compound of the present invention can form a salt, a pharmaceutically acceptable salt is preferable. Examples of such pharmaceutically acceptable salts for a compound having an acidic group such as a carboxyl group and the like include an ammonium salt, salts with alkali metals such as sodium, potassium, and the like, salts with alkaline earth metals such as calcium, magnesium, and the like, an aluminum salt, a zinc salt, salts with an organic amines such as triethylamine, ethanolamine, morpholine, pyrrolidine, piperidine, piperazine, dicyclohexylamine, and the like, and salts with a basic amino acid such as arginine, lysine, and the like. Examples of such pharmaceutically acceptable salts for a compound having a basic group include salts with an inorganic acid such as hydrochloric acid, sulfuric acid, phosphoric acid, nitric acid, hydrobromic acid, and the like, salts with an organic carboxylic acid such as acetic acid, citric acid, benzoic acid, maleic acid, fumaric acid, tartaric acid, succinic acid, tannic acid, butyric acid, hibenzic acid (2-(4-hydroxybenzoyl)benzoic acid), pamoic acid, enanthic acid, decanoic acid, teoclic acid, salicylic acid, lactic acid, oxalic acid, mandelic acid, malic acid, and the like, and salts with an organic sulfonic acid such as methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, and the like.
The compound of the present invention also encompasses all optical isomers, stereoisomers, tautomers, rotamers, and mixtures thereof at optional ratios. These can be obtained each as a single product according to a synthesis method and separation method known per se. For example, an optical isomer can be obtained by using an optically active synthesis intermediate or by optically resolving a racemate of a synthesis intermediate or final product by a conventional method.
The compound of the present invention also includes solvates of the compound such as hydrates, alcohol adducts, and the like.
The compound of the present invention may be converted to a prodrug. The prodrug of the present invention means a compound that is converted in the body to produce the compound of the present invention. For example, when an active form contains a carboxyl group or a phosphoric acid group, an ester thereof, amide thereof, and the like can be mentioned. When an active form contains a carboxyl group, a group to be converted to a carboxyl group by oxidative metabolism, such as a hydroxymethyl group and the like can be mentioned. In addition, when the active form contains an amino group, examples thereof include amide thereof, a carbamate thereof and the like. When the active form contains a hydroxyl group, examples thereof include esters thereof, carbonates thereof, carbamates thereof, and the like. When the compound of the present invention is is converted to a prodrug, it may be bonded to amino acid or saccharide.
The present invention also encompasses a metabolite of the compound of the present invention. The metabolite of the compound of present invention means a compound resulting from the conversion of the compound of the present invention by a metabolic enzyme and the like in the body. For example, a compound wherein a hydroxyl group is introduced on the benzene ring of the compound of the present invention due to the metabolism, a compound wherein glucuronic acid, glucose, or an amino acid is bonded to the carboxylic acid moiety of the compound of the present invention or a hydroxyl group is added by the metabolism, and the like can be mentioned.
The compound of the present invention and a pharmaceutically acceptable salt thereof have a superior blood glucose elevation suppressing action for mammals such as humans, bovines, horses, dogs, mice, rats, and the like, and can be used as a medicament, which is administered as it is or as a pharmaceutical composition containing the same mixed with a pharmaceutically acceptable carrier according to a method known per se. While oral administration is generally preferable, parenteral administration can also be employed (e.g., routes such as intravenous, subcutaneous, intramuscular, suppository, enema, ointment, patch, sublingual, eye drop, inhalation administrations, and the like). While the dose used for the above-mentioned objects is determined according to the desired treatment effect, administration method, duration of treatment, age, body weight, and the like, a daily dose of 1 μg to 10 g for oral administration and 0.01 μg to 1 g, preferably 0.1 μg to 1 g, for parenteral administration is used, which is generally administered to an adult by an oral or parenteral route in one to several portions per day. In addition, the content of the compound of the present invention in the above-mentioned pharmaceutical composition is about 0.01 wt % to 100 wt % of the whole composition.
Examples of the pharmaceutically acceptable carrier for the pharmaceutical composition of the present invention include various organic or inorganic carrier substances conventionally used as preparation materials. For example, an excipient, lubricant, binder, disintegrant, water-soluble polymer, and basic inorganic salt in a solid preparation; a solvent, solubilizing agents, suspending agent, isotonicity agent, buffering agent, and soothing agent in a liquid preparation, and the like can be mentioned. Where necessary, general additives such as a preservative, antioxidant, colorant, sweetening agent, souring agent, effervescing agent, flavor, and the like can also be used.
The dosage form of such pharmaceutical composition may be a tablet, powder, pill, granule, capsule, suppository, solution, sugar-coated agent, depot, syrup, suspension, emulsion, troche, sublingual agent, adhesive preparation, oral disintegrant (tablet), inhalant, enema, ointment, patch, tape, or eye drop, and these can be produced using conventional formulation auxiliaries and according to a conventional method.
The pharmaceutical composition of the present invention can be produced according to a method conventionally used in the technical field of pharmaceutical formulation, for example, the method described in the Japanese Pharmacopoeia and the like. Specific production methods of the preparation are explained in detail in the following.
For example, when the compound of the present invention is prepared as an oral preparation, a excipient and, where necessary, a binder, disintegrant, lubricant, colorant, flavoring agent, and the like are further added, and the mixture is processed to give, for example, a tablet, powder, pill, granule, capsule, suppository, solution, sugar-coated agent, depot, syrup, and the like according to a conventional method. Examples of the excipient include lactose, cornstarch, sucrose, glucose, sorbitol, crystalline cellulose, and the like. Examples of the binder include polyvinyl alcohol, polyvinyl ether, ethylcellulose, methylcellulose, gum arabic, tragacanth, gelatin, shellac, hydroxypropylcellulose, hydroxypropylstarch, polyvinylpyrrolidone, and the like. Examples of the disintegrant include starch, agar, gelatin powder, crystalline cellulose, calcium carbonate, sodium hydrogen carbonate, calcium citrate, dextran, pectin, and the like. Examples of the lubricant include magnesium stearate, talc, polyethylene glycol, silica, hydrogenated vegetable oil, and the like. As the colorant, one acceptable to add to a pharmaceutical product is used, and as the flavoring agent, cocoa powder, menthol, aromatic acid, peppermint oil, borneol, powdered cinnamon bark, and the like are used. Where necessary, these tablets and granules are applied with a coating as appropriate such as sugar coating, gelatin coating, and the like.
When an injection is to be prepared, a pH adjuster, buffering agent, stabilizer, preservative, and the like are added where necessary, and the mixture is processed to give subcutaneous, intramuscular, or intravenous injection according to a conventional method.
While the compound of the present invention can be used as an agent for the treatment or prophylaxis of diabetes as mentioned above, it can also be used in combination with other therapeutic agents for diabetes and agents for the treatment or prophylaxis of diabetic complications, which are used generally. Examples of the therapeutic agents for diabetes and agents for the treatment or prophylaxis of diabetic complications, which are used generally, include combinations and mixtures of one or more kinds of insulin preparation, insulin derivative, insulin-like agent, insulin secretagogue, insulin sensitizer, biguanide, gluconeogenesis inhibitor, glucose absorption inhibitor, renal glucose reabsorption inhibitor, β3 adrenoceptor agonist, glucagon-like peptide-1 (7-37), glucagon-like peptide-1 (7-37) analogs, glucagon-like peptide-1 receptor agonist, dipeptidyl peptidase IV inhibitor, aldose reductase inhibitor, inhibitor of advanced glycation end product formation, glycogen synthase kinase-3 inhibitor, glycogen phosphorylase inhibitor, antihyperlipidemic drug, anorectic agent, lipase inhibitor, antihypertensive agent, peripheral circulation improving agent, antioxidant, a therapeutic drug for diabetic neuropathy, and the like.
A medicament to be used in combination with the compound of the present invention may be mixed to give a single agent or each may be formulated into separate preparations, or prepared into a combination preparation (set, kit, pack) obtained by packaging each of the separately formulated preparations in one container.
The administration form of combined use is not particularly limited and, for example, (1) administration as a single preparation, (2) simultaneous administration of separate preparations by the same administration route, (3) administration of separate preparations in a staggered manner by the same administration route, (4) simultaneous administration of separate preparations by different administration routes, (5) administration of separate preparations in a staggered manner by different administration routes, and the like can be mentioned.
In addition, the compound of the present invention is also useful even when contained in food.
A food composition containing the compound of the present invention is useful as a food for the treatment or prophylaxis of diabetes.
The “food” of the present invention means general foods, which include food for specified health uses and food with nutrient function claims defined by Food with Health Claims of Consumer Affairs Agency, Government of Japan, in addition to general foods including so-called health food, and further encompasses dietary supplements.
The form of the food composition of the present invention is not particularly limited, and the composition may take any form as long as it can be orally ingested.
Examples thereof include powder, granule, tablet, hard capsules, soft capsule, liquid (drinks, jelly drinks, and the like), candy, chocolate, and the like, all of which can be produced according to a method known per se in the technical field.
The content of the compound of the present invention in the food composition is appropriately determined to afford an appropriate dose within the indicated range.
The food composition of the present invention can use other food additives as necessary. Examples of such food additives include those generally used as components of health foods such as a fruit juice, dextrin, cyclic oligosaccharide, saccharides (monosaccharides such as fructose, glucose, and the like, and polysaccharides), acidulant, flavor, powdered green tea, and the like, which are used for controlling and improving taste, emulsifier, collagen, whole milk powder, polysaccharide thickener, agar, and the like, which are used for improving texture, and further, vitamins, eggshell calcium, calcium pantothenate, the other minerals, royal jelly, propolis, honey, dietary fiber, Agaricus, chitin, chitosan, flavonoids, carotenoids, lutein, traditional Japanese herbal medicine, chondroitin, various amino acids, and the like.
A production method of a representative compound from the heteroarylcarboxylic acid ester derivatives represented by the formula (I), which is the compound of the present invention, is shown below.
Heteroarylcarboxylic acid ester derivative (F) represented by the formula (I) wherein X is a lower alkylene group or a lower alkenylene group, A is —OR5, and R5 is a lower alkyl group can be produced as follows.
Figure US08609715-20131217-C00027
Alkenylene derivative (C) can be synthesized by reacting aldehyde (A) (wherein E1 is a protecting group such as a methyl group, an ethyl group, a tert-butyl group, a benzyl group, and the like) with Wittig reagent (B) (wherein X′ is X or a group capable of chemically converting to X together with methyne between HetAr and X′ in (C)) in, for example, a solvent that does not adversely influence the reaction, such as tetrahydrofuran and the like, in the presence of, for example, a base such as sodium hydride and the like. Alkenylene derivative (C) can be converted to carboxylic acid derivative (D) by deprotection such as hydrolysis and the like in, for example, a solvent that does not adversely influence the reaction, such as tetrahydrofuran, methanol, and the like, by using, for example, a base such as sodium hydroxide and the like. Objective heteroarylcarboxylic acid ester derivative (F) wherein X is a lower alkenylene group can be produced by esterifying carboxylic acid derivative (D) with amidinophenol derivative (E). In addition, heteroarylcarboxylic acid ester derivative (F) wherein X is a lower alkylene group can be produced by, during any stage in the production steps, conducting a step of treating with a catalyst such as 10% palladium/carbon under a hydrogen atmosphere in, for example, a solvent that does not adversely influence the reaction such as methanol, ethanol, ethyl acetate, and the like.
The esterification reaction can be performed by a known method which is, for example, (1) a method using acid halide, (2) a method using a condensation agent, and the like.
(1) The method using acid halide is performed, for example, by reacting an acid chloride obtained by reaction with thionyl chloride, oxalyl chloride, and the like in a solvent that does not adversely influence the reaction, such as dichloromethane and the like, or without solvent in the presence or absence of, for example, a catalyst such as N,N-dimethylformamide and the like, with alcohol in a solvent that does not adversely influence the reaction such as dichloromethane, tetrahydrofuran, and the like in the presence of a base such as pyridine and triethylamine.
(2) The method using a condensation agent is performed, for example, by reacting carboxylic acid with alcohol in, for example, a solvent that does not adversely influence the reaction such as tetrahydrofuran, N,N-dimethylformamide, dichloromethane, and the like in, for example, the presence or absence of a base such as pyridine, triethylamine, and the like, by using a condensation agent such as 1-ethyl-3-(3′-dimethylaminopropyl)carbodiimide (WSC), 1,3-dicyclohexylcarbodiimide, and the like.
Heteroarylcarboxylic acid ester derivative (i) of the formula (I) wherein A is —OR5 and R5 is a hydrogen atom can be produced by subjecting ester derivative (H) obtained by using Wittig reagent (G) (wherein E2 is a protecting group such as a methyl group, an ethyl group, an isopropyl group, a tert-butyl group, a benzyl group, and the like) instead of Wittig reagent (B) to, for example, deprotection by hydrolysis with a base such as sodium hydroxide and the like, hydrolysis with an acid such as hydrochloric acid, trifluoroacetic acid and the like, or treating with, for example, 10% palladium/carbon and the like under a hydrogen atmosphere, and the like.
Figure US08609715-20131217-C00028
In addition, heteroarylcarboxylic acid ester derivative (K) of the formula (I) wherein A is a group of the formula (II) can be produced by amidating carboxylic acid, thiocarboxylic acid, or sulfonic acid derivative (i) with amine (J). The amidation reaction of carboxylic acid and thiocarboxylic acid derivative is performed using the corresponding amine instead of alcohol and in the same manner as in the aforementioned esterification reaction. The amidation reaction of the sulfonic acid derivative is performed using the corresponding amine instead of alcohol in the same manner as in (1) the method using acid halide for the aforementioned esterification reaction.
Figure US08609715-20131217-C00029
In addition, heteroarylcarboxylic acid ester derivative (K) of the formula (I) wherein A is a group of the formula (II) can also be produced as follows.
Figure US08609715-20131217-C00030
Carboxylic acid, thiocarboxylic acid, or sulfonic acid derivative (M) can be obtained by deprotecting ester, thioester, or sulfonic acid ester derivative (L) by, for example, hydrolysis with a base such as sodium hydroxide and the like, hydrolysis with an acid such as hydrochloric acid, trifluoroacetic acid, and the like or treatment with, for example, 10% palladium/carbon and the like under a hydrogen atmosphere. Amide derivative (N) can be synthesized by amidating carboxylic acid, thiocarboxylic acid, or sulfonic acid derivative (M) with amine (J). Amide derivative (N) can be converted to carboxylic acid derivative (O) by hydrolysis in, for example, a solvent that does not adversely influence the reaction, such as tetrahydrofuran, methanol, and the like, by using, for example, a base such as sodium hydroxide and the like. The objective heteroarylcarboxylic acid ester derivative (K) can be produced by esterifying carboxylic acid derivative (O) with amidinophenol derivative (E).
In addition, heteroarylcarboxylic acid ester derivative (S) of the formula (I) wherein Y is a thiocarbonyl group and A is a group of the formula (II) can also be produced as follows.
Figure US08609715-20131217-C00031
Thioamide derivative (Q) can be synthesized by reacting amide derivative (P) with Lawesson's reagent and the like in, for example, a solvent that does not adversely influence the reaction such as toluene and the like. Thioamide derivative (Q) can be converted to carboxylic acid derivative (R) by hydrolysis in, for example, a solvent that does not adversely influence the reaction, such as tetrahydrofuran, methanol, and the like, by using, for example, a base such as sodium hydroxide and the like. The objective heteroarylcarboxylic acid ester derivative (S) can be produced by esterifying carboxylic acid derivative (R) with amidinophenol derivative (E).
Other features of the invention will become apparent in the course of the following descriptions of exemplary embodiments which are given for illustration of the invention and are not intended to be limiting thereof.
EXAMPLES Example 1 Synthesis of 4-amidino-2-nitrophenol hydrochloride (M-8)
4-Amidinophenol hydrochloride (1.0 g, 5.8 mmol) was dissolved in concentrated sulfuric acid (2.5 mL), and concentrated nitric acid (0.38 mL) was added at −15° C. The reaction mixture was stirred for 1 hour while maintaining the temperature of the reaction mixture at −15° C. to −2° C., and slowly added to ice water. The mixture was neutralized by slowly adding sodium hydrogen carbonate, and the precipitated orange solid was collected by filtration. The solid was washed with water and acetone, and suspended in methanol. 4N Hydrochloric acid/dioxane was added to dissolve the solid. Diisopropyl ether was added to the solution, and the precipitated solid was collected by filtration. The solid was washed with diisopropyl ether and dried to give the title compound (0.98 g) as a pale-yellow powder.
1H-NMR (300 MHz, DMSO-d6) δ 12.40 (1H, br), 9.36 (2H, br), 9.05 (2H, br), 8.42 (1H, d, J=2.3 Hz), 7.98 (1H, dd, J=8.9, 2.3 Hz), 7.34 (1H, d, J=8.9 Hz).
MS (ESI) m/z 182 (M+H)+
Example 2 Synthesis of 4-amidino-2-bromophenol trifluoroacetic acid salt (M-9)
4-Amidinophenol hydrochloride (1.0 g, 5.8 mmol) was dissolved in methanol (20 mL), the mixture was cooled to −78° C., and a solution of bromine (0.30 mL, 5.8 mmol) in methanol (10 mL) was added slowly. The reaction mixture was gradually warmed to room temperature and stirred overnight. The mixture was concentrated under reduced pressure and the obtained residue was purified by high performance liquid chromatography (water-acetonitrile, each containing 0.1% trifluoroacetic acid) to give the title compound (0.24 g, 0.73 mmol, 13%).
1H-NMR (300 MHz, DMSO-d6) δ 11.58 (1H, br), 9.12 (2H, br), 8.83 (2H, br), 8.04 (1H, d, J=2.4 Hz), 7.69 (1H, dd, J=8.7, 2.4 Hz), 7.10 (1H, d, J=8.7 Hz).
MS (ESI) m/z 215 [M(79Br)+H]+, 217 [M(81Br)+H]+
Example 3 Synthesis of 4-amidino-2-chlorophenol trifluoroacetic acid salt (M-10)
4-Amidinophenol hydrochloride (0.50 g, 2.9 mmol) was dissolved in N,N-dimethylformamide (25 mL), N-chlorosuccinimide (0.39 g, 2.9 mmol) was added, and the mixture was stirred overnight. The reaction mixture was concentrated under reduced pressure, and the obtained residue was purified by high performance liquid chromatography (water-acetonitrile, each containing 0.1% trifluoroacetic acid) to give the title compound (0.25 g, 0.88 mmol, 30%).
1H-NMR (300 MHz, DMSO-d6) δ 11.50 (1H, br), 9.12 (2H, br), 8.81 (2H, br), 7.91 (1H, d, J=2.3 Hz), 7.66 (1H, dd, J=8.7, 2.3 Hz), 7.13 (1H, d, J=8.7 Hz).
MS (ESI) m/z 171 [M(35Cl)+H]+, 173 [M(37Cl)+H]+
Example 4 Synthesis of 4-amidino-2-fluorophenol trifluoroacetic acid salt (M-11)
To 3-fluoro-4-hydroxybenzonitrile (3.0 g) were added ethanol (3 mL) and 4N hydrochloric acid-dioxane (27 mL), and the mixture was stirred at room temperature. After 18 hours, the mixture was concentrated and dried with a vacuum pump. Then, the mixture was dissolved in ethanol (60 mL), ammonium carbonate (10.5 g) was added, and the mixture was stirred at room temperature. After 20 hours, ethanol (150 mL) was added, the solid was filtered off, and the obtained solution was concentrated. The residue was purified by high performance liquid chromatography to give the title compound (786 mg, 2.9 mmol, 13%).
1H-NMR (300 MHz, DMSO-d6) δ 11.28 (1H, br s), 9.19 (2H, br s), 9.02 (2H, br s), 7.75 (1H, dd, J=2.4, 12.0 Hz), 7.59 (1H, m), 7.18 (1H, dd, J=8.4, 8.7 Hz).
MS (ESI) m/z 155 (M+H)+
Example 5 Synthesis of 4-amidino-3-fluorophenol trifluoroacetic acid salt (M-12)
In the same manner as in the synthesis of M-11 except that 2-fluoro-4-hydroxybenzonitrile was used instead of 3-fluoro-4-hydroxybenzonitrile, the title compound was obtained (yield 12%).
1H-NMR (300 MHz, DMSO-d6) δ 9.38-8.61 (4H, br), 7.50 (1H, dd, J=9.6, 8.4 Hz), 6.78-6.73 (2H, m).
MS (ESI) m/z 155 (M+H)+
Example 6 Synthesis of 2-(diethylphosphono)propanoic acid tert-butyl ester (M-13)
2-Bromo-propanoic acid tert-butyl ester (17.4 g, 83 mmol) and triethyl phosphite (14.5 g, 87 mmol) were mixed, and the mixture was stirred at 110° C. overnight. The reaction mixture was dried under reduced pressure to give the title compound (23.9 g).
1H-NMR (300 MHz, CDCl3) δ 4.20-4.08 (4H, m), 2.92 (1H, dq, J=30.6, 7.2 Hz), 1.48 (9H, s), 1.45 (3H, d, J=7.2 Hz), 1.40-1.30 (6H, m).
Example 7 Synthesis of 2-(diethylphosphono)butanoic acid tert-butyl ester (M-14)
Diethylphosphonoacetic acid tert-butyl ester (1.0 g, 4.0 mmol) was dissolved in N,N-dimethylformamide (1.4 mL), and 60% sodium hydride (0.17 g, 4.4 mmol) was added at 0° C. After stirring at room temperature for 30 minutes, the reaction mixture was cooled again to 0° C., ethyl iodide (0.33 mL, 4.1 mmol) was added, and the mixture was stirred at room temperature overnight. The reaction mixture was diluted with ethyl acetate, washed successively with 0.5N hydrochloric acid, water and saturated brine, and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (ethyl acetate/hexane=57/43) to give the title compound (0.92 g, 3.3 mmol, 83%).
1H-NMR (300 MHz, CDCl3) δ 4.20-4.09 (4H, m), 2.76 (1H, ddd, J=22.1, 10.4, 4.3 Hz), 2.00-1.83 (2H, m), 1.48 (9H, s), 1.35 (3H, t, J=7.2 Hz), 1.34 (3H, t, J=7.1 Hz), 0.99 (3H, td, J=7.5, 1.1 Hz).
Example 8 Synthesis of 2-(diethylphosphono)pentanoic acid tert-butyl ester (M-15)
In the same manner as in the synthesis of M-14 except that propyl bromide was used instead of ethyl iodide, the title compound was obtained (yield 77%).
1H-NMR (300 MHz, CDCl3) δ 4.20-4.09 (4H, m), 2.85 (1H, ddd, J=22.3, 11.2, 3.8 Hz), 2.05-1.73 (4H, m), 1.47 (9H, s), 1.45-1.29 (6H, m), 0.93 (3H, t, J=7.2 Hz).
Example 9 Synthesis of 1-(diethylphosphono)ethanesulfonic acid isopropyl ester (M-16)
Step 1. Synthesis of ethanesulfonic acid isopropyl ester
To a solution of 2-propanol (2.4 ml, 32 mmol) in dichloromethane (50 mL), were added triethylamine (3.5 mL, 25 mmol) and ethanesulfonyl chloride (2.0 mL, 21 mmol), and the mixture was stirred at room temperature for 3 hours. The reaction mixture was washed successively with 1N hydrochloric acid, saturated aqueous sodium hydrogen carbonate and saturated brine, and dried over sodium sulfate. The drying agent was filtered off, and the filtrate was concentrated under reduced pressure to give the title compound (2.4 g, 16 mmol, 75%).
1H-NMR (300 MHz, CDCl3) δ 4.81 (1H, sep, J=6.4 Hz), 3.25 (2H, q, J=7.3 Hz), 1.30 (6H, d, J=6.4 Hz), 1.21 (3H, t, J=7.3 Hz).
Step 2. Synthesis of 1-(diethylphosphono)ethanesulfonic acid isopropyl ester (M-16)
A solution of ethanesulfonic acid isopropyl ester (1.0 g, 6.6 mmol) in tetrahydrofuran (15 mL) was cooled to −78° C., and n-butyllithium (1.57 M, 4.6 mL, 7.2 mmol) was added. After stirring at −78° C. for 20 minutes, diethyl chlorophosphate (0.52 mL, 3.6 mmol) was added to the reaction mixture, and the mixture was further stirred for 30 minutes. 1N Hydrochloric acid was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine and dried over sodium sulfate. The solvent was evaporated under reduced pressure and the obtained residue was purified by silica gel column chromatography (hexane/ethyl acetate=40/60) to give the title compound (0.61 g, 2.1 mmol, 58%).
1H-NMR (300 MHz, CDCl3) δ 5.08 (1H, sep, J=6.3 Hz), 4.29-4.18 (4H, m), 3.57 (1H, dq, J=19.2, 7.3 Hz), 1.69 (3H, dd, J=15.6, 7.3 Hz), 1.45 (6H, d, J=6.3 Hz), 1.37 (6H, t, J=6.9 Hz).
Example 10 Synthesis of 5-[(1E)-2-(tert-butoxycarbonyl)-prop-1-en-1-yl]furan-2-carboxylic acid (M-1)
Step 1. Synthesis of 5-[(1E)-2-(tert-butoxycarbonyl)-prop-1-en-1-yl]furan-2-carboxylic acid methyl ester
5-Formyl-2-furancarboxylic acid (5 g, 35.7 mmol) was dissolved in acetone (100 mL), and trimethylsilyl-diazomethane/2M hexane solution (23.2 mL, 46.4 mmol) was slowly added dropwise at room temperature. After stirring at room temperature for 10 minutes, the solvent was evaporated under reduced pressure to give 5-formyl-2-furancarboxylic acid methyl ester as a crude product.
A tetrahydrofuran solution (30 mL) of M-13 (14.3 g, 53.6 mmol) was added dropwise to a stirring suspension of 60% sodium hydride (1.86 g, 46.4 mmol) in tetrahydrofuran (120 mL) at 0° C. The mixture was stirred at room temperature for 30 minutes, and a tetrahydrofuran solution (30 mL) of the crude product obtained earlier was added dropwise at 0° C. After stirring at room temperature overnight, the mixture was worked up according to a conventional method, and the object product was extracted by column chromatography (5-10% ethyl acetate/hexane mixed solvent) to give the title compound (5.55 g, 20.8 mmol, 2 steps 58%).
1H-NMR (300 MHz, CDCl3) δ 7.39 (1H, d, J=0.9 Hz), 7.22 (1H, d, J=3.6 Hz), 6.64 (1H, d, J=3.6 Hz), 3.92 (3H, s), 2.21 (3H, d, J=0.9 Hz), 1.53 (9H, s).
MS (ESI) m/z 267 (M+H)+
Step 2. Synthesis of 5-[(1E)-2-(tert-butoxycarbonyl)-prop-1-en-1-yl]furan-2-carboxylic acid (M-1)
5-[(1E)-2-(tert-butoxycarbonyl)-prop-1-en-1-yl]furan-2-carboxylic acid methyl ester (1.11 g, 4.17 mmol) obtained in step 1 was dissolved in methanol (7.65 mL), 1N aqueous lithium hydroxide solution (6.25 mL, 6.25 mmol) was added, and the mixture was stirred at room temperature for 100 minutes. 1N aqueous hydrochloric acid solution (6.25 mL) was added, the mixture was stirred for 10 minutes, and the solvent was evaporated under reduced pressure. To the residue were added ethyl acetate and 0.5N aqueous hydrochloric acid solution, the organic layer was extracted, and the aqueous layer was extracted three times with ethyl acetate. The organic layers were collected, washed with saturated brine and dried by dehydration with sodium sulfate. The solvent of the filtrate after filtration was evaporated under reduced pressure to give the title compound.
1H-NMR (300 MHz, DMSO-d6) δ 7.33-7.25 (2H, m), 6.98 (1H, d, J=3.6 Hz), 2.15 (3H, s), 1.48 (9H, s).
MS (ESI) m/z 253 (M+H)+
Example 11 Synthesis of 5-(2-tert-butoxycarbonylpropyl)furan-2-carboxylic acid (M-2)
Step 1. Synthesis of 5-(2-tert-butoxycarbonylpropyl)-furan-2-carboxylic acid methyl ester
(2E)-(5-Methoxycarbonylfuran-2-yl)-2-methylpropenoic acid tert-butyl ester (2.96 g, 11.1 mmol) was dissolved in methanol (100 ml), 10% palladium/carbon (0.3 g) was added, and the mixture was stirred at room temperature for 2 hours under a hydrogen atmosphere. After completion of the reaction, palladium/carbon was removed by celite filtration, and the solvent was evaporated under reduced pressure to give the title compound (2.72 g).
1H-NMR (300 MHz, DMSO-d6) δ 7.20 (1H, d, J=3.3 Hz), 6.35 (1H, d, J=3.3 Hz), 3.76 (3H, s), 2.90-2.60 (3H, m), 1.34 (9H, s), 1.07 (3H, d, J=6.9 Hz).
Step 2. Synthesis of 5-(2-tert-butoxycarbonylpropyl)-furan-2-carboxylic acid (M-2)
5-(2-tert-Butoxycarbonylpropyl)furan-2-carboxylic acid methyl ester (1.0 g, 3.76 mmol) obtained in step 1 was dissolved in tetrahydrofuran (4.5 mL) and methanol (3 mL), 1N aqueous sodium hydroxide solution (4.5 mL) was added, and the mixture was stirred overnight. The mixture was neutralized with 1N hydrochloric acid, extracted with ethyl acetate, and washed successively with water and saturated brine. After drying over anhydrous magnesium sulfate, the drying agent was filtered off, and the solvent was evaporated to give the title compound (0.98 g).
1H-NMR (300 MHz, DMSO-d6) δ 7.11 (1H, s), 6.32 (1H, s), 2.95-2.65 (3H, m), 2.50 (3H, s), 1.35 (9H, s).
MS (ESI) m/z 253 (M+H)+
Example 12 Synthesis of 5-[(1E)-2-(tert-butoxycarbonyl)-prop-1-en-1-yl]thiophene-2-carboxylic acid (M-3)
Step 1. Synthesis of 5-[(1E)-2-(tert-butoxycarbonyl)-prop-1-en-1-yl]thiophene-2-carboxylic acid methyl ester
M-13 (2.08 g, 7.8 mmol) was dissolved in tetrahydrofuran (30 mL), 60% sodium hydride (0.37 g, 9.25 mmol) was added at 0° C., and the mixture was stirred for 30 minutes. To the reaction mixture was added a solution of 5-formyl-2-thiophenecarboxylic acid methyl ester (1.02 g, 6.0 mmol) in tetrahydrofuran (5 mL), and the mixture was stirred at room temperature overnight. The solvent was evaporated, and the residue was partitioned between ethyl acetate and 1N hydrochloric acid, and washed successively with water and saturated brine. After drying over anhydrous magnesium sulfate, the residue was purified by silica gel column chromatography to give the title compound (1.18 g).
1H-NMR (300 MHz, CDCl3) δ 7.75 (1H, d, J=4.2 Hz), 7.69 (1H, s), 7.19 (1H, d, J=4.2 Hz), 3.90 (3H, s), 2.19 (3H, s), 1.54 (9H, s).
Step 2. Synthesis of 5-[(1E)-2-(tert-butoxycarbonyl)-prop-1-en-1-yl]thiophene-2-carboxylic acid (M-3)
5-[(1E)-2-(tert-Butoxycarbonyl)-prop-1-en-1-yl]thiophene-2-carboxylic acid methyl ester (1.18 g, 4.19 mmol) obtained in step 1 was dissolved in tetrahydrofuran (5 mL), 1N aqueous lithium hydroxide solution (4.6 ml) was added, and the mixture was stirred overnight. The mixture was neutralized with 1N hydrochloric acid, and extracted with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate, and the solvent was evaporated to give the title compound (1.06 g).
1H-NMR (300 MHz, CDCl3) δ 7.70 (1H, d, J=3.9 Hz), 7.66 (1H, s), 7.63 (1H, d, J=3.9 Hz), 7.16 (1H, d, J=3.9 Hz), 2.16 (3H, s), 1.51 (9H, s).
MS (ESI) m/z 269 (M+H)+
Example 13 Synthesis of 5-(2-tert-butoxycarbonylpropyl)-thiophene-2-carboxylic acid (M-4)
Using 5-[(1E)-2-(tert-butoxycarbonyl)-prop-1-en-1-yl]thiophene-2-carboxylic acid methyl ester obtained in Example 12, step 1 and in the same manner as in Example 11, the title compound was obtained.
1H-NMR (300 MHz, CDCl3) δ 7.72 (1H, d, J=3.6 Hz), 6.85 (1H, d, J=3.6 Hz), 3.24-2.65 (3H, m), 1.42 (9H, s), 1.19 (3H, d, J=6.9 Hz).
MS (ESI) m/z 271 (M+H)+
Example 14 Synthesis of 2-[{3-triisopropylsilyloxypropyl}-amino]acetic acid tert-butyl ester (M-5)
To a solution of 3-amino-1-propanol (2.0 mL, 26 mmol) in dichloromethane (20 mL) was added triisopropylsilyl trifluoromethanesulfonate (7.2 mL, 27 mmol), and the mixture was stirred at room temperature for 1 hour. Triethylamine (3.7 mL, 26 mmol) and bromoacetic acid tert-butyl ester (3.1 mL, 21 mmol) were added to the reaction mixture, and the mixture was further stirred at room temperature for 1 hour. The reaction mixture was diluted with dichloromethane and washed with saturated aqueous sodium hydrogen carbonate. The organic layer was dried over sodium sulfate and concentrated under reduced pressure, and the obtained residue was purified by silica gel column chromatography (dichloromethane/methanol=97/3) to give the title compound (1.85 g, 5.4 mmol, 25%).
1H-NMR (300 MHz, CDCl3) δ 3.96 (2H, t, J=5.4 Hz), 3.80 (2H, s), 3.34 (2H, t, J=5.9 Hz), 2.03 (2H, m), 1.50 (9H, s), 1.17-1.07 (21H, m).
Example 15 Synthesis of N-(3-triisopropylsilyloxypropyl)-taurine isopropyl ester (M-7)
Step 1. Synthesis of vinylsulfonic acid isopropyl ester
2-Chloroethylsulfonyl chloride (2 g, 12.3 mmol), isopropanol (1 mL), and pyridine (2.7 ml) were dissolved in dichloromethane (20 mL), and the mixture was stirred at room temperature for 3 hours. The reaction mixture was washed successively with 1N hydrochloric acid and water, and the organic layer was dried over anhydrous magnesium sulfate. The drying agent was filtered, and the solvent was evaporated to give the title compound (1.06 g).
1H-NMR (300 MHz, CDCl3) δ 6.56 (1H, dd, J=9.9, 16.8 Hz), 6.39 (1H, d, J=16.8 Hz), 6.07 (1H, d, J=9.9 Hz), 4.81 (1H, sep, J=6.3 Hz), 1.40 (6H, d, J=6.3 Hz).
Step 2. Synthesis of N-(3-triisopropylsilyloxypropyl)-taurine isopropyl ester (M-7)
Vinylsulfonic acid isopropyl ester (0.3 g, 2.00 mmol) obtained in step 1 and 3-triisopropylsilyloxypropylamine (0.9 g, 3.89 mmol) were dissolved in methanol (10 mL), and the mixture was stirred at room temperature overnight. The solvent was evaporated and the residue was purified by silica gel column chromatography to give the title compound (0.65 g).
1H-NMR (300 MHz, CDCl3) δ 4.97 (1H, sep, J=6.0 Hz), 3.78 (2H, t, J=6.9 Hz), 3.29 (2H, t, J=6.9 Hz), 3.13 (2H, t, J=6.9 Hz), 2.78 (2H, t, J=6.9 Hz), 1.74 (2H, m), 1.42 (6H, d, J=6.0 Hz), 1.05 (21H, m).
Example 16 Synthesis of (2E)-3-[5-(4-amidinophenoxycarbonyl)-furan-2-yl]-2-methylpropenoic acid trifluoroacetic acid salt (A-3)
M-1, 4-hydroxybenzamidine hydrochloride (712 mg, 4.17 mmol) and WSC hydrochloride (869 mg, 4.53 mmol) were dissolved in pyridine (10 mL), and the mixture was stirred at room temperature overnight. The solvent was evaporated under reduced pressure, trifluoroacetic acid (10 mL) was added, and the mixture was stirred at room temperature for 15 minutes. The solvent was evaporated under reduced pressure, and the resultant solid was washed with diethyl ether, collected by filtration with Kiriyama funnel, and dried in a desiccator to give the title compound (1.46 g, 3.41 mmol, 3 steps 82%).
1H-NMR (300 MHz, DMSO-d6) δ 9.35 (2H, br s), 8.95 (2H, br s), 7.91 (2H, d, J=8.7 Hz), 7.72 (1H, d, J=3.9 Hz), 7.59 (2H, d, J=8.7 Hz), 7.43 (1H, s), 7.14 (1H, d, J=3.9 Hz), 2.73 (1H, s), 2.24 (3H, s).
MS (ESI) m/z 315 (M+H)+
Example 17 Synthesis of 3-[5-(4-amidinophenoxycarbonyl)furan-2-yl]-2-methylpropionic acid trifluoroacetic acid salt (A-6)
10% Palladium/carbon (49.5 mg) and A-3 (495 mg, 1.16 mmol) were suspended in methanol (3.0 mL), and the suspension was stirred at room temperature overnight under a hydrogen atmosphere (1 atm). After completion of the reaction, palladium/carbon was removed by celite filtration. The solvent was evaporated under reduced pressure, and the object product was extracted by high performance liquid chromatography (10-40% water (containing 0.1% trifluoroacetic acid)/acetonitrile (containing 0.1% trifluoroacetic acid) mixed solvent) to give the title compound (246 mg, 0.57 mmol, 49.3%).
1H-NMR (300 MHz, DMSO-d6) δ 9.35 (2H, br s), 9.10 (2H, br s), 7.90 (2H, d, J=6.9 Hz), 7.61-7.52 (3H, m), 6.52 (1H, d, J=3.6 Hz), 3.13-2.98 (1H, m), 2.91-2.70 (2H, m), 1.14 (3H, d, J=6.9 Hz).
MS (ESI) m/z 317 (M+H)+
Example 18 Synthesis of N-{(2E)-3-[5-(4-amidino-2-phenoxycarbonyl)furan-2-yl]-2-methylpropenoyl}-N-(3-hydroxypropyl)-β-alanine trifluoroacetic acid salt (A-12)
Step 1. Synthesis of 3-triisopropylsilyloxypropylamine
3-Hydroxylpropylamine (100 μL, 1.31 mmol) was dissolved in dichloromethane (4.4 mL), and triisopropylsilyl triflate (371 μL, 1.38 mmol) was added dropwise at room temperature. After stirring at room temperature for 15 minutes, the mixture was worked up according to a conventional method to give the title compound as a crude product.
Step 2. Synthesis of N-(3-triisopropylsilyloxypropyl)-β-alanine tert-butyl ester (M-6)
The crude product obtained in step 1 was dissolved in toluene (3.0 mL), acrylic acid tert-butyl ester (173 μL, 1.19 mmol) was added, and the mixture was stirred under reflux for 6 hours. The solvent was evaporated under reduced pressure, and crudely purified by silica gel column chromatography (0-4% methanol/dichloromethane mixed solvent) to give the title compound as a crude product.
Step 3. Synthesis of N-{(2E)-3-[5-(4-amidino-2-phenoxycarbonyl)furan-2-yl]-2-methylpropenoyl}-N-(3-hydroxypropyl)-β-alanine trifluoroacetic acid salt (A-12)
A-3 (87 mg, 0.20 mmol) was dissolved in thionyl chloride (500 μL), and the mixture was stirred at 70° C. for 10 minutes. Thionyl chloride was evaporated under reduced pressure to give acid chloride. The obtained acid chloride was dissolved in dichloromethane (500 μL), the amine obtained in step 2 and pyridine (250 μL) were added thereto, and the mixture was stirred at room temperature for 30 minutes. After evaporation of the solvent, trifluoroacetic acid (500 μL: containing 5% water) was added, and the mixture was stirred at room temperature overnight. Trifluoroacetic acid was evaporated under reduced pressure, saturated aqueous sodium hydrogen carbonate solution (1 mL) was added, and the mixture was stirred for 1 hour. The object product was extracted by high performance liquid chromatography (5-35% water (containing 0.1% trifluoroacetic acid)/acetonitrile (containing 0.1% trifluoroacetic acid) mixed solution) to give the title compound (4.0 mg, 0.007 mmol, 3.5%).
MS (ESI) m/z 444 (M+H)+
Example 19 Synthesis of N-{(2E)-3-[5-(4-amidinophenoxycarbonyl)furan-2-yl]-2-methylpropenyl}-L-glutamic acid trifluoroacetic acid salt (A-13)
A-3 (49 mg, 0.11 mmol) was dissolved in thionyl chloride (0.5 mL), and the mixture was heated at 70° C. for 5 minutes. Thionyl chloride was evaporated under reduced pressure, and the obtained residue was dissolved in dichloromethane (0.35 mL). Glutamic acid di-tert-butyl ester hydrochloride (50.8 mg, 0.17 mmol) and pyridine (0.15 ml) were added, and the mixture was stirred at room temperature for 40 minutes. The solvent was evaporated under reduced pressure, trifluoroacetic acid (0.5 mL: containing 5% water) was added, and the mixture was stirred at room temperature for 2 hours. The solvent was evaporated again, water (0.5 mL) was added, and the mixture was stirred at room temperature overnight. The solvent was evaporated under reduced pressure, and the object product was extracted by high performance liquid chromatography (5-35% water (containing 0.1% trifluoroacetic acid)/acetonitrile (containing 0.1% trifluoroacetic acid) mixed solution) to give the title compound (32 mg, 0.06 mmol, 50%).
1H-NMR (300 MHz, DMSO-d6) δ 9.35 (2H, br s), 9.02 (2H, br s), 8.35 (1H, d, J=7.5 Hz), 7.91 (2H, d, J=8.7 Hz), 7.72 (1H, d, J=3.3 Hz), 7.59 (2H, d, J=7.5 Hz), 7.18 (1H, s), 7.04 (1H, d, J=3.3 Hz), 4.35-4.22 (2H, m), 2.42-2.30 (2H, m), 2.22 (3H, s), 2.15-1.81 (2H, m).
MS (ESI) m/z 444 (M+H)+
Example 20 Synthesis of 3-[5-(4-amidinophenoxycarbonyl)furan-2-yl]-2-ethylpropionic acid trifluoroacetic acid salt (A-29)
Step 1. Synthesis of [5-(benzyloxycarbonyl)furan-2-yl]-2-ethylpropenoic acid tert-butyl ester
5-Formyl-2-furancarboxylic acid benzyl ester (200 mg, 0.87 mmol) and M-14 (364.4 mg, 1.30 mmol) were dissolved in tetrahydrofuran (3.0 mL), and 60% sodium hydride (45.3 mg, 1.13 mmol) was added at 0° C. After removing from the ice bath, the mixture was stirred at room temperature for 30 minutes. The mixture was worked up according to a conventional method to give the title compound as a crude product.
Step 2. Synthesis of 3-(5-hydroxycarbonylfuran-2-yl)-2-ethylpropionic acid tert-butyl ester
The crude product obtained in step 1 and 10% palladium/carbon (30 mg) were suspended in ethanol (3.0 mL), and the suspension was stirred overnight at ambient temperature and normal pressure under a hydrogen atmosphere. Palladium/carbon was removed by celite filtration, and the solvent was evaporated under reduced pressure to give the title compound as a crude product.
Step 3. Synthesis of 3-[5-(4-amidinophenoxycarbonyl)-furan-2-yl]-2-ethylpropionic acid trifluoroacetic acid salt (A-29)
The crude product obtained in step 2 and 4-hydroxybenzamidine hydrochloride (180 mg, 1.04 mmol) were dissolved in pyridine (3.0 mL), and WSC hydrochloride (217 mg, 1.13 mmol) was added with stirring at room temperature. After stirring at room temperature for 100 minutes, the solvent was evaporated under reduced pressure. Trifluoroacetic acid (3.0 mL) was added to the obtained residue, and the mixture was stirred at room temperature for 15 minutes. The solvent was evaporated, and the object product was extracted by column chromatography (5-35% water (containing 0.1% trifluoroacetic acid)/acetonitrile (containing 0.1% trifluoroacetic acid) mixed solvent) to give the title compound (225 mg, 0.57 mmol, 3 steps 66%).
1H-NMR (300 MHz, DMSO-d6) δ 9.34 (2H, br s), 9.13 (2H, br s), 7.90 (2H, d, J=8.7 Hz), 7.63-7.49 (3H, m), 6.51 (1H, d, J=3.6 Hz), 3.10-2.82 (2H, m), 2.69-2.55 (1H, m), 1.64-1.49 (2H, m), 0.90 (3H, t, J=7.5 Hz).
MS (ESI) m/z 331 (M+H)+
Example 21 Synthesis of N-[5-(4-amidinophenoxycarbonyl)furan-2-ylacetic acid trifluoroacetic acid salt (A-32)
Step 1. Synthesis of 5-ethoxycarbonylfuran-2-ylacetic acid
5-Chloromethyl-2-furancarboxylic acid ethyl ester (1.0 g, 5.3 mmol), potassium iodide (0.044 g, 0.27 mmol), and chloro(1,5-cyclooctadiene)rhodium(I) dimer (0.26 g, 0.53 mmol) were dissolved in formic acid (25 mL), and the mixture was stirred at 75° C. for 6 hours under a carbon monoxide atmosphere. The solvent was evaporated, and the residue was partitioned between ethyl acetate and aqueous sodium hydrogen carbonate solution. The organic layer was washed with saturated brine and dried over anhydrous magnesium sulfate. The drying agent was filtered off, the solvent was evaporated, and the residue was purified by silica gel column chromatography to give the title compound (0.61 g).
1H-NMR (300 MHz, CDCl3) δ 7.13 (1H, d, J=3.6 Hz), 6.42 (1H, d, J=3.6 Hz), 4.35 (2H, q, J=7.5 Hz), 3.83 (2H, s), 1.37 (3H, t, J=7.5 Hz).
MS (ESI) m/z 199 (M+H)+
Step 2. Synthesis of 5-ethoxycarbonylfuran-2-ylacetic acid tert-butyl ester
5-Ethoxycarbonylfuran-2-ylacetic acid (0.61 g, 3.08 mmol) obtained in step 1 was dissolved in thionyl chloride (10 mL), and the mixture was stirred at 70° C. for 1 hour. The solvent was evaporated under reduced pressure, tert-butanol (5 ml) and triethylamine (2 mL) were added, and the mixture was stirred for 30 minutes. The solvent was evaporated, and the residue was purified by silica gel column chromatography to give the title compound (0.37 g).
1H-NMR (300 MHz, CDCl3) δ 7.13 (1H, d, J=3.3 Hz), 6.36 (1H, d, J=3.3 Hz), 4.35 (2H, q, J=6.9 Hz), 3.68 (2H, s), 1.25 (9H, s), 1.25 (3H, t, J=6.9 Hz).
Step 3. Synthesis of 5-tert-butoxycarbonylmethyl-2-furancarboxylic acid
5-Ethoxycarbonylfuran-2-ylacetic acid tert-butyl ester (0.37 g, 1.46 mmol) obtained in step 2 was dissolved in tetrahydrofuran (2 mL), dissolved in 1N aqueous sodium hydroxide solution (1.5 mL), and the mixture was stirred overnight. 1N Hydrochloric acid (1.5 mL) was added to the reaction mixture, and the mixture was neutralized, purified by high performance liquid chromatography and freeze-dried to give the title compound (80 mg).
1H-NMR (300 MHz, CDCl3) δ 7.26 (1H, d, J=3.6 Hz), 6.42 (1H, d, J=3.6 Hz), 3.70 (2H, s), 1.47 (9H, s).
Step 4. Synthesis of 5-(4-amidinophenoxycarbonyl)furan-2-ylacetic acid trifluoroacetic acid salt (A-32)
5-tert-Butoxycarbonylmethyl-2-furancarboxylic acid (80 mg, 0.24 mmol) obtained in step 3 and 4-hydroxybenzamidine hydrochloride (80 mg, 0.46 mmol) were dissolved in pyridine (5 mL), WSC hydrochloride (0.10 g, 0.52 mmol) was added, and the mixture was stirred overnight. After evaporation of the solvent, trifluoroacetic acid (5 ml) was added, and the mixture was stirred for 30 minutes. The mixture was purified by high performance liquid chromatography and freeze-dried to give the title compound.
1H-NMR (300 MHz, DMSO-d6) δ 9.34 (2H, s), 9.01 (2H, s), 7.89 (2H, d, J=8.7 Hz), 6.64 (1H, d, J=3.6 Hz), 7.57 (3H, m), 3.89 (2H, s).
MS (ESI) m/z 289 (M+H)+
Example 22 Synthesis of N-{3-[5-(4-amidino-2-fluorophenoxycarbonyl)furan-2-yl]-2-methylpropanoyl}-N-(D)-aspartic acid trifluoroacetic acid salt (A-35)
A-33 (68 mg, 0.15 mmol) and (D)-aspartic acid dibenzyl ester 4-toluenesulfonate (96 mg, 0.20 mmol) were dissolved in pyridine (0.5 mL), WSC hydrochloride (44 mg, 0.23 mmol) was added, and the mixture was stirred at room temperature overnight. After evaporation of the solvent, ethanol (2 mL) and 10% palladium/carbon (10 mg) were added, and the mixture was stirred at room temperature overnight under a hydrogen atmosphere. The reaction mixture was filtered through celite, and the filtrate was concentrated under reduced pressure to give a residue. The obtained residue was purified by high performance liquid chromatography (water-acetonitrile, each containing 0.1% trifluoroacetic acid) to give the title compound (12.7 mg).
1H-NMR (DMSO-d6) δ 9.42 (br s, 2H), 9.19 (br s, 2H), 8.42-8.31 (m, 1H), 7.93 (d, J=11.4 Hz, 1H), 7.81-7.69 (m, 2H), 7.61-7.56 (m, 1H), 6.56-6.45 (m, 1H), 4.61-4.42 (m, 1H), 3.11-2.88 (m, 2H), 2.87-2.47 (m, 3H), 1.06 (t, J=6.6 Hz, 1H).
MS (ESI) m/z 450 (M+H)+
Example 23 Synthesis of 1-[5-(4-amidinophenoxycarbonyl)furan-2-yl]propane-2-sulfonic acid trifluoroacetic acid salt (A-36)
Step 1. Synthesis of isopropyl 1-[5-(benzyloxycarbonyl)-furan-2-yl]propane-2-sulfonate
Using M-16 and 4-hydroxybenzamidine hydrochloride and by an operation in the same manner as in Example 20, the title compound was obtained.
1H-NMR (300 MHz, CDCl3) δ 7.46-7.33 (6H, m), 7.25 (1H, d, J=3.7 Hz), 6.71 (1H, d, J=3.7 Hz), 5.36 (2H, s), 4.77 (1H, sep, J=6.2 Hz), 2.45 (1H, d, J=1.2 Hz), 1.39 (3H, d, J=6.2 Hz).
Step 2. Synthesis of 1-[5-(4-amidinophenoxycarbonyl)-furan-2-yl]propane-2-sulfonic acid trifluoroacetic acid salt (A-36)
Isopropyl 1-[5-(benzyloxycarbonyl)furan-2-yl]propane-2-sulfonate obtained in step 1 was stirred in 4N hydrochloric acid overnight, and the mixture was purified by high performance liquid chromatography and freeze-dried to give the title compound.
1H-NMR (300 MHz, DMSO-d6) δ 9.32 (2H, br), 8.90 (2H, br), 7.87 (2H, d, J=8.7 Hz), 7.55 (2H, d, J=8.7 Hz), 7.51 (1H, d, J=3.6 Hz), 6.54 (1H, d, J=3.6 Hz), 2.73-2.57 (3H, m), 1.05 (3H, d, J=6.9 Hz).
MS (ESI) m/z 353 (M+H)+
Example 24 Synthesis of N-[5-(4-amidinophenoxycarbonyl)furan-2-ylacetyl]-(L)-aspartic acid trifluoroacetic acid salt (A-39)
5-Carboxymethyl-2-furancarboxylic acid (117 mg, 0.69 mmol) obtained as a byproduct in Example 21, step 3 and L-aspartic acid di-tert-butyl ester hydrochloride (193 mg, 0.68 mmol) were dissolved in dichloromethane (5 mL), WSC hydrochloride (158 mg, 0.82 mmol) and triethylamine (0.5 mL) were added, and the mixture was stirred overnight. After evaporation of the solvent, the residue was purified by high performance liquid chromatography and freeze-dried. The obtained solid (31 mg) and 4-hydroxybenzamidine hydrochloride (15 mg, 0.087 mmol) were dissolved in pyridine (5 ml), WSC hydrochloride (30 mg, 0.16 mmol) was added, and the mixture was stirred overnight. After evaporation of the solvent, trifluoroacetic acid (5 mL) was added, and the mixture was stirred for 30 min. The mixture was purified by high performance liquid chromatography and freeze-dried to give the title compound (23 mg).
1H-NMR (300 MHz, DMSO-d6) δ 9.34 (2H, s), 9.09 (2H, s), 8.55 (1H, d, J=7.8 Hz), 7.89 (2H, d, J=8.7 Hz), 7.56 (3H, m), 6.58 (1H, d, J=3.6 Hz), 4.53 (1H, m), 2.89 (2H, s), 2.64 (2H, m).
MS (ESI) m/z 404 (M+H)+
Example 25 Synthesis of (2E)-3-[5-(4-amidinophenoxycarbonyl)-thiophen-2-yl]-2-methylpropenoic acid trifluoroacetic acid salt (B-1)
Step 1. Synthesis of 3-[5-(4-amidinophenoxycarbonyl)-thiophen-2-yl]-2-methylpropenoic acid tert-butyl ester
5-(2-(tert-Butoxycarbonyl)-1-propenyl)-2-thiophenecarboxylic acid (0.51 g, 1.89 mmol) and 4-hydroxybenzamidine hydrochloride (0.33 g, 1.89 mmol) were dissolved in pyridine (10 mL), WSC hydrochloride (0.54 g, 2.8 mmol) was added, and the mixture was stirred overnight. The mixture was purified by high performance liquid chromatography and freeze-dried to give the title compound (0.63 g).
1H-NMR (300 MHz, DMSO-d6) δ 9.33 (2H, s), 8.98 (2H, s), 8.07 (1H, d, J=3.9 Hz), 7.89 (2H, d, J=8.7 Hz), 7.78 (1H, s), 7.63 (1H, d, J=3.9 Hz), 7.58 (1H, d, J=8.7 Hz), 2.15 (3H, s), 1.49 (9H, s).
Step 2. Synthesis of (2E)-3-[5-(4-amidinophenoxycarbonyl)thiophen-2-yl]-2-methylpropenoic acid trifluoroacetic acid salt (B-1)
To 3-[5-(4-amidinophenoxycarbonyl)thiophen-2-yl]-2-methylpropenoic acid tert-butyl ester (0.63 g) was added trifluoroacetic acid (5 mL), and the mixture was stirred for 30 minutes. The solvent was evaporated to give the title compound (0.62 g).
1H-NMR (300 MHz, DMSO-d6) δ 9.35 (2H, s), 9.00 (2H, s), 8.09 (1H, d, J=3.9 Hz), 7.88 (3H, m), 7.60 (3H, m), 2.18 (3H, s).
MS (ESI) m/z 331 (M+H)+
Example 26 Synthesis of 3-[5-(4-amidinophenoxycarbonyl)-thiophen-2-yl]-2-methylpropanoic acid trifluoroacetic acid salt (B-6)
B-1 (50 mg, 0.11 mmol) was dissolved in a mixed solution of ethanol/water (1/1, 5 mL), a catalytic amount of 10% palladium/carbon was added, and the mixture was stirred at room temperature for 5 hours under a hydrogen atmosphere. The reaction mixture was filtered, and the solvent was evaporated to give the title compound.
1H-NMR (300 MHz, DMSO-d6) δ 9.34 (2H, s), 9.01 (2H, s), 7.91 (2H, m), 7.56 (1H, d, J=9.0 Hz), 7.10 (1H, d, J=3.6 Hz), 3.37 (1H, m), 3.01 (1H, m), 2.73 (1H, m), 1.13 (3H, d, J=4.2 Hz).
MS (ESI) m/z 333 (M+H)+
Example 27 Synthesis of N-{(2E)-3-[5-(4-amidinophenoxycarbonyl)thiophen-2-yl]-2-methylpropenoyl}-N-hydroxypropyltaurine trifluoroacetic acid salt (B-7)
B-1 (30 mg, 0.068 mmol) was suspended in thionyl chloride (4 and the suspension was stirred at 70° C. for 30 minutes. After evaporation of the solvent, dichloromethane (2 mL), M-7 (25 mg, 0.072 mmol) and pyridine (50 μL) were added, and the mixture was stirred for 30 minutes. After evaporation of the solvent, trifluoroacetic acid (3 mL) was added, and the mixture was stirred for 30 minutes. After evaporation of the solvent, 4M hydrochloric acid (2 ml) and acetonitrile (0.5 mL) were added, and the mixture was stirred at room temperature for 2 days. The mixture was purified by high performance liquid chromatography and freeze-dried to give the title compound (4.9 mg).
1H-NMR (300 MHz, DMSO-d6) δ 9.35 (2H, s), 8.91 (2H, s), 8.03 (1H, d, J=4.2 Hz), 7.90 (2H, d, J=8.7 Hz), 7.60 (2H, d, J=8.7 Hz), 7.40 (1H, d, J=4.2 Hz), 6.84 (1H, s), 4.48 (1H, br s), 3.55 (2H, m), 3.20-3.45 (4H, m), 2.70 (2H, m), 2.15 (3H, s), 1.67 (2H, m).
MS (ESI) m/z 496 (M+H)+
Example 28 Synthesis of N-{3-[5-(4-amidino-2-nitrophenoxycarbonyl)thiophen-2-yl]-2-methylpropanoyl}-N-(3-hydroxypropyl)glycine hydrochloride (B-11)
Step 1. Synthesis of N-{(1E)-3-[5-(methoxycarbonyl)-thiophen-2-yl]-2-methylpropenoyl}-N-[3-(triisopropylsilyloxy)-propyl]glycine tert-butyl ester
To 5-[(1E)-2-(tert-butoxycarbonyl)-2-methyl-prop-1-en-1-yl]thiophene-2-carboxylic acid methyl ester (600 mg, 2.13 mmol) obtained in Example 12, step 1 was added trifluoroacetic acid (5 mL), and the mixture was stirred at room temperature for 10 minutes. The reaction mixture was concentrated under reduced pressure. The obtained residue was dissolved in dichloromethane (15 ml), oxalyl chloride (0.37 ml, 4.26 mmol) and N,N-dimethylformamide (50 μL) were added, and the mixture was stirred at room temperature for 15 minutes. The reaction mixture was concentrated under reduced pressure, the obtained residue was dissolved in dichloromethane (10 mL), and M-5 (0.81 g, 2.34 mmol) obtained in step 1 and pyridine (5 mL) were added. After stirring at room temperature for 15 minutes, the reaction mixture was concentrated under reduced pressure, and the obtained residue was purified by silica gel column chromatography (hexane/ethyl acetate=80/20) to give the title compound (477 mg, 0.86 mmol, 40%).
MS (ESI) m/z 554 (M+H)+
Step 2. Synthesis of N-{3-[5-(4-amidino-2-nitrophenoxycarbonyl)thiophen-2-yl]-2-methylpropanoyl}-N-(3-hydroxypropyl)glycine hydrochloride (B-11)
The compound (477 mg, 0.86 mmol) obtained in step 1 was dissolved in tetrahydrofuran (15 mL) and methanol (3 mL), and water (1 mL), and 1N aqueous sodium hydroxide solution (1.0 mL, 1.0 mmol) were added thereto. After stirring at room temperature for 22 hours, 1N aqueous sodium hydroxide solution (0.43 mL, 0.43 mmol) was added to the reaction mixture, and the mixture was further stirred for 4 hours. 1N Aqueous sodium hydroxide solution (1.2 mL, 1.2 mmol) was added to the reaction mixture, and the mixture was stirred for 3 hours and acidified with 1N hydrochloric acid. To the reaction mixture was added saturated brine, and the mixture was extracted three times with dichloromethane. The extract was dried over sodium sulfate, and the solvent was evaporated under reduced pressure to give a residue (430 mg).
The obtained residue (400 mg) was dissolved in ethanol (12 mL) and chloroform (50 μL), 10% palladium/carbon (40 mg) was added, and the mixture was stirred at room temperature overnight under a hydrogen atmosphere. The reaction mixture was filtered through celite, and the filtrate was concentrated under reduced pressure to give a residue (335 mg).
To the obtained residue (335 mg) were added M-8 (209 mg, 0.96 mmol), WSC hydrochloride (169 mg, 0.88 mmol), and pyridine (33 mL), and the mixture was stirred at room temperature for 15 hours. The reaction mixture was concentrated under reduced pressure, trifluoroacetic acid (10 mL) was added to the obtained residue, and the mixture was stirred at room temperature for 1 hour. Trifluoroacetic acid was evaporated under reduced pressure to give a residue. Water (5 mL) and acetonitrile (2 mL) were added to the obtained residue, and the mixture was stirred overnight and purified by high performance liquid chromatography (water-acetonitrile, each containing 0.1% trifluoroacetic acid) to give trifluoroacetic acid salt of the title compound.
To the obtained trifluoroacetic acid salt were added 0.1N hydrochloric acid (3.6 ml) and water (10 mL), and the mixture was freeze-dried to give the title compound (162 mg, 0.30 mmol, 38%).
1H-NMR (300 MHz, DMSO-d6) δ 9.62 (2H, br), 9.30 (2H, br), 8.64 (1H, d, J=2.1 Hz), 8.26 (1H, dd, J=8.4, 2.1 Hz), 7.94-7.91 (2H, m), 7.14-7.11 (1H, m), 4.57-3.77 (3H, m), 3.51-2.92 (6H, m), 1.62-1.51 (2H, m), 1.12-1.04 (3H, m).
MS (ESI) m/z 493 (M+H)+
Example 29 Synthesis of 3-[5-(4-amidino-2-bromophenoxycarbonyl)thiophen-2-yl]-2-methylpropionic acid trifluoroacetic acid salt (B-16)
M-9 (33 mg, 0.10 mmol), M-4 (27 mg, 0.10 mmol), and WSC hydrochloride (21 mg, 0.11 mmol) were dissolved in pyridine (1.0 ml), and the mixture was stirred overnight and concentrated under reduced pressure. Trifluoroacetic acid (1.5 mL) was added to the residue, and the mixture was stirred for 30 minutes and concentrated under reduced pressure. The obtained residue was purified by high performance liquid chromatography (water-acetonitrile, each containing 0.1% trifluoroacetic acid) to give the title compound (9.0 mg, 0.017 mmol, 17%).
MS (ESI) m/z 411 [M(79Br)+H]+, 413 [M(81Br)+H]+
Example 30 Synthesis of (2E)-3-[4-(4-amidinophenoxycarbonyl)-thiazol-2-yl]-2-methylpropenoic acid trifluoroacetic acid salt (C-1)
Step 1. Synthesis of 2-formyl-4-thiazolecarboxylic acid ethyl ester
2-(Diethoxymethyl)-4-thiazolecarboxylic acid ethyl ester (2.90 g, 11.8 mmol) synthesized according to Bull. Chem. Soc. Jpn., 58, 352 (1985), which is incorporated herein by reference in its entirety, was dissolved in acetone (37.3 mL), 1N aqueous hydrochloric acid solution (3.73 mL) was added, and the mixture was stirred with heating at 60° C. for 4 hours. After evaporation of the solvent, the mixture was worked up according to a conventional method to give the title compound as a crude product (2.13 g).
Step 2. Synthesis of 3-[4-(ethoxycarboxyl)thiazol-2-yl]-2-methylpropenoic acid tert-butyl ester
To tetrahydrofuran (38.0 mL) was added 60% sodium hydride (669 mg, 15.3 mmol) at 0° C. to give a suspension, a tetrahydrofuran solution (8 mL) of M-13 (4.17 g, 15.7 mmol) was added dropwise thereto, and the mixture was heated to room temperature. After stirring for 30 minutes, the mixture was cooled again to 0° C., and a tetrahydrofuran solution (10 mL) of the crude product (2.07 g) obtained in step 1 was added dropwise. Thereafter, the mixture was heated to room temperature and stirred at room temperature overnight. The mixture was worked up according to a conventional method, and the object product was extracted by column chromatography (10-15% ethyl acetate/hexane mixed solvent) to give the title compound (1.84 g, 6.19 mmol, 2 steps 55%).
1H-NMR (300 MHz, CDCl3) δ 8.29 (1H, s), 7.88 (1H, t, J=1.2 Hz), 4.46 (2H, q, J=7.2 Hz), 2.30 (3H, d, J=1.2 Hz), 1.54 (9H, s), 1.43 (3H, t, J=7.2 Hz).
MS (ESI) m/z 278 (M+H)+
Step 3. Synthesis of (2E)-3-[4-(4-amidinophenoxycarbonyl)thiazol-2-yl]-2-methylpropenoic acid trifluoroacetic acid salt (C-1)
Using 3-[4-(ethoxycarboxyl)thiazol-2-yl]-2-methylpropenoic acid tert-butyl ester obtained in step 2 and 4-hydroxybenzamidine hydrochloride and by an operation in the same manner as in Example 16, the title compound was obtained.
1H-NMR (DMSO-d6) δ 9.36 (2H, br s), 9.09 (2H, br s), 7.93 (2H, J=8.6 Hz), 7.75 (1H, s), 7.63 (2H, d, J=8.6 Hz), 2.33 (3H, s), 2.30 (1H, s).
MS (ESI) m/z 332 (M+H)+
The compounds A-1, A-2, A-4, A-5, A-7, A-9 to A-11, A-14 to A-21, A-26 to A-28, A-30, A-31, A-38, A-40, B-2 to B-5, B-10, B-12, B-18, B-20 to B-24, C-2, and C-3 shown in the following Table 2 were each synthesized using M-1 to M-16 and commercially available reagents and by an operation in the same manner as in the above-mentioned Example 19. Furthermore, B-18 was converted to a salt according to Example 28, step 2, and hydrochloride thereof was also obtained (B-18 hydrochloride).
The compounds A-8, A-33, A-34, A-37, B-1, B-8, B-9, B-17, and B-24 shown in the following Table 2 were each synthesized using M-1 to M-16 and commercially available reagents and by an operation in the same manner as in the above-mentioned Example 17.
The compounds B-13 to B-15 shown in the following Table 2 were each synthesized using M-1 to M-16 and commercially available reagents and by an operation in the same manner as in the above-mentioned Example 28.
Example 31 Synthesis of 3-[5-(4-amidinophenoxycarbonyl)furan-2-yl]-2S-methylpropionic acid trifluoroacetic acid salt (A-41)
Step 1. Optical resolution of 5-(2-tert-butoxycarbonylpropyl)furan-2-carboxylic acid methyl ester
5-(2-tert-Butoxycarbonylpropyl)furan-2-carboxylic acid methyl ester (303 mg, 1.13 mmol) synthesized in Example 11, step 1 was optically resolved by high performance liquid chromatography using a chiral column (CHIRALCEL (registered trademark) OD, 20 mm×250 mm, 2-propanol:n-hexane=1:99, 1 mL/minute) to give respective optically active forms (S form: 105 mg, R form: 131 mg).
Step 2. Synthesis of 3-[5-(4-amidinophenoxycarbonyl)-furan-2-yl]-2S-methylpropionic acid trifluoroacetic acid salt (A-41)
The optically active S form (105 mg, 0.39 mmol) obtained in step 1 was dissolved in ethanol (1.3 mL), 1N aqueous lithium hydroxide solution (1 mol/L, 0.47 mL, 0.47 mmol) was added, and the mixture was stirred at room temperature for 4 hours. 1N Hydrochloric acid (0.47 mL) was added to the reaction mixture, and the mixture was concentrated under reduced pressure. 0.5N Hydrochloric acid and ethyl acetate were added to the obtained residue, the organic layer was extracted, and the aqueous layer was extracted three times with ethyl acetate. The organic layers were collected, washed with saturated brine, and dried by dehydration with sodium sulfate. After filtration, the solvent of the filtrate was evaporated under reduced pressure.
To the obtained residue were added 4-amidinophenol hydrochloride (88 mg, 0.51 mmol) and WSC hydrochloride (112 mg, 0.59 mmol), and the mixture was dissolved in pyridine (1.5 mL). After stirring at room temperature overnight, the reaction mixture was concentrated under reduced pressure, the obtained residue was dissolved in trifluoroacetic acid (containing 5% water, 1.5 mL), and the mixture was stirred at room temperature for 2 hours. The reaction mixture was concentrated under reduced pressure, and the obtained residue was purified by high performance liquid chromatography (acetonitrile-water, each containing 0.1% trifluoroacetic acid, 5-35%) to give the title compound (90.0 mg, 0.209 mmol, 53%).
1H-NMR (300 MHz, DMSO-d6) δ 9.35 (2H, br s), 9.08 (2H, br s), 7.90 (2H, dd, J=6.9, 1.8 Hz), 7.61-7.49 (3H, m), 6.52 (1H, d, J=3.6 Hz), 3.15-2.98 (1H, m), 2.90-2.70 (2H, m), 1.14 (3H, d, J=6.9 Hz).
MS (ESI) m/z 317 (M+H)+
Example 32 Synthesis of 3-[5-(4-amidinophenoxycarbonyl)furan-2-yl]-2R-methylpropionic acid trifluoroacetic acid salt (A-42)
The optically active R form (130 mg, 0.48 mmol) obtained in Example 31, step 1 was dissolved in ethanol (1.0 mL), 1N aqueous lithium hydroxide solution (1 mol/L, 0.73 mL, 0.73 mmol) was added, and the mixture was stirred at room temperature for 2 hours. 1N Hydrochloric acid (0.73 mL) was added to the reaction mixture, and the mixture was concentrated under reduced pressure. 0.5N Hydrochloric acid and ethyl acetate were added to the obtained residue, the organic layer was extracted, and the aqueous layer was extracted three times with ethyl acetate. The organic layers were collected, washed with saturated brine, and dried by dehydration with sodium sulfate. After filtration, the solvent of the filtrate was evaporated under reduced pressure.
To the obtained residue were added 4-amidinophenol hydrochloride (108 mg, 0.62 mmol) and WSC hydrochloride (138 mg, 0.72 mmol), and the mixture was dissolved in pyridine (1.6 mL). After stirring at room temperature overnight, the reaction mixture was concentrated under reduced pressure, the obtained residue was dissolved in trifluoroacetic acid (containing 5% water, 1.6 mL), and the mixture was stirred at room temperature for 2 hours. The reaction mixture was concentrated under reduced pressure and the obtained residue was purified by high performance liquid chromatography (acetonitrile-water, each containing 0.1% trifluoroacetic acid, 5-35%) to give the title compound (112 mg, 0.260 mmol, 54%).
1H-NMR (300 MHz, DMSO-d6) δ 9.35 (2H, br s), 9.08 (2H, br s), 7.90 (2H, dd, J=6.9, 1.8 Hz), 7.61-7.49 (3H, m), 6.52 (1H, d, J=3.6 Hz), 3.15-2.98 (1H, m), 2.90-2.70 (2H, m), 1.14 (3H, d, J=6.9 Hz).
MS (ESI) m/z 317 (M+H)+
Example 33 Synthesis of N-{3-[5-(4-amidinophenoxycarbonyl)-furan-2-yl]-2S-methylpropionyl}-L-aspartic acid trifluoroacetic acid salt (A-43)
A-41 (31 mg, 0.072 mmol) was dissolved in thionyl chloride (500 μL), and the mixture was stirred at 70° C. for 20 minutes. Thionyl chloride was evaporated under reduced pressure, and the obtained residue and L-aspartic acid di-tert-butyl ester hydrochloride (30.4 mg, 0.11 mmol) were dissolved in dichloromethane (350 μL). Pyridine (150 μL) was added, and the mixture was stirred at room temperature overnight. The reaction mixture was concentrated under reduced pressure, trifluoroacetic acid (500 μL) was added to the obtained residue, and the mixture was stirred at room temperature for 30 minutes. The reaction mixture was concentrated under reduced pressure and the obtained residue was purified by high performance liquid chromatography (acetonitrile-water, each containing 0.1% trifluoroacetic acid, 5-35%) to give the title compound (32 mg, 0.059 mmol, 81%).
1H-NMR (300 MHz, DMSO-d6) δ 9.34 (2H, br s), 9.10 (2H, br s), 8.32 (1H, d, J=8.7 Hz), 7.90 (2H, d, J=8.7 Hz), 7.54 (2H, d, J=8.7 Hz), 7.50 (1H, d, J=3.3 Hz), 6.46 (1H, d, J=3.3 Hz), 4.59-4.49 (1H, m), 3.08-2.47 (5H, m), 1.07 (3H, d, J=5.4 Hz).
MS (ESI) m/z 432 (M+H)+
Example 34 Synthesis of N-[3-[5-(4-amidinophenoxycarbonyl)-furan-2-yl]-2R-methylpropionyl]-L-aspartic acid trifluoroacetic acid salt (A-44)
A-42 (30.8 mg, 0.072 mmol) was dissolved in thionyl chloride (500 μL), and the mixture was stirred at 70° C. for 20 minutes. Thionyl chloride was evaporated under reduced pressure, and the obtained residue and L-aspartic acid di-tert-butyl ester hydrochloride (30.3 mg, 0.11 mmol) were dissolved in dichloromethane (350 μL). Pyridine (150 μL) was added, and the mixture was stirred at room temperature overnight. The reaction mixture was concentrated under reduced pressure, trifluoroacetic acid (500 μL) was added to the obtained residue, and the mixture was stirred at room temperature for 30 minutes. The reaction mixture was concentrated under reduced pressure, and the obtained residue was purified by high performance liquid chromatography (acetonitrile-water, each containing 0.1% trifluoroacetic acid, 5-35%) to give the title compound (33 mg, 0.061 mmol, 85%).
1H-NMR (300 MHz, DMSO-d6) δ 9.34 (2H, br s), 9.09 (2H, br s), 8.36 (1H, d, J=8.4 Hz), 7.90 (2H, d, J=8.7 Hz), 7.55 (2H, d, J=8.7 Hz), 7.51 (1H, d, J=3.6 Hz), 6.50 (1H, d, J=3.6 Hz), 4.57-4.45 (1H, m), 3.05-2.42 (5H, m), 1.05 (3H, d, J=6.6 Hz).
MS (ESI) m/z 432 (M+H)+
Example 35 Synthesis of N-{3-[5-(4-amidinophenoxycarbonyl)-furan-2-yl]-2S-methylpropionyl}-D-aspartic acid trifluoroacetic acid salt (A-45)
A-41 (31 mg, 0.072 mmol) was dissolved in thionyl chloride (500 μL), and the mixture was stirred at 70° C. for 20 minutes. Thionyl chloride was evaporated under reduced pressure, and the obtained residue and D-aspartic acid dibenzyl ester tosylate (56.7 mg, 0.12 mmol) were dissolved in dichloromethane (350 μL). Pyridine (150 μL) was added, and the mixture was stirred at room temperature for 2 hours. The reaction mixture was concentrated under reduced pressure, and the obtained residue was dissolved in ethanol (1 mL). 10% Palladium/carbon (5 mg) was added, and the mixture was stirred at room temperature overnight under a hydrogen atmosphere. After completion of the reaction, palladium/carbon was removed by celite filtration. The solvent was evaporated under reduced pressure, and the obtained residue was purified by high performance liquid chromatography (acetonitrile-water, each containing 0.1% trifluoroacetic acid, 5-45%) to give the title compound (8.0 mg, 0.015 mmol, 19%).
1H-NMR (300 MHz, DMSO-d6) δ 9.34 (2H, br s), 9.09 (2H, br s), 8.36 (1H, d, J=8.4 Hz), 7.90 (2H, d, J=8.7 Hz), 7.55 (2H, d, J=8.7 Hz), 7.51 (1H, d, J=3.6 Hz), 6.50 (1H, d, J=3.6 Hz), 4.57-4.45 (1H, m), 3.05-2.42 (5H, m), 1.05 (3H, d, J=6.6 Hz).
MS (ESI) m/z 432 (M+H)+
Example 36 Synthesis of N-{3-[5-(4-amidinophenoxycarbonyl)-furan-2-yl]-2R-methylpropionyl}-D-aspartic acid trifluoroacetic acid salt (A-46)
A-42 (34.4 mg, 0.080 mmol) was dissolved in thionyl chloride (500 μL), and the mixture was stirred at 70° C. for 20 minutes. Thionyl chloride was evaporated under reduced pressure, and the obtained residue and D-aspartic acid dibenzyl ester tosylate (58.2 mg, 0.12 mmol) were dissolved in dichloromethane (350 μL). Pyridine (150 μL) was added, and the mixture was stirred at room temperature for 2 hours. The reaction mixture was concentrated under reduced pressure, and the obtained residue was dissolved in ethanol (1 mL). 10% Palladium/carbon (5 mg) was added, and the mixture was stirred at room temperature overnight under a hydrogen atmosphere. After completion of the reaction, palladium/carbon was removed by celite filtration. The solvent was evaporated under reduced pressure, and the obtained residue was purified by high performance liquid chromatography (acetonitrile-water, each containing 0.1% trifluoroacetic acid, 5-35%) to give the title compound (33.0 mg, 0.061 mmol, 76%).
1H-NMR (300 MHz, DMSO-d6) δ 9.34 (2H, br s), 9.10 (2H, br s), 8.32 (1H, d, J=8.7 Hz), 7.90 (2H, d, J=8.7 Hz), 7.54 (2H, d, J=8.7 Hz), 7.50 (1H, d, J=3.3 Hz), 6.46 (1H, d, J=3.3 Hz), 4.59-4.49 (1H, m), 3.08-2.47 (5H, m), 1.07 (3H, d, J=5.4 Hz).
MS (ESI) m/z 432 (M+H)+
Example 37 Synthesis of N-{3-[5-(4-amidino-2-fluorophenoxycarbonyl)thiophen-2-yl]-2R-methylpropionyl}-L-aspartic acid trifluoroacetic acid salt (B-25)
Step 1. Synthesis of (2R)-5-(2-tert-butoxycarbonylpropyl)thiophene-2-carboxylic acid
Using 5-(2-tert-butoxycarbonylpropyl)thiophene-2-carboxylic acid methyl ester obtained as an intermediate of Example 13, and in the same manner as in Example 31, optical resolution was performed. The obtained (2R)-5-(2-tert-acid methyl ester (0.18 g, 0.63 mmol) was suspended in methanol (1.6 mL) and tetrahydrofuran (1.6 mL), 1N aqueous lithium hydroxide solution (1.6 mL) was added, and the mixture was stirred overnight. 1N Hydrochloric acid (2 mL) was added to the to reaction mixture, and the mixture was extracted with ethyl acetate. The extract was washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to give the title compound (0.17 g).
MS (ESI) m/z 271 (M+H)+
Step 2. Synthesis of N-{3-[5-(4-amidino-2-fluorophenoxycarbonyl)thiophen-2-yl]-2R-methylpropionyl}-L-aspartic acid trifluoroacetic acid salt (B-25)
The obtained (2R)-5-(2-tert-butoxycarbonylpropyl)-thiophene-2-carboxylic acid (0.17 g, 0.66 mmol), 4-amidino-2-fluorophenol hydrochloride (0.27 g, 0.99 mmol), and WSC hydrochloride (0.82 g, 1.31 mmol) were dissolved in pyridine, and the mixture was stirred for 2 hours. Trifluoroacetic acid (5 mL) was added, and the mixture was stirred for 20 minutes. The solvent was evaporated under reduced pressure, purified by high performance liquid chromatography and freeze-dried to give a white solid (75 mg). The obtained white solid (30 mg, 0.06 mmol), L-aspartic acid di-tert-butyl ester hydrochloride (20 mg, 0.07 mmol), and WSC hydrochloride (35 mg, 0.18 mmol) were dissolved in pyridine (3 mL), and the mixture was stirred for 3 hours. The solvent was evaporated under reduced pressure, trifluoroacetic acid (3 mL) was added, and the mixture was stirred for 20 minutes. The solvent was evaporated under reduced pressure, and purified by high performance liquid chromatography and freeze-dried to give the title compound (28 mg).
1H-NMR (400 MHz, DMSO-d6) δ 9.41 (2H, s), 9.12 (2H, s), 8.32 (1H, d, J=8.0 Hz), 7.93 (2H, m), 7.74 (2H, m), 7.09 (1H, d, J=3.6 Hz), 4.50 (1H, m), 3.16 (1H, dd, J=14.8, 7.6 Hz), 2.90 (1H, dd, J=14.8, 6.4 Hz), 2.75-2.65 (2H, m), 2.55 (1H, dd, J=8.4, 1.2 Hz), 1.05 (3H, d, J=6.8 Hz).
MS (ESI) m/z 466 (M+H)+
Example 38 Synthesis of N-{3-[5-(4-amidino-2-fluorophenoxycarbonyl)thiophen-2-yl]-2R-isobutylpropionyl}-L-aspartic acid trifluoroacetic acid salt (B-26)
Step 1. Synthesis of 2-(diethylphosphono)-4-methylpentanoic acid tert-butyl ester (M-17)
Using isobutyl bromide instead of ethyl iodide and in the same manner as in Example 7, the compound was synthesized.
1H-NMR (300 MHz, DMSO-d6) δ 4.08-3.98 (4H, m), 2.85 (1H, ddd, J=22.8, 11.4, 3.3 Hz), 1.85-1.75 (1H, m), 1.60-1.45 (2H, m), 1.50 (9H, s), 1.22 (6H, m), 0.88 (6H, d, J=7.5 Hz).
MS (ESI) m/z 309 (M+H)+
Step 2. Synthesis of N-{3-[5-(4-amidino-2-fluorophenoxycarbonyl)thiophen-2-yl]-2R-isobutylpropionyl}-L-aspartic acid trifluoroacetic acid salt (B-26)
Using M-17 obtained in step 1 and in the same manner as in Examples 12, 13 and 37, the title compound was synthesized.
1H-NMR (400 MHz, DMSO-d6) δ 9.41 (2H, s), 9.15 (2H, s), 8.39 (1H, d, J=8.0 Hz), 7.93 (2H, m), 7.75 (2H, m), 7.10 (1H, d, J=4.0 Hz), 4.51 (1H, m), 3.07 (1H, dd, J=14.8, 8.0 Hz), 2.92 (1H, dd, J=14.8, 6.4 Hz), 2.80-2.65 (2H, m), 2.55 (1H, m), 1.50 (2H, m), 1.13 (1H, m), 0.80 (6H, m).
MS (ESI) m/z 508 (M+H)+
Example 39 Synthesis of 5-{2-methyl-2-[(2-phenylethyl)-carbamoyl]ethyl}furan-2-carboxylic acid 4-amidinophenyl ester trifluoroacetic acid salt (A-47)
A-6 (50 mg, 0.12 mmol), phenethylamine (17 mg, 0.14 mmol), and WSC hydrochloride (46 mg, 0.24 mmol) were dissolved in pyridine (2 mL), and the mixture was stirred at room temperature for 2 hours. The solvent was evaporated under reduced pressure and the residue was purified by high performance liquid chromatography to give the title compound (31 mg).
1H-NMR (300 MHz, DMSO-d6) δ 9.32 (2H, s), 9.00 (2H, s), 8.00 (1H, t, J=5.4 Hz), 7.87 (2H, d, J=8.7 Hz), 7.52 (2H, m), 7.30-7.10 (6H, m), 6.40 (1H, d, J=3.3 Hz), 3.30-3.20 (2H, m), 3.00-2.90 (1H, m), 2.70-2.60 (4H, m), 1.01 (3H, d, J=6.6 Hz).
MS (ESI) m/z 420 (M+H)+
Example 40 Synthesis of N-{3-[5-(4-amidinophenoxycarbonyl)-furan-2-yl]-2-methylpropanoyl}nipecotic acid trifluoroacetic acid salt (A-52)
A-6 (30 mg, 0.07 mmol), nipecotic acid tert-butyl ester (13 mg, 0.07 mmol), and WSC hydrochloride (63 mg, 0.33 mmol) were dissolved in pyridine (3 mL), and the mixture was stirred at room temperature overnight. The solvent was evaporated under reduced pressure, trifluoroacetic acid (3 mL) was added, and the mixture was stirred at room temperature for 30 minutes. The solvent was evaporated under reduced pressure and the residue was purified by high performance liquid chromatography to give the title compound (20 mg).
1H-NMR (400 MHz, DMSO-d6) δ 9.34 (2H, s), 8.98 (2H, s), 7.89 (2H, m), 7.55 (3H, m), 6.48 (1H, d, J=3.2 Hz), 3.90-3.80 (2H, m), 3.55-3.25 (2H, m), 3.08-2.98 (2H, m), 2.80-2.70 (2H, m), 2.10-1.20 (4H, m), 1.07 (3H, d, J=6.4 Hz).
MS (ESI) m/z 428 (M+H)+
Example 41 Synthesis of N-{3-[5-(4-amidino-2-methoxyphenoxycarbonyl)furan-2-yl]-propanoyl}-L-aspartic acid trifluoroacetic acid salt (A-53)
Step 1. Synthesis of 4-amidino-2-methoxyphenol hydrochloride
To 3-methoxy-4-hydroxybenzonitrile (2.0 g, 13.4 mmol) were added ethanol (3 mL) and 4N hydrochloric acid/1,4-dioxane (27 mL), and the mixture was stirred at room temperature overnight. The solvent was evaporated under reduced pressure and the residue was dissolved in ethanol (50 mL). Ammonium carbonate (6.4 g, 67 mmol) was added, and the mixture was stirred at room temperature overnight. The solvent was evaporated under reduced pressure, water was added and the mixture was freeze-dried to give the title compound (1.82 g).
1H-NMR (400 MHz, DMSO-d6) δ 9.40-8.70 (5H, br s), 7.46 (1H, d, J=2.4 Hz), 7.40 (1H, dd, J=8.4, 2.4 Hz), 6.97 (1H, d, J=8.4 Hz), 3.86 (3H, s).
MS (ESI) m/z 167 (M+H)+
Step 2. Synthesis of 5-(2-tert-butoxycarbonylethenyl)-furan-2-carboxylic acid benzyl ester
A solution of diethylphosphonoacetic acid tert-butyl ester (1.54 g, 6.09 mmol) in tetrahydrofuran (3 mL) was added dropwise to a suspension of 60% sodium hydride (0.19 g, 4.87 mmol) in tetrahydrofuran (50 mL) with stirring at 0° C. After stirring at room temperature for 20 minutes, a solution of 5-formyl-2-furancarboxylic acid benzyl ester (1.0 g, 4.06 mmol) in tetrahydrofuran (3 mL) was added, and the mixture was stirred at room temperature for 1 hour. The mixture was worked up according to a conventional method, and the object product was extracted by column chromatography (10-30% ethyl acetate/hexane mixed solvent) to give the title compound (1.17 g).
1H-NMR (400 MHz, CDCl3) δ 7.45-7.35 (5H, m), 7.32 (1H, d, J=16.0 Hz), 7.20 (1H, d, J=3.6 Hz), 6.62 (1H, d, J=3.6 Hz), 6.49 (1H, d, J=16.0 Hz), 5.35 (2H, s), 1.50 (9H, s).
Step 3. Synthesis of 5-(2-tert-butoxycarbonylethyl)-furan-2-carboxylic acid (M−22)
5-(2-tert-Butoxycarbonylethenyl)furan-2-carboxylic acid benzyl ester (0.97 g, 2.80 mmol) was dissolved in methanol (50 mL), 10% palladium/carbon (0.1 g) was added, and the mixture was stirred at room temperature for 2 hours under a hydrogen atmosphere. After completion of the reaction, palladium/carbon was removed by celite filtration, and the solvent was evaporated under reduced pressure to give the title compound (0.66 g).
1H-NMR (400 MHz, CDCl3) δ 7.23 (1H, d, J=3.6 Hz), 6.22 (1H, d, J=3.6 Hz), 3.01 (2H, t, J=7.6 Hz), 2.63 (2H, t, J=7.6 Hz), 1.44 (9H, s).
MS (ESI) m/z 241 (M+H)+
Step 4. Synthesis of N-{3-[5-(4-amidino-2-methoxyphenoxycarbonyl)furan-2-yl]-propanoyl}-L-aspartic acid trifluoroacetic acid salt (A-53)
4-Amidino-2-methoxyphenol hydrochloride (63 mg, 0.31 mmol) obtained in step 1, M-22 (50 mg, 0.21 mmol) and WSC hydrochloride (80 mg, 0.42 mmol) were dissolved in pyridine, and the mixture was stirred for 1 hour. The solvent was evaporated, and the residue was purified by high performance liquid chromatography to give a white solid (39 mg). The obtained white solid (20 mg), L-aspartic acid di-tert-butyl ester hydrochloride (20 mg, 0.07 mmol), and WSC hydrochloride (20 mg, 0.10 mmol) were dissolved in pyridine (3 mL), and the mixture was stirred overnight. The solvent was evaporated under reduced pressure, trifluoroacetic acid (3 mL) was added, and the mixture was stirred for 30 minutes. The solvent was evaporated under reduced pressure, and the residue was purified by high performance liquid chromatography and freeze-dried to give the title compound (19 mg).
1H-NMR (400 MHz, DMSO-d6) δ 9.35 (2H, s), 9.01 (2H, s), 8.37 (1H, d, J=8.0 Hz), 7.57 (1H, d, J=2.0 Hz), 7.52-7.44 (3H, m), 6.47 (1H, d, J=2.0 Hz), 4.55 (1H, m), 3.88 (3H, s), 2.97 (2H, t, J=7.6 Hz), 2.68-2.55 (4H, m).
MS (ESI) m/z 448 (M+H)+
Example 42 Synthesis of N-{3-[5-(4-amidinophenoxycarbonyl)-furan-2-yl]-propanoyl}-N-(2-carboxyethyl)-glycine trifluoroacetic acid salt (A-54)
Step 1. Synthesis of N-(2-carboxyethyl)glycine di-tert-butyl ester hydrochloride (M-20)
β-Alanine tert-butyl ester hydrochloride (1.0 g, 5.5 mmol) was dissolved in dichloromethane (10 ml), triethylamine (1.52 mL, 11.1 mmol) and bromoacetic acid tert-butyl ester (0.57 g, 2.9 mmol) were added, and the mixture was stirred for 2 hours. The solvent was evaporated, and the residue was purified by high performance liquid chromatography. To the fraction containing the object product was added 0.1N hydrochloric acid (30 mL), and the mixture was freeze-dried to give the title compound (0.52 g).
1H-NMR (400 MHz, CDCl3) δ 3.75 (2H, s), 3.29 (2H, t, J=6.4 Hz), 2.94 (2H, d, J=6.4 Hz), 1.51 (9H, s), 1.47 (9H, s).
MS (ESI) m/z 246 (M+H)+
Step 2. Synthesis of (2E)-3-[5-(benzyloxycarbonyl)furan-2-yl]-2-propenoic acid
To 5-(2-tert-butoxycarbonylethenyl)furan-2-carboxylic acid benzyl ester (0.15 g, 0.46 mmol) obtained in Example 41, step 2 was added trifluoroacetic acid (3 ml), and the mixture was stirred for 30 minutes. The solvent was evaporated under reduced pressure to give the title compound.
1H-NMR (400 MHz, CDCl3) δ 7.80 (1H, d, J=15.6 Hz), 7.75 (1H, d, J=3.6 Hz), 7.45-7.35 (5H, m), 7.25 (1H, d, J=3.6 Hz), 6.35 (1H, d, J=15.6 Hz), 5.34 (2H, s).
Step 3. Synthesis of N-{3-[5-(4-amidinophenoxycarbonyl)-furan-2-yl]-propanoyl}-N-(2-carboxyethyl)glycine trifluoroacetic acid salt (A-54)
(2E)-3-[5-(benzyloxycarbonyl)furan-2-yl]-2-propenoic acid (40 mg, 0.15 mmol) was suspended in thionyl chloride (4 mL), and the suspension was stirred at 70° C. for 30 minutes. After evaporation of the solvent, dichloromethane (2 mL), M-20 (42 mg, 0.16 mmol) and triethylamine (42 μL, 0.3 mmol) were added, and the mixture was stirred for 30 minutes. After evaporation of the solvent, the residue was purified by silica gel column chromatography. The obtained solid was dissolved in ethanol (5 mL), a catalytic amount of 10% palladium/carbon was added, and the mixture was stirred at room temperature for 1 hour under a hydrogen atmosphere. The reaction mixture was filtered through celite, and the filtrate was concentrated under reduced pressure to give a residue (30 mg). The obtained residue, 4-hydroxybenzamidine hydrochloride (15 mg, 0.09 mmol) and WSC hydrochloride (20 mg, 0.10 mmol) were dissolved in pyridine (3 mL), and the mixture was stirred at room temperature overnight. After evaporation of the solvent, trifluoroacetic acid (3 mL) was added, and the mixture was stirred for 30 minutes. After evaporation of the solvent, the residue was purified by high performance liquid chromatography and freeze-dried to give the title compound (14 mg).
1H-NMR (400 MHz, DMSO-d6) δ 9.34 (2H, s), 8.96 (2H, s), 7.89 (2H, dd, J=6.8, 2.0 Hz), 7.54 (3H, m), 6.52 (0.5H, d, J=3.6 Hz), 6.48 (0.5H, d, J=3.6 Hz), 4.23 (1H, s), 3.96 (1H, s), 3.60 (1H, t, J=6.8 Hz), 3.46 (1H, t, J=6.8 Hz), 2.98-2.85 (2H, m), 2.70-2.40 (2H, m).
MS (ESI) m/z 418 (M+H)+
Example 43 Synthesis of N-{3-[5-(4-amidinophenoxycarbonyl)-furan-2-yl]-propionyl}-N-allylglycine trifluoroacetic acid salt (A-55)
Step 1. Synthesis of N-allylglycine tert-butyl ester (M-21)
Allylamine (10 mL, 0.13 mol) was cooled to 0° C., and a solution of bromoacetic acid tert-butyl ester (1.0 mL, 6.7 mmol) in dichloromethane (10 mL) was slowly added. After stirring at 0° C. for 3 hours, the reaction mixture was concentrated under reduced pressure. The obtained residue was dissolved in diethyl ether, washed successively with saturated aqueous sodium hydrogen carbonate and saturated brine, and dried over anhydrous sodium sulfate. The obtained solution was concentrated under reduced pressure to give the title compound as a yellow liquid (1.15 g, 6.7 mmol, 99%).
1H-NMR (400 MHz, DMSO-d6) δ 5.87 (1H, ddt, J=17.1, 10.2, 6.1 Hz), 5.19 (1H, ddt, J=17.1, 3.2, 1.7 Hz), 5.11 (1H, ddt, J=10.2, 3.2, 1.2 Hz), 3.29 (2H, s), 3.25 (2H, ddd, J=6.1, 1.7, 1.2 Hz), 1.47 (9H, s).
MS (ESI) m/z 172 (M+H)+
Step 2. Synthesis of N-{3-[5-(4-amidinophenoxycarbonyl)-furan-2-yl]-propionyl}-N-allylglycine trifluoroacetic acid salt (A-55)
A-37 (31.5 mg, 0.076 mmol) was dissolved in thionyl chloride (500 μL), and the mixture was stirred at room temperature for 30 minutes. The reaction mixture was concentrated under reduced pressure, M-21 (38.9 mg, 0.23 mmol), dichloromethane (300 μL), and pyridine (200 μL) were added to the obtained residue, and the mixture was stirred at room temperature for 25 minutes. The reaction mixture was concentrated under reduced pressure, trifluoroacetic acid (containing 5% water, 500 μL) was added to the obtained residue, and the mixture was stirred at room temperature for 35 minutes. The reaction mixture was concentrated under reduced pressure, and the obtained residue was purified by high performance liquid chromatography (acetonitrile-water, each containing 0.1% trifluoroacetic acid, 5-35%) to give the title compound (28.3 mg, 0.056 mmol, 74%).
1H-NMR (400 MHz, DMSO-d6) δ 9.35 (1H, br s), 9.26-9.02 (2H, m), 7.95-7.86 (2H, m), 7.58-7.51 (2H, m), 6.52-6.47 (3H, m), 5.94-5.62 (1H, m), 5.23-5.03 (2H, m), 4.13-3.88 (4H, m), 3.04-2.91 (2H, m), 2.83-2.65 (2H, m).
MS (ESI) m/z 400 (M+H)+
Example 44 Synthesis of N-{3-[5-(4-amidino-2-fluorophenoxycarbonyl)thiophen-2-yl]propanoyl}-L-aspartic acid trifluoroacetic acid salt (B-32)
Step 1. Synthesis of 5-(2-tert-butoxycarbonylethyl)-thiophene-2-carboxylic acid benzyl ester
Using 5-formyl-2-thiophenecarboxylic acid benzyl ester and in the same manner as in Example 12, the title compound was synthesized.
1H-NMR (400 MHz, CDCl3) δ 7.72 (1H, d, J=4.0 Hz), 7.61 (1H, d, J=16.0 Hz), 7.43-7.30 (5H, m), 7.18 (1H, d, J=4.0 Hz), 6.28 (1H, d, J=16.0 Hz), 5.38 (2H, s), 1.52 (9H, s).
Step 2. Synthesis of 5-(2-tert-butoxycarbonylethyl)-thiophene-2-carboxylic acid (M-23)
The compound (0.5 g, 1.45 mmol) obtained in step 1 was dissolved in methanol (5 mL) and chloroform (0.5 ml), palladium hydroxide (0.1 g) was added, and the mixture was stirred at room temperature overnight under a hydrogen atmosphere. The reaction mixture was filtered through celite, and the solvent was evaporated under reduced pressure to give the title compound.
1H-NMR (300 MHz, DMSO-d6) δ 7.54 (1H, d, J=3.3 Hz), 6.94 (1H, d, J=3.3 Hz), 3.04 (2H, t, J=7.5 Hz), 2.59 (2H, t, J=7.5 Hz), 1.38 (9H, s).
MS (ESI) m/z 257 (M+H)+
Step 3. Synthesis of N-{3-[5-(4-amidino-2-fluorophenoxycarbonyl)thiophen-2-yl]propanoyl}-L-aspartic acid trifluoroacetic acid salt (B-32)
The title compound was synthesized in the same manner as in Example 38.
1H-NMR (400 MHz, DMSO-d6) δ 9.41 (2H, s), 9.11 (2H, s), 8.33 (1H, d, J=8.0 Hz), 7.93 (2H, m), 7.73 (2H, m), 7.12 (1H, d, J=3.6 Hz), 4.55 (1H, m), 3.13 (2H, t, J=7.2 Hz), 2.68 (1H, dd, J=12.4, 6.0 Hz), 2.62-2.55 (3H, m).
MS (ESI) m/z 452 (M+H)+
Example 45 Synthesis of N-{3-[5-(4-amidino-2-fluorophenoxycarbonyl)thiophen-2-yl]propionyl}-N-allylglycine trifluoroacetic acid salt (B-38)
3-[5-(4-Amidino-2-fluorophenoxycarbonyl)thiophen-2-yl]propanoic acid trifluoroacetic acid salt (38 mg, 0.084 mmol) was dissolved in thionyl chloride (500 μL), and the mixture was stirred at room temperature for 20 minutes. The reaction mixture was concentrated under reduced pressure, M-21 (18.8 mg, 0.11 mmol), dichloromethane (200 μL) and pyridine (300 μL) were added to the obtained residue, and the mixture was stirred for 90 minutes. The reaction mixture was concentrated under reduced pressure, trifluoroacetic acid (500 μL) was added to the obtained residue, and the mixture was stirred at room temperature for 30 minutes. The reaction mixture was concentrated under reduced pressure, and the obtained residue was purified by high performance liquid chromatography (acetonitrile-water, each containing 0.1% trifluoroacetic acid, 5-35%) to give the title compound (25.5 mg, 0.047 mmol, 55%).
1H-NMR (400 MHz, DMSO-d6) δ 9.41 (2H, br s), 9.07 (2H, br), 7.96-7.89 (2H, m), 7.79-7.70 (2H, m), 7.14 (1H, d, J=3.6 Hz), 5.92-5.62 (1H, m), 5.23-5.06 (2H, m), 4.11-3.90 (4H, m), 3.21-3.09 (2H, m), 2.84-2.62 (2H, m).
MS (ESI) m/z 434 (M+H)+
Example 46 Synthesis of N-{3-[5-(4-amidinophenoxycarbonyl)-thiophen-2-yl]-2-methylpropanoyl}-L-cysteic acid trifluoroacetic acid salt (B-39)
Step 1. Synthesis of L-cysteic acid methyl ester hydrochloride (M-18)
L-cysteic acid (300 mg, 1.77 mmol) was dissolved in methanol (12 mL), and thionyl chloride (2.5 mL, 34 mmol) was slowly added at 0° C. After stirring at room temperature overnight, the reaction mixture was concentrated under reduced pressure, and the obtained residue was suspended in diisopropyl ether. The suspension was filtered to give the title compound as white crystals (291 mg, 1.33 mmol, 75%).
1H-NMR (300 MHz, DMSO-d6) δ 8.26 (3H, br s), 4.23 (1H, m), 3.72 (3H, s), 3.00 (1H, dd, J=14.3, 3.5 Hz), 2.92 (1H, dd, J=14.3, 8.0 Hz).
MS (ESI) m/z 184 (M+H)+
Step 2. Synthesis of N-[3-[5-(4-amidinophenoxycarbonyl)-thiophen-2-yl]-2-methylpropanoyl]-L-cysteic acid trifluoroacetic acid salt (B-39)
B-6 (10 mg, 0.022 mmol), M-18 (5.9 mg, 0.027 mmol), and WSC hydrochloride (6.4 mg, 0.034 mmol) were dissolved in pyridine (1 mL), and the mixture was stirred at room temperature overnight. The reaction mixture was concentrated under reduced pressure, 4N hydrochloric acid (0.5 mL) and dioxane (0.5 mL) were added to the obtained residue, and the mixture was stirred at 60° C. for 3 hours. The reaction mixture was concentrated under reduced pressure, and the obtained residue was purified by high performance liquid chromatography (water-acetonitrile, each containing 0.1% trifluoroacetic acid) to give the title compound (7.4 mg, 0.012 mmol, 56%).
1H-NMR (400 MHz, DMSO-d6) δ 9.34 (2H, br), 8.89 (2H, br), 8.22-8.18 (1H, m), 7.90-7.86 (3H, m), 7.60-7.56 (2H, m), 7.12-7.11 (1H, m), 4.39-4.33 (1H, m), 3.22-2.60 (5H, m), 1.09-1.06 (3H, m).
MS (ESI) m/z 484 (M+H)+
Example 47 Synthesis of N-{3-[5-(4-amidinophenoxycarbonyl)-thiophen-2-yl]-2-methylpropanoyl}aminomethylphosphonic acid trifluoroacetic acid salt (B-40)
Step 1. Synthesis of aminomethylphosphonic acid diethyl ester hydrochloride (M-19)
To a solution of phthalimidomethylphosphonic acid diethyl ester (4.56 g, 15.3 mmol) in ethanol (55 mL) was added hydrazine monohydrate (0.89 mL, 18.4 mmol), and the mixture was heated under reflux for 5 hours. The insoluble material was filtered off, and the filtrate was concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (dichloromethane/methanol=95/5), and to the obtained oil (1.21 g) were added water (15 mL) and 1N hydrochloric acid (8.0 mL). The mixture was concentrated under reduced pressure and lyophilized to give the title compound (1.48 g, 7.27 mmol, 48%).
1H-NMR (300 MHz, DMSO-d6) δ 8.50 (3H, br s), 4.12 (4H, m), 3.30 (2H, d, J=13.5 Hz), 1.28 (6H, t, J=7.1 Hz).
MS (ESI) m/z 168 (M+H)+
Step 2. Synthesis of N-{3-[5-(4-amidinophenoxycarbonyl)-thiophen-2-yl]-2-methylpropanoyl}aminomethylphosphonic acid trifluoroacetic acid salt (B-40)
Using B-6 (10 mg, 0.022 mmol) and M-19 (5.5 mg, 0.027 mmol), and by an operation in the same manner as in Example 46, the title compound (6.6 mg, 0.012 mmol, 55%) was obtained.
1H-NMR (400 MHz, DMSO-d6) δ 9.45 (2H, br s), 9.20 (2H, br s), 7.98 (1H, br s), 7.85-7.87 (3H, m), 7.50 (1H, br s), 7.08 (1H, d, J=3.0 Hz), 3.17-2.75 (5H, m), 1.05 (3H, d, J=6.6 Hz).
MS (ESI) m/z 426 (M+H)+
Example 48 Synthesis of 5-[5-(4-amidinophenoxycarbonyl)furan-2-yl]-4-methylpentanoic acid trifluoroacetic acid salt (A-58)
Step 1. Synthesis of 5-(1-hydroxy-2-methylprop-2-enyl)furan-2-carboxylic acid benzyl ester
5-Formyl-2-furancarboxylic acid benzyl ester (300 mg, 1.30 mmol) was dissolved in tetrahydrofuran (12 mL), 2-propenylmagnesium bromide (0.5 mol/L tetrahydrofuran solution, 2.6 mL, 1.3 mmol) was added at −78° C., and the mixture was stirred for 15 minutes. 1N Hydrochloric acid was added to the reaction mixture, the mixture was heated to room temperature and extracted with ethyl acetate. The extract was washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (hexane/ethyl acetate=70/30) to give the title compound (332 mg, 1.23 mmol, 94%).
1H-NMR (300 MHz, CDCl3) δ 7.45-7.33 (5H, m), 7.16 (1H, d, J=3.3 Hz), 6.38 (1H, d, J=3.3 Hz), 5.33 (2H, s), 5.21 (1H, s), 5.19 (1H, s), 5.05 (1H, s), 1.75 (3H, s).
Step 2. Synthesis of (E)-5-(4-ethoxycarbonyl-2-methylbut-1-enyl)furan-2-carboxylic acid benzyl ester
To the compound (332 mg, 1.23 mmol) obtained in step 1 were added triethyl orthoformate (5.0 mL, 27 mmol) and propionic acid (0.020 mL, 0.27 mmol), and the mixture was stirred at 138° C. overnight. The reaction mixture was purified by silica gel column chromatography (hexane/ethyl acetate=90/10) to give the title compound (149 mg, 0.435 mmol, 35%).
1H-NMR (300 MHz, CDCl3) δ 7.45-7.35 (5H, m), 7.19 (1H, d, J=3.5 Hz), 6.29 (1H, d, J=3.5 Hz), 6.16 (1H, br s), 5.33 (2H, s), 4.14 (2H, q, J=7.2 Hz), 2.51 (4H, br s), 2.05 (3H, d, J=0.9 Hz), 1.25 (3H, t, J=7.2 Hz).
MS (ESI) m/z 343 (M+H)+
Step 3. Synthesis of 5-(4-ethoxycarbonyl-2-methylbutyl)furan-2-carboxylic acid
To a solution of the compound (149 mg, 0.435 mmol) obtained in step 2 in ethanol (3 mL) was added 5% palladium/carbon (15 mg), and the mixture was stirred under a hydrogen atmosphere for 9 hours. The catalyst was filtered off, and the solvent was evaporated under reduced pressure. The obtained residue was purified by high performance liquid chromatography (water-acetonitrile, each containing 0.1% trifluoroacetic acid) to give the title compound (75 mg, 0.30 mmol, 68%).
1H-NMR (300 MHz, CDCl3) δ 7.25 (1H, d, J=3.4 Hz), 6.21 (1H, d, J=3.4 Hz), 4.13 (2H, q, J=7.2 Hz), 2.72 (1H, dd, J=15.0, 6.5 Hz), 2.56 (1H, dd, J=15.0, 7.6 Hz), 2.41-2.25 (2H, m), 1.99-1.92 (1H, m), 1.80-1.68 (1H, m), 1.57-1.45 (1H, m), 1.25 (3H, t, J=7.2 Hz), 0.93 (3H, d, J=6.7 Hz).
MS (ESI) m/z 255 (M+H)+
Step 4. Synthesis of 5-[5-(4-amidinophenoxycarbonyl)-furan-2-yl]-4-methylpentanoic acid ethyl ester trifluoroacetic acid salt
To the compound (75 mg, 0.30 mmol) obtained in step 3, 4-amidinophenol hydrochloride (56 mg, 0.32 mmol), and WSC hydrochloride (68 mg, 0.35 mmol) was added pyridine (1.5 mL), and the mixture was stirred at room temperature overnight. The reaction mixture was concentrated under reduced pressure, and the obtained residue was purified by high performance liquid chromatography (water-acetonitrile, each containing 0.1% trifluoroacetic acid) to give the title compound (80 mg, 0.16 mmol, 55%).
1H-NMR (300 MHz, DMSO-d6) δ 9.14 (4H, br s), 7.88 (2H, d, J=8.7 Hz), 7.54 (1H, d, J=3.5 Hz), 7.54 (2H, d, J=8.7 Hz), 6.52 (1H, d, J=3.5 Hz), 4.03 (2H, q, J=7.1 Hz), 2.75 (1H, dd, J=15.0, 6.2 Hz), 2.60 (1H, dd, J=15.0, 7.6 Hz), 2.40-2.26 (2H, m), 1.92-1.83 (1H, m), 1.68-1.56 (1H, m), 1.48-1.38 (1H, m), 1.16 (3H, t, J=7.1 Hz), 0.88 (3H, d, J=6.7 Hz).
MS (ESI) m/z 373 (M+H)+
Step 5. Synthesis of 5-[5-(4-amidinophenoxycarbonyl)-furan-2-yl]-4-methylpentanoic acid trifluoroacetic acid salt (A-58)
To the compound (77 mg, 0.16 mmol) obtained in step 4 were added 4N hydrochloric acid (1 mL) and 1,4-dioxane (1 ml), and the mixture was stirred at 60° C. for 5 hours. The reaction mixture was concentrated under reduced pressure, and the obtained residue was purified by high performance liquid chromatography (water-acetonitrile, each containing 0.1% trifluoroacetic acid) to give the title compound (33 mg, 0.072 mmol, 46%).
1H-NMR (300 MHz, DMSO-d6) δ 9.23 (4H, br s), 7.88 (2H, d, J=8.7 Hz), 7.55 (1H, d, J=3.4 Hz), 7.54 (2H, d, J=8.7 Hz), 6.52 (1H, d, J=3.4 Hz), 1.73-2.37 (7H, m), 0.89 (3H, d, J=6.7 Hz).
MS (ESI) m/z 345 (M+H)+
Example 49 Synthesis of N-{5-[5-(4-amidinophenoxycarbonyl)furan-2-yl]-4-methylpentanoyl}-L-aspartic acid trifluoroacetic acid salt (A-59)
To A-58 (30 mg, 0.065 mmol), L-aspartic acid di-tert-butyl ester hydrochloride (17 mg, 0.059 mmol), and WSC hydrochloride (13 mg, 0.065 mmol) was added pyridine (1 ml), and the mixture was stirred at room temperature overnight. The reaction mixture was concentrated under reduced pressure, trifluoroacetic acid (1 mL) was added to the obtained residue, and the mixture was stirred at room temperature for 2 hours. The reaction mixture was concentrated under reduced pressure, and the obtained residue was purified by high performance liquid chromatography (water-acetonitrile, each containing 0.1% trifluoroacetic acid) to give the title compound (23 mg, 0.040 mmol, 62%).
1H-NMR (300 MHz, DMSO-d6) δ 9.33 (2H, br s), 9.10 (2H, br s), 8.10 (1H, d, J=7.6 Hz), 7.89 (2H, d, J=8.8 Hz), 7.56 (2H, d, J=8.8 Hz), 7.55 (1H, d, J=3.5 Hz), 6.53-6.51 (1H, m), 4.50-4.43 (1H, m), 2.75 (1H, dd, J=15.0, 6.2 Hz), 2.69-2.47 (3H, m), 2.25-2.11 (2H, m), 1.88-1.81 (1H, m), 1.63-1.57 (1H, m), 1.41-1.34 (1H, m), 0.89 (3H, d, J=6.6 Hz).
MS (ESI) m/z 460 (M+H)+
Example 50 Synthesis of 5-[5-(4-amidinophenoxycarbonyl)furan-2-yl]-4-carboxypentanoic acid trifluoroacetic acid salt (A-60)
Step 1. Synthesis of 2-{[5-(benzyloxycarbonyl)furan-2-yl](hydroxy)methyl}prop-2-enoic acid tert-butyl ester
5-Formyl-2-furancarboxylic acid benzyl ester (0.2 g, 0.87 mmol), acrylic acid tert-butyl ester (0.52 mL), and 1,4-diazabicyclo[2.2.2]octane (20 mg, 0.18 mmol) were mixed, and the mixture was stirred for 4 days. Excess acrylic acid tert-butyl ester was evaporated under reduced pressure and the residue was purified by silica gel column chromatography to give the title compound (0.26 g).
1H-NMR (300 MHz, CDCl3) δ 7.43-7.32 (5H, m), 7.16 (1H, d, J=3.6 Hz), 6.39 (1H, d, J=3.6 Hz), 6.31 (1H, s), 5.85 (1H, s), 5.55 (1H, br s), 5.32 (2H, s), 3.40 (1H, m), 1.45 (9H, s).
MS (ESI) m/z 359 (M+H)+
Step 2. Synthesis of 5-[5-(benzyloxycarbonyl)furan-2-yl]-4-tert-butoxycarbonyl-4-pentenoic acid ethyl ester
2-{[5-(Benzyloxycarbonyl)furan-2-yl](hydroxy)methyl}prop-2-enoic acid tert-butyl ester (90 mg, 0.25 mmol) was dissolved in ethyl orthoformate (2.0 mL, 10.9 mmol), propanoic acid (8 mg, 0.10 mmol) was added, and the mixture was stirred at 138° C. for 5 hours. The mixture was purified by silica gel column chromatography to give the title compound.
MS (ESI) m/z 429 (M+H)+
Step 3. Synthesis of 5-[2-(tert-butoxycarbonyl)-5-ethoxy-5-oxopentyl]furan-2-carboxylic acid
5-[5-(Benzyloxycarbonyl)furan-2-yl]-4-tert-butoxycarbonyl-4-pentenoic acid ethyl ester obtained in step 2 was dissolved in ethanol (5 mL), a catalytic amount of 10% palladium/carbon was added, and the mixture was stirred at room temperature for 1 hour under a hydrogen atmosphere. The reaction mixture was filtered through celite, and the filtrate was concentrated under reduced pressure to give the title compound (82 mg).
MS (ESI) m/z 341 (M+H)+
Step 4. Synthesis of 5-[5-(4-amidinophenoxycarbonyl)-furan-2-yl]-4-carboxypentanoic acid trifluoroacetic acid salt (A-60)
Using 5-{2-(tert-butoxycarbonyl)-5-ethoxy-5-oxopentyl}furan-2-carboxylic acid and 4-hydroxybenzamidine hydrochloride, and in the same manner as in Example 46, the title compound was synthesized.
1H-NMR (300 MHz, DMSO-d6) δ 9.31 (2H, br s), 9.26 (2H, br s), 7.90 (2H, d, J=8.7 Hz), 7.55 (3H, m), 6.51 (1H, d, J=3.6 Hz), 3.00 (1H, m), 2.90 (1H, m), 2.73 (1H, m), 2.28 (2H, m), 1.77 (2H, m).
MS (ESI) m/z 375 (M+H)+
Example 51 Synthesis of N-{3-[5-(4-amidinophenoxycarbonyl)-furan-2-yl]-2-(carboxyethyl)propanoyl}-L-aspartic acid trifluoroacetic acid salt (A-61)
Step 1. Synthesis of 5-[5-(4-amidinophenoxycarbonyl)-furan-2-yl]-2-(2-ethoxycarbonyl)ethylpropanoic acid trifluoroacetic acid salt
5-[2-(tert-Butoxycarbonyl)-5-ethoxy-5-oxopentyl]furan-2-carboxylic acid (82 mg, 0.19 mmol) obtained in Example 50, step 3,4-hydroxybenzamidine hydrochloride (65 mg, 0.33 mmol), and WSC hydrochloride (92 mg, 0.50 mmol) were dissolved in pyridine (3 mL), and the mixture was stirred at room temperature overnight. The reaction mixture was concentrated under reduced pressure, trifluoroacetic acid (2 mL) was added to the obtained residue, and the mixture was stirred at room temperature for 30 minutes. The reaction mixture was concentrated under reduced pressure, and the obtained residue was purified by high performance liquid chromatography to give the title compound (11 mg).
MS (ESI) m/z 403 (M+H)+
Step 2. Synthesis N-{3-[5-(4-amidinophenoxycarbonyl)-furan-2-yl]-2-(carboxyethyl)propanoyl}-L-aspartic acid trifluoroacetic acid salt (A-61)
Using 5-[5-(4-amidinophenoxycarbonyl)furan-2-yl]-2-(2-ethoxycarbonyl)ethylpropanoic acid trifluoroacetic acid salt and 4-hydroxybenzamidine hydrochloride and in the same manner as in Example 46, the title compound was synthesized.
1H-NMR (300 MHz, DMSO-d6) δ 9.34 (2H, s), 9.06 (2H, s), 8.40 (1H, m), 8.89 (2H, d, J=8.7 Hz), 7.55 (2H, d, J=8.7 Hz), 7.50 (1H, d, J=3.3 Hz), 6.48 (1H, m), 4.50 (1H, m), 2.95-2.40 (5H, m), 2.22 (2H, m), 1.80-1.60 (2H, m).
MS (ESI) m/z 490 (M+H)+
Example 52 Synthesis of N-{3-[4-(4-amidinophenoxycarbonyl)-furan-2-yl]-2-methylpropanoyl}-L-aspartic acid trifluoroacetic acid salt (A-62)
Step 1. Synthesis of 4-ethoxycarbonylfuran-2-carboxylic acid
3-Furancarboxylic acid ethyl ester (1.4 g, 10.0 mmol) was dissolved in acetic acid (10 mL), bromine (1.6 g, 10.0 mmol) was added, and the mixture was stirred overnight. The solvent was evaporated under reduced pressure, and the obtained residue was purified by silica gel column chromatography (hexane/ethyl acetate=80/20). The obtained crude fraction was dissolved in N,N-dimethylformamide (15 mL), palladium acetate (0.18 g, 0.78 mmol), triphenylphosphine (0.41 g, 1.55 mmol), triethylamine (2.2 mL, 15.5 mmol), and water (0.7 mL, 38.8 mmol) were added, and the mixture was stirred at 80° C. overnight under a carbon monoxide atmosphere. 1N Hydrochloric acid was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The extract was washed with saturated brine, dried over anhydrous sodium sulfate and concentrated under reduced pressure. The obtained residue was purified by high performance liquid chromatography to give the title compound (0.47 g).
1H-NMR (300 MHz, DMSO-d6) δ 8.59 (1H, s), 7.37 (1H, s), 4.26 (2H, q, J=6.9 Hz), 1.28 (3H, t, J=6.9 Hz).
Step 2. Synthesis of 5-hydroxymethyl-3-furancarboxylic acid ethyl ester
4-Ethoxycarbonylfuran-2-carboxylic acid (0.47 g, 2.53 mmol) was dissolved in tetrahydrofuran (10 mL), triethylamine (0.53 mL, 3.80 mmol) and ethyl chloroformate (0.29 mL, 3.04 mmol) were added at 0° C., and the mixture was stirred at room temperature for 1 hour. The reaction mixture was filtered through celite, water (0.23 mL, 12.7 mmol) and sodium borohydride (0.19 g, 5.06 mmol) were added to the filtrate, and the mixture was stirred overnight. 1N Hydrochloric acid was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The extract was washed with saturated brine, dried over anhydrous sodium sulfate and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (hexane/ethyl acetate=50/50) to give the title compound (0.34 g).
1H-NMR (300 MHz, CDCl3) δ 7.97 (1H, s), 6.64 (1H, s), 4.62 (2H, s), 4.32 (2H, q, J=6.9 Hz), 1.34 (3H, t, J=6.9 Hz).
Step 3. Synthesis 5-formyl-3-furancarboxylic acid ethyl ester
5-Hydroxymethyl-3-furancarboxylic acid ethyl ester (0.34 g, 2.0 mmol) was dissolved in dichloromethane (20 ml), manganese dioxide (1.4 g, 15.9 mmol) was added, and the mixture was stirred overnight. The reaction mixture was filtered through celite, and the solvent was evaporated under reduced pressure to give the title compound (0.26 g).
1H-NMR (300 MHz, CDCl3) δ 9.65 (1H, s), 8.75 (1H, s), 7.80 (1H, s), 4.62 (2H, s), 4.27 (2H, q, J=6.9 Hz), 1.30 (3H, t, J=6.9 Hz).
Step 4. Synthesis of 5-(2-tert-butoxycarbonylpropyl)-furan-3-carboxylic acid
M-13 (0.62 g, 2.33 mmol) was added dropwise to a suspension of 60% sodium hydride (0.74 g, 1.86 mmol) in tetrahydrofuran (10 mL) with stirring at 0° C. After stirring at room temperature for 20 minutes, a solution of 5-formyl-3-furancarboxylic acid ethyl ester (0.26 g, 1.55 mmol) in tetrahydrofuran (3 mL) was added dropwise at 0° C. After stirring at room temperature overnight, the mixture was worked up according to a conventional method and purified by column chromatography to give an oil (0.37 g). The obtained oil was dissolved in ethanol (10 ml), 10% palladium/carbon (0.04 g) was added, and the mixture was stirred at room temperature for 5 hours under a hydrogen atmosphere. After completion of the reaction, palladium/carbon was removed by celite filtration, and the solvent was evaporated under reduced pressure. The obtained residue was dissolved in tetrahydrofuran (1.9 ml) and methanol (0.95 mL), 1N aqueous sodium hydroxide solution (1.9 mL) was added, and the mixture was stirred overnight. 1N Hydrochloric acid (2.5 mL) was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The extract was washed with saturated brine, dried over anhydrous sodium sulfate and concentrated under reduced pressure to give the title compound (0.33 g).
1H-NMR (300 MHz, CDCl3) δ 8.11 (1H, s), 6.34 (1H, s), 2.85 (1H, dd, J=14.7, 7.5 Hz), 2.70-2.55 (2H, m), 1.33 (9H, s), 1.03 (3H, d, J=6.6 Hz).
Step 5. Synthesis of N-{3-[4-(4-amidinophenoxycarbonyl)-furan-2-yl]-2-methylpropanoyl}-L-aspartic acid trifluoroacetic acid salt (A-62)
Using 5-(2-tert-butoxycarbonylpropyl)furan-3-carboxylic acid, 4-hydroxybenzamidine, and L-aspartic acid di-tert-butyl ester hydrochloride, and in the same manner as in Example 40, the title compound was obtained.
1H-NMR (300 MHz, DMSO-d6) δ 9.33 (2H, s), 9.05 (2H, s), 8.51 (1H, s), 8.24 (0.5H, d, J=7.8 Hz), 8.26 (0.5H, d, J=7.8 Hz), 7.89 (2H, d, J=8.7 Hz), 7.52 (2H, d, J=8.7 Hz), 6.61 (0.5H, s), 6.58 (0.5H, s), 4.54 (1H, m), 3.10-2.80 (5H, m), 1.02 (3H, m).
MS (ESI) m/z 432 (M+H)+
Example 53 Synthesis of 3-[4-(4-amidino-2-fluorophenoxycarbonyl)furan-2-yl]-2-methylpropanoic acid trifluoroacetic acid salt (A-63)
Using 5-(2-tert-butoxycarbonylpropyl)furan-3-carboxylic acid obtained in Example 52, step 4, and M-11 instead of M-1 and 4-hydroxybenzamidine hydrochloride, and by an operation in the same manner as in Example 16, the title compound was obtained (yield 52%).
1H-NMR (400 MHz, DMSO-d6) δ 12.35 (1H, br s), 9.41 (2H, br s), 9.18 (2H, br s), 8.62 (1H, d, J=0.8 Hz), 7.92 (1H, dd, J=11.6, 1.6 Hz), 7.76-7.70 (2H, m), 6.63 (1H, d, J=0.8 Hz), 2.99 (1H, dd, J=15.0, 6.6 Hz), 2.83-2.72 (2H, m), 1.11 (3H, d, J=6.8 Hz).
MS (ESI) m/z 335 (M+H)+
Example 54 Synthesis of N-[3-[2-(4-amidinophenoxycarbonyl)-furan-4-yl]-2-methylpropanoyl]-L-aspartic acid trifluoroacetic acid salt (A-67)
Step 1. Synthesis of 4-formyl-2-furancarboxylic acid benzyl ester
3-Furfural (0.96 g, 10 mmol) was dissolved in toluene (10 mL), N,N′-dimethylethylenediamine (1.08 mL, 10.0 mmol) and p-toluenesulfonic acid monohydrate (10 mg, 0.11 mmol) were added, and the mixture was stirred at 105° C. overnight. The solvent was evaporated under reduced pressure and the residue was partitioned between ethyl acetate and 5% aqueous sodium hydrogen carbonate solution. The organic layer was washed with saturated brine, and dried over anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure. The obtained residue was dissolved in tetrahydrofuran (20 mL), 1.54N n-butyllithium/hexane solution (3 mL) was added dropwise at −78° C., and the mixture was stirred for 1 hour. Dry ice was added to the reaction mixture, and the mixture was stirred at room temperature for 2 hour. The solvent was evaporated under reduced pressure, N,N-dimethylformamide (10 mL), potassium carbonate (0.55 g, 4.0 mmol), and benzyl bromide (2.04 g, 11.9 mmol) were added to the obtained residue, and the mixture was stirred at 60° C. overnight. 1N Hydrochloric acid was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The extract was washed with saturated brine, dried over anhydrous sodium sulfate and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography to give the title compound (0.33 g).
1H-NMR (400 MHz, CDCl3) δ 9.96 (1H, s), 8.17 (1H, s), 7.52 (1H, s), 7.45-7.35 (5H, m), 5.37 (2H, s).
Step 2. Synthesis of 4-(2-tert-butoxycarbonylpropyl)-furan-2-carboxylic acid
The title compound was obtained in the same manner as in Example 52, step 4.
1H-NMR (400 MHz, DMSO-d6) δ 7.68 (1H, s), 7.10 (1H, s), 2.65-2.55 (3H, m), 1.35 (9H, s), 1.04 (3H, d, J=6.8 Hz).
Step 3. Synthesis of N-{3-[2-(4-amidinophenoxycarbonyl)-furan-4-yl]-2-methylpropanoyl}-L-aspartic acid trifluoroacetic acid salt (A-67)
The title compound was obtained in the same manner as in Example 52, step 5.
1H-NMR (300 MHz, DMSO-d6) δ 9.33 (2H, s), 8.97 (2H, s), 8.23 (1H, m), 7.90-7.80 (3H, m), 7.55 (2H, d, J=8.4 Hz), 7.47 (1H, s), 4.48 (1H, m), 3.10-2.90 (3H, m), 2.70-2.50 (2H, m), 1.02 (3H, m).
MS (ESI) m/z 432 (M+H)+
Example 55 Synthesis of 3-[4-(4-amidino-2-fluorophenoxycarbonyl)thiophen-2-yl]-2-methylpropanoic acid trifluoroacetic acid salt (B-51) Step 1. Synthesis of 5-(2-tert-butoxycarbonylpropyl)-thiophene-3-carboxylic acid
Using 3-thiophenecarboxylic acid methyl ester instead of 3-furancarboxylic acid ethyl ester, palladium hydroxide instead of palladium/carbon, and lithium hydroxide instead of sodium hydroxide, and in the same manner as in Example 52, step 1 to step 4, the title compound was synthesized.
1H-NMR (300 MHz, CDCl3) δ 8.03 (1H, d, J=1.2 Hz), 7.25 (1H, d, J=1.2 Hz), 3.13 (1H, dd, J=14.8, 8.0 Hz), 2.86 (1H, dd, J=14.8, 6.4 Hz), 2.66 (1H, m), 1.45 (9H, s), 1.16 (3H, d, J=7.2 Hz).
MS (ESI) m/z 271 (M+H)+
Step 2. Synthesis of 3-[4-(4-amidino-2-fluorophenoxycarbonyl)thiophen-2-yl]-2-methylpropanoic acid trifluoroacetic acid salt (B-51)
Using the compound obtained in step 1 and M-11 instead of M-1 and 4-amidinophenol hydrochloride, and by an operation in the same manner as in Example 16, the title compound was obtained (yield 58%).
1H-NMR (400 MHz, DMSO-d6) δ 12.37 (1H, br s), 9.41 (2H, br s), 9.18 (2H, br s), 8.53 (1H, d, J=1.2 Hz), 7.93 (1H, dd, J=10.6, 1.0 Hz), 7.74-7.75 (2H, m), 7.38 (1H, d, J=1.2 Hz), 3.12 (1H, dd, J=15.3, 7.8 Hz), 2.98 (1H, dd, J=15.3, 6.0 Hz), 2.71 (1H, m), 1.13 (3H, d, J=7.2 Hz).
MS (ESI) m/z 351 (M+H)+
Example 56 Synthesis of N-{3-[4-(4-amidino-2-fluorophenoxycarbonyl)thiophen-2-yl]propanoyl}-L-aspartic acid trifluoroacetic acid salt (B-54) Step 1. Synthesis of 5-(2-tert-butoxycarbonylethyl)-thiophene-3-carboxylic acid
Using diethylphosphonoacetic acid tert-butyl ester instead of M-13 and in the same manner as in Example 55, step 1, the title compound was synthesized.
1H-NMR (300 MHz, DMSO-d6) δ 8.03 (1H, d, J=1.2 Hz), 7.17 (1H, d, J=1.2 Hz), 3.00 (2H, t, J=6.4 Hz), 2.58 (2H, t, J=6.4 Hz), 1.38 (9H, s).
MS (ESI) m/z 257 (M+H)+
Step 2. Synthesis of N-{3-[4-(4-amidino-2-fluorophenoxycarbonyl)thiophen-2-yl]propanoyl}-L-aspartic acid trifluoroacetic acid salt (B-54)
Using the compound obtained in step 1 and in the same manner as in Example 55 and Example 38, the title compound was synthesized.
1H-NMR (400 MHz, DMSO-d6) δ 9.40 (2H, br s), 9.09 (2H, br s), 8.49 (1H, s), 8.30 (1H, d, J=8.0 Hz), 7.92 (1H, d, J=8.0 Hz), 7.73 (2H, m), 7.38 (1H, s), 4.55 (1H, m), 3.07 (2H, t, J=7.6 Hz), 2.70-2.55 (4H, m).
MS (ESI) m/z 452 (M+H)+
Example 57 Synthesis of N-{4-[5-(4-amidinophenoxycarbonyl)-furan-2-yl]benzoyl}-L-aspartic acid trifluoroacetic acid salt (A-68)
4-Amidinophenol hydrochloride (50 mg, 0.29 mmol) was dissolved in pyridine (1.5 mL), 4-(5-chlorocarbonylfuran-2-yl)benzoic acid ethyl ester (81 mg, 0.29 mmol) was added, and the mixture was stirred at room temperature overnight. The reaction mixture was concentrated under reduced pressure, and 4N hydrochloric acid/dioxane (2 mL) and water (1 mL) were added to the obtained residue. After stirring at 60° C. overnight, the mixture was concentrated under reduced pressure. L-Aspartic acid di-tert-butyl ester hydrochloride (22 mg, 0.078 mmol), WSC hydrochloride (15 mg, 0.078 mmol), and pyridine (1 mL) were added to the obtained residue, and the mixture was stirred at room temperature overnight. The reaction mixture was concentrated under reduced pressure, and trifluoroacetic acid (2 mL) was added to the obtained residue. After stirring at room temperature for 2 hours, the reaction mixture was concentrated under reduced pressure, and the obtained residue was purified by high performance liquid chromatography (water-acetonitrile, each containing 0.1% trifluoroacetic acid) to give the title compound (17 mg, 0.029 mmol, 10%).
1H-NMR (400 MHz, DMSO-d6) δ 9.36 (2H, br s), 8.98 (2H, br s), 8.88 (1H, d, J=8.0 Hz), 8.01 (4H, s), 7.93 (2H, d, J=8.8 Hz), 7.79 (1H, d, J=3.6 Hz), 7.62 (2H, d, J=8.8 Hz), 7.48 (1H, J=3.6 Hz), 4.80-4.75 (1H, m), 2.87 (1H, dd, J=16.0, 5.6 Hz), 2.73 (1H, dd, J=16.0, 8.0 Hz).
MS (ESI) m/z 466 (M+H)+
Example 58 Synthesis of N-{3-[5-(4-amidinophenoxycarbonyl)-furan-2-yl]benzoyl}-L-aspartic acid trifluoroacetic acid salt (A-71) Step 1. Synthesis of 5-(3-methoxycarbonylphenyl)furan-2-carboxylic acid
To 5-bromofuran-2-carboxylic acid (0.50 g, 2.6 mmol), 3-methoxycarbonylphenylboronic acid (0.52 g, 2.9 mmol), tetrakis(triphenylphosphine)palladium (45 mg, 0.039 mmol), and sodium hydrogen carbonate (0.49 g, 5.9 mmol) were added toluene (3.5 mL), tetrahydrofuran (3.0 ml) and water (3.5 mL), and the mixture was stirred at 90° C. for 2 hours. Water was added to the reaction mixture, and the mixture was washed with ethyl acetate. The aqueous layer was acidified with 1N hydrochloric acid, and the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated brine, dried over anhydrous sodium sulfate and concentrated under reduced pressure to give the title compound as a pale-yellow powder (0.58 g, 2.3 mmol, 91%).
1H-NMR (400 MHz, CDCl3) δ 8.44 (1H, d, J=1.6 Hz), 8.06-8.01 (2H, m), 7.54 (1H, dd, J=8.0, 7.6 Hz), 7.42 (1H, d, J=3.6 Hz), 6.89 (1H, d, J=3.6 Hz), 3.97 (3H, s).
MS (ESI) m/z 247 (M+H)+
Step 2. Synthesis of N-{3-[5-(4-amidinophenoxycarbonyl)-furan-2-yl]benzoyl}-L-aspartic acid trifluoroacetic acid salt (A-71)
To the carboxylic acid obtained by using the compound (100 mg, 0.41 mmol) obtained in step 1 and 4-amidinophenol hydrochloride (70 mg, 0.41 mmol) instead of B-6 and M-18, and by an operation in the same manner as in Example 46, step 2 were added L-aspartic acid di-tert-butyl ester hydrochloride (114 mg, 0.41 mmol), WSC hydrochloride (93 mg, 0.48 mmol), and pyridine (5 mL), and the mixture was stirred at room temperature overnight. The reaction mixture was concentrated under reduced pressure, and trifluoroacetic acid (5 mL) was added to the obtained residue. After stirring at room temperature for 2 hours, the reaction mixture was concentrated under reduced pressure, and the obtained residue was purified by high performance liquid chromatography (water-acetonitrile, each containing 0.1% trifluoroacetic acid) to give the title compound (15 mg, 0.026 mmol, 6%).
MS (ESI) m/z 466 (M+H)+
Example 59 Synthesis of O-{3-[5-(4-amidinophenoxycarbonyl)-furan-2-yl]-2-methylpropionyl}-D-malic acid trifluoroacetic acid salt (A-72)
A-6 (34.5 mg, 0.08 mmol) was dissolved in thionyl chloride (500 μL), and the mixture was stirred at 70° C. for 15 minutes. The reaction mixture was concentrated under reduced pressure, D-malic acid dibenzyl ester (37.8 mg, 0.12 mmol), dichloromethane (350 μL), and pyridine (150 μL) were added to the obtained residue, and the mixture was stirred at room temperature for 25 minutes. The reaction mixture was concentrated under reduced pressure, water was added, and the mixture was freeze-dried overnight. After freeze-drying, palladium/carbon (10 mg) and ethanol (1 mL) were added, and the mixture was stirred at room temperature for 3 hours. The reaction mixture was filtered through celite to remove palladium/carbon. The filtrate was concentrated under reduced pressure, and the obtained residue was purified by high performance liquid chromatography (acetonitrile-water, each containing 0.1% trifluoroacetic acid, 15-55%) to give the title compound (14.4 mg, 0.026 mmol, 33%).
1H-NMR (300 MHz, DMSO-d6) δ 9.34 (2H, br s), 9.01 (2H, br s), 7.89 (2H, d, J=8.7 Hz), 7.56 (2H, d, J=8.7 Hz), 7.54 (1H, s), 6.61-6.49 (1H, m), 5.28-2.19 (1H, m), 3.39-2.60 (5H, m), 1.24-1.04 (3H, m).
MS (ESI) m/z 433 (M+H)+
Example 60 Synthesis of S-{3-[5-(4-amidinophenoxycarbonyl)-furan-2-yl]-2-methylpropionyl}thiomalic acid trifluoroacetic acid salt (A-73) Step 1. Synthesis of S-{3-[5-(4-amidinophenoxycarbonyl)-furan-2-yl]-2-methylpropionyl}thiomalic acid diethyl ester trifluoroacetic acid salt
A-6 (30 mg, 0.070 mmol) was dissolved in thionyl chloride (500 μL), and the mixture was stirred at 60° C. for 10 minutes. The reaction mixture was concentrated under reduced pressure, and thiomalic acid diethyl ester (21.6 mg, 0.105 mmol), dichloromethane (350 μL), and pyridine (150 μL) were added to the obtained residue, and the mixture was stirred at room temperature for 45 minutes. The reaction mixture was concentrated under reduced pressure, and the obtained residue was purified by high performance liquid chromatography (acetonitrile-water, each containing 0.1% trifluoroacetic acid, 5-45%) to give the title compound (40 mg, 0.065 mmol, 93%).
Step 2. Synthesis of S-{3-[5-(4-amidinophenoxycarbonyl)-furan-2-yl]-2-methylpropionyl}thiomalic acid trifluoroacetic acid salt (A-73)
To S-{3-[5-(4-amidinophenoxycarbonyl)furan-2-yl]-2-methylpropionyl}thiomalic acid diethyl ester trifluoroacetic acid salt (40 mg, 0.065 mmol) obtained in step 1 was added 4N hydrochloric acid/dioxane solution:water=3:1 (500 μL), and the mixture was stirred at 60° C. overnight. The reaction mixture was concentrated under reduced pressure, and the obtained residue was purified by high performance liquid chromatography (acetonitrile-water, each containing 0.1% trifluoroacetic acid, 10-45%) to give the title compound (5.0 mg, 0.0089 mmol, 14%).
1H-NMR (400 MHz, DMSO-d6) δ 9.34 (2H, s), 9.15 (2H, s), 7.93-7.87 (2H, m), 7.59-7.51 (3H, m), 6.54 (1H, d, J=3.6 Hz), 4.37-4.28 (1H, m), 3.21-3.03 (2H, m), 3.01-2.62 (3H, m), 1.25-1.13 (3H, m).
MS (ESI) m/z 449 (M+H)+
Example 61 Synthesis of (N′-carboxymethyl-{3-[5-(4-amidinophenoxycarbonyl)furan-2-yl]-2-methylpropane}hydrazido)-acetic acid trifluoroacetic acid salt (A-74) Step 1. Synthesis of N,N-bis(tert-butoxycarbonylmethyl)-N′-benzyloxycarbonylhydrazine
Benzyloxycarbonylhydrazine (3.0 g, 18 mmol), bromoacetic acid tert-butyl ester (7.9 mL, 54 mmol), and diisopropylethylamine (6.3 ml, 36 mmol) were dissolved in toluene (30 mL), and the mixture was stirred at 75° C. overnight. After allowing to cool to room temperature, saturated brine was added, and the mixture was extracted three times with dichloromethane. The extract was dried over anhydrous sodium sulfate and concentrated under reduced pressure, and the obtained residue was purified by silica gel column chromatography (hexane/ethyl acetate=2/1) to give the title compound (5.8 g, 15 mmol, 81%).
1H-NMR (400 Mz, CDCl3) δ 7.40-7.20 (5H, m), 7.00 (1H, br s), 5.20 (2H, s), 3.60 (4H, s), 1.45 (18H, s).
MS (ESI) m/z 397 (M+H)+
Step 2. Synthesis of N,N-bis(tert-butoxycarbonylmethyl)-hydrazine
The compound (5.8 g, 15 mmol) obtained in step 1 was dissolved in methanol (60 mL), 10% palladium/carbon (M) (3.0 g) was added, and the mixture was stirred overnight under a hydrogen atmosphere. The reaction mixture was filtered through a filter cell, and the filtrate was concentrated. The obtained residue was purified by silica gel column chromatography (dichloromethane/methanol=9/1) to give the title compound (2.9 g, 11 mmol, 76%).
1H-NMR (400 Mz, CDCl3) δ 3.60 (4H, s), 1.45 (18H, s).
MS (ESI) m/z 261 (M+H)+
Step 3. Synthesis of (N′-carboxymethyl-{3-[5-(4-amidinophenoxycarbonyl)furan-2-yl]-2-methylpropane}hydrazido)-acetic acid trifluoroacetic acid salt (A-74)
To the compound (15 mg, 0.056 mmol) obtained in step 2 were added A-6 (20 mg, 0.046 mmol), WSC hydrochloride (13 mg, 0.070 mmol), and pyridine (1 mL), and the mixture was stirred at room temperature overnight. The reaction mixture was concentrated under reduced pressure, and trifluoroacetic acid (1 mL) was added to the obtained residue. After stirring at room temperature for 2 hours, the reaction mixture was concentrated under reduced pressure, and the obtained residue was purified by high performance liquid chromatography (water-acetonitrile, each containing 0.1% trifluoroacetic acid) to give the title compound (13 mg, 0.023 mmol, 50%).
1H-NMR (400 MHz, DMSO-d6) δ 12.50 (2H, br s), 9.59 (1H, s), 9.34 (2H, br s), 9.04 (2H, br s), 7.89 (2H, d, J=8.7 Hz), 7.54 (2H, d, J=8.7 Hz), 7.49 (1H, d, J=3.5 Hz), 6.45 (1H, d, J=3.5 Hz), 3.70 (4H, s), 2.93 (1H, dd, J=14.6, 7.8 Hz), 2.78-2.70 (2H, m), 1.03 (3H, d, J=6.6 Hz).
MS (ESI) m/z 447 (M+H)+
Example 62 Synthesis of N-{5-[5-(4-amidinophenoxycarbonyl)-thiophen-2-yl]thiophen-2-ylcarbonyl}-L-aspartic acid trifluoroacetic acid salt (B-59) Step 1. Synthesis of 2,2′-bithiophene-5,5′-dicarboxylic acid
2,2′-Bithiophene (0.50 g, 3.0 mmol) was dissolved in tetrahydrofuran (10 mL), n-butyllithium (2.76 M hexane solution, 2.4 mL, 6.6 mmol) was added at room temperature under an argon atmosphere, and the mixture was stirred at 50° C. for 30 minutes. After cooling to room temperature, carbon dioxide was blown into the reaction mixture. The reaction mixture was concentrated under reduced pressure and the obtained residue was washed with hexane to give a yellow powder (0.97 g) containing a lithium salt of the title compound as a main component. The obtained powder was dissolved in water and acidified with 1N hydrochloric acid, and the precipitate was collected by filtration to give the title compound as a green powder (0.55 g, 2.2 mmol, 72%).
MS (ESI) m/z 255 (M+H)+
Step 2. Synthesis of N-{5-[5-(4-amidinophenoxycarbonyl)-thiophen-2-yl]thiophen-2-ylcarbonyl}-L-aspartic acid trifluoroacetic acid salt (B-59)
To the compound (0.20 g, 0.79 mmol) obtained in step 1, 4-amidinophenol hydrochloride (0.14 g, 0.79 mmol), and WSC hydrochloride (0.18 g, 0.94 mmol) was added pyridine (10 mL), and the mixture was stirred at room temperature overnight. L-aspartic acid di-tert-butyl ester hydrochloride (0.22 g, 0.79 mmol) and WSC hydrochloride (0.18 g, 0.79 mmol) were added to the reaction mixture, and the mixture was further stirred at room temperature overnight. The reaction mixture was concentrated under reduced pressure, and trifluoroacetic acid (2 mL) was added to the obtained residue. After stirring at room temperature for 2 hours, the reaction mixture was concentrated under reduced pressure, and the obtained residue was purified by high performance liquid chromatography (water-acetonitrile, each containing 0.1% trifluoroacetic acid) to give the title compound (1.4 mg, 0.0023 mmol, 0.3%).
MS (ESI) m/z 488 (M+H)+
Example 63 Synthesis of N-[5-(4-amidino-2-fluorophenoxycarbonyl)thiophen-2-ylacetyl]-L-aspartic acid trifluoroacetic acid salt (B-60) Step 1. Synthesis of 5-tert-butoxycarbonylmethyl-2-thiophenecarboxylic acid
5-Bromomethyl-2-thiophenecarboxylic acid methyl ester (2.6 g, 10.4 mmol) and chloro(1,5-cyclooctadiene)rhodium(I) dimer (0.5 g, 1.02 mmol) were dissolved in formic acid (30 mL), and the mixture was stirred at 75° C. overnight under a carbon monoxide atmosphere. After evaporation of the solvent, thionyl chloride (10 mL) was added, and the mixture was stirred at 70° C. for 1 hour. The solvent was evaporated under reduced pressure, tert-butanol (10 mL) and triethylamine (2 mL) were added, and the mixture was stirred for 30 minutes. After evaporation of the solvent, water was added, and the mixture was extracted with ethyl acetate. The extract was concentrated and purified by silica gel column chromatography to give an oil (0.62 g). The oil (0.42 g) was dissolved in methanol (4.1 mL), 1N aqueous lithium hydroxide solution (4.1 mL) was added, and the mixture was stirred for 2 hours. The reaction mixture was neutralized with 1N hydrochloric acid (5 mL), purified by high performance liquid chromatography and freeze-dried to give the title compound (29 mg).
1H-NMR (400 MHz, CDCl3) δ 7.74 (1H, d, J=4.0 Hz), 6.96 (1H, d, J=4.0 Hz), 3.78 (2H, s), 1.48 (9H, s).
Step 2. Synthesis of 5-(4-amidino-2-fluorophenoxycarbonyl)thiophen-2-ylacetic acid trifluoroacetic acid salt
The compound (29 mg, 0.12 mmol) obtained in step 1 and M-11 (34 mg, 0.18 mmol) were suspended in pyridine (3 mL), WSC hydrochloride (70 mg, 0.36 mmol) was added, and the mixture was stirred for 2 hours. The solvent was evaporated, trifluoroacetic acid (3 ml) was added, and the mixture was stirred for 15 minutes. The reaction mixture was concentrated under reduced pressure, and the obtained residue was purified by high performance liquid chromatography (acetonitrile-water, each containing 0.1% trifluoroacetic acid, 5-35%) to give the title compound (19 mg).
1H-NMR (400 MHz, DMSO-d6) δ 9.41 (2H, br s), 9.14 (2H, br s), 7.97 (1H, d, J=3.6 Hz), 7.94 (1H, m), 7.80 (2H, m), 7.20 (1H, d, J=3.6 Hz), 4.05 (2H, s).
MS (ESI) m/z 323 (M+H)+
Step 3. Synthesis of N-[5-(4-amidino-2-fluorophenoxycarbonyl)thiophen-2-ylacetyl]-L-aspartic acid trifluoroacetic acid salt (B-60)
Using the compound obtained in step 2 and in the same manner as in Example 37, the title compound was obtained.
1H-NMR (400 MHz, DMSO-d6) δ 9.41 (2H, br s), 9.10 (2H, br s), 8.64 (1H, d, J=4.0 Hz), 7.98 (2H, m), 7.75 (2H, m), 7.14 (1H, d, J=3.6 Hz), 4.55 (1H, m), 3.90 (2H, s), 3.08-2.98 (1H, m), 2.70-2.60 (1H, m).
MS (ESI) m/z 438 (M+H)+
Example 64 Synthesis of N-{3-[5-(4-amidino-2-fluorophenoxycarbonyl)thiazol-2-yl]-methylpropionyl}-L-aspartic acid trifluoroacetic acid salt (C-4) Step 1. Synthesis of 5-(tert-butyldimethylsilyloxy)-methylthiazole
5-Hydroxymethylthiazole (5.0 g, 43 mmol), imidazole (7.4 g, 109 mmol), and diisopropylethylamine (14 g, 109 mmol) were dissolved in N,N-dimethylformamide (50 ml), tert-butyldimethylsilyl chloride (13.1 g, 87 mmol) was added, and the mixture was stirred at room temperature for 20 hours. Ethyl acetate (200 ml) and water (100 mL) were added to the reaction mixture, the mixture was partitioned, and the organic layer was washed with saturated brine. The organic layer was dried over anhydrous sodium sulfate and purified by silica gel column chromatography to give the title compound.
1H-NMR (300 MHz, DMSO-d6) δ 8.71 (1H, s), 7.70 (1H, s), 4.90 (2H, s), 0.90 (9H, s), 0.08 (6H, s).
Step 2. Synthesis of 5-(tert-butyldimethylsilyloxy)-methyl-2-formylthiazole
The compound (4.5 g, 20 mmol) obtained in step 1 was dissolved in tetrahydrofuran (30 mL), and 2.5M n-butyllithium/hexane solution (16 mL, 40 mmol) was added dropwise at −78° C. The reaction mixture was stirred at −78° C. for 35 minutes, N,N-dimethylformamide (4 mL) was added dropwise, and the mixture was stirred at −30° C. for 1 hour. The reaction mixture was neutralized with water and 2N hydrochloric acid, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel chromatography to give the title compound (1.6 g).
1H-NMR (300 MHz, DMSO-d6) δ 9.91 (1H, s), 7.89 (1H, s), 4.95 (2H, s), 0.90 (9H, s), 0.10 (6H, s).
Step 3. Synthesis of 5-[2-(tert-butoxycarbonyl)-1-propenyl]-2-(tert-butyldimethylsilyloxy)methylthiazole
To a suspension of 60% sodium hydride (0.12 g, 3.0 mmol) in tetrahydrofuran (5 mL) was added M-13 (0.92 g, 2.57 mmol) at 0° C., and the mixture was stirred for 35 minutes. A solution of the compound (0.5 g, 2.0 mmol) obtained in step 2 in tetrahydrofuran (20 ml) was added, and the mixture was stirred at room temperature for 2 hours. Ethyl acetate (30 mL) and water (5 mL) were added to the reaction mixture, the mixture was partitioned, and the organic layer was washed with saturated brine. The organic layer was dried over anhydrous sodium sulfate and purified by silica gel column chromatography to give the title compound (0.68 g).
1H-NMR (300 MHz, CDCl3) δ 7.74 (1H, s), 7.70 (1H, s), 4.93 (2H, s), 2.29 (3H, s), 1.53 (9H, s), 0.92 (9H, s), 0.11 (6H, s).
Step 4. Synthesis of 5-[2-(tert-butoxycarbonyl)propyl]-2-(tert-butyldimethylsilyloxy)methylthiazole
The compound (0.5 g, 1.4 mmol) obtained in step 3 was dissolved in ethanol (20 ml), palladium/carbon (0.1 g) was added, and the mixture was stirred at 50° C. for 20 hours under a hydrogen atmosphere (55 psi). The reaction mixture was filtered, and the solvent was evaporated under reduced pressure to give the title compound (0.3 g).
1H-NMR (300 MHz, CDCl3) δ 7.42 (1H, s), 4.82 (2H, s), 3.32-3.23 (1H, m), 3.01-2.91 (1H, m), 2.89-2.80 (1H, m), 1.38 (9H, s), 1.17 (3H, d, J=6.8 Hz), 0.87 (9H, s), 0.05 (6H, s).
Step 5. Synthesis of 5-[2-(tert-butoxycarbonyl)propyl]-2-formylmethylthiazole
To a solution of n-tetrabutylammonium fluoride (0.39 g, 1.5 mmol) in tetrahydrofuran (5 mL) was added a solution of the compound (0.30 g, 0.76 mmol) obtained in step 4 in tetrahydrofuran (2 mL), and the mixture was stirred at room temperature overnight. The solvent was evaporated under reduced pressure, and the residue was partitioned between ethyl acetate and water. The organic layer was washed with saturated brine. The organic layer was dried over anhydrous sodium sulfate and the solvent was evaporated under reduced pressure. The residue was purified by silica gel chromatography to give an oil (0.16 g). The obtained oil was dissolved in dichloromethane (15 mL), manganese dioxide (0.27 g, 3.0 mmol) was added, and the mixture was refluxed overnight. The solvent was evaporated under reduced pressure, and the residue was purified by silica gel chromatography to give an oil (0.10 g).
1H-NMR (300 MHz, CDCl3) δ 9.97 (1H, s), 8.27 (1H, s), 3.42-3.34 (1H, m), 3.11-3.03 (1H, m), 2.96-2.89 (1H, m), 1.39 (9H, s), 1.20 (3H, d, J=6.9 Hz).
Step 6. Synthesis of 5-[2-(tert-butoxycarbonyl)propyl]-thiazole-2-carboxylic acid
To a solution of the compound (1.8 g, 7.0 mmol) obtained in step 5 in tert-butanol (27.1 ml) were added water (6.0 mL), 2-methyl-2-butene (3.7 g, 52.9 mmol), sodium dihydrogen phosphate (3.1 g, 17.6 mmol), and sodium chlorite (3.2 g, 35.2 mmol), and the mixture was stirred at room temperature for 20 minutes. The solvent was evaporated, and the pH was adjusted to 8-9 with water and sodium hydrogen carbonate solution. The reaction mixture was washed with ethyl acetate, and the aqueous layer was adjusted to pH 5-6 with 2N hydrochloric acid. The aqueous layer was extracted with ethyl acetate, and the organic layer was washed with saturated brine and dried over anhydrous sodium sulfate. The solvent was evaporated to give the title compound (1.1 g).
1H-NMR (300 MHz, CDCl3) δ 13.44 (1H, br s), 8.21 (1H, s), 3.30-3.20 (1H, m), 3.18-3.03 (1H, m), 2.91-2.84 (1H, m), 1.35 (9H, s), 1.14 (3H, d, J=7.2 Hz).
Step 7. Synthesis of N-{3-[5-(4-amidino-2-fluorophenoxycarbonyl)thiazol-2-yl]-methylpropionyl}-L-aspartic acid trifluoroacetic acid salt (C-4)
Using the compound obtained in step 6 and in the same manner as in Example 37, the title compound was obtained.
1H-NMR (400 MHz, DMSO-d6) δ 9.42 (2H, s), 9.16 (2H, s), 8.62 (1H, s), 8.36 (1H, m), 7.95 (1H, dd, J=11.0, 2.0 Hz), 7.76 (2H, m), 4.50 (1H, m), 3.30 (1H, m), 3.10-2.85 (1H, m), 2.75-2.55 (3H, m), 1.10 (3H, m).
MS (ESI) m/z 467 (M+H)+
Example 65 Synthesis of 3-{3-[4-(4-amidinophenoxycarbonyl)-1,3-thiazol-2-yl]-N-(carboxymethyl)propanamido}propanoic acid trifluoroacetic acid salt (C-5) Step 1. Synthesis of 3-[4-(ethoxycarboxyl)thiazol-2-yl]propenoic acid tert-butyl ester
Using 2-formyl-4-thiazolecarboxylic acid ethyl ester obtained in Example 30, step 1 and diethylphosphonoacetic acid tert-butyl ester, and in the same manner as in Example 30, the title compound was obtained.
1H-NMR (400 MHz, CDCl3) δ 8.19 (1H, s), 7.75 (1H, d, J=16.0 Hz), 6.64 (1H, d, J=16.0 Hz), 4.45 (2H, q, J=6.8 Hz), 1.53 (9H, s), 1.42 (3H, t, J=6.8 Hz).
Step 2. Synthesis of 2-[(1E)-2-{[2-(tert-butoxy)-2-oxoethyl][3-(tert-butoxy)-3-oxopropyl]carbamoyl}eth-1-en-1-yl]-1,3-thiazole-4-carboxylic acid ethyl ester
The compound (0.45 g, 1.51 mmol) obtained in step 1 was dissolved in trifluoroacetic acid (10 mL), and the mixture was stirred for 1 hour. The solvent was evaporated to give a white solid (0.36 g). The white solid (0.26 g, 1.06 mmol) was dissolved in dichloromethane (15 mL), oxalyl chloride (0.15 mL, 1.75 mmol) and N,N-dimethylformamide (1 drop) were added, and the mixture was stirred for 10 minutes. The solvent was evaporated under reduced pressure, a solution of M-20 (0.32 g, 1.08 mmol) in dichloromethane (10 mL) and pyridine (0.25 mL) were added, and the mixture was stirred for 2 hours. The solvent was evaporated under reduced pressure, and the residue was purified by silica gel column chromatography to give the title compound.
1H-NMR (400 MHz, CDCl3) δ 8.21 (0.5H, s), 8.19 (0.5H, s), 7.80 (0.5H, d, J=15.2 Hz), 7.74 (0.5H, d, J=14.8 Hz), 7.39 (0.5H, d, J=15.2 Hz), 7.08 (0.5H, d, J=14.8 Hz), 4.43 (2H, m), 4.23 (1H, s), 4.13 (1H, s), 3.81 (1H, t, J=6.8 Hz), 3.71 (1H, t, J=6.8 Hz), 2.62 (2H, m), 1.43 (21H, m).
Step 3. Synthesis of 2-(2-{[2-(tert-butoxy)-2-oxoethyl][3-(tert-butoxy)-3-oxopropyl]carbamoyl}ethyl)-1,3-thiazole-4-carboxylic acid
The compound (0.4 g, 0.85 mmol) obtained in step 2 was dissolved in methanol (9 mL) and chloroform (1 mL), palladium hydroxide (0.08 g) was added, and the mixture was stirred at room temperature overnight under a hydrogen atmosphere. The reaction mixture was filtered through celite, and the solvent was evaporated. The residue was dissolved in methanol (1 mL), 1N aqueous lithium hydroxide solution (1.55 ml) was added, and the mixture was stirred for 3 hours. The mixture was neutralized with 1N hydrochloric acid, and extracted with ethyl acetate. The reaction mixture was concentrated under reduced pressure, and the obtained residue was purified by high performance liquid chromatography (acetonitrile-water, each containing 0.1% trifluoroacetic acid) to give the title compound (0.26 g).
1H-NMR (400 MHz, CDCl3) δ 8.16 (1H, s), 4.12 (1H, s), 4.02 (1H, s), 3.69 (1H, t, J=6.8 Hz), 3.60 (1H, t, J=6.8 Hz), 3.43-3.35 (2H m), 3.01 (1H, t, J=6.8 Hz), 2.77 (1H, t, J=6.8 Hz), 2.58-2.48 (2H, m), 1.45 (18H, m).
Step 4. Synthesis of 3-{3-[4-(4-amidinophenoxycarbonyl)-1,3-thiazol-2-yl]-N-(carboxymethyl)propanamido}propanoic acid trifluoroacetic acid salt (C-5)
Using the compound obtained in step 3 and in the same manner as in Example 37, the title compound was obtained.
1H-NMR (400 MHz, DMSO-d6) δ 9.35 (2H, s), 9.02 (2H, s), 8.72 (1H, s), 7.91 (2H, d, J=8.4 Hz), 7.57 (2H, d, J=8.4 Hz), 4.22 (1H, s), 3.97 (1H, s), 3.65-3.30 (4H, m), 2.95 (1H, t, J=6.8 Hz), 2.75 (1H, t, J=6.8 Hz), 2.55 (1H, t, J=6.8 Hz), 2.45 (1H, t, J=6.8 Hz).
MS (ESI) m/z 449 (M+H)+
Example 66 Synthesis of N-{3-[5-(4-amidino-2-fluorophenoxycarbonyl)-3-methylthiophen-2-yl]propanoyl}-L-aspartic acid trifluoroacetic acid salt (B-61) Step 1. Synthesis of 1,3-dimethyl-2-(3-methylthiophen-2-yl)imidazolidine
2-Formyl-3-methylthiophene (3.0 g, 23.8 mmol) and N,N′-dimethylethylenediamine (2.3 g, 26.2 mmol) were dissolved in toluene (80 mL), and the mixture was stirred at 120° C. overnight. The solvent was evaporated under reduced pressure, and the obtained residue was purified by silica gel column chromatography to give the title compound (3.1 g, 15.8 mmol).
1H-NMR (400 MHz, CDCl3) δ 7.23 (1H, d, J=5.2 Hz), 6.77 (1H, d, J=5.2 Hz), 3.79 (1H, s), 3.40-3.33 (2H, m), 2.60-2.55 (2H, m), 2.25 (9H, s).
Step 2. Synthesis of 5-formyl-4-methylthiophene-2-carboxylic acid benzyl ester
1,3-Dimethyl-2-(3-methylthiophen-2-yl)imidazolidine (3.1 g, 15.8 mmol) obtained in step 1 was dissolved in tetrahydrofuran (80 mL), 2.76N n-butyllithium/hexane solution (6.9 mL) was added dropwise at −78° C., and the mixture was stirred for 30 minutes. Dry ice was added to the reaction mixture, and the mixture was stirred at room temperature for 1 hour. The solvent was evaporated under reduced pressure, N,N-dimethylformamide (80 mL), potassium carbonate (6.54 g, 47.4 mmol), and benzyl bromide (8.0 g, 46.8 mmol) were added to the obtained residue, and the mixture was stirred at 60° C. for 3 hour. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The extract was washed with saturated brine, dried over anhydrous sodium sulfate and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography to give the title compound (1.84 g).
1H-NMR (400 MHz, CDCl3) δ 10.07 (1H, s), 7.63 (1H, s), 7.45-7.35 (5H, m), 5.35 (2H, s), 2.57 (3H, s).
Step 3. Synthesis of (E)-3-(5-benzyloxycarbonyl-3-methylthiophen-2-yl)-2-propenoic acid tert-butyl ester
A solution of diethylphosphonoacetic acid tert-butyl ester (0.44 g, 1.74 mmol) in tetrahydrofuran (3 ml) was added dropwise to a suspension of 60% sodium hydride (0.055 g, 1.38 mmol) in tetrahydrofuran (15 mL) with stirring at 0° C. After stirring at room temperature for 30 minutes, a solution of 5-formyl-4-methylthiophene-2-carboxylic acid benzyl ester (0.3 g, 1.15 mmol) obtained in step 2 in tetrahydrofuran (3 mL) was added dropwise at 0° C. After stirring at room temperature for 2 hours, the mixture was worked up according to a conventional method, and purified by silica gel column chromatography to give the title compound (0.35 g).
1H-NMR (400 MHz, CDCl3) δ 7.70 (1H, d, J=15.6 Hz), 7.55 (1H, s), 7.45-7.35 (5H, m), 6.23 (1H, d, J=15.6 Hz), 5.32 (2H, s), 2.31 (3H, s), 1.52 (9H, s).
Step 4. Synthesis of 3-(5-hydroxycarbonyl-3-methylthiophen-2-yl)propanoic acid tert-butyl ester
(E)-3-(5-Benzyloxycarbonyl-3-methylthiophen-2-yl)-2-propenoic acid tert-butyl ester (1.42 g, 4.12 mmol) obtained in step 3 was dissolved in ethanol (12 mL), 10% palladium/carbon (142 mg) was added, and the mixture was stirred at room temperature overnight under a hydrogen atmosphere. After completion of the reaction, palladium/carbon was removed by celite filtration, and the solvent was evaporated under reduced pressure to give the title compound (1.02 g, 3.77 mmol, 92%).
1H-NMR (400 MHz, CDCl3) δ 7.48 (1H, s), 2.98 (2H, t, J=7.6 Hz), 2.51 (2H, t, J=7.6 Hz), 2.11 (3H, s), 1.43 (9H, s).
Step 5. Synthesis of 3-[5-(4-amidino-2-fluorophenoxycarbonyl)-3-methylthiophen-2-yl]propanoic acid trifluoroacetic acid salt
The compound (1.02 g, 3.77 mmol) obtained in step 4, M-11 (1.08 g, 5.66 mmol), and WSC hydrochloride (1.45 g, 7.55 mmol) were dissolved in pyridine (10 ml), and the mixture was stirred at room temperature overnight. The reaction mixture was concentrated, and the solvent was evaporated under reduced pressure. Trifluoroacetic acid (10 ml) was added, and the mixture was stirred at room temperature for 1 hour. The solvent was evaporated under reduced pressure, and the obtained residue was purified by high performance liquid chromatography (water-acetonitrile, each containing 0.1% trifluoroacetic acid) to give the title compound (535 mg, 1.15 mmol, 31%).
1H-NMR (400 MHz, DMSO-d6) δ 9.41 (2H, br s), 9.14 (2H, br s), 7.96-7.89 (1H, m), 7.86 (1H, s), 7.77-7.71 (2H, m), 3.05 (2H, t, J=7.2 Hz), 2.61 (2H, t, J=7.2 Hz), 2.22 (3H, s).
MS (ESI) m/z 351 (M+H)+
Step 6. Synthesis of N-{3-[5-(4-amidino-2-fluorophenoxycarbonyl)-3-methylthiophen-2-yl]propanoyl}-L-aspartic acid trifluoroacetic acid salt (B-61)
The compound (432 mg, 0.93 mmol) obtained in step 5, aspartic acid di-tert-butyl ester (393 mg, 1.40 mmol), and WSC hydrochloride (357 mg, 1.86 mmol) were dissolved in pyridine (3.0 mL), and the mixture was stirred at room temperature. The solvent was evaporated under reduced pressure, trifluoroacetic acid (3.0 mL) was added to the residue, and the mixture was stirred at room temperature for 3 hours. The reaction mixture was concentrated under reduced pressure, and the obtained residue was purified by high performance liquid chromatography (water-acetonitrile, each containing 0.1% trifluoroacetic acid) to give the title compound (474 mg, 0.82 mmol, 88%).
1H-NMR (400 MHz, DMSO-d6) δ 9.40 (2H, br s), 9.11 (2H, br s), 8.29 (1H, d, J=7.2 Hz), 7.92 (1H, d, J=11.2 Hz), 7.84 (1H, s), 7.77-7.71 (2H, m), 4.57-4.46 (1H, m), 3.03 (2H, t, J=7.6 Hz), 2.71-2.49 (4H, m), 2.21 (3H, s).
MS (ESI) m/z 466 (M+H)+
Example 67 Synthesis of N-{3-[5-(4-amidino-2-fluorophenoxycarbonyl)thiophen-2-yl]propanoyl}-N-allyl-L-aspartic acid trifluoroacetic acid salt (B-63) Step 1. Synthesis of N-allyl-L-aspartic acid di-tert-butyl ester hydrochloride
L-aspartic acid di-tert-butyl ester hydrochloride (1.0 g, 3.5 mmol) was dissolved in acetonitrile (7 ml), potassium carbonate (0.98 g, 7.1 mmol) and allyl bromide (0.29 mL, 3.4 mmol) were added, and the mixture was stirred at room temperature overnight. The insoluble material was removed by filtration, the filtrate was concentrated under reduced pressure, and the obtained residue was purified by silica gel column chromatography (hexane/ethyl acetate=95/5) to give N-allyl-L-aspartic acid di-tert-butyl ester (0.50 g, 1.8 mmol).
1H-NMR (400 MHz, CDCl3) δ 5.86 (1H, dddd, J=17.2, 10.2, 6.1, 5.9 Hz), 5.16-5.21 (1H, m), 5.06-5.10 (1H, m), 3.47 (1H, dd, J=6.8, 5.9 Hz), 3.30-3.36 (1H, m), 3.15-3.20 (1H, m), 2.60 (1H, dd, J=15.7, 5.9 Hz), 2.51 (1H, dd, J=15.7, 6.8 Hz), 1.47 (9H, s), 1.45 (9H, s).
MS (ESI) m/z 286 (M+H)+
The obtained N-allyl-L-aspartic acid di-tert-butyl ester was dissolved in acetonitrile (10 mL), and water (17 mL) and 1N hydrochloric acid (1.8 mL, 1.8 mmol) were added. The solution was concentrated under reduced pressure and freeze-dried to give the title compound (0.54 g, 1.7 mmol, 47%).
1H-NMR (400 MHz, DMSO-d6) δ 9.25 (2H, br s), 5.84-5.94 (1H, m), 5.48 (1H, d, J=17.2 Hz), 5.41 (1H, d, J=9.6 Hz), 4.11 (1H, br s), 3.65 (2H, br s), 2.96 (1H, br d, J=17.8 Hz), 2.86 (1H, dd, J=17.8, 5.8 Hz), 1.45 (9H, s), 1.44 (9H, s).
MS (ESI) m/z 286 (M+H)+
Step 2. Synthesis of N-{3-[5-(4-amidino-2-fluorophenoxycarbonyl)thiophen-2-yl]propanoyl}-N-allyl-L-aspartic acid trifluoroacetic acid salt (3-63)
Using N-allyl-L-aspartic acid di-tert-butyl ester hydrochloride obtained in step 1, M-11, and M-23, and by an operation in the same manner as in Example 33, the title compound (yield 24%) was obtained.
1H-NMR (400 MHz, DMSO-d6) δ 9.56-9.10 (4H, m), 7.98-7.89 (2H, m), 7.79-7.70 (2H, m), 718-7.09 (1H, m), 5.95-5.65 (1H, m), 5.46-4.95 (2H, m), 4.61-4.48 (1H, m), 4.18-3.84 (2H, m), 3.71-2.41 (6H, m).
MS (ESI) m/z 492 (M+H)+
Example 68 Synthesis of N-{3-[5-(4-amidino-2-fluorophenoxycarbonyl)thiophen-2-yl]-2,2-dimethylpropanoyl}-L-aspartic acid trifluoroacetic acid salt (B-64) Step 1. Synthesis of 5-chloromethylthiophene-2-carboxylic acid tert-butyl ester
5-Formylthiophene-2-carboxylic acid (5.27 g, 33.7 mmol), di-tert-butyl dicarbonate (8.1 g, 37.1 mmol), and N,N-dimethylaminopyridine (0.41 g, 3.39 mmol) were dissolved in tert-butanol (120 mL) and dichloromethane (40 mL), and the mixture was stirred overnight. The solvent was evaporated under reduced pressure, and 0.5N aqueous hydrochloric acid solution was added to the residue, and the mixture was extracted with ethyl acetate. The extract was washed with saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The obtained residue was dissolved in tetrahydrofuran (100 mL) and methanol (10 mL), sodium borohydride (1.28 g, 33.7 mmol) was added at 0° C., and the mixture was stirred for 3 hours. The solvent was evaporated under reduced pressure, 0.5N aqueous hydrochloric acid solution was added to the residue, and the mixture was extracted with ethyl acetate. The extract was washed with saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The obtained residue was dissolved in dichloromethane (100 ml), methanesulfonyl chloride (2.87 mL, 37.1 mmol) and diisopropylethylamine (8.9 mL, 51.1 mmol) were added at 0° C., and the mixture was stirred for 2 days. The solvent was evaporated under reduced pressure, 0.5N aqueous hydrochloric acid solution was added to the residue, and the mixture was extracted with ethyl acetate. The extract was washed with saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography to give the title compound (7.5 g).
1H-NMR (400 MHz, DMSO-d6) Et 7.56 (1H, d, J=4.0 Hz), 7.04 (1H, d, J=4.0 Hz), 4.75 (2H, s), 1.57 (9H, s).
Step 2. Synthesis of 3-(5-carboxythiophen-2-yl)-2,2-dimethylpropanoic acid
Diisopropylamine (478 μL, 3.40 mmol) was dissolved in tetrahydrofuran (2.0 mL), the mixture was stirred at −78° C. for 15 minutes, and 2.6N n-butyllithium/hexane solution (1.31 mL, 3.40 mmol) was added dropwise. After dropwise addition, the mixture was stirred at 0° C. for 30 minutes, and isobutyric acid (158 μL, 1.70 mmol) was added dropwise at −78° C. After the completion of the dropwise addition, the mixture was stirred at 0° C. for 20 minutes, 5-chloromethylthiophene-2-carboxylic acid tert-butyl ester (360 mg, 1.55 mmol) dissolved in tetrahydrofuran (1.5 mL) was added at 0° C., and the mixture was stirred at room temperature overnight. Ethyl acetate and 1N aqueous hydrochloric acid solution were added to the reaction mixture, the mixture was partitioned, and the organic layer was separated. The aqueous layer was extracted three times with ethyl acetate, and the organic layers was combined and washed with saturated brine. The organic layer was dried over magnesium sulfate, and the solvent was evaporated to give the title compound as a crude product.
Step 3. Synthesis of N-[3-(5-carboxythiophen-2-yl)-2,2-dimethylpropanoyl]-L-aspartic acid dimethyl ester
The crude product obtained in step 2 was dissolved in thionyl chloride (3.0 mL), and the mixture was stirred at 60° C. for 30 minutes. The reaction mixture was concentrated under reduced pressure, L-aspartic acid dimethyl ester hydrochloride (460 mg, 2.33 mmol), dichloromethane (1.0 ml), and pyridine (2.0 mL) were added to the obtained residue, and the mixture was stirred at room temperature for 1 hour. The reaction mixture was concentrated under reduced pressure, trifluoroacetic acid (3.0 mL) was added to the obtained residue, and the mixture was stirred at room temperature for 5 hours. The reaction mixture was concentrated under reduced pressure, and the obtained residue was purified by high performance liquid chromatography (water-acetonitrile, each containing 0.1% trifluoroacetic acid) to give the title compound (59.7 mg, 0.16 mmol, yield in 4 steps 10%).
MS (ESI) m/z 372 (M+H)+
Step 4. Synthesis of N-{3-[5-(4-amidino-2-fluorophenoxycarbonyl)thiophen-2-yl]-2,2-dimethylpropanoyl}-L-aspartic acid trifluoroacetic acid salt (B-64)
The compound (56 mg, 0.15 mmol) obtained in step 3, M-11 (43.1 mg, 0.23 mmol), and WSC hydrochloride (57.8 mg, 0.30 mmol) were dissolved in pyridine (500 μL), and the mixture was stirred at room temperature for 1 hour. The solvent was evaporated, and the residue was azeotropically distilled with benzene. 4N Hydrochloric acid/1,4-dioxane solution (750 μL) and water (250 μL) were added, and the mixture was stirred at 60° C. overnight. The reaction mixture was concentrated under reduced pressure, and the obtained residue was purified by high performance liquid chromatography (acetonitrile-water, each containing 0.1% trifluoroacetic acid, 10-40%) to give the title compound (11 mg, 0.019 mmol, 12%).
1H-NMR (400 MHz, DMSO-d6) δ 9.41 (2H, br s), 9.10 (2H, br s), 7.96-7.89 (3H, m), 7.79-7.71 (2H, m), 7.07 (1H, d, J=4.0 Hz), 4.57 (1H, dt, J=7.2, 6.8 Hz), 3.13 (2H, s), 2.76 (1H, dd, J=16.4, 6.8 Hz), 2.58 (1H, dd, J=16.4, 6.8 Hz), 1.14 (3H, s), 1.13 (3H, s).
MS (ESI) m/z 480 (M+H)+
Compound B-37 shown in the following Table 2 was synthesized using M-20 and by an operation in the same manner as in the above-mentioned Example 18.
The compounds A-22, A-23, A-24, A-25, A-66, B-33, B-35, B-52, and B-53 shown in the following Table 2 were each synthesized using M-1 to M-23 and commercially available reagents and by an operation in the same manner as in the above-mentioned Examples 33 and 34.
Compound B-36 shown in the following Table 2 was synthesized using M-1 to M-23 and commercially available reagents and by an operation in the same manner as in the above-mentioned Example 35.
The compounds B-27, B-28, and B-29 shown in the following Table 2 were each synthesized using M-1 to M-23 and commercially available reagents and by an operation in the same manner as in the above-mentioned Example 38.
The compounds A-48, A-49, A-50, and A-51 shown in the following Table 2 were each synthesized using M-1 to M-23 and commercially available reagents and by an operation in the same manner as in the above-mentioned Example 39.
The compounds B-30, B-31, and B-34 shown in the following Table 2 were each synthesized using M-1 to M-23 and commercially available reagents and by an operation in the same manner as in the above-mentioned Example 40.
Compound B-45 shown in the following Table 2 was synthesized using M-1 to M-23 and commercially available reagents and by an operation in the same manner as in the above-mentioned Examples 44 and 46.
Compound B-46 shown in the following Table 2 was synthesized using M-1 to M-23 and commercially available reagents and by an operation in the same manner as in the above-mentioned Examples 44 and 47.
The compounds A-57, B-41, and B-44 shown in the following Table 2 were each synthesized using M-1 to M-23 and commercially available reagents and by an operation in the same manner as in the above-mentioned Example 46.
The compounds A-56, B-42, and B-43 shown in the following Table 2 were each synthesized using M-1 to M-23 and commercially available reagents and by an operation in the same manner as in the above-mentioned Example 47.
The compounds A-64 and A-65 shown in the following Table 2 were each synthesized using M-1 to M-23 and commercially available reagents and by an operation in the same manner as in the above-mentioned Examples 47 and 52.
Compound A-70 shown in the following Table 2 was synthesized using M-1 to M-23 and commercially available reagents and by an operation in the same manner as in the above-mentioned Examples 47 and 57.
The compounds B-47 and B-48 shown in the following Table 2 were each synthesized using M-1 to M-23 and commercially available reagents and by an operation in the same manner as in the above-mentioned Example 48.
The compounds B-49 and B-50 shown in the following Table 2 were each synthesized using M-1 to M-23 and commercially available reagents and by an operation in the same manner as in the above-mentioned Example 49.
Compound B-55 shown in the following Table 2 was synthesized using M-1 to M-23 and commercially available reagents and by an operation in the same manner as in the above-mentioned Examples 55 and 56.
The compounds A-69, B-56, and B-57 shown in the following Table 2 were each synthesized using M-1 to M-23 and commercially available reagents and by an operation in the same manner as in the above-mentioned Example 57.
Compound B-58 shown in the following Table 2 was synthesized using M-1 to M-23 and commercially available reagents and by an operation in the same manner as in the above-mentioned Example 58.
The compounds B-62, B-65, and B-66 shown in the following Table 2 were each synthesized using M-11, M-23, and commercially available reagents and by an operation in the same manner as in the above-mentioned Example 33.
The structural formulas and physical properties of the synthesis intermediate compounds M-1 to M-16 are shown in Table 1-1 and Table 1-2, and the structural formulas and physical properties of M-17 to M-23 are shown in Table 1-3.
TABLE 1-1
Compound
No. Structure Analysis data
M-1
Figure US08609715-20131217-C00032
 		1H-NMR (300 MHz, DMSO-d6) δ 7.33-7.25 (2H, m), 6.98 (1H, d, J = 3.6 Hz), 2.15 (3H, s), 1.48 (9H, s). MS (ESI) m/z 253 (M + H)+
M-2
Figure US08609715-20131217-C00033
 		1H-NMR (300 MHz, DMSO-d6) δ 7.11 (1H, s), 6.32 (1H, s), 2.95-2.65 (3H, m), 2.50 (3H, s), 1.35 (9H, s). MS (ESI) m/z 253 (M + H)+
M-3
Figure US08609715-20131217-C00034
 		1H-NMR (300 MHz, CDCl3) δ 7.70 (1H, d, J = 3.9 Hz), 7.66 (1H, s), 7.63 (1H, d, J = 3.9 Hz), 7.16 (1H, d, J = 3.9 Hz), 2.16 (3H, s), 1.5 (9H, s). MS (ESI) m/z 269 (M + H)+
M-4
Figure US08609715-20131217-C00035
 		1H-NMR (300 MHz, CDCl3) δ 7.72 (1H, d, J = 3.6 Hz), 6.85 (1H, d, J = 3.6 Hz), 3.24-2.65 (3H, m), 1.42 (9H, s), 1.19 (3H, d, J = 6.9 Hz). MS (ESI) m/z 271 (M + H)+
M-5
Figure US08609715-20131217-C00036
 		1H-NMR (300 MHz, CDCl3) δ 3.96 (2H, t, J = 5.4 Hz), 3.80 (2H, s), 3.34 (2H, t, J = 5.9 Hz), 2.03 (2H, m), 1.50 (9H, s), 1.17- 1.07 (21H, m).
M-6
Figure US08609715-20131217-C00037
 		MS (ESI) m/z 360 (M + H)+
M-7
Figure US08609715-20131217-C00038
 		1H-NMR (300 MHz, CDCl3) δ 4.97 (1H, sep, J = 6.0 Hz), 3.78 (2H, t, J = 6.9 Hz), 3.29 (2H, t, J = 8.9 Hz), 3.13 (2H, t, J = 6.9 Hz), 2.78 (2H, t, J = 6.9 Hz), 1.74 (2H, m), 1.42 (6H, d, J = 6.0 Hz), 1.05 (21H, m).
M-8
Figure US08609715-20131217-C00039
 		1H-NMR (300 MHz, DMSO-d6) δ 12.40 (1H, br), 9.36 (2H, br), 9.05 (2H, br), 8.42 (1H, d, J = 2.3 Hz), 7.98 (1H, dd, J = 8.9, 2.3 Hz), 7.34 (1H, d, J = 8.9 Hz). MS (ESI) m/z 182 (M + H)+
TABLE 1-2
Compound No. Structure Analysis data
M-9 
Figure US08609715-20131217-C00040
 		1H-NMR (300 MHz, DMSO-d6) δ 11.58 (1H, br), 9.12 (2H, br), 8.83 (2H, br), 8.04 (1H, d, J = 2.4 Hz), 7.69 (1H, dd, J = 8.7, 2.4 Hz), 7.10 (1H, d, J = 8.7 Hz). MS (ESI) m/z 215 [M(79Br) + H]+, 217[M(81Br) + H]+
M-10
Figure US08609715-20131217-C00041
 		1H-NMR (300 MHz, ,DMSO-d6) δ 11.50 (1H, br), 9.12 (12H, br), 8.81 (2H, br), 7.91 (1H, d, J = 2.3 Hz), 7.66 (1H, dd, J = 8.7, 2.3 Hz), 7.13 (1H, d, J = 8.7 Hz). MS (ESI) m/z 171 [M(35Cl) + H]+, 173 [M(37Cl) + H]+
M-11
Figure US08609715-20131217-C00042
 		1H-NMR (300 MHz, DMSO-d6) δ 11.28 (1H, brs), 9.19 (2H, brs), 9.02 (2H, brs), 7.75 (1H, dd, J = 2.4, 12.0 Hz), 7.59 (1H, m), 7.18 (1H, dd, J = 8.4, 8.7 Hz). MS (ESI) m/z 155 (M + H)+
M-12
Figure US08609715-20131217-C00043
 		1H-NMR (300 MHz, DMSO-d6) δ 9.38-8.61 (4H, br), 7.50 (1H, dd, J = 9.6, 8.4 Hz), 6.78-6.73 (2H, m). MS(ESI) m/z 155 (M + H)+
M-13
Figure US08609715-20131217-C00044
 		1H-NMR (300 MHz, CDCl3) δ 4.20-4.08 (4H, m), 2.92 (1H, dq, J = 30.6, 7.2 Hz), 1.48 (9H, s), 1.45 (3H, d, J = 7.2 Hz), 1.40-1.30 (6H, m).
M-14
Figure US08609715-20131217-C00045
 		1H-NMR (300 MHz, CDCl3) δ 4.20-4.09 (4H, m), 2.76 (1H, ddd, J = 22.1, 10.4, 4.3 Hz), 2.00-1.83 (2H, m), 1.48 (9H, s), 1.35 (3H, t, J = 7.2 Hz), 1.34 (3H, t, J = 7.1 Hz), 0.99 (3H, td, J = 7.5, 1.1 Hz).
M-15
Figure US08609715-20131217-C00046
 		1H-NMR (300 MHz, CDCl3) δ 4.20-4.09 (4H, m), 2.85 (1H, ddd, J = 22.3, 11.2, 3.8 Hz), 2.05-1.73 (4H, m), 1.47 (9H, s), 1.45-1.29 (6H, m), 0.93 (3H, t, J = 7.2 Hz).
M-16
Figure US08609715-20131217-C00047
 		1H-NMR (300 MHz, CDCl3) δ 5.08 (1H, sep, J = 6.3 Hz), 4.29- 4.18 (4H, m), 3.57 (1H, dq, J = 19.2, 7.3 Hz), 1.69 (3H, dd, J = 15.6, 7.3 Hz), 1.45 (6H, d, J = 6.3 Hz), 1.37 (6H, t, J = 6.9 Hz).
TABLE 1-3
Compound No. Structure Analysis data
M-17
Figure US08609715-20131217-C00048
 		1H-NMR (300 MHz, DMSO-d6) δ 4.08-3.98 (4H, m), 2.85 (1H, ddd, J = 22.8, 11.4, 3.3 Hz), 1.85-1.75 (1H, m), 1.60-1.45 (2H, m), 1.50 (9H, s), 1.22 (6H, m), 0.88 (6H, d, J = 7.5 Hz). MS (ESI) m/z 309 (M + H)+
M-18
Figure US08609715-20131217-C00049
 		1H-NMR (300 MHz, DMSO-d6) δ 8.26 (3H, br s), 4.23 (1H, m), 3.72 (3H, s), 3.00 (1H, dd, J = 14.3, 3.5 Hz), 2.92 (1H, dd, J = 14.3, 8.0 Hz). MS (ESI) m/z 184 (M + H)+
M-19
Figure US08609715-20131217-C00050
 		1H-NMR (300 MHz, DMSO-d6) δ 8.50 (3H, br s), 4.12 (4H, m), 3.30 (2H, d, J = 13.5 Hz), 1.28 (6H, t, J = 7.1 Hz). MS (ESI) m/z 168 (M + H)+
M-20
Figure US08609715-20131217-C00051
 		1H-NMR (400 MHz, CDCl3) δ 3.75 (2H, s), 3.29 (2H, t, J = 6.4 Hz), 2.94 (2H, d, J = 6.4 Hz), 1.51 (9H, s), 1.47 (9H, s). MS (ESI) m/z 246 (M + H)+
M-21
Figure US08609715-20131217-C00052
 		1H-NMR (400 MHz, DMSO-d6) δ 5.87 (1H, ddt, J = 17.1, 10.2, 6.1 Hz), 5.19 (1H, ddt, J = 17.1, 3.2, 1.7 Hz), 5.11 (1H, ddt, J = 10.2, 3.2, 1.2 Hz), 3.29 (2H, s), 3.25 (2H, ddd, J = 6.1, 1.7, 1.2 Hz). 1.47 (9H, s). MS (ESI) m/z 172 (M + H)+
M-22
Figure US08609715-20131217-C00053
 		1H-NMR (400 MHz, CDCl3) δ 7.23 (1H, d, J = 3.6 Hz), 6.22 (1H, d, J = 3.6 Hz), 3.01 (2H, t, J = 7.6 Hz), 2.63 (2H, t, J = 7.6 Hz), 1.44 (9H, s). MS (ESI) m/z 241 (M + H)+
M-23
Figure US08609715-20131217-C00054
 		1H-NMR (300 MHz, DMSO-d6) δ 7.54 (1H, d, J = 3.3 Hz), 6.94 (1H, d, J = 3.3 Hz), 3.04 (2H, t, J = 7.5 Hz), 2.59 (2H, t, J = 7.5 Hz), 1.38 (9H, s). MS (ESI) m/z 257 (M + H)+
The structural formulas and physical properties of compounds A-1 to A-40, B-1 to B-24, and C-1 to C-3 are shown in Table 2-1 to Table 2-10, and the structural formulas and physical properties of A-41 to A-74, B-25 to B-66, C-4, and C-5 are shown in Table 2-11 to Table 2-22.
TABLE 2-1
Com-
pound No. Structure Analysis data
A-1
Figure US08609715-20131217-C00055
 		1H-NMR (DMSO-d6) δ 9.34 (br s, 2H), 8.95 (br s, 2H), 8.12 (d, J = 7.8 Hz, 1H), 7.91 (d, J = 8.7 Hz, 2H), 7.72 (d, J = 3.9 Hz, 1H), 7.60 (d, J = 8.7 Hz, 2H), 7.21 (s, 1H), 7.05 (d, J = 3.9 Hz, 1H), 4.37 (m, 1H), 3.76 (m, 2H), 2.73 (s, 1H), 2.24 (s, 3H). MS (ESI) m/z 402 (M + H)+
A-2
Figure US08609715-20131217-C00056
 		1H-NMR (DMSO-d6) δ 9.34 (br s, 2H), 8.95 (br s, 2H), 8.48 (m, 1H), 7.91 (d, J = 8.7 Hz, 2H), 7.72 (d, J = 3.9 Hz, 1H), 7.60 (d, J = 8.7 Hz, 2H), 7.21 (s, 1H), 7.05 (d, J = 3.9 Hz, 1H), 3.84 (m, 2H), 2.73 (s, 1H), 2.24 (s, 3H). MS (ESI) m/z 372 (M + H)+
A-3
Figure US08609715-20131217-C00057
 		1H-NMR (300 MHz, DMSO-d6) δ 9.35 (2H, br s), 8.95 (2H, br s), 7.91 (2H, d, J = 8.7 Hz), 7.72 (1H, d, J = 3.9 Hz), 7.59 (2H, d, J = 8.7 Hz), 7.43 (1H, s), 7.14 (1H, d, J = 3.9 Hz), 2.73 (1H, s), 2.24 (3H, s). MS (ESI) m/z 315 (M + H)+
A-4
Figure US08609715-20131217-C00058
 		MS (ESI) m/z 374 (M + H)+
A-5
Figure US08609715-20131217-C00059
 		MS (ESI) m/z 404 (M + H)+
A-6
Figure US08609715-20131217-C00060
 		1H-NMR (300 MHz, DMSO-d6) δ 9.35 (2H, br s), 9.10 (2H, br s), 7.90 (2H, d, J = 6.9 Hz), 7.61-7.52 (3H, m), 6.52 (1H, d, J = 3.6 Hz), 3.13-2.98 (1H, m), 2.91-2.70 (2H, m), 1.14 (3H, d, J = 6.9 Hz). MS (ESI) m/z 317 (M + H)+
A-7
Figure US08609715-20131217-C00061
 		MS (ESI) m/z 430 (M + H)+
A-8
Figure US08609715-20131217-C00062
 		1H-NMR (300 MHz, DMSO-d6) δ 9.65-9.28 (4H, m), 8.63 (1H, d, J = 2.3 Hz), 8.24 (1H, dd, J = 8.6, 2.3 Hz), 7.97 (1H, d, J = 8.6 Hz), 7.91 (1H, d, J = 3.5 Hz), 7.43 (1H, s), 7.18 (1H, d, J = 3.5 Hz), 2.22 (3H, s). MS (ESI) m/z 360 (M + H)+
TABLE 2-2
Com-
pound No. Structure Analysis data
A-9 
Figure US08609715-20131217-C00063
 		MS (ESI) m/z 432 (M + H)+
A-10
Figure US08609715-20131217-C00064
 		MS (ESI) m/z 448 (M + H)+
A-11
Figure US08609715-20131217-C00065
 		MS (ESI) m/z 386 (M + H)+
A-12
Figure US08609715-20131217-C00066
 		MS (ESI) m/z 444 (M + H)+
A-13
Figure US08609715-20131217-C00067
 		1H-NMR (300 MHz, DMSO-d6) δ 9.35 (2H, br s), 9.02 (2H, br s), 8.35 (1H, d, J = 7.5 Hz), 7.91 (2H, d, J = 8.7 Hz), 7.72 (1H, d, J = 3.3 Hz), 7.59 (2H, d, J = 7.5 Hz), 7.18 (1H, s), 7.04 (1H, d, J = 3.3 Hz), 4.35-4.22 (2H, m), 2.42- 2.30 (2H, m), 2.22 (3H, s), 2.15-1.81 (2H, m). MS (ESI) m/z 444 (M + H)+
A-14
Figure US08609715-20131217-C00068
 		MS (ESI) m/z 416 (M + H)+
A-15
Figure US08609715-20131217-C00069
 		MS (ESI) m/z 446 (M + H)+
A-16
Figure US08609715-20131217-C00070
 		MS (ESI) m/z 418 (M + H)+
TABLE 2-3
Com-
pound
No. Structure Analysis data
A-17
Figure US08609715-20131217-C00071
 		MS (ESI) m/z 380 (M + H)+
A-18
Figure US08609715-20131217-C00072
 		1H-NMR (DMSO-d6) δ 9.35 (br s, 2H), 9.12 (br s, 2H), 8.41-8.27 (m, 1H), 7.90 (d, J = 8.7 Hz, 2H), 7.55 (d, J = 8.7 Hz, 2H), 7.54-7.49 (m, 1H), 6.57-6.42 (m, 1H), 4.62- 4.40 (m, 1H), 3.13-2.42 (m, 5H), 1.17-0.99 (m, 3H). MS (ESI) m/z 432 (M + H)+
A-19
Figure US08609715-20131217-C00073
 		MS (ESI) m/z 414 (M + H)+
A-20
Figure US08609715-20131217-C00074
 		MS (ESI) m/z 430 (M + H)+
A-21
Figure US08609715-20131217-C00075
 		MS (ESI) m/z 430 (M + H)+
A-22
Figure US08609715-20131217-C00076
 		1H-NMR (300 MHz, DMSO-d6) δ 12.53 (1H, br s), 9.34 (2H, s), 8.98 (2H, br s), 8.25 (1H, d, J = 7.9 Hz), 7.89 (2H, d, J = 8.7 Hz), 7.55(2H, d, J = 8.7 Hz), 7.51 (1H, d, J = 3.5 Hz), 7.34 (1H, s), 6.90 (1H, s), 6.51 (1H, d, J = 3.5 Hz), 4.49 (1H, m), 2.99 (1H, dd, J = 14.4, 6.4 Hz), 2.81-2.41 (4H, m), 1.05 (3H, d, J = 6.6 Hz). MS (ESI) m/z 431 (M + H)+
A-23
Figure US08609715-20131217-C00077
 		1H-NMR (300 MHz, DMSO-d6) δ 9.33 (2H, br s), 9.05 (2H, br s), 8.20 (1H, d, J = 7.6 Hz), 7.89 (2H, d, J = 8.8 Hz), 7.55 (2H, d, J = 8.8 Hz), 7.51 (1H, d, J = 3.5 Hz), 7.35 (1H, s), 6.88 (1H, s), 6.48 (1H, d, J = 3.5 Hz), 4.49 (1H, m), 2.97 (1H, dd, J = 13.7, 6.0 Hz), 2.83-2.38 (4H, m), 1.07 (3H, d, J = 6.2 Hz). MS (ESI) m/z 431 (M + H)+
A-24
Figure US08609715-20131217-C00078
 		1H-NMR (300 MHs, DMSO-d6) δ 12.56 (1H, br s), 9.34 (2H, br s), 8.98 (2H, br s), 8.28 (1H, d, J = 7.6 Hz), 7.89 (2H, d, J = 8.7 Hz), 7.55 (2H, d, J = 8.7 Hz), 7.52 (1H, d, J = 3.5 Hz), 7.29 (1H, s), 6.78 (1H, s), 6.51 (1H, d, J = 3.5 Hz), 4.15 (1H, m), 2.99 (1H, dd, J = 14.1, 6.5 Hz), 2.82-2.70 (2H, m), 2.15-2.10 (2H, m), 1.98-1.76 (2H, m), 1.08 (3H, d, J = 6.5 Hz). MS (ESI) m/z 445 (M + H)+
TABLE 2-4
Com-
pound
No. Structure Analysis data
A-25
Figure US08609715-20131217-C00079
 		1H-NMR (300 MHz, DMSO-d6) δ 12.56 (1H, br s), 9.34 (2H, br s), 9.00 (2H, br s), 8.26 (1H, d, J = 7.9 Hz), 7.89 (2H, d, J = 8.7 Hz), 7.55 (2H, d, J = 8.7Hz), 7.52 (1H, d, J = 3.5 Hz), 7.25 (1H, s), 6.77 (1H, s), 6.48 (1H, d, J = 3.5 Hz), 4.15 (1H, m), 2.99 (1H, dd, J = 13.2, 6.2 Hz), 2.82-2.72 (2H, m), 2.10-2.04 (2H, m), 1.93-1.74 (2H, m), 1.07 (3H, d, J = 6.4 Hz). MS (ESI) m/z 445 (M + H)+
A-26
Figure US08609715-20131217-C00080
 		1H-NMR (300 MHz, DMSO-d6) δ 9.34 (2H, br), 9.02 (2H, br), 7.89 (2H, d, J = 8.9 Hz), 7.55 (2H, d, J = 8.9 Hz), 7.51 (1H, d, J = 3.5 Hz), 6.50 (1H, d, J = 3.5 Hz), 4.17 (2H, s), 3.94 (2H, s), 3.10-2.95 (2H, m), 2.76 (1H, dd, J = 14.9, 5.9 Hz), 1.06 (3H, d, J = 6.5 Hz). MS (ESI) m/z 432 (M + H)+
A-27
Figure US08609715-20131217-C00081
 		1H-NMR (DMSO-d6) δ 9.34 (br s, 2H), 9.05 (br s, 2H), 8.33-8.18 (m, 1H), 7.90 (d, J = 8.7 Hz, 2H), 7.61-7.42 (m, 3H), 6.57-6.42 (m, 1H), 427-4.16 (m. 1H), 3.09-2.90 (m, 1H), 2.90-2.63 (m, 2H), 2.37-2.08 (m, 2H), 2.05-1.87 (m, 1H), 1.86-1.63 (m, 1H), 1.08 (d, J = 5.7 Hz, 3H). MS (ESI) m/z 446 (M + H)+
A-28
Figure US08609715-20131217-C00082
 		1H-NMR (DMSO-d6) δ 9.35 (br s, 2H), 9.12 (br s, 2H), 8.41-8.27 (m, 1H), 7.90 (d, J = 8.7 Hz, 2H), 7.55 (d, J = 8.7 Hz, 2H), 7.54-7.49 (m, 1H), 6.57-6.42 (m, 1H), 4.62- 4.40 (m, 1H), 3.13-2.42 (m, 5H), 1.17-0.99 (m, 3H). MS (ESI) m/z 432 (M + H)+
A-29
Figure US08609715-20131217-C00083
 		1H-NMR (300 MHz, DMSO-d6) δ 9.34 (2H, br s), 9.13 (2H, br s), 7.90 (2H, d, J = 8.7 Hz), 7.63-7.49 (3H, m), 6.51 (1H, d, J = 3.6 Hz), 3.10-2.82 (2H, m), 2.69-2.55 (1H, m), 1.64-1.49 (2H, m), 0.90 (3H, t, J = 7.5 Hz). MS(ESI) m/z 331 (M + H)+
A-30
Figure US08609715-20131217-C00084
 		MS (ESI) m/z 460 (M + H)+
A-31
Figure US08609715-20131217-C00085
 		1H-NMR (DMSO-d6) δ 9.34 (br s, 2H), 9.05 (br s, 2H), 8.43-8.29 (m, 1H), 7.89 (d, J = 8.4 Hz, 1H), 7.54 (d, J = 8.4 Hz, 1H), 7.52-7.46 (m, 1H), 6.53-6.42 (m, 1H), 4.60- 4.44 (m, 1H), 3.07-2.51 (m, 5H), 1.61-1.38 (m, 2H), 0.97- 0.77 (m, 3H). MS (ESI) m/z 446 (M + H)+
TABLE 2-5
Com-
pound
No. Structure Analysis data
A-32
Figure US08609715-20131217-C00086
 		1H-NMR (300 MHz, DMSO-d6) δ 9.34 (2H, s), 9.01 (2H, s), 7.89 (2H, d, J = 8.7 Hz), 6.64 (1H, d, J = 3.6 Hz), 7.57 (3H, m), 3.89 (2H, s). MS (ESI) m/z 289 (M + H)+
A-33
Figure US08609715-20131217-C00087
 		1H-NMR (DMSO-d6) δ 9.42 (br s, 2H), 9.16 (br s, 2H), 7.93 (d, J = 9.9 Hz, 1H), 7.78-7.70 (m, 2H), 7.62 (d, J = 3.3 Hz, 1H), 6.55 (d, J = 3.3 Hz, 1H), 3.13-2.99 (m, 1H), 2.92-2.73 (m, 2H), 1.14 (d, J = 6.9 Hz, 3H). MS (ESI) m/z 335 (M+H)+
A-34
Figure US08609715-20131217-C00088
 		MS (ESI) m/z 345 (M + H)+
A-35
Figure US08609715-20131217-C00089
 		1H-NMR (DMSO-d6) δ 9.42 (br s, 2H), 9.19 (br s, 2H), 8.42-8.31 (m, 1H), 7.93 (d, J = 11.4 Hz, 1H), 7.81-7.69 (m, 2H), 7.61-7.56 (m, 1H), 6.56-6.45 (m, 1H), 4.61-4.42 (m, 1H), 3.11-2.88 (m, 2H), 2.87-2.47 (m, 3H), 1.06 (t, J = 6.6 Hz,1H). MS (ESI) m/z 450 (M + H)+
A-36
Figure US08609715-20131217-C00090
 		1H-NMR (300 MHz, DMSO-d6) δ 9.32 (2H, br), 8.90 (2H, br), 7.87 (2H, d, J = 8.7 Hz), 7.55 (2H, d, J = 8.7 Hz), 7.51 (1H, d, J = 3.6 Hz), 6.54 (1H, d, J = 3.6 Hz), 2.73-2.57 (3H, m), 1.05 (3H, d, J = 6.9 Hz). MS (ESI) m/z 353 (M + H)+
A-37
Figure US08609715-20131217-C00091
 		1H-NMR (300 MHz, DMSO-d6) δ 9.33 (2H, s), 9.01 (2H, s), 7.89 (2H, d, J = 8.4 Hz), 7.54 (3H, m), 6.52 (1H, d, J = 3.6 Hz), 2.98 (2H, t, J = 7.2 Hz), 2.66 (2H, t, J = 7.2 Hz). MS (ESI) m/z 303 (M + H)+
A-38
Figure US08609715-20131217-C00092
 		1H-NMR (300 MHz, DMSO-d6) δ 9.34 (2H, s), 9.02 (2H, s), 8.36 (1H, d, J = 8.1 Hz), 7.89 (2H, d, J = 8.7 Hz), 7.53 (3H, m), 6.48 (1H, d, J = 3.3 Hz), 4.54 (1H, m), 2.97 (2H, t, J = 7.2 Hz), 2.50-2.73 (4H, m). MS (ESI) m/z 418 (M + H)+
TABLE 2-6
Com-
pound Structure Analysis data
No.
A-39
Figure US08609715-20131217-C00093
 		1H-NMR (300 MHz, DMSO-d6) δ 9.34 (2H, s), 9.09 (2H, s), 8.55 (1H, d, J = 7.8 Hz), 7.89 (2H, d, J = 8.7 Hz), 7.56 (3H, m), 6.58 (1H, d, J = 3.6 Hz), 4.53 (1H, m), 2.89 (2H, s), 2.64 (2H, m). MS(ESI) m/z 404 (M + H)+
A-40
Figure US08609715-20131217-C00094
 		MS(ESI) m/z 360 (M + H)+
TABLE 2-7
Com-
pound
No. Structure Analysis data
B-1
Figure US08609715-20131217-C00095
 		1H-NMR (300 MHz, DMSO-d6) δ 9.35 (2H, s), 9.00 (2H, s), 8.09 (1H, d, J = 3.9 Hz), 7.88 (3H, m), 7.60 (3H, m), 2.18 (3H, s). MS (ESI) m/z 331 (M+H)+
B-2
Figure US08609715-20131217-C00096
 		1H-NMR (300 MHz, DMSO-d6) δ 9.30 (2H, brs), 9.10 (2H, brs), 8.50 (1H, t, J = 5.7 Hz), 8.06 (1H, d, J = 3.0 Hz), 7.89 (2H, d, J = 8.1 Hz), 7.58 (2H, d, J = 8.1 Hz), 7.54 (1H, s), 7.50 (1H, d, J = 3.0 Hz), 3.82 (2H, d, J = 5.7 Hz), 2.18 (3H, s). MS (ESI) m/z 388 (M + H)+
B-3
Figure US08609715-20131217-C00097
 		1H-NMR (300 MHz,DMSO-d6) δ 9.35 (2H, s), 8.99 (2H, s), 8.61 (1H, m), 8.06 (1 H, d, J = 3.6 Hz), 7.89 (2H, d, J = 8.4 Hz), 7.59 (2H, d, J = 8.4 Hz), 7.54 (1H, s), 7.50 (1H, d, J = 3.9 Hz), 4.36 (1H, m), 3.74 (2H, d, J = 4.8 Hz), 2.19 (3H, s). MS (ESI) m/z 418 (M + H)+
B-4
Figure US08609715-20131217-C00098
 		1H-NMR (300 MHz, DMSO-d6) δ 9.35 (2H, s), 8.99 (2H, s), 8.04 (1H, m), 7.90 (2H, d, J = 8.7 Hz), 7.59 (2H, d, J = 8.7 Hz), 7.43 (1H, m), 6.84 (1H, m), 4.01 (2H, s), 3.20-3.50 (4H, m), 2.17 (3H, s), 1.70 (2H, m). MS (ESI) m/z 446 (M + H)+
B-5
Figure US08609715-20131217-C00099
 		1H-NMR (300 MHz, DMSO-d6) δ 9.34 (2H, s), 8.99 (2H, s), 7.90 (3H, m), 7.56 (2H, d, J = 9.0 Hz), 7.07 (1H, m), 4.01 (1H, d, J = 11.7 Hz), 3.80 (1H, d, J = 17.1 Hz), 3.42 (2H, m), 3.15 (3H, m), 2.90 (2H, m), 1.55 (2H, m), 1.10 (3H, d, J = 4.8 Hz). MS (ESI) m/z 448 (M + H)+
B-6
Figure US08609715-20131217-C00100
 		1H-NMR (300 MHz, DMSO-d6) δ 9.34 (2H, s), 9.01 (2H, s), 7.90 (2H, m), 7.56 (1H, d, J = 9.0 Hz), 7.10 (1H, d, J = 3.6 Hz), 3.37 (1H, m), 3.01 (1H, m), 2.73 (1H, m), 1.13 (3H, d, J = 4.2 Hz). MS (ESI) m/z 333(M + H)+
B-7
Figure US08609715-20131217-C00101
 		1H-NMR (300 MHz, DMSO-d6) δ 9.35 (2H, s), 8.91 (2H, s), 8.03 (1H, d, J = 4.2 Hz), 7.90 (2H, d, J = 8.7 Hz), 7.60 (2H, d, J = 8.7 Hz), 7.40 (1H, d, J = 4.2 Hz), 6.84 (1H, s), 4.48 (1H, brs), 3.55 (2H, m), 3.20-3.45 (4H, m), 2.70 (2H, m), 2.15 (3H, s), 1.67 (2H, m). MS (ESI) m/z 496 (M + H)+
B-8
Figure US08609715-20131217-C00102
 		1H-NMR (300 MHz, DMSO-d6) δ 9.56 (2H, br), 9.26 (2H, br), 8.65 (1H, d, J = 2.4 Hz), 8.27 (1H, dd, J = 8.6, 2.4 Hz), 8.15 (1H, d, J = 5.2 Hz), 7.98 (1H, d, J = 8.6 Hz), 7.90 (1H, s), 7.69 (1H, d, J = 5.2 Hz), 2.19 (3H, s). MS (ESI) m/z 376 (M + H)+
TABLE 2-8
Compound No. Structure Analysis data
B-9
Figure US08609715-20131217-C00103
 		MS (ESI) m/z 378 (M + H)+
B-10
Figure US08609715-20131217-C00104
 		MS (ESI) m/z 491(M + H)+
B-11
Figure US08609715-20131217-C00105
 		1H-NMR (300 MHz, DMSO-d6) δ 9.62 (2H, br), 9.30 (2H, br), 8.64 (1H, d, J = 2.1 Hz), 8.26 (1H, dd, J = 8.4, 2.1 Hz), 7.94-7.91 (2H, m), 7.14-7.11 (1H, m), 4.57-3.77 (3H, m), 3.51-2.92 (6H, m), 1.62-1.51 (2H, m), 1.12-1.04 (3H, m). MS (ESI) m/z 493 (M + H)+
B-12
Figure US08609715-20131217-C00106
 		MS (ESI) m/z 390 (M + H)+
B-13
Figure US08609715-20131217-C00107
 		1H-NMR (300 MHz, DMSO-d6) δ 9.57 (2H, s), 9.17 (2H, s), 8.64 (1H, s), 8.25 (1H, dd, J = 2.4, 8.7 Hz), 8.09 (1H, d, J = 4.2 Hz), 7.98 (1H, d, J = 8.7 Hz), 7.43 (1H, d, J = 4.2 Hz), 6.86 (1H, s), 3.60-3.25 (6H, m), 2.71 (2H, m), 2.15 (3H, s), 1.68 (2H, m). MS (ESI) m/z 540 (M + H)+
B-14
Figure US08609715-20131217-C00108
 		MS (ESI) m/z 465 (M + H)+
B-15
Figure US08609715-20131217-C00109
 		MS (ESI) m/z 465 (M + H)+
B-16
Figure US08609715-20131217-C00110
 		MS (ESI) m/z 411 [M(79Br) + H]+, 413[M(81Br) + H]+
TABLE 2-9
Compound No. Structure Analysis data
B-17
Figure US08609715-20131217-C00111
 		1H-NMR (300 MHz, DMSO-d6) δ 12.42 (1H, br), 9.43 (2H, s), 9.24 (2H, brs), 8.11 (1H, d, J = 2.2 Hz), 7.96 (1H, d, J = 3.7 Hz), 7.86 (1H, dd, J = 8.7, 2.2 Hz), 7.78 (1H, d, J = 8.7 Hz), 7.13 (1H, d, J = 3.7 Hz), 3.19 (1H, dd, J = 14.8, 8.0 Hz), 3.04 (1H, dd, J = 14.8, 6.0 Hz), 2.75 (1H, m), 1.14 (3H, d, J = 7.2 Hz). MS (ESI) m/z 367[M(35Cl) + H]+, 368[M(37Cl) + H]+
B-18
Figure US08609715-20131217-C00112
 		1H-NMR(300 MHz, DMSO-d6) δ 9.34 (2H, s), 8.99 (2H, s), 8.29 (1H, m), 7.90 (2H, d, J = 8.4 Hz), 7.56 (2H, d, J = 8.4 Hz), 7.05 (1H, m), 4.50 (1H, m), 3.20-2.50 (5H, s), 1.06 (3H, m). MS (ESI) m/z 448 (M + H)+
B-19
Figure US08609715-20131217-C00113
 		1H-NMR (300 MHz, DMSO-d6) δ 12.41 (1H, brs), 9.41 (2H, s), 9.15 (2H, brs), 7.97-7.75 (4H, m), 7.13 (1H, d, J = 3.9 Hz), 3.19 (1H, dd, J = 15.0, 8.4 Hz), 3.04 (1H, dd, J = 15.0, 6.0 Hz), 2.75 (1H, m), 1.14 (3H, d, J = 7.2 Hz). MS (ESI) m/z 351 (M + H)+
B-20
Figure US08609715-20131217-C00114
 		1H-NMR (300 MHz, DMSO-d6) δ 9.41 (2H, br), 9.12 (2H, br), 8.33-8.27 (1H, m), 7.95-7.92 (2H, m), 7.76-7.74 (2H, m), 7.10-7.07 (1H, m), 4.54-4.48 (1H, m), 3.46-2.50 (5H, m), 1.10-1.04 (3H, m). MS (ESI) m/z 466 (M + H)+
B-21
Figure US08609715-20131217-C00115
 		1H-NMR (300 MHz, DMSO-d6) δ 12.24 (1H, br), 9.41 (2H, br), 9.13 (2H, br), 8.23-8.17 (1H, m), 7.94-7.91 (2H, m), 7.76-7.74 (2H, m), 7.10-7.07 (1H, m), 4.24-4.17 (1H, m), 3.47-1.71 (7H, m), 1.1 0-1.07 (3H, m). MS (ESI) m/z 480 (M + H)+
B-22
Figure US08609715-20131217-C00116
 		1H-NMR (300 MHz, DMSO-d6) δ 9.41 (2H, br), 9.12 (2H, br), 8.33-8.27 (1H, m), 7.95-7.92 (2H, m), 7.76-7.74 (2H, m), 7.10-7.07 (1H, m), 4.54-4.48 (1H, m), 3.46-2.50 (5H, m), 1.10-1.04 (3H, m). MS (ESI) m/z 466 (M + H)+
B-23
Figure US08609715-20131217-C00117
 		1H-NMR (300 MHz, DMSO-d6) δ 9.36 (2H, br), 9.02 (2H, br), 8.31-8.19 (1H, m), 7.91-7.87 (3H, m), 7.55 (2H, d, J = 8.5 Hz), 7.08-7.04 (1H, m), 4.52-4.42 (1H, m), 3.51- 2.54 (5H, m), 1.09-1.04 (3H, m). MS (ESI) m/z 448 (M + H)+
B-24
Figure US08609715-20131217-C00118
 		1H-NMR (300 MHz, DMSO-d6) δ 12.40 (1H, br), 9.49 (2H, br), 9.24 (2H, br), 7.91 (1H, d, J = 3.8 Hz), 7.80 (1H, dd, J = 8.5, 8.2 Hz), 7.63 (1H, dd, J = 10.9, 2.0 Hz), 7.41 (1H, dd, J = 8.5, 2.0 Hz), 7.11 (1H. dd, J = 3.8 Hz), 3.18 (1H, dd, J = 15.0, 7.6 Hz), 3.03 (1H, dd, J = 15.0, 6.2 Hz), 2.77-2.70 (1H, m), 1.13 (3H, d, J = 7.0 Hz). MS (ESI) m/z 351 (M + H)+
TABLE 2-10
Compound No. Structure Analysis data
C-1
Figure US08609715-20131217-C00119
 		1H-NMR (DMSO-d6) δ 9.36 (2H, br s), 9.09 (2H, br s), 7.93 (2H, d, J = 8.6 Hz), 7.75 (1H, s), 7.63 (2H, d, J = 8.6 Hz), 2.33 (3H, s), 2.30 (1H, s). MS (ESI) m/z 332 (M + H)+
C-2
Figure US08609715-20131217-C00120
 		MS (ESI) m/z 447 (M + H)+
C-3
Figure US08609715-20131217-C00121
 		MS (ESI) m/z 419 (M + H)+
TABLE 2-11
Compound No. Structure Analysis data
A-41
Figure US08609715-20131217-C00122
 		1H-NMR (300 MHz, DMSO-d6) δ 9.35 (2H, br s), 9.08 (2H, br s), 7.90 (2H, dd, J = 6.9, 1.8 Hz), 7.61-7.49 (3H, m), 6.52 (1H, d, J = 3.6 Hz), 3.15-2.98 (1H, m), 2.90-2.70 (2H, m), 1.14 (3H, d, J = 6.9 Hz). MS (ESI) m/z 317 (M + H)+
A-42
Figure US08609715-20131217-C00123
 		1H-NMR (300 MHz, DMSO-d6) δ 9.35 (2H, br s), 9.08 (2H, br s), 7.90 (2H, dd, J = 6.9, 1.8 Hz), 7.61-7.49 (3H, m), 6.52 (1H, d, J = 3.6 Hz,), 3.15-2.98 (1H, m), 2.90-2.70 (2H, m), 1.14 (3H, d, J = 6.9 Hz). MS (ESI) m/z 317 (M + H)+
A-43
Figure US08609715-20131217-C00124
 		1H-NMR (300 MHz, DMSO-d6) δ 9.34 (2H, br s), 9.10 (2H, br s), 8.32 (1H, d, J = 8.7 Hz), 7.90 (2H, d, J = 8.7 Hz), 7.54 (2H, d, J = 8.7 Hz), 7.50 (1H, d, J = 3.3 Hz), 6.46 (1H, d, J = 3.3 Hz), 4.59-4.49 (1H, m), 3.08-2.47 (5H, m), 1.07 (3H, d, J = 5.4 Hz). MS (ESI) m/z 432 (M + H)+
A-44
Figure US08609715-20131217-C00125
 		1H-NMR (300 MHz, DMSO-d6) δ 9.34 (2H, br s), 9.09 (2H, br s), 8.36 (1H, d, J = 8.4 Hz), 7.90 (2H, d, J = 8.7 Hz), 7.55 (2H, d, J = 8.7 Hz), 7.51 (1H, d, J = 3.6 Hz), 6.50 (1H, d, J = 3.6 Hz), 4.57-4.45 (1H, m), 3.05-2.42 (5H, m), 1.05 (3H, d, J = 6.6 Hz). MS (ESI) m/z 432 (M + H)+
A-45
Figure US08609715-20131217-C00126
 		1H-NMR (300 MHz, DMSO-d6) δ 9.34 (2H, br s), 9.09 (2H, br s), 8.36 (1H, d, J = 8.4 Hz), 7.90 (2H, d, J = 8.7 Hz), 7.55 (2H, d, J = 8.7 Hz), 7.51 (1H, d, J = 3.6 Hz), 6.50 (1H, d, J = 3.6 Hz), 4.57-4.45 (1H, m), 3.05-2.42 (5H, m), 1.05 (3H, d, J = 6.6 Hz). MS (ESI) m/z 432 (M + H)+
A-46
Figure US08609715-20131217-C00127
 		1H-NMR (300 MHz, DMSO-d6) δ 9.34 (2H, br s), 9.10 (2H, br s), 8.32 (1H, d, J = 8.7 Hz), 7.90 (2H, d, J = 8.7 Hz), 7.54 (2H, d, J = 8.7 Hz), 7.50 (1H, d, J = 3.3 Hz), 6.46 (1H, d, J = 3.3 Hz), 4.59-4.49 (1H, m), 3.08-2.47 (5H, m), 1.07 (3H, d, J = 5.4 Hz). MS (ESI) m/z 432 (M + H)+
A-47
Figure US08609715-20131217-C00128
 		1H-NMR (300 MHz, DMSO-d6) δ 9.32 (2H, s), 9.00 (2H, s), 8.00 (1H, t, J = 5.4 Hz), 7.87 (2H, d, J = 8.7 Hz), 7.52 (2H, m), 7.30-7.1 0 (6H, m), 6.40 (1H, d, J = 3.3 Hz), 3.30-3.20 (2H, m), 3.00-2.90 (1H, m), 2.70-2.60 (4H, m), 1.01 (3H, d, J = 6.6 Hz). MS (ESI) m/z 420 (M + H)+
A-48
Figure US08609715-20131217-C00129
 		1H-NMR (300 MHz, DMSO-d6) δ 9.20-9.05 (4H, br s), 7.92-7.82 (3H, m), 7.52 (3H, m), 6.45 (1H, d, J = 3.6 Hz), 3.30- 3.20 (2H, m), 3.10-2.90 (1H, m), 2.75-2.65 (2H, m), 1.47 (1H, m), 1.24 (2H, m), 1.05 (3H, d, J = 6.6 Hz), 0.83 (6H, d, J = 6.6 Hz). MS (ESI) m/z 386 (M + H)+
TABLE 2-12
Compound No. Structure Analysis data
A-49
Figure US08609715-20131217-C00130
 		1H-NMR (300 MHz, DMSO-d6) δ 9.35 (2H, s), 9.19 (2H, s), 8.27 (1H, t, J = 5.4 Hz), 7.91 (2H, d, J = 4.0 Hz), 7.54 (3H, m), 6.50 (1H, d, J = 3.6 Hz), 3.18-2.98 (5H, m), 2.85-2.65 (8H, m), 1.08 (3H, d, J = 6.6 Hz). MS(ESI) m/z 387 (M + H)+
A-50
Figure US08609715-20131217-C00131
 		1H-NMR (300 MHz, DMSO-d6) δ 9.34 (2H, s), 9.02 (2H, s), 7.95 (1H, t, J = 5.4 Hz), 7.89 (2H, d, J = 8.7 Hz), 7.54 (3H, m), 6.47 (1H, d, J = 3.6 Hz), 3.30 (2H, m), 3.10 (2H, m), 2.98 (1H, m), 2.78-2.68 (2H, m), 1.06 (3H, d, J = 6.3 Hz). MS (ESI) m/z 360 (M + H)+
A-51
Figure US08609715-20131217-C00132
 		1H-NMR (300 MHz, DMSO-d6) δ 9.34 (2H, s), 8.93 (2H, s), 7.89 (2H, d, J = 9.0 Hz), 7.54 (3H, m), 6.47 (1H, d, J = 3.6 Hz), 3.60-3.00 (5H, m), 2.72 (2H, m), 1.90-1.70 (4H, m), 1.07 (3H, d, J = 5.7 Hz). MS (ESI) m/z 370 (M + H)+
A-52
Figure US08609715-20131217-C00133
 		1H-NMR (400 MHz, DMSO-d6) δ 9.34 (2H, s), 8.98 (2H, s), 7.89 (2H, m), 7.55 (3H, m), 6.48 (1H, d, J = 3.2 Hz), 3.90- 3.80 (2H, m), 3.55-3.25 (2H, m), 3.08-2.98 (2H, m), 2.80- 2.70 (2H, m), 2.10-1.20 (4H, m), 1.07 (3H, d, J = 6.4 Hz). MS (ESI) m/z 428 (M + H)+
A-53
Figure US08609715-20131217-C00134
 		1H-NMR (400 MHz, DMSO-d6) δ 9.35 (2H, s), 9.01 (2H, s), 8.37 (1H, d, J = 8.0 Hz), 7.57 (1H, d, J = 2.0 Hz), 7.52-7.44 (3H, m), 6.47 (1H, d, J = 2.0 Hz), 4.55 (1H, m), 3.88 (3H, s), 2.97 (2H, t, J = 7.6 Hz), 2.68-2.55 (4H, m). MS(ESI) m/z 448 (M + H)+
A-54
Figure US08609715-20131217-C00135
 		1H-NMR (400 MHz, DMSO-d6) δ 9.34 (2H, s), 8.96 (2H, s), 7.89 (2H, dd, J = 6.8, 2.0 Hz), 7.54 (3H, m), 6.52 (0.5H, d, J = 3.6 Hz), 6.48 (0.5H, d, J = 3.6 Hz), 4.23 (1H, s), 3.96 (1H, s), 3.60 (1H, t, J = 6.8 Hz), 3.46 (1H, t, J = 6.8 Hz), 2.98-2.85 (2H, m), 2.70-2.40 (2H, m). MS (ESI) m/z 418 (M + H)+
A-55
Figure US08609715-20131217-C00136
 		1H-NMR (400 MHz, DMSO-d6) δ 9.35 (1H, br s), 9.26- 9.02 (2H, m), 7.95-7.86 (2H, m), 7.58-7.51 (2H, m), 6.52 6.47 (3H, m), 5.94-5.62 (1H, m), 5.23-5.03 (2H, m), 4.13- 3.88 (4H, m), 3.04-2.91 (2H, m), 2.83-2.65 (2H, m). MS (ESI) m/z 400 (M + H)+
A-56
Figure US08609715-20131217-C00137
 		MS (ESI) m/z 410 (M + H)+
TABLE 2-13
Compound
No. Structure Analysis data
A-57
Figure US08609715-20131217-C00138
 		1H-NMR (300 MHz, DMSO-d6) δ 8.89 (2H, br), 8.89 (1H, br), 8.26-8.21 (1H, m), 7.89 (2H, d, J = 8.5 Hz), 7.59-7.56 (2H, m), 7.51-7.49 (1H, m), 6.57-6.55 (1H, m), 4.38-4.34 (1H, m), 3.12-2.72 (5H, m), 1.08 (3H, d, J = 6.5 Hz). MS (ESI) m/z 468 (M + H)+
A-58
Figure US08609715-20131217-C00139
 		1H-NMR (300 MHz, DMSO-d6) δ 9.23 (4H, br s), 7.88 (2H, d, J = 8.7 Hz), 7.55 (1H, d, J = 3.4 Hz), 7.54 (2H, d, J = 8.7 Hz), 6.52 (1H, d, J = 3.4 Hz), 1.73-2.37 (7H, m), 0.89 (3H, d, J = 6.7 Hz). MS (ESI) m/z 345 (M + H)+
A-59
Figure US08609715-20131217-C00140
 		1H-NMR (300 MHz, DMSO-d6) δ 9.33 (2H, br s), 9.10 (2H, br s), 8.10 (1H, d, J = 7.6 Hz), 7.89 (2H, d, J = 8.8 Hz), 7.56 (2H, d, J = 8.8 Hz). 7.55 (1H, d, J = 3.5 Hz), 6.53-6.51 (1H, m), 4.50- 4.43 (1H, m), 2.75 (1H, dd, J = 15.0, 6.2 Hz), 2.69-2.47 (3H, m), 2.25-2.11 (2H, m), 1.88-1.81 (1H, m), 1.63-1.57 (1H, m), 1.41-1.34 (1H, m), 0.89 (3H, d, J = 6.6 Hz). MS(ESI) m/z 460 (M + H)+
A-60
Figure US08609715-20131217-C00141
 		1H-NMR (300 MHz, DMSO-d6) δ 9.31 (2H, br s), 9.26 (2H, br s), 7.90 (2H, d, J = 8.7 Hz), 7.55 (3H, m), 6.51 (1H, d, J = 3.6 Hz), 3.00 (1H, m), 2.90 (1H, m), 2.73 (1H, m), 2.28 (2H, m), 1.77 (2H, m). MS (ESI) m/z 375 (M + H)+
A-61
Figure US08609715-20131217-C00142
 		1H-NMR (300 MHz, DMSO-d6) δ 9.34 (2H, s), 9.06 (2H, s), 8.40 (1H, m), 8.89 (2H, d, J = 8.7 Hz), 7.55 (2H, d, J = 8.7 Hz), 7.50 (1H, d, J = 3.3 Hz), 6.48 (1H, m), 4.50 (1H, m), 2.95- 2.40 (5H, m), 2.22 (2H, m), 1.80-1.60 (2H, m). MS (ESI) m/z 490 (M + H)+
A-62
Figure US08609715-20131217-C00143
 		1H-NMR (300 MHz, DMSO-d6) δ 9.33 (2H, s), 9.05 (2H, s), 8.51 (1H, s), 8.24 (0.5H, d, J = 7.8 Hz), 8.26 (0.5H, d, J = 7.8 Hz), 7.89 (2H, d, J = 8.7 Hz), 7.52 (2H, d, J = 8.7 Hz), 6.61 (0.5H, s), 6.58 (0.5H, s), 4.54 (1H, m), 3.10-2.80 (5H, m), 1.02 (3H, m). MS (ESI) m/z 432 (M + H)+
A-63
Figure US08609715-20131217-C00144
 		1H-NMR (400 MHz, DMSO-d6) δ 12.35 (1H, br s), 9.41 (2H, br s), 9.18 (2H, br s), 8.62 (1H, d, J = 0.8 Hz), 7.92 (1H, dd, J = 11.6, 1.6 Hz), 7.76-7.70 (2H, m), 6.63 (1H, d, J= 0.8 Hz), 2.99 (1H, dd, J = 15.0, 6.6 Hz), 2.83-2.72 (2H, m), 1.11 (3H, d, J = 6.8 Hz). MS (ESI) m/z 335 (M + H)
A-64
Figure US08609715-20131217-C00145
 		1H-NMR (400 MHz, DMSO-d6) δ 9.33 (2H, s), 8.94 (2H, s), 8.52 (1H, s), 8.09 (1H, t, J = 6.8 Hz), 7.89 (2H, d, J = 6.8 Hz), 7.52 (2H, d, J = 6.8 Hz), 6.59 (1H, s), 2.92 (1H, dd, J = 14.8, 6.8 Hz), 2.79 (2H, m), 2.67 (2H, m), 1.03 (3H, d, J = 6.8 Hz). MS (ESI) m/z 410 (M + H)+
TABLE 2-14
Compound No. Structure Analysis data
A-65
Figure US08609715-20131217-C00146
 		1H-NMR (400 MHz, DMSO-d6) δ 9.33 (2H, s), 8.91 (2H, s), 8.50 (1H, s), 8.19 (1H, t, J = 7.2 Hz), 7.88 (2H, d, J = 6.4 Hz), 7.55 (2H, m), 6.65 (0.5H, s), 6.62 (0.5H, s), 4.35 (1H, m), 2.91 (1H, m), 2.80 (2H, m), 2.65 (2H, m), 1.05 (3H, d, J = 6.8 Hz). MS (ESI) m/z 468 (M + H)+
A-66
Figure US08609715-20131217-C00147
 		1H-NMR (400 MHz, DMSO-d6) δ 9.40 (2H, br s), 9.07 (2H, br s), 8.61 (1H, d, J = 0.8 Hz), 8.29 (1H, m), 7.92 (1H, dd, J = 11.6, 2.0 Hz), 7.75-7.69 (2H, m), 6.59 (1H, m), 4.52 (1H, 2.90 (1H, m), 2.75-2.55 (4H, m), 1.02 (3H, m). MS (ESI) m/z 450 (M + H)+
A-67
Figure US08609715-20131217-C00148
 		1H-NMR (300 MHz, DMSO-d6) δ 9.33 (2H, s), 8.97 (2H, s), 8.23 (1H, m), 7.90-7.80 (3H, m), 7.55 (2H, d, J = 8.4 Hz), 7.47 (1H, s), 4.48 (1H, m), 3.10-2.90 (3H, m), 2.70-2.50 (2H, m), 1.02 (3H, m). MS (ESI) m/z 432 (M + H)+
A-68
Figure US08609715-20131217-C00149
 		1H-NMR (400 MHz, DMSO-d6) δ 9.36 (2H, s), 8.98 (2H, br s), 8.88 (1H, d, J = 8.0 Hz), 8.01 (4H, s), 7.93 (2H, d, J = 8.8 Hz), 7.79 (1H, d, J = 3.6 Hz), 7.62 (2H, d, J = 8.8 Hz), 7.48 (1H, d, J = 3.6 Hz), 4.80-4.75 (1H, m), 2.87 (1H, dd, J = 16.0, 5.6 Hz), 2.73 (1H, dd, J = 16.0, 8.0 Hz). MS (ESI) m/z 466 (M + H)+
A-69
Figure US08609715-20131217-C00150
 		1H-NMR (400 MHz, DMSO-d6) δ 12.62 (1H, br s), 9.36 (2H, br s), 9.00 (2H, br s), 8.97 (1H, t, J = 6.0 Hz), 8.04- 8.01 (4H, m), 7.92 (2H, d, J = 8.8 Hz), 7.78 (1H, d, J = 3.6 Hz), 7.76 (2H, d, J = 8.8 Hz), 7.47 (1H, d, J = 3.6 Hz), 3.95 (2H, d, J = 6.0 Hz). MS (ESI) m/z 408 (M + H)+
A-70
Figure US08609715-20131217-C00151
 		1H-NMR (400 MHz, DMSO-d6) δ 9.31 (2H, br s), 9.20 (2H, br s), 8.66 (1H, t, J = 5.6 Hz), 8.03 (2H, d, J = 8.4 Hz), 7.96 (2H, d, J = 8.4 Hz), 7.90 (2H, d, J = 8.8 Hz), 7.77 (1H, d, J = 4.0 Hz), 7.60 (2H, d, J = 8.8 Hz), 7.45 (1H, d, J = 4.0 Hz), 3.56 (2H, dd, J = 12.2, 5.6 Hz). MS (ESI) m/z 444 (M + H)+
A-71
Figure US08609715-20131217-C00152
 		MS (ESI) m/z 466 (M + H)+
TABLE 2-15
Compound No. Structure Analysis data
A-72
Figure US08609715-20131217-C00153
 		1H-NMR (300 MHz, DMSO-d6) δ 9.34 (2H, br s), 9.01 (2H, br s), 7.89 (2H, d, J = 8.7 Hz), 7.56 (2H, d, J = 8.7 Hz), 7.54 (1H, s), 6.61-6.49 (1H, m), 5.28-2.19 (1H, m), 3.39-2.60 (5H, m), 1.24-1.04 (3H, m). MS (ESI) m/z 433 (M + H)+
A-73
Figure US08609715-20131217-C00154
 		1H-NMR (400 MHz, DMSO-d6) δ 9.34 (2H, s), 9.15 (2H, s), 7.93-7.87 (2H, m), 7.59-7.51 (3H, m), 6.54 (1H, d, J = 3.6 Hz), 4.37-4.28 (1H, m), 3.21-3.03 (2H, m), 3.01-2.62 (3H, m), 1.25-1.13 (3H, m). MS (ESI) m/z 449 (M + H)+
A-74
Figure US08609715-20131217-C00155
 		1H-NMR (400 MHz, DMSO-d6) δ 12.50 (2H, br s), 9.59 (1H, s), 9.34 (2H, br s), 9.04 (2H, br s), 7.89 (2H, d, J = 8.7 Hz), 7.54 (2H, d, J = 8.7 Hz), 7.49 (1H, d, J = 3.5 Hz), 6.45 (1H, d, J = 3.5 Hz), 3.70 (4H, s), 2.93 (1H, dd, J = 14.6, 7.8 Hz), 2.78-2.70 (2H, m), 1.03 (3H, d, J = 6.6 Hz). MS(ESI) m/z 447 (M + H)+
TABLE 2-16
Compound
No. Structure Analysis data
B-25
Figure US08609715-20131217-C00156
 		1H-NMR (400 MHz, DMSO-d6) δ 9.41 (2H, s), 9.12 (2H, s), 8.32 (1H, d, J = 8.0 Hz), 7.93 (2H, m), 7.74 (2H, m), 7.09 (1H, d, J = 3.6 Hz), 4.50 (1H, m), 3.16 (1H, dd, J = 14.8, 7.6 Hz), 2.90 (1H, dd, J = 14.8, 6.4 Hz), 2.15-2.65 (2H, m), 2.55 (1H, dd, J = 8.4, 1.2 Hz), 1.05 (3H, 6.8 Hz). MS (ESI) m/z 466 (M + H)+
B-26
Figure US08609715-20131217-C00157
 		1H-NMR (400 MHz, DMSO-d6) δ 9.41 (2H, s), 9.15 (2H, s), 8.39 (1H, d, J = 8.0 Hz), 7.93 (2H, m), 7.75 (2H, m), 7.10 (1H, d, J = 4.0 Hz), 4.51 (1H, m), 3.07 (1H, dd, J = 14.8, 8.0 Hz), 2.92 (1H, dd, J = 14.8, 6.4 Hz), 2.80-2.65 (2H, m), 2.55 (1H, m), 1.50 (2H, m), 1.13 (1H, m), 0.80 (6H, m). MS (ESI) m/z 508 (M + H)+
B-27
Figure US08609715-20131217-C00158
 		1H-NMR (400 MHz, DMSO-d6) δ 9.41 (2H, s), 9.08 (2H, s), 8.33 (1H, d, J = 8.0 Hz), 7.92 (2H, m), 7.73 (2H, m), 7.07 (1H, d, J = 4.4 Hz), 4.53 (1H, m), 3.06 (1H, dd, J = 14.8, 8.4 Hz), 2.93 (1H, dd, J = 14.3, 6.0 Hz), 2.80-2.50 (3H, m), 1.55 (2H, m), 1.15 (1H, m), 0.88 (3H, d, J = 6.8 Hz), 0.81 (3H, d, J = 6.8 Hz). MS (ESI) m/z 508 (M + H)+
B-28
Figure US08609715-20131217-C00159
 		1H-NMR (400 MHz, DMSO-d6) δ 9.41 (2H, s), 9.09 (2H, s), 8.33 (1H, m), 7.90 (2H, m), 7.74 (2H, m), 7.09 (1H, d, J = 3.6 Hz), 4.48 (1H, m), 3.10 (1H, dd, J = 14.8, 8.4 Hz), 2.93 (1H, dd, J = 14.8, 6.0 Hz), 2.75-2.60 (2H, m), 2.55 (1H, m), 1.55-1.20 (4H, m), 0.82 (3H, t, J = 6.8 Hz). MS (ESI) m/z 494 (M + H)+
B-29
Figure US08609715-20131217-C00160
 		1H-NMR (400 MHz, DMSO-d6) δ 9.41 (2H, s), 9.10 (2H, s), 8.29 (1H, m), 7.90 (2H, m), 7.74 (2H, m), 7.06 (1H, d, J = 4.0 Hz), 4.53 (1H, m), 3.10 (1H, dd. J = 14.8, 6.4 Hz), 2.94 (1H, dd, J = 14.8, 5.6 Hz), 2.75-2.50 (3H, m), 1.55- 1.20 (4H, m), 0.85 (3H, J = 7.2 Hz). MS (ESI) m/z 494 (M + H)+
B-30
Figure US08609715-20131217-C00161
 		1H-NMR (300 MHz, DMSO-d6) δ 9.48 (2H, br s), 9.20 (2H, br s), 8.20 (1H, br s), 7.88 (1H, d, J = 3.8 Hz), 7.79 (1H, dd, J = 8.4, 8.2 Hz), 7.62 (1H, d, J = 10.9 Hz), 7.40 (1H, dd, J = 8.4, 2.0 Hz), 7.08 (0.5H, d, J = 3.8 Hz), 7.05 (0.5H, d, J = 3.8 Hz), 4.44 (1H, br m), 2.40-3.45 (5H, m), 1.07 (1.5H, d, J = 7.1 Hz), 1.05 (1.5H, d, J = 7.9 Hz). MS (ESI) m/z 466 (M + H)+
B-31
Figure US08609715-20131217-C00162
 		1H-NMR (300 MHz, DMSO-d6) δ 9.42 (2H, br s), 9.10 (2H, br s), 8.21 (1H, br s), 8.10 (1H, d, J = 2.2 Hz), 7.92 (1H, d, J = 3.8 Hz), 7.86 (1H, dd, J = 8.5, 2.2 Hz), 7.77 (1H, d, J = 8.5 Hz), 7.10 (0.5H, d, J = 3.8 Hz), 7.08 (0.5H, d, J = 3.8 Hz), 4.45 (1H, br m), 2.51-3.42 (5H, m), 1.08 (1.5H, d, J = 7.0 Hz), 1.06 (1.5H, d, J = 8.2 Hz). MS (ESI) m/z 466 (M + H)+
B-32
Figure US08609715-20131217-C00163
 		1H-NMR (400 MHz, DMSO-d6) δ 9.41 (2H, s), 9.11 (2H, s), 8.33 (1H, d, J = 8.0 Hz), 7.93 (2H, m), 7.73 (2H, m), 7.12 (1H, d, J = 3.6 Hz), 4.55 (1H, m), 3.13 (2H, t, J = 7.2 Hz), 2.68 (1H, dd, J = 12.4, 6.0 Hz), 2.62-2.55 (3H, m). MS (ESI) m/z 452 (M + H)+
TABLE 2-17
Compound No. Structure Analysis data
B-33
Figure US08609715-20131217-C00164
 		1H-NMR (300 MHz, DMSO-d6) δ 9.34 (2H, s), 9.04 (2H, s), 8.35 (0.5H, d, J = 7.8 Hz), 8.29 (0.5H, d, J = 7.8 Hz), 7.91- 7.82 (3H, m), 7.55 (2H, d, J = 7.2 Hz), 7.05 (1H, m), 4.53 (1H, m), 3.15-2.90 (2H, m), 2.75-2.50 (3H, m), 1.55-1.18 (4H, m), 0.85 (3H, m). MS (ESI) m/z 476 (M + H)
B-34
Figure US08609715-20131217-C00165
 		MS (ESI) m/z 462 (M + H)+
B-35
Figure US08609715-20131217-C00166
 		1H-NMR (300 MHz, DMSO-d6) δ 9.41 (2H, s), 9.21 (2H, s), 8.15 (1H, m), 7.96-7.91 (2H, m), 7.72 (2H, m), 7.10 (1H, m), 4.26 (1H, m), 3.75-3.60 (2H, m), 3.22-3.10 (1H, m), 2.96- 2.75 (2H, m), 1.07 (3H, m). MS (ESI) m/z 438 (M + H)+
B-36
Figure US08609715-20131217-C00167
 		1H-NMR (400 MHz, DMSO-d6) δ 9.41 (2H, s), 9.07 (2H, s), 8.33 (1H, d, J = 8.0 Hz), 7.93 (2H, m), 7.73 (2H, m), 7.12 (1H, d, J = 3.6 Hz), 4.55 (1H, m), 3.13 (1H, t, J = 7.6 Hz), 2.68 (1H, dd, J = 12.0, 5.6 Hz), 2.60-2.50 (4H, m). MS (ESI) m/z 452 (M + H)+
B-37
Figure US08609715-20131217-C00168
 		1H-NMR (400 MHz, DMSO-d6) δ 9.42 (2H, s), 9.15 (2H, s), 7.93(2H, m), 7.75 (2H, m), 7.16 (0.5H, d, J = 4.0 Hz), 7.13 (0.5H, d, J = 4.0 Hz), 4.21 (1H, s), 3.97 (1H, s), 3.60- 3.40 (2H, m), 3.14 (2H, t, J = 6.8 Hz), 2.90 (1H, t, J = 6.8 Hz), 2.66 (1H, t, J = 6.8 Hz), 2.54 (1H, t, J = 6.8 Hz), 2.46 (1H, t, J = 6.8 Hz). MS (ESI) m/z 466 (M + H)+
B-38
Figure US08609715-20131217-C00169
 		1H-NMR (400 MHz, DMSO-d6) δ 9.41 (2H, br s), 9.07 (2H, br), 7.96-7.89 (2H, m), 7.79-7.70 (2H, m), 7.14 (1H, d, J = 3.6 Hz), 5.92-5.62 (1H, m), 5.23-5.06 (2H, m), 4.11- 3.90 (4H, m), 3.21-3.09 (2H, m), 2.84-2.62 (2H, m). MS (ESI) m/z 434 (M + H)+
B-39
Figure US08609715-20131217-C00170
 		1H-NMR (400 MHz, DMSO-d6) δ 9.34 (2H, br), 8.89 (2H, br), 8.22-8.18 (1H, m), 7.90-7.86 (3H, m), 7.60-7.56 (2H, m), 7.12-7.11 (1H, m), 4.39-4.33 (1H, m), 3.22-2.60 (5H, m), 1.09-1.06 (3H, m). MS (ESI) m/z 484 (M + H)+
B-40
Figure US08609715-20131217-C00171
 		1H-NMR (400 MHz, DMSO-d6) δ 9.45 (2H, br s), 9.20 (2H, br s), 7.98 (1H, br s), 7.85-7.87 (3H, m), 7.50 (1H, br s), 7.08 (1H, d, J = 3.0 Hz), 3.17-2.75 (5H, m), 1.05 (3H, d, J = 6.6 Hz). MS (ESI) m/z 426 (M + H)+
TABLE 2-18
Compound
No. Structure Analysis data
B-41
Figure US08609715-20131217-C00172
 		1H-NMR (400 MHz, DMSO-d6) δ 9.39 (2H, br), 9.09 (2H, br), 8.20 (1H, t, J = 4.7 Hz), 7.94 (1H, d, J = 1.5 Hz), 7.91 (1H, J = 3.0 Hz), 7.81-7.72 (2H, m), 7.14 (1H, dd, J = 2.9, 1.1 Hz), 4.39-4.33 (1H, m), 3.22-2.63 (5H, m), 1.09-1.06 (3H, m). MS (ESI) m/z 502 (M + H)+
B-42
Figure US08609715-20131217-C00173
 		1H-NMR (400 MHz, DMSO-d6) δ 9.43 (2H, br s), 9.34 (2H, br s), 8.09 (1H, br s), 7.93-7.90 (2H, m), 7.75-7.73 (2H, m), 7.10 (1H, d, J = 3.0 Hz), 3.26-3.12 (3H, m), 2.88 (1H, dd, J = 11.0, 5.0 Hz), 2.84-2.75 (1H, m), 1.05 (3H, d, J = 6.8 Hz). MS (ESI) m/z 444 (M + H)+
B-43
Figure US08609715-20131217-C00174
 		1H-NMR (400 MHz, DMSO-d6) δ 9.42 (2H, s), 9.08 (2H, s), 8.10 (2H, m), 7.93 (1H, d, J = 3.6 Hz), 7.86 (1H, dd, J = 8.4, 2.4 Hz), 7.76 (1H, d, J = 8.4 Hz), 7.09 (1H, d, J = 3.6 Hz), 3.20- 3.10 (1H, m), 2.92 (1H, d, J = 14.4 Hz), 2.87 (1H, d, J = 14.4 Hz), 2.79 (2H, m), 1.06 (3H, d, J = 6.8). MS (ESI) m/z 460 (M + H)+
B-44
Figure US08609715-20131217-C00175
 		1H-NMR (400 MHz, DMSO-d6) δ 9.03 (2H, s), 8.23 (2H, s), 8.20 (1H, t, J = 8.4 Hz), 8.09 (1H, d, J = 1.6 Hz), 7.91 (1H, d, J = 3.6 Hz), 7.92-7.77 (2H, m), 7.13 (1H, d. J = 1 .6 Hz), 4.37 (1H, m), 3.20-3.10 (1H, m), 2.95-2.75 (3H, m), 2.65 (1H, m), 1.08 (3H, m). MS (ESI) m/z 518 (M + H)+
B-45
Figure US08609715-20131217-C00176
 		MS (ESI) m/z 502 (M + H)+
B-46
Figure US08609715-20131217-C00177
 		MS (ESI) m/z 444 (M + H)+
B-47
Figure US08609715-20131217-C00178
 		1H-NMR (400 MHz, DMSO-d6) δ 12.04 (1H, br s), 9.35 (2H, br s), 9.02 (2H, br s), 7.92 (1H, d, J = 3.8 Hz), 7.90 (2H, d, J = 8.7 Hz), 7.57 (2H, d, J = 8.7 Hz), 7.08 (1H, d, J = 3.8 Hz), 2.91 (1H, dd, J = 14.6, 6.3 Hz), 2.77 (1H, dd, J = 14.6, 7.7 Hz), 2.35-2.19 (2H, m), 1.85-1.76 (1H, m), 1.67- 1.58 (1H, m), 1.44-1.35 (1H, m), 0.90 (3H, d, J = 6.6 Hz). MS (ESI) m/z 361 (M + H)+
TABLE 2-19
Compound
No. Structure Analysis data
B-48
Figure US08609715-20131217-C00179
 		1H-NMR (400 MHz, DMSO-d6) δ 12.05 (1H, br s), 9.42 (2H, br s), 9.17 (2H, br s), 7.97 (1H, d, J = 3.8 Hz), 7.93 (1H, dd, J = 10.8, 1.6 Hz), 7.79-7.73 (2H, m), 7.11 (1H, d, J = 3.8 Hz), 2.93 (1H, dd, J = 14.6, 6.3 Hz), 2.78 (1H, dd, J = 14.6, 7.5 Hz), 2.35-2.20 (2H, m), 1.85-1.77 (1H, m), 1.67- 1.58 (1H, m), 1.44-1.35 (1H, m), 0.90 (3H, d, J = 6.6 Hz). MS (ESI) m/z 379 (M + H)+
B-49
Figure US08609715-20131217-C00180
 		MS (ESI) m/z 494 (M + H)+
B-50
Figure US08609715-20131217-C00181
 		MS (ESI) m/z 476 (M + H)+
B-51
Figure US08609715-20131217-C00182
 		1H-NMR (400 MHz, DMSO-d6) δ 12.37 (1H, br s), 9.41 (2H, br s), 9.18 (2H, br s), 8.53 (1H, d, J = 1.2 Hz), 7.93 (1H, dd, J = 10.6, 1.0 Hz), 7.74-7.75 (2H, m), 7.38 (1H, d, J = 1.2 Hz), 3.12 (1H, dd, J = 15.3, 7.8 Hz), 2.98 (1H, dd, J = 15.3, 6.0 Hz), 2.71 (1H, m), 1.13 (3H, d, J = 7.2 Hz). MS (ESI) m/z 351 (M + H)+
B-52
Figure US08609715-20131217-C00183
 		1H-NMR (400 MHz, DMSO-d6) δ 9.41 (2H, br s), 9.19 (2H, br s), 8.50 (1H, d, J = 1.6 Hz), 8.30 (1H, m), 7.91 (1H, dd, J = 11.6, 1.6 Hz), 7.73 (2H, m), 7.35 (1H, d, J = 3.6 Hz), 4.55- 4.45 (1H, m), 3.10-3.00 (1H, m), 2.88-2.50 (4H, m), 1.07 (3H, m). MS (ESI) m/z 466 (M + H)+
B-53
Figure US08609715-20131217-C00184
 		1H-NMR (400 MHz, DMSO-d6) δ 9.33 (2H, s), 9.50 (2H, s), 8.42 (1H, d, J = 3.2 Hz), 8.32-8.26 (1H, m), 7.88 (2H, d, J = 6.8 Hz), 7.54 (2H, d, J = 6.8 Hz), 7.34 (1H, d, J = 8.4 Hz), 4.50 (1H, m), 3.10-3.00 (1H, m), 2.88-2.80 (1H, m), 2.70- 2.55 (3H, m), 1.03 (3H, m). MS (ESI) m/z 448 (M + H)+
B-54
Figure US08609715-20131217-C00185
 		1H-NMR (400 MHz, DMSO-d6) δ 9.40 (2H, br s), 9.09 (2H, br s), 8.49 (1H, s), 8.30 (1H, d, J = 8.0 Hz), 7.92 (1H, d, J = 8.0 Hz), 7.73 (2H, m), 7.38 (1H, s), 4.55 (1H, m), 3.07 (2H, t, J = 7.6 Hz), 2.70-2.55 (4H, m). MS (ESI) m/z 452 (M + H)+
TABLE 2-20
Compound No. Structure Analysis data
B-55
Figure US08609715-20131217-C00186
 		1H-NMR (300 MHz, DMSO-d6) δ 9.35 (2H, br s), 9.06 (2H, s), 8.22 (1H, m), 7.90 (3H, m), 7.73 (1H, d, J = 7.8 Hz), 7.56 (2H, d, J = 7.8 Hz), 4.55 (1H, m), 2.95-2.80 (1H, m), 2.78-2.55 (4H, m), 1.00 (3H, m). MS (ESI) m/z 448 (M + H)+
B-56
Figure US08609715-20131217-C00187
 		MS (ESI) m/z 482 (M + H)+
B-57
Figure US08609715-20131217-C00188
 		MS (ESI) m/z 500 (M + H)+
B-58
Figure US08609715-20131217-C00189
 		MS (ESI) m/z 482 (M + H)+
B-59
Figure US08609715-20131217-C00190
 		MS (ESI) m/z 488 (M + H)+
B-60
Figure US08609715-20131217-C00191
 		1H-NMR (400 MHz, DMSO-d6) δ 9.41 (2H, br s), 9.10 (2H, br s), 8.64 (1H, d, J = 4.0 Hz), 7.98 (2H, m), 7.75 (2H, m), 7.14 (1H, d, J = 3.6 Hz), 4.55 (1H, m), 3.90 (2H, s), 3.08- 2.98 (1H, m). 2.70-2.60 (1H, m). MS (ESI) m/z 438 (M + H)+
TABLE 2-21
Compound
No. Structure Analysis data
B-61
Figure US08609715-20131217-C00192
 		1H-NMR (400 MHz, DMSO-d6) δ 9.40 (2H. br s), 9.11 (2H, br s), 8.29 (1H, d, J = 7.2 Hz), 7.92 (1H, d, J = 11.2 Hz), 7.84 (1H, s), 7.77-7.71 (2H, m), 4.57-4.46 (1H, m), 3.03 (2H, t, J = 7.6 Hz), 2.71-2.49 (4H, m), 2.21 (3H, s). MS (ESI) m/z 466 (M + H)+
B-62
Figure US08609715-20131217-C00193
 		1H-NMR (400 MHz, DMSO-d6) δ 9.52-9.28 (2H, br s), 9.28-9.03 (2H, br s), 8.22 (1H, d, J = 8.0 Hz), 7.96-7.89 (2H, m), 7.78-7.71 (2H, m), 7.12 (1H, d, J = 8.0 Hz), 4.22 (1H, td, J = 8.0, 4.2 Hz), 3.15 (2H, t, J = 5.4 Hz), 2.63-2.51 (2H, m), 2.29-2.18 (2H, m), 2.01-1.87 (1H, m), 1.82-1.69 (1H, m). MS (ESI) m/z 466 (M + H)+
B-63
Figure US08609715-20131217-C00194
 		1H-NMR (400 MHz, DMSO-d6) δ 9.56-9.10 (4H, m), 7.98-7.89 (2H, m), 7.79-7.70 (2H, m), 718-7.09 (1H, m), 5.95-5.65 (1H, m), 5.46-4.95 (2H, m), 4.61-4.48 (1H, m), 4.18-3.84 (2H, m), 3.71-2.41 (6H, m). MS (ESI) m/z 492 (M + H)+
B-64
Figure US08609715-20131217-C00195
 		1H-NMR (400 MHz, DMSO-d6) δ 9.41 (2H, br s), 9.10 (2H, br s), 7.96-7.89 (3H, m), 7.79-7.71 (2H, m), 7.07 (1H, d, J = 4.0 Hz), 4.57 (1H, dt, J = 7.2, 6.8 Hz), 3.13 (2H, s), 2.76 (1H, dd, J = 16.4, 6.8 Hz), 2.58 (1H, dd, J = 16.4, 6.8 Hz), 1.14 (3H, s), 1.13 (3H, s). MS (ESI) m/z 480 (M + H)+
B-65
Figure US08609715-20131217-C00196
 		1H-NMR (400 MHz, DMSO-d6) δ 9.42 (2H, br s), 9.24 (1H, br s), 9.16 (2H, br s), 8.24 (1H, d, J = 8.0 Hz), 7.96-7.88 (2H, m), 7.79-7.71 (2H, m), 7.00 (1H, d, J = 4.8 Hz), 6.98 (2H, d, J = 8.4 Hz), 6.64 (2H, d, J = 8.4 Hz), 4.37 (1H, ddd, J = 9.2, 8.0, 4.8 Hz), 3.07 (2H, t, J = 7.2 Hz), 2.93 (1H, dd, J = 14.0, 4.8 Hz), 2.73 (1H, dd, J = 14.0, 9.2 Hz), 2.52 (3H, t, J = 7.2 Hz). MS (ESI) m/z 500 (M + H)+
B-66
Figure US08609715-20131217-C00197
 		1H-NMR (400 MHz, DMSO-d6) δ 9.41 (2H, s), 9.11 (2H, s), 8.17 (1H, d, J = 7.6 Hz), 7.93 (2H, m), 7.75 (2H, m), 7.13 (1H, d, J = 3.6 Hz), 4.31 (1H, m), 3.71-3.66 (1H, m), 3.63-3.58 (1H, m), 3.14 (2H, t, J = 7.2 Hz), 2.62 (2H, t, J = 7.2 Hz). MS (ESI) m/z 424 (M + H)+
TABLE 2-22
Compound No. Structure Analysis data
C-4
Figure US08609715-20131217-C00198
 		1H-NMR (400 MHz, DMSO-d6) δ 9.42 (2H, s), 9.16 (2H, s), 8.62 (1H, s), 8.36 (1H, m), 7.95 (1H, dd, J = 11.0, 2.0 Hz), 7.76 (2H, m). 4.50 (1H, m), 3.30 (1H, m), 3.10-2.85 (1H, m), 2.75-2.55 (3H, m), 1.10 (3H, m). MS (ESI) m/z 467 (M + H)+
C-5
Figure US08609715-20131217-C00199
 		1H-NMR (400 MHz, DMSO-d6) δ 9.35 (2H, s), 9.02 (2H, s), 8.72 (1H, s), 7.91 (2H, d, J = 8.4 Hz), 7.57 (2H, d, J = 8.4 Hz), 4.22 (1H, s), 3.97 (1H, s), 3.65-3.30 (4H, m), 2.95 (1H, t, J = 6.8 Hz), 2.75 (1H, t, J = 6.8 Hz), 2.55 (1H, t, J = 6.8 Hz), 2.45 (1H, t, J = 6.8 Hz). MS (ESI) m/z 4.49 (M + H)+
Experimental Example 1 Measurement of Trypsin Inhibitory Activity
Using a 96 well plate (#3915, Costar), a test compound (25 μL) was mixed with 20 μM fluorescence enzyme substrate (Boc-Phe-Ser-Arg-AMC, 50 μL) mixed with 200 mM Tris-HCl buffer (pH 8.0), and human trypsin (Sigma, 25 μL) was added. Using a fluorescence plate reader fmax (Molecular Devices, Inc.), the reaction rate was measured from the time-course changes at excitation wavelength 355 nm and fluorescence wavelength 460 nm. The Ki value was calculated from the concentration of the test compound, reciprocal of reaction rate, and Km value of the enzyme substrate, and by using Dixon plot. The results are shown in Table 3.
Experimental Example 2 Measurement of Enteropeptidase Inhibitory Activity
Using a 96 well plate (#3915, Costar), a test compound (25 μL), 400 mM Tris-HCl buffer (pH 8.0, 25 μL) and 0.5 mg/mL fluorescence enzyme substrate (Gly-Asp-Asp-Asp-Asp-Lys-β-Naphtylamide, 25 μL) were mixed, and recombinant human enteropeptidase (R&D Systems, Inc., 25 μL) was added. Using a fluorescence plate reader fmax (Molecular Devices, Inc.), the reaction rate was measured from the time-course changes at excitation wavelength 320 nm and fluorescence wavelength 405 nm. The Ki value was calculated from the concentration of the test compound, reciprocal of reaction rate, and Km value of the enzyme substrate, and by using Dixon plot. The results are shown in Table 3.
TABLE 3
Enteropeptidase Trypsin inhibitory
Compound inhibitory activity activity
No. Ki (nM) Ki (nM)
A-1 2.27 0.52
A-2 1.97 0.44
A-3 1.15 0.69
A-4 2.68 1.26
A-5 1.37 1.13
A-6 0.62 1.53
A-7 1.49 1.01
A-9 3.17 7.32
A-10 6.73 9.15
A-12 3.31 1.13
A-14 3.52 0.48
A-15 1.63 1.16
A-16 1.88 1.84
A-17 2.43 1.76
A-18 0.61 1.07
A-19 1.91 2.92
A-20 2.54 1.88
A-21 4.81 3.25
A-22 0.95 2.0
A-23 2.0 1.3
A-24 1.9 2.4
A-25 2.1 2.0
A-26 0.68 2.29
A-27 0.57 0.95
A-28 0.42 0.75
A-29 0.82 1.67
A-30 1.03 1.28
A-31 0.50 0.62
A-32 0.62 2.89
A-33 0.65 0.79
A-34 0.98 1.65
A-35 0.25 0.38
A-36 0.58 1.33
A-37 0.64 1.46
A-38 0.57 0.86
A-39 0.67 1.60
A-41 0.50 0.89
A-42 0.71 3.8
A-43 0.40 0.52
A-44 0.33 0.62
A-45 0.46 0.97
A-46 0.35 0.47
A-47 1.9 5.7
A-48 1.3 4.5
A-49 7.6 3.4
A-50 4.4 2.3
A-51 4.9 3.6
A-52 2.5 1.2
A-54 0.60 1.3
A-55 1.3 1.4
A-56 1.1 1.7
A-57 0.39 2.0
A-58 0.70 0.72
A-59 0.35 0.12
A-60 0.31 6.7
A-61 0.42 3.7
A-62 2.1 4.2
A-63 0.53 0.92
A-64 2.5 3.1
A-65 1.0 4.5
A-66 0.32 0.44
A-67 0.52 0.20
A-68 2.2 0.23
A-69 4.7 0.62
A-70 2.7 0.30
A-71 1.6 0.054
A-72 0.68 2.3
A-73 0.88 0.53
A-74 2.6 3.8
B-2 9.29 6.34
B-3 5.72 4.76
B-6 1.44 7.19
B-7 2.15 7.36
B-8 0.84 0.22
B-11 1.41 2.39
B-12 2.21 5.75
B-16 0.29 1.51
B-17 0.42 1.76
B-18 1.36 1.76
B-19 0.42 0.91
B-20 0.28 0.18
B-21 0.56 0.15
B-22 0.50 0.39
B-23 1.47 1.54
B-24 0.49 0.83
B-25 0.79 0.19
B-26 2.2 1.0
B-27 0.95 1.3
B-28 1.1 0.43
B-29 0.58 1.3
B-30 0.52 0.33
B-31 0.33 0.66
B-32 0.31 0.48
B-33 2.8 3.6
B-34 2.2 2.7
B-35 0.40 0.97
B-36 0.51 0.84
B-37 0.50 4.5
B-38 0.75 1.4
B-39 0.95 2.2
B-40 2.0 1.8
B-41 0.27 0.21
B-42 0.37 0.22
B-43 0.42 0.49
B-44 0.21 0.57
B-45 0.48 1.1
B-46 0.38 0.44
B-47 2.5 1.8
B-48 0.88 0.37
B-49 0.41 0.18
B-50 0.89 0.47
B-51 0.72 1.6
B-52 0.39 0.51
B-53 4.8 8.5
B-54 0.58 0.79
B-55 0.98 5.0
B-56 9.5 0.70
B-57 3.0 0.27
B-58 9.8 3.5
B-59 8.2 4.4
B-60 0.64 3.2
B-61 0.13 0.5
B-62 0.57 0.4
B-63 0.55 0.9
B-64 0.14 0.6
B-65 3.20 3.7
B-66 0.73 1.2
C-2 5.67 0.39
C-4 3.7 0.2
Thus, the compound of the present invention was confirmed to show superior enteropeptidase inhibitory activity and superior trypsin inhibitory activity. Therefore, it has been shown that the compound of the present invention having an inhibitory activity on enteropeptidase and trypsin decreases digestive capacity for protein, lipid, and carbohydrates, and is effective as a therapeutic and prophylactic drug for obesity and hyperlipidemia.
Experimental Example 3 Evaluation of Antidiabetic Action
KK-Ay/JCL mice (male, 5- to 7-week-old, CLEA Japan, Inc.) known to spontaneously develop obese type 2 diabetes were purchased and, after one week of preliminary rearing period, grouped (6 per group) with the body weight and non-fasting blood glucose levels as indices. The animals were individually housed in a polycarbonate cage and allowed to drink water freely from a watering bottle. During the test period, they were allowed to freely ingest a mixture of a test compound (B-18 hydrochloride, B-20 hydrochloride, A-28 hydrochloride, B-23 hydrochloride, or B-32 hydrochloride) (5.6 mg/100 g or 16.8 mg/100 g) and powder feed CRF-1 (Oriental Yeast Co., Ltd.). CRF-1 alone was given to the control group. After one week of dosing period, the blood (6 μL) was drawn from the tail vein of the animals, and the blood glucose level was measured by ACCU-CHEK Aviva (Roche Diagnostics K.K.). The results are shown in Table 4. A significant difference from the control group was detected by Dunnett's multiple comparison test or Student's t-test (significance level less than 5%). Thus, the test compound showed a significant hypoglycemic action. The compound of the present invention having an enteropeptidase inhibitory activity and a trypsin inhibitory activity was shown to have a blood glucose elevation suppressing or hypoglycemic action. In addition, it has also been shown that the compound of the present invention shows an insulin sensitizing activity and is also useful as a prophylactic or therapeutic agent for obesity, diabetic complications, or metabolic syndrome, since it shows a blood glucose elevation suppressing or hypoglycemic action.
TABLE 4
Mean blood
Dose glucose level Standard
(mg/100 g) (mg/dL) error p value
Control group 447 22
B-18 5.6 217 40 <0.001
hydrochloride
B-18 16.8 138 7 <0.001
hydrochloride
Control group 415 27
B-20 5.6 197 27 <0.001
hydrochloride
A-28 5.6 219 46 <0.001
hydrochloride
B-23 5.6 198 23 <0.001
hydrochloride
Control group 478 28
B-32 5.6 249 39 <0.001
hydrochloride
INDUSTRIAL APPLICABILITY
The trypsin and enteropeptidase inhibitory compound relating to the present invention can be used as an active ingredient of a therapeutic or prophylactic drug of diabetes or diabetic complications.
Where a numerical limit or range is stated herein, the endpoints are included. Also, all values and subranges within a numerical limit or range are specifically included as if explicitly written out.
Obviously, numerous modifications and variations of the present invention are possible in light of the above teachings. It is therefore to be understood that, within the scope of the appended claims, the invention may be practiced otherwise than as specifically described herein.
All patents and other references mentioned above are incorporated in full herein by this reference, the same as if set forth at length.

Claims (10)

The invention claimed is:
1. A compound represented by formula (I):
Figure US08609715-20131217-C00200
wherein
R1, R2, R3, and R4 may be the same or different and are each independently a hydrogen atom, a nitro group, a halogeno group, a cyano group, a hydroxyl group, a thiol group, an amino group, a guanidino group, a formyl group, a lower alkyl group, a lower alkenyl group, a lower alkynyl group, a lower acyl group, a carboxyl group, a sulfo group, a phosphono group, a lower alkoxyl group, a lower alkylthio group, a lower alkylamino group, a lower acyloxy group, a lower acylamino group, a lower alkoxycarbonyl group, a carbamoyl group, a lower alkylcarbamoyl group, a lower alkylsulfonylamino group, or a sulfamoyl group;
HetAr is a furan ring optionally having substituent(s);
X is a lower alkylene group optionally having substituent(s), a lower alkenylene group optionally having substituent(s), a lower alkynylene group optionally having substituent(s), or a thiophenylene group;
Y is a carbonyl group, a thiocarbonyl group, or a sulfonyl group; and
A is a group of formula (II):
Figure US08609715-20131217-C00201
wherein R6 and R7 may be the same or different and are each independently a hydrogen atom, a hydroxyl group, a lower alkyl group optionally having substituent(s), a lower alkenyl group optionally having substituent(s), a lower alkynyl group optionally having substituent(s) or a lower alkoxyl group optionally having substituent(s), or R6 and R7 may be bonded to form a cyclic amino group optionally having substituent(s);
or a pharmaceutically acceptable salt thereof.
2. A compound represented by formula (I):
Figure US08609715-20131217-C00202
wherein
R1, R2, R3, and R4 may be the same or different and are each independently a hydrogen atom, a nitro group, a halogeno group, a cyano group, a hydroxyl group, a thiol group, an amino group, a guanidino group, a formyl group, a lower alkyl group, a lower alkenyl group, a lower alkynyl group, a lower acyl group, a carboxyl group, a sulfo group, a phosphono group, a lower alkoxyl group, a lower alkylthio group, a lower alkylamino group, a lower acyloxy group, a lower acylamino group, a lower alkoxycarbonyl group, a carbamoyl group, a lower alkylcarbamoyl group, a lower alkylsulfonylamino group, or a sulfamoyl group;
HetAr is a furan ring optionally having substituent(s);
X is a lower alkylene group optionally having substituent(s), a lower alkenylene group optionally having substituent(s), or a lower alkynylene group optionally having substituent(s);
Y is a carbonyl group, a thiocarbonyl group, or a sulfonyl group;
a group of formula (II):
Figure US08609715-20131217-C00203
wherein R6 and R7 may be the same or different and are each independently a hydrogen atom, a hydroxyl group, a lower alkyl group optionally having substituent(s), a lower alkenyl group optionally having substituent(s), a lower alkynyl group optionally having substituent(s), or a lower alkoxyl group optionally having substituent(s), or R6 and R7 may be bonded to form a cyclic amino group optionally having substituent(s),
or a pharmaceutically acceptable salt thereof.
3. A compound or pharmaceutically acceptable salt thereof according to claim 1, wherein R1, R2, R3, and R4 are each independently a hydrogen atom, a nitro group, or a halogeno group.
4. A compound or pharmaceutically acceptable salt thereof according to claim 1, wherein -HetAr— is a heteroaromatic ring group represented by formula (III-1) or (III-2):
Figure US08609715-20131217-C00204
wherein Z1 and Z2 are each independently CRa, and Z3 is an oxygen atom, wherein each Ra may be the same or different and is independently a hydrogen atom, a nitro group, a halogeno group, a cyano group, a hydroxyl group, a thiol group, an amino group, a guanidino group, a formyl group, a lower alkyl group, a lower alkenyl group, a lower alkynyl group, a lower acyl group, a carboxyl group, a sulfo group, a phosphono group, a lower alkoxyl group, a lower alkylthio group, a lower alkylamino group, a lower acyloxy group, a lower acylamino group, a lower alkoxycarbonyl group, a carbamoyl group, a lower alkylcarbamoyl group, a lower alkylsulfonylamino group, or a sulfamoyl group.
5. A compound or pharmaceutically acceptable salt thereof according to claim 1, wherein X is a lower alkylene group optionally having substituent(s) or a lower alkenylene group optionally having substituent(s), wherein said substituent(s) is selected from the group consisting of a halogeno group, a hydroxyl group, an amino group, a lower alkyl group, a lower alkoxyl group, and a lower acyl group.
6. A compound or pharmaceutically acceptable salt thereof according to claim 1, wherein Y is a carbonyl group or a sulfonyl group.
7. A compound or pharmaceutically acceptable salt thereof according to claim 1, wherein A is a group of formula (IV):
Figure US08609715-20131217-C00205
wherein R60 is a carboxyl group, a sulfo group, a phosphono group, a lower alkoxycarbonyl group, or a hydroxyl group,
D is a lower alkylene group optionally having substituent(s), a lower alkenylene group optionally having substituent(s) or a lower alkynylene group optionally having substituent(s), wherein said substituent(s) is selected from the group consisting of a nitro group, a halogeno group, a cyano group, a hydroxyl group, a thiol group, an amino group, a guanidino group, a formyl group, a lower acyl group, a carboxyl group, a sulfo group, a phosphono group, a lower alkoxyl group, a lower alkylthio group, a lower alkylamino group, a lower acyloxy group, a lower acylamino group, a lower alkoxycarbonyl group, a carbamoyl group, a lower alkylcarbamoyl group, a lower alkylsulfonylamino group, an arylsulfonylamino group optionally having substituent(s), a cycloalkyl group optionally having substituent(s), an aryl group optionally having substituent(s), an aryloxy group optionally having substituent(s), an arylthio group optionally having substituent(s), an aralkyl group optionally having substituent(s), an aralkyloxy group optionally having substituent(s), an aralkylthio group optionally having substituent(s), a heterocyclic group optionally having substituent(s), a heterocyclic oxy group optionally having substituent(s), a heterocyclic thio group optionally having substituent(s), and an oxo group, and
R70 is a hydrogen atom, a hydroxyl group, a lower alkyl group optionally having substituent(s), or a lower alkoxyl group optionally having substituent(s),
or R70 and D may be bonded to form a cyclic amino group optionally having substituent(s).
8. A compound or pharmaceutically acceptable salt thereof according to claim 7, wherein R60 is a carboxyl group, a sulfo group, a lower alkoxycarbonyl group, or a hydroxyl group,
D is a lower alkylene group optionally having substituent(s), wherein said substituent(s) is selected from the group consisting of a halogeno group, a hydroxyl group, a thiol group, an amino group, a guanidino group, a carboxyl group, a sulfo group, a lower alkoxyl group, a lower alkylthio group, a lower alkylamino group, a lower acylamino group, a lower alkoxycarbonyl group, a carbamoyl group, a lower alkylcarbamoyl group, a lower alkylsulfonylamino group, an arylsulfonylamino group optionally having substituent(s), an aryl group optionally having substituent(s), a heterocyclic group optionally having substituent(s), and an oxo group, and
R70 is a hydrogen atom, a hydroxyl group, a lower alkyl group optionally having substituent(s) or a lower alkoxyl group optionally having substituent(s),
or R70 and D may be bonded to form a cyclic amino group optionally having substituent(s).
9. A compound or pharmaceutically acceptable salt thereof according to claim 1, wherein R1, R2, R3, and R4 are each independently a hydrogen atom, a nitro group, or a fluorine atom, and
HetAr is furan optionally having substituent(s).
10. A pharmaceutical composition comprising a compound or pharmaceutically acceptable salt thereof according to claim 1 and a pharmaceutically acceptable excipient.
US13/484,822 2009-12-07 2012-05-31 Heteroarylcarboxylic acid ester derivative Active US8609715B2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US14/089,040 US8877805B2 (en) 2009-12-07 2013-11-25 Heteroarylcarboxylic acid ester derivative
US14/496,363 US9115107B2 (en) 2009-12-07 2014-09-25 Heteroarylcarboxylic acid ester derivative
US14/799,130 US20150313889A1 (en) 2009-12-07 2015-07-14 Heteroarylcarboxylic acid ester derivative

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2009277827 2009-12-07
JP2009-277827 2009-12-07
JP2010-214406 2010-09-24
JP2010214406 2010-09-24
PCT/JP2010/071929 WO2011071048A1 (en) 2009-12-07 2010-12-07 Heteroarylcarboxylic acid ester derivative

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2010/071929 Continuation WO2011071048A1 (en) 2009-12-07 2010-12-07 Heteroarylcarboxylic acid ester derivative

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US14/089,040 Continuation US8877805B2 (en) 2009-12-07 2013-11-25 Heteroarylcarboxylic acid ester derivative

Publications (2)

Publication Number Publication Date
US20120283222A1 US20120283222A1 (en) 2012-11-08
US8609715B2 true US8609715B2 (en) 2013-12-17

Family

ID=44145592

Family Applications (4)

Application Number Title Priority Date Filing Date
US13/484,822 Active US8609715B2 (en) 2009-12-07 2012-05-31 Heteroarylcarboxylic acid ester derivative
US14/089,040 Active US8877805B2 (en) 2009-12-07 2013-11-25 Heteroarylcarboxylic acid ester derivative
US14/496,363 Active US9115107B2 (en) 2009-12-07 2014-09-25 Heteroarylcarboxylic acid ester derivative
US14/799,130 Abandoned US20150313889A1 (en) 2009-12-07 2015-07-14 Heteroarylcarboxylic acid ester derivative

Family Applications After (3)

Application Number Title Priority Date Filing Date
US14/089,040 Active US8877805B2 (en) 2009-12-07 2013-11-25 Heteroarylcarboxylic acid ester derivative
US14/496,363 Active US9115107B2 (en) 2009-12-07 2014-09-25 Heteroarylcarboxylic acid ester derivative
US14/799,130 Abandoned US20150313889A1 (en) 2009-12-07 2015-07-14 Heteroarylcarboxylic acid ester derivative

Country Status (8)

Country Link
US (4) US8609715B2 (en)
EP (1) EP2511271B1 (en)
JP (1) JP5482800B2 (en)
CN (1) CN102822154B (en)
DK (1) DK2511271T3 (en)
ES (1) ES2532201T3 (en)
PL (1) PL2511271T3 (en)
WO (1) WO2011071048A1 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130338132A1 (en) * 2012-06-14 2013-12-19 Ajinomoto Co., Inc. Heteroarylcarboxylic acid ester derivative
US9346821B2 (en) 2011-06-07 2016-05-24 Ajinomoto Co., Inc. Heterocyclic carboxylic acid ester derivative
US20160376248A1 (en) * 2014-03-11 2016-12-29 Ea Pharma Co., Ltd. Method for producing heteroarylcarboxylic acid ester derivative, and production intermediate of same
US12023320B2 (en) 2020-08-19 2024-07-02 Ea Pharma Co., Ltd. Therapeutic agent for fatty liver disease

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013039187A1 (en) 2011-09-15 2013-03-21 アステラス製薬株式会社 Guanidinobenzoic acid compound
BR112015022762B1 (en) 2013-03-13 2022-08-16 Takeda Pharmaceutical Company Limited GUANIDINOBENZOIC ACID ESTER COMPOUND, PHARMACEUTICAL COMPOSITION, AND, USE OF THE COMPOUND
US9346776B2 (en) 2014-02-13 2016-05-24 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
US9428470B2 (en) * 2014-02-13 2016-08-30 Takeda Pharmaceutical Company Limited Heterocyclic compound
SG11201607555SA (en) * 2014-03-11 2016-10-28 Ea Pharma Co Ltd Production method for heteroarylcarboxylic acid ester derivative, production intermediate thereof, and crystal
US9975903B2 (en) 2014-12-26 2018-05-22 Takeda Pharmaceutical Company Limited Condensed heterocyclic compound
KR102121647B1 (en) 2015-01-15 2020-06-10 고꾸리쯔 다이가꾸 호우징 오사까 다이가꾸 Method for inducing differentiation of corneal epithelial cells from pluripotent stem cells
JP2018080109A (en) * 2015-03-16 2018-05-24 武田薬品工業株式会社 Therapeutic agent
US10017487B2 (en) 2015-03-27 2018-07-10 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
EP3438091A4 (en) * 2016-03-30 2019-11-27 Ajinomoto Co., Inc. Compound having enhancing activity for glucagon-like peptide-1 receptor actions
CA3081564A1 (en) 2017-11-02 2019-05-09 Ube Industries, Ltd. Double-headed protease inhibitor
CN108148026B (en) * 2018-01-25 2020-06-05 华中科技大学 Method for preparing 2, 5-furandicarboxylic acid by catalytic carbonylation
BR112020022790A2 (en) * 2018-05-09 2021-02-02 Lg Chem, Ltd new compound that exhibits enteropeptidase inhibitory activity
US20210403420A1 (en) * 2018-08-27 2021-12-30 Scohia Pharma, Inc. Benzoate compound
CN113121516A (en) * 2019-12-31 2021-07-16 中国科学院化学研究所 Compound and method for preparing compound by catalyzing 5-chloromethyl furfural with carbene
CN115385878B (en) * 2022-07-12 2023-08-01 浙江海洋大学 Natural active compound moenofuran and preparation method and application thereof

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS56161385A (en) 1980-05-16 1981-12-11 Torii Yakuhin Kk Ester derivative
WO1999041231A1 (en) 1998-02-17 1999-08-19 Ono Pharmaceutical Co., Ltd. Amidino derivatives and drugs containing the same as the active ingredient
US20020128315A1 (en) 1994-09-20 2002-09-12 Hisao Nakai Leukotriene B4 antagonist compounds and method for treatment
WO2006050999A2 (en) 2004-11-15 2006-05-18 Obe Therapy Biotechnology S.A.S Methods of reducing body fat
WO2006057152A1 (en) 2004-11-08 2006-06-01 Ono Pharmaceutical Co., Ltd. Therapeutic agent for diabetes comprising protease-inhibiting compound
JP2008266174A (en) 2007-04-18 2008-11-06 Kowa Co Agent for inhibiting formation of advanced glycation end product by using amidinophenol derivative as active component
WO2009071601A1 (en) 2007-12-03 2009-06-11 Obe Therapy Biotechnology Boropeptide inhibitors of enteropeptidase and their uses in treatment of obesity, overweight and/or diseases associated with an abnormal fat metabolism

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS55161385A (en) 1979-06-01 1980-12-15 Hitachi Ltd Package erroneous insertion detecting system
JP2009277827A (en) 2008-05-14 2009-11-26 Panasonic Corp Capacitor
JP5469354B2 (en) 2009-03-16 2014-04-16 公立大学法人首都大学東京 Pipe processing apparatus and pipe processing method
EP2725016B1 (en) 2011-06-07 2016-12-21 EA Pharma Co., Ltd. Heterocyclic carboxylic acid ester derivative
US9024044B2 (en) 2012-06-14 2015-05-05 Ajinomoto Co., Inc. Heteroarylcarboxylic acid ester derivative

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS56161385A (en) 1980-05-16 1981-12-11 Torii Yakuhin Kk Ester derivative
US20020128315A1 (en) 1994-09-20 2002-09-12 Hisao Nakai Leukotriene B4 antagonist compounds and method for treatment
WO1999041231A1 (en) 1998-02-17 1999-08-19 Ono Pharmaceutical Co., Ltd. Amidino derivatives and drugs containing the same as the active ingredient
US6358960B1 (en) 1998-02-17 2002-03-19 Ono Pharmaceutical Co., Ltd. Amidino derivatives and drugs containing the same as the active ingredient
WO2006057152A1 (en) 2004-11-08 2006-06-01 Ono Pharmaceutical Co., Ltd. Therapeutic agent for diabetes comprising protease-inhibiting compound
US20080009537A1 (en) 2004-11-08 2008-01-10 Yoshiki Sakai Therapeutic Agent for Diabetes Comprising Protease-Inhibiting Compound
WO2006050999A2 (en) 2004-11-15 2006-05-18 Obe Therapy Biotechnology S.A.S Methods of reducing body fat
US20070298025A1 (en) 2004-11-15 2007-12-27 Obe Therapy Biotechnology S.A.S. Pharmaceutical Compositions and Methods for Reducing Body Fat
JP2008266174A (en) 2007-04-18 2008-11-06 Kowa Co Agent for inhibiting formation of advanced glycation end product by using amidinophenol derivative as active component
WO2009071601A1 (en) 2007-12-03 2009-06-11 Obe Therapy Biotechnology Boropeptide inhibitors of enteropeptidase and their uses in treatment of obesity, overweight and/or diseases associated with an abnormal fat metabolism
US20100311690A1 (en) 2007-12-03 2010-12-09 Obe Therapy Biotechnology Boropeptide inhibitors of enteropeptidase and their uses in treatment of obesity, overweight and/or diseases associated with an abnormal fat metabolism

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
International Search Report issued in PCT/JP2010/071929 on Jan. 18, 2011.
King, Med. Chem. Principle and Practice (1994), pp. 206-208. *
M. Matsushima et al., "Biomedical Research", vol. 22 , No. 5 (2001) pp. 257-260.
T. Yokoyama et al., "Advances in Experimental Medicine and Biology", (1989) 247B pp. 271-276.
U.S. Appl. No. 13/517,805, filed Jun. 14, 2012, Koshiba, et al.

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9346821B2 (en) 2011-06-07 2016-05-24 Ajinomoto Co., Inc. Heterocyclic carboxylic acid ester derivative
US20130338132A1 (en) * 2012-06-14 2013-12-19 Ajinomoto Co., Inc. Heteroarylcarboxylic acid ester derivative
US9024044B2 (en) * 2012-06-14 2015-05-05 Ajinomoto Co., Inc. Heteroarylcarboxylic acid ester derivative
US9227949B2 (en) 2012-06-14 2016-01-05 Ajinomoto Co., Inc. Heteroarylcarboxylic acid ester derivative
US9655879B2 (en) 2012-06-14 2017-05-23 Ea Pharma Co., Ltd. Heteroarylcarboxylic acid ester derivative
US20160376248A1 (en) * 2014-03-11 2016-12-29 Ea Pharma Co., Ltd. Method for producing heteroarylcarboxylic acid ester derivative, and production intermediate of same
US12023320B2 (en) 2020-08-19 2024-07-02 Ea Pharma Co., Ltd. Therapeutic agent for fatty liver disease

Also Published As

Publication number Publication date
DK2511271T3 (en) 2015-03-23
CN102822154B (en) 2016-06-01
PL2511271T3 (en) 2015-06-30
US9115107B2 (en) 2015-08-25
JPWO2011071048A1 (en) 2013-04-22
WO2011071048A1 (en) 2011-06-16
JP5482800B2 (en) 2014-05-07
ES2532201T3 (en) 2015-03-25
EP2511271A1 (en) 2012-10-17
US8877805B2 (en) 2014-11-04
EP2511271A4 (en) 2013-05-15
US20140080790A1 (en) 2014-03-20
US20150011511A1 (en) 2015-01-08
CN102822154A (en) 2012-12-12
US20120283222A1 (en) 2012-11-08
EP2511271B1 (en) 2015-01-21
US20150313889A1 (en) 2015-11-05

Similar Documents

Publication Publication Date Title
US9115107B2 (en) Heteroarylcarboxylic acid ester derivative
US9655879B2 (en) Heteroarylcarboxylic acid ester derivative
US9346821B2 (en) Heterocyclic carboxylic acid ester derivative
KR20150126043A (en) Substituted 3-phenylpropylamine derivatives for the treatment of ophthalmic diseases and disorders
WO1998022430A9 (en) N-(ARYL/HETEROARYLACETYL) AMINO ACID ESTERS, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, AND METHODS FOR INHIBITING b-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS BY USE OF SUCH COMPOUNDS
FR2992317A1 (en) PROCESS FOR THE PREPARATION OF CHIRAL PEPTIDES
EP1654247B1 (en) Alkynyl aryl carboxamides
US7365225B2 (en) Aryl dicarboxamides
JP2006528157A5 (en)
FR2997081A1 (en) MIXED INHIBITORS OF N-AMINOPEPTIDASE AND NEPRILYSIN

Legal Events

Date Code Title Description
AS Assignment

Owner name: AJINOMOTO CO., INC., JAPAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KONISHI, ATSUSHI;TOKUMASU, MUNETAKA;SUZUKI, TAMOTSU;AND OTHERS;SIGNING DATES FROM 20120709 TO 20120710;REEL/FRAME:028636/0376

STCF Information on status: patent grant

Free format text: PATENTED CASE

CC Certificate of correction
FEPP Fee payment procedure

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

AS Assignment

Owner name: EA PHARMA CO., LTD., JAPAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:AJINOMOTO CO., INC.;REEL/FRAME:039094/0087

Effective date: 20160614

FPAY Fee payment

Year of fee payment: 4

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 8TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1552); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

Year of fee payment: 8